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ABSTRACT
Pilot Study:
a) 21 Generalised Anxiety Disorder (GAD) patients were treated
double-blind with either diazepam or placebo for 6 weeks. This
active treatment period was preceded by one-week single-bl ind
placebo 'wash-in', and followed by two-week single-blind 'wash-
out' • Results showed that diazepam used in moderate doses for 6
weeks produced anxiety recurrence and withdrawal symptoms.
b) 10 GAD patients were randomly allocated to Cognitive-
Behaviour Therapy (CBT) and compared with the above diazepam and
placebo groups. All treatments were balanced for degree of
Psychologist/patient contact. At cessation of active treatment
CRT superiority was indicated. Post-Study psychotropic
prescription and
months follow-up.
psychological treatment were assessed at 12
The CST group had the lowest incidence of
Subsequent treatment interventions.
Main Study :
101 GAD patients were randomly allocated to diazepam, placebo,
CST, CST + diazepam, and CST + placebo, and treated over 10 weeks.
Outcome measures at end of treatment arid at 6 months follow-up
re~ealed the superiority of all CBT treatments; especially CBT
alone, and CST + diazepam. Diazepam was more effective than
placebo. eBT + diazepam, and diazepam groups showed no anxiety
recurrence during graded withdrawal.
Secondary Study : 2
205 long-term benzodiazepine users were matrhed for age and
sex with controls. Inspection of medical case notes showed that
benzodiazepine users had higher rates of previous physical illness,
GP attendance, and non-psychotropic drug prescription. Differences
emerged between anx iolytic, hypnotic, and an xiolytic + hypnotic
benzodiazepine users in ag~, history of physical illness, and
previously prescribed medication.
Tertiary Study :
44 long-term benzodiazepine users were interviewed. The
incidence of psychological ill-health and social problems was lower
than expected. Patients were dependent on medication, and
reported concern if their medication were to be stopped.
Nevertheless 40% considered stopping benzodiazepines •
..';....~Results from the above studies are discussed in relation to
clinical management of GAD, and current concerns about
benzodiazepine dependence and withdrawal.
3CHAPTER 1 : INTRODUCTION.
Anxiety is a ubiquitous phenomenon of everyday life (Lader
1972) • Generalised Anxiety Disorder (GAD) is regarded as being
the most prevalent of all anxiety states (Weissman 1985). Since
the introduction of benzodiazepines in the mid 1960's they have
been the pharmacological treatment of choice for all anxiety states
(Greenblatt and Shader 1987), and continue to be so for the
treatment of GAD (Woods and Charney 1988).
However for a number of years there has been a growing concern
about the efficacy of benzodiazepines and dependency (Committee of
Safety of Medicines, 1980). Short-term prescription and withdrawal
from long-term use are now recommended (Commi ttee on Safety of
Medicines 1988).
Unfortunately the efficacy of benzodiazepines and their
.~.'"
Subsequent withdrawal when prescribed for the treatment for GAD in
a primary care setting have not been thoroughl y investigated.
Furthermore, information about the characteristics, attitudes, and
psycholog ica 1 ill hea 1th of long term ben zod iazepine users is
lacking.
Even the efficacy of specific psychological techniques for the
management of GAD is inconclusive; reduction'in anxiety is small
and rarely of clinical significance cast 1982). As a consequence
multidimensional and mixed treatment approaches have been advocated
(Mathews 1985), for example, combining cognitive and behavioural
approaches with progressive relaxation training. To date however
4the ~tandard pharmacological trp.atment for GAD has not bp.en
adequately evaluated in comf1ari~on with multidimensional
psychological trp.atment approaches.
The current study examines a number of the issues rai~ed
above. Chapter 2 presents the historical perspective of GAD
classification and definition. Problems associated with GAD
differential diagnosis are discussed. Studies assessing GAD
prevalence, and possible precipitating and antecedent factors are
reviewed. Chapter 3 is concerned with the introduction,
development, and extent of use of benzodiazepines. Studies
evaluating characteristics of long term users and problems of
dependency, wi thdrawa 1, and possible functional and organic
impairment are evaluated. A detailed review of the studies
investigating the efficacy of anxiolytic and psychological
treatment is presented in Chapter 4. Chapter 5 lists the detailed
aims of the studies presented in the chapters that follow.
The Pilot Study reported in Chapter 6 is divided into two sections.
Firstly, a 'Controlled Comparison of Withdrawal Symptoms and
An xiety Recurrence Fo 11owing Six Weeks Doub 1e-Bl ind Dia zepam or
Placebo Treatment for Generalised Anxiety Disorder in Primary
Care'; and secondly, a 'Controlled Comparison of Cognitive-
Behaviour Therapy, Diazepam and Placebo in the Management of
Generalised Anxiety Disorder in Primary Care. The Main Study of
Chapter 7 involves 'A Controlled Comparison of the Efficacy of
Diazepam, Placebo, Cognitive-Behaviour Therapy, Diazepam plus
Cognitive-Behaviour Therapy, and Placebo plus Cognitive-Behaviour
5Therapy in the Management of Generalised Anxiety Disorder in
Pr imary Care'. Chapter 8 is a 'Controlled Comparison of
Characteristics of Long Term Benzodiazepine Users in General
Practice' and Chapter 9 follows with an assessment of
'Psychological Ill-Health and Attitude to Benzodiazepine Use and
Withdrawa I Among Long -Term Ben zod iazepine Users'. Finally in
Chapter 10 the findings of the previous studies are discussed and
suggestions are made for future research.
CHAPTER 2 .. NATURE OF GENERALISED ANXIETY DISORDER .
2.1 Historical Perspective
The word "anxiety" is derived from a variety of sources
(Lader 1972) • Firstly, from the Latin "anxietas", meaning
disquiet; secondly from the Latin "angor" which refers to a sense
of constriction; and thirdly, partly as a mistranslation of the
German word "angst".
An anxiety state has been regarded as a cluster of symptoms
based on fear, the source of which is not recognized by the patient
(MiIes et aI 1951). Accord ing .to Marks and Lader (1973) the
anxiety may be chronic and sustained, but more characteristically
is episodic lasting from a few minutes to hours or days. The
chief symptoms are fear, apprehension, inattention, palpitations,
respiratory distress, dizziness, faintness, sweating, irritability,
tremor, chest pains, feelings of impending disaster and fears of
death.
Throughout history numerous terms have been given to
conditions that were indistinguishable from anxiety states. The
cardiovascular symptoms led to several synonyms such as "muscular
exhaustion of the heart" (Hartshorne 1864). Da Costa (1871) coined
the term "irritable heart" and subsequent authors referred
to "Da Costa's Syndrome" (Wood 1941). Dur ing Wor 1d War I
"neurocirculatory asthenia" came into vogue (Oppenheimer et al
1918) followed by "cardiac neurosis" and "vasomotor neurosis"
7(Schnur 1939). Over the same !"Jeriodothf?r writers nssLJmed that the
symptoms were brought on by exercise nnrl so the "effort syndromf?"
came into being (Lf?wis 1919).
The "nervous" symptoms of an anxiety state led to several
other names. "Neurasthenia" or "nervous exhaustion" was an early
term (Beard 1869). The term "neurosis" was itself first introduced
in the medical literature by Cullen (1772). However Freud (1894)
is credited with the label "anxiety neurosis", referring to a
syndrome of morbid anxiety with anxious expectation as its primary
symptom.
forms
As described by Freud, anxiety neurosis subsumed two
chronic anxiety and anxiety attacks. Freud regarded
anxiety neurosis as a chronic form of generalized or free-floating
anxiety that could co-exist or occur independently from a pattern
of anxiety attacks "which could erupt suddenly into consciousness
without being called forth by any train of thought". Yet other
synonyms such as "somatisation psychogenic reaction" were
introduced (Wheeler et al 1950) but failed to achieve the
popularity and prominent status of "anxiety neurosis" as a
diagnostic category. The Freudian notion of anxiety neurosis was
taken up with such alacrity that anxiety neurosis and hysteria
together accounted for all aspects of functional psychiatric
illness in Osler's 1912 classic medical textbook. According to
Tyrer (1984a)there was little chanQe in the nomenclature of anxiety
disorders in the ensuing years, although the delineation of
depressive illness, obsessional neurosis, the affective psychose~
and personality disorders probably reclassified many patients who
Amight otherwise have been labelled nsanxiety neurosis. This
reclassification restricted the diagnosis of anxiety neurosis to
a more homogeneous population. However, further divisions ensued.
Approximately thirty years ago phobic anxiety was
detached from anxiety neurosis. This followed the introduction of
behav iour therapy, in the form of desensi tization, as a spec ific
treatment for phobic anxiety (Wolpe 1958). The subsequent
demonstration that generalised anxiety not only failed to respond
to desensitization but actually hindered improvement in phobic
symptoms (Marks et al 1968) emphasised the practical importance of
making the diagnostic distinction between phobic states and
generalised anxiety states. The process of attrition of anxiety
neurosis continued with the reported efficacy of tricyclic
antidepressants (Klein and Fink 1962) and monoamine-oxidase
inhibitors (Klein 1964) in the management of panic symptoms and
then the subsequent notion of panic disorder (PO) as distinct from
generalised anxiety emerged. - Tyrer (1984a.),while discussing the
erosion of anxiety neurosis and the developmen~ of specific
diagnostic subcategories of phobic disorders and anxiety states,
concluded that Generalised Anxiety Disorder alone remained the
"atavistic ghost" of its anxiety neurosis predecessor.
2.2 Classification
Two major classification systems have emerged in recent times
in an attempt to clarify the diagnostic confusion and multiplicity
of unreconciled syndromes.
9Firstly, the ninth pdi.tion of the International Classifi.cation
of Diseases (ICD-9) (World Health Organisation 1978) a It hrnrrj h
widely used for disease classification, has limited clinical
usefulness for anxiety disorders. According to Lipschitz (198A)
it is not .~ diaQnostic manu a L, but rathg>r is a compt la t Lnn of
diseases for the purpose of statistical reporting for morbidity nnd
mortality. Its descriptions of diagnoses are guides for
classification, rather than operational rules for aSSigning these
diagnoses to patients (Kramer et 031 1979). As a result of these
constraints the ICD-9 categories have been regarded as too
ambiguous and overinclusive for ICD-9 to function as a clinically
useful diagnostic manual CJablensky 1985).
Secondly, the third edition of the Diagnostic and Statistical
Manual of the Mental Disorders CDSM III) of the American
Psychiatric Association attempts to provide for clinical diagnoses
the sort of-operational criteria that determine research diagnoses
by stating explicit inclusion and exclusion criteria for each
category, and by supplying in its glossary operational definitions
for its terminology (Lipschitz 1988).
The evolution of the present day view of anxiety can be
clearly traced through the Diagnostic and Statistical Manual of
Mental Disorders (DSM). In contrast to DSM III (1980), DSM r
<1952) and DSM IT C1968) reflect predominantly the influence of
Freud, Meyer and the psychoanalytic movement in the classification
of anXiety. In DSM III anxiety is no longer listed under the
neuroses but emerges in its own right as Anxiety Disorders. In
10
fact there is no longer a separate category of neurosis
or psychoneuroses, although the term "neuroses" is retained
parenthetically under the subcategories as noted in Table 2.1. Tn
DSM III there are specific listed criteria for determining the
appropriate diagnosis for any given disorder. Although nowhere in
DSM I or II does the contribution of the somatic component of the
disorder appear, in DSM III the presence of significant
physiological components is often vital
diagnosis.
Another striking feature of DSM III is the shift from the
to the appropriate
reactive and intrapsychic models to the phenomenological model,
thereby supporting the generally atheoretical ~pproach taken in DSM
III with regard to aetiology. Despite extensive field testing of
the DSM III diagnostic criteria before their official adoption,
Some criteria have been reported to be ambiguous. Therefore all
of the diagnostic criteria, plus the systematic descriptions of the
various disorders were recently reviewed, and a revised version
(DSM III-R; 1987) published. The studies to be presented in this
thesis were initiated prior to the publication of DSM III-R and so
Used the definition of Generalised Anxiety Disorder (GAD) published
in DSM JJ J.
t 1
Table 2.1. Anxiety Di~orders, American Psychiatric Association
DSII t (t9S2)
PSYCHIJtfIJROTJ C DISORDERS
Psychoneurotic Reactions:
Anxiety reaction
Dissociative reaction
Conversion Reaction
Phobic Reaction
Obsessive-co'pulsive
reaction
Depressive reaction
Psychoneurotic reaction
PSYCHIATRIC NOMENCLATURE
DSII II (t 968) DSPI III ( t980 t
tflJlOSES ANXIETY DIS!JlDERS
Neuroses :
Anxiety neurosis
Hysterical neurosis
- conversion type
- dissociative type
Phobic Neurosis
Obsessive-co.pulsive
neurosis
Neurasthenic,neurosis
Depersonalisation
neurosis
Hypochondriachal neurosis
Other neurOSl!S
(Unspecified Neurosis)
Phobic Disorders
(or Phobic NeurOSl!S)
Agoraphobia Nith panic
attacks
Agoraphobia Nithout panic
attacks
Social phobia
Si.ple phobia
Anxiety State lor Anxiety
Neurosis)
Panic disorder
Generalized anxiety
disorder
Obsessive-co.pulsive
disorder
lor ObsessiVe-cOllPU Isive
DSII III R (1987)
ANXIETY DISORDERS
(OR ANXIETY AND PHOBIC
tflJIDSES)
Panic disorder
Panic disorder with
agoraphobia
Agoraphobia without
history of panic disorder
Social Phobia
Silllplephobia
Obsessive-co'pulsive
disorder
Post-trclUlcltic
disorder
Generalized anxiety
stress
disorder
Anxiety disorder not
neurosis) otherwise specified
Post traumatic stress
disorder - acute
- chronic or delayed
Atypical anxiety disorder
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7.3 Definition
The current DSM III definition of GAD is reproduced below:
Anxiety States (or Anxiety Neuroses)
Generalised Anxiety Disorder
Differential diagnosis. Physical disorders, suc:h as
hyperthyroidism; Organic Mental Disorders, such as Caffeine
Intoxication; Adjustment Disorder with Anxious Mood; Schizophrenia;
Depressive Disorders; Hypochondriasis; Obsessive Compulsive
Disorder; Panic Disorder.
Diagnostic: Criteria.
A. Generalised, persistent anxiety is manifested by symptoms from
three of the following four categories:
(1) Motor tension: shakiness, jitteriness, jumpiness, trembling,
t.ension, muscle aches, fatigability, inability to relax, eyelid
tWitch, furrowed brow, strained face, fidgeting, restlessness, easy
startle.
(2) Autonomic hyperactivity sweating, heart pounding or racing,
cold clammy hands, dry mouth, dizziness, light headedness,
paresthesias (tingling in hands or feet), upset stomach, hot or
cold spells, frequent urination, diarrhoea, discomfort in the pit.
of the stomach, lump in the throat, flushing, pallor, high resting
~ulse and res~iration rate.
(3) Apprehensive expectation anxiety, wo~ry, fear, rumination,
and anticipation of misfortune to self or others.
(4) Vigilance and scanning hyperattentiveness resulting in
distrActihility, difficulty in concentrating, insomnia, fpPling "on
edge", irritahility, impatiencp.
A. The anxious mood has hppn continuous for at lpast onp month.
C. Not due to another mental disorder, such as Depressive Disorder
or Schizophrenia.
D. At least 18 years of age.
The DSM III-R criteria for GAD are somewhat more restrictive
in comparison to DSM III. In particular, DSM III-R requires that
at least 6 symptoms (as opposed to a minimum of 2 symptoms in DSM
III) from a I ist of 18 symptoms covering the "motor tension",
"autonomic hyperactivity" and "vigilance and scanning" sections be
present. The only other substantial alteration is that
"unrealistic or excessive worry (apprehensive expectation) about
two .or more life circumstances" be present "for a period of six
months or longer, during which the person has been bothered more
days than not by these concerns". In general the DSM III-R
diagnosis implies that some of the symptoms of GAD be present for
at least a 6-month period as opposed to the minimum 1 month
recommendation of DSM III, and in addition that the cognitive
component of worry and apprehensive expectation be a prerequisite
for GAD diagnosis. The impl ications of thpse changes for the
present study will be discussed in Chapter 10.
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2.4 DifferpntiNI Oiagnosis
The sep.=1rat ion of GAD ann PD h.~c;f1ronuc:prl much deb.=1tp wh ir:h
continues with regard to DSM III-R classification. As previoLJsly
mentioned the rationale for distinguishing GAD from PO is based
largely on pharmacological studies (Klein and Fink 1962; Klein
1981; Zitrin et al 1983) which claim to show t ha t generalised
anxiety does not respond to drugs that are effective in r~ducing
panic attacks. However, in DSM III and DSM III-R, patients are
diagnosed as GAD if they report both chronic anxiety and panic
attacks, providing the panic attacks do not occur often enough to
meet the panic frequency criteria of PD. This diagnostic process
reflects both the residual status of GAD an? the potentially mixed
nature of this anxiety state. In order to clarify such issues
researchers have attempted to investigate distinctions between PD
and GAD. Hoehn-Saric (1982) failed to find differences between 69
.~.....
patients with PO and 64 with GAD in terms of their childhood
history, social characteri?tics, and personality features. The
major difference between the groups was in their clinical
presentation. PO patients reported some somatic symptoms of
anxiety more frequently than GAD patients, especially with regard
to hyperventilation and cardiovascular symptoms rather than
muscular and gastrointestinal symptoms. PD patients also reported
more negative affects, such as depression and irritability. In an
earlier study Hoehn-Saric (1981) found gr~ater introversion in GAD
patients, than in PO patients, as measured by the Eysenck
Personality Inventory (Eysenck and Eysenck 1975) but he later
1!'1
failpd t.o r-P[11ir;:)tpthis findinl] (Hoehn-Sarir 1987). Hp ronrillden
that GAD r-epr-esents .=l heter-ogeneous gr-OLJ[1of disor-der-s which
differs from PD in having less sever-e symptoms. In a not
dissimilar- study comparing 48 PD and 18 GAD patients, Ander-son et
a I (1984) repor-ted fewer- autonomic <symptoms and an earlier- mor-e
gr-adual onset for- the GAD gr-oup. They also suggested that GAD had
a mor-e chronic cour-se yet mor-e favour-able outcome as deter-mined by
number- of symptoms at inter-view. However they noted "these
findings may have been chance differ-ences related to small sample
size". They also stated that some GAD patients reported persistent
symptoms leading to secondary depression and psychiatric treatment.
Rapee (1985) compar-ed 38 PD and 48 GAD patients and concluded that
PD is characterised by sudden onset around the mid to late 20~s
age gr-oup, and is distinguished by symptoms which are chiefly
hyperventilatory in nature and which are accompanied by thoughts
..~.'~
of serious physical or mental illness. In comparison GAD was found
to be characterised by a gradual onset of somatic symptoms which
are generally accompanied by a realisation that the symptoms are
.the r-esult of anxiety and are har-mless. These results ar-e similar
to those of Hibber-t (1984) who compar-ed the anxiety r-elated
thoughts of 8 GAD and 17 PD patients and stated that PO patients
r-eported exper-iencing cognitions associated with disastrous
consequences center-ing on the theme of per-sonal physical har-m,
whereas GAD patients r-epor-ted less dr-amatic cognitions. Hibber-t
(1984) explained this finding by suggesting that PO patients, in
compar-ison to GAD patients, systematically misconstr-ue their
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Somatic experiences as d.'lngproLJs.ina w.'lYwhich is consistent with
t.he proposals of Beck et NI (1974) arrd findings of Butler and
Mathews (1983) that anxious people overestimate subjective personal
risk.
The problem of differential diagnosis has also been tackled
by investigators assessj.ng the reliahility of DSM III anxiety
disorders. DiNardo et al (1983) assessed 60 consecutie outpatients
at an anxiety disorder clinic using a structured interview
consisting of symptoms and signs defined in the DSM III.
Interv iews were conduc ted by 2 assessors. PD was found to be
distinguishable from other anxiety disorders with high levels of
inter rat.er reliability (kappa coefficients greater than .692).
The only anxiety disorder that demonstrated poor diagnostic
reliability was GAD (kappa coefficient = .467). GAD was the most
consistently chosen alternative di.agnosis , which indicated that
the symptoms of GAD are commonly associated with other disorders.
DiNardo et al (1983) concluded that "GAD becomes a residual
category, used when the cli.nician has ruled out other disorders".
Cameron et al (1986) compared 316 patients representing all
specific DSM lIT anxiety disorders, except post-traumatic stress
disorder, on a number of variables, including symptom profiles and
demographic delta. Symptom severity profiles showed both
similarities and differences between anxiety disorders. PD, GAD
and elgoraphobia with or without panic were similar to each other
and were more severel y debi Iitating than the other disorders.
Small differences between PD and GAD existed and concerned symptom
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nrofi1p. (pc;neci~lly "nhdominnl r.ramnc;") and nt)e of onset. Common
symptoms throughotJt the riingnostic categories were cognitive
symptoms, cardiorespiratory symptoms
symptoms.
and sweating, and
Bar 1ow et a L ..(1986)gastrointestinal and urinary
classified 108 patients into the various DSM III anxiety disorder
categories. Although patients with a primary diagnosis of GAD were
more chronic than PD patients, most patients in each category met
the DSM III criteria for GAD with the exception of simple phobics.
On the basis of t.hese data Barlow et al (1986) concluded that GAD
was a residual category within the anxiety disorders,
symptoms were almost always present.
In addition Barlow et al (1986) suggested that the cardinal
sincE:' GAD
feature of GAD was "apprehensive expectation" with "accompanying
autonomic symptoms" and that patients could be characterised as
"chronic worriers". Given the apparent residual nature of GAD it
is hardly surprising that researchers (DiNardo et al 1983; Barlow
1985) have reported the diag~ostic reliability of GAD as relatively
low (kappa coefficient = .467), at a level which according to
Cerny et a1 (1984) is respectable but nevertheless well below the
reliability of other anxiety disorders. However as Cerny et al
(1984) have illustrated this relatively low reliability coefficient
may be due t.o severa I fac tors assoc iated wi th DiNardo et al' s
(1983) study. Firstly, the smnll sample of patients diagnosed as
GAD (N=12, or 11.11. of the sample). Secondly, 841. of patients
diagnosed as agoraphobia with panic and 78.61. of those diagnosed
as PD also met the diagnosis for GAD. Fifty per cent of GAD
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patients also reporten uncued panic .:lttar.ksbut .~t a frpC"jlJF?nryton
low to meet the criteria for PD. Thirdly, 83'l.of the GAD patients
were given at least one other diagnosis, a situation which does
not enhance diagnostic clarity. Fourthly, severity ratings of the
anxiety symptOMS that are reportedly characteristic of GAD did not
discriminate between the various anxiety disorders.
In general, the above data suggest that the symptoms defining
GAD appear frequently in other anxiety disorders and that low-
frequency panic attacks occur often in GAD and that GAD patients
have been struggling with anxiety-related pro~lems longer than PO
patients. The ubiquity of GAD symptoms and the likelihood of
additional diagnoses make the reliable classification of GAD
problematic. In addition the relationship of panic to GAD has not
been specified clearly, partially because the research on these DSM
III and DSM III-R anxiety states is sparse. Furthermore, as
suggested by Tyrer C1986) "panic is not nearly as distinct a
symptom as DSM III," and by implication DSM III-R, "would have us
believe".
Cerny et al (1984) have reported an alternative view that it
may be heuristic to conceptual ise GAD as a primary diagnostic
category, whose card ina I fea t.ure is based on the fOCl)S of the
apprehensive expectation, rather than as a residual disorder. In
t.his reconceptualization the chronic worry of GAD is distinguished
from the anticipatory anxiety often found in other an)(iety
disorder categories not only by the duration of the worry but also
by its content. Accordingly GAD is diagnosed only if the
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apprehensive expectation is focused on multiple life circumstances
that are unrelated to anxiety anticipatory of phobic exposure or
panic attack. These suggestions clarify and begin to define
operationally the differences between anticipatory anxiety and
chronic worry. According to Cerny et al (1984) it may well be that
GAD patients who experience low frequency panic are troubled by
both anticipatory anxiety and chronic worry, while those without
panic struggle with chronic worry only. Such a distinction may be
both practically and theoretically useful. However, it maintains
the assumption that GAD symptoms are primarily cognitive and
somatic in nature and fai Is to enquire whether a behavioural
component exists. In other words, GAD is conceptualised as
comprising two of the three components of Lang' s (1971) Three
Systems Theory. This is reflected in Barlow et aI's (1984) comment
that "exposure is of little or no use to those with generalised
anxiety disorder •••• since they avoid nothing to begin wi th".
However, Butler et al (1987~) attempted to ascertain to what extent
avoidance behaviour and situational anxiety was present in a sample
of 45 GAD patients. Seventy eight per cent of the patients
reported anticipatory anxiety, 80% reported some form of
Clinicalsituational anxiety and 64% reported avoidance.
observation of the same GAD patients confirmed that the reported
situational anxiety and avoidance behaviour was less consistent and
circumscribed than that required for a diagnosis of phobic
disorder. This finding is at variance with GAD symptom profiles
reported in the literature. Butler et al (1987b) reported that the
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situational anxiety in GAO patients was variahle, and reslJlted in
a diffuse pattern of avoidance which contrasted with the more
focUS5~d avoidance of a sma 11er number of si tua tions in phob ic
patients. The pattern of avoidance in GAD resembled that observed
in social phobia and, according to Butler et al (19a7b) was likely
to require the modified form of exposure treatment developed for
social phobics by Butler (1985). In the Iight of this latter
finding the differential diagnosis and subsequent treatment of GAD
may be even more problematic as the disorder appears to consist of
cognitive, somatic and behavioural symptoms, with or without
episodic panic attacks, the diagnosis being conferred in the
absence of any other primary anxiety disorder.
2.5 Prevalence
Although its definition will significantly affect its
prevalence, generalised anxiety is regarded as prevalent in the
population. Dunn (1983) reported anxiety neurosis to be the most
common psychiatric disorder diagnosed by general practitioners in
Britain. Lader (1975), from a community survey, reported that 44%
of the subjects experienced some anxiety symptoms, 31% could be
classified as having subclinical neurosis, and 5% suffered enough
from severe anxiety to seek treatment.
George et a1 (1986) found an overall prevalence rate of about
8% for GAD similar to that of Lader's (1975) treatment seeking I
grpup. Weissman (1985) reported GAD prevalence varying from 2.5 to
6.4%, making GAD the most commonly reported an:<iety disorder,
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occurring two to five times more frequently than PD. In general
little socio-demographic data is available regarding GAD. Weissman
(1985) found that GAD was more common in middle and younger aged
females, in non-whites, in the unmarried, and in those from lower
socioeconomic groupings.
2.6 Genetic and Family Studies
Family and twin studies have generally been concerned with
the distinction between PD and GAD. In reviewing the rather sparse
literature Breir et al (1985) concluded that there was strong
evidence that PD, but not GAD, had high familial prevalence and
genetic transmission. However, the data are at present ambiguous
and inconclusive. Crowe et al (1983) found a higher degree of PD
among relatives of probands with PD than among control relatives,
but no difference in the prevalence of GAD. Noyes et al. (1987)
.':".';'
reported the frequency of GAD as higher among first degree
relatives of probands wit~ GAD than among relatives of control, P~
and agoraphobic probands. Also the frequency of PD was higher
among relatives of probands with PD than among relatives of
controls. There existed no difference in the frequency of PD among
relatives of probands with PD and the relatives of GAD probands.
Findings of the above studies should be treated with caution
as a number of methodological shortcomings exist with regard to
group selection, subject recruitment, non-blind assessment of
subjects, and the relatively small sample sizes.
Finally only one twin study has been published. Torgersen (1983)
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found that monozygotic twins had a rate of PD and agoraphobia with
panic attacks five times higher than that of same sex dizygotic
twins. GAD however, demonstrated no evidence of genetic
transmission.
2.7 Antecedents and Precipitants
In a retrospective study of 17 PD and 16 GAD subjects, Raskin
et al (1982) concluded that both groups experienced a similar
incidence of early loss, separation disorder in childhood, and
separations or threatened separations as precipitants of anxiety.
The authors also reported that anxiety related problems of
separation seemed to be the main cause of symptoms in both groups.
However, in the absence of a normal control group, it is difficult
to evaluate the importance of early separations and separation
disorder in childhood in the development of either PD or GAD.
Furthermore, those with PD had a significantly higher incidence of
a grossly disturbed childhood environment and previous major
depressive episodes. Unfortunately given the small sample size and
the unreplicated nature of the findings, these results need to be
treated with caution.
In a retrospective community study of 2,902 subjects Blazer
et al (1987), investigated the association between the onset of GAD
and the occurrence of 19 designated life events during the
preceding 12 months. Males reporting fou~ or more life events had
a risk of GAD 8.5 times that of males reporting zero to three life
events. By contrast, the association between total life events and
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GAD was not statistically significant for fema]ps. Howpvp.r, whpn
using a more subjective measure, namely "unexpected, npgative, very
important events" , both males and females who reported
experiencing one or more such events had a threefold increase in
the risk of developing GAD. As the authors note, theirs is the
first paper to demonstrate such a relationship, albeit with
limitations. For example, the findings indicate that the means by
which one scales life events has an appreciable impact on the
predictive value of these events. Furthermore it could not be
determined whether GAD occurred immediately after a life event or
many months afterwards. Nevertheless, despite the increasing
emphasis on the biological aetiology of anxiety, this study
emphasises the importance of environmental factors in the onset of
anxiety disorders, and the importance of an individual's personal
interpretation of the significance of life events.
2.8 Summary
The preceding chapter presents the historical perspective,
classification, and definition of GAD. The heterogeneous character
of GAD was reflected in the problems associated with differential
diagnosis. The relatively high prevalence rate of GAD, in
conjunc: tion wi th uncerta inty concern ing aet io logy and the wide
variety of presenting symptoms has reSIJ1ted in a wide range of
therapeutic interventions. Pharmac:ological and psychological
treatment approaches have been adopted in the management of GAD and
each will be discussed in detail in the forthcoming chapters.
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CHAPTER 3 : BENZODIAZEPINFS
3.1 Historical Perspective
"The development of the benzodiazepines and their
proliferation must be one of the landmarks of post-war clinical
medicine" (Clare 1987) • The benzodiazepines, initially
chlordiazepoxide (Librium) and diazepam (Valium) were introduced
over 25 years ago and were later followed by a large number of
derivatives (Sternbach 1982). Benzodiazepines largely replaced the
barbiturates because they were regarded as being more effective in
alleviating anxiety, caused fewer and less severe side effects,
were safer in overdosage, and because they induced liver enzymes
much less, did not cause metabolic interactions with other drugs
(Lader 1983). Furthermore. benzodiazepines were regarded as being
less liable to induce dependence and subsequent withdrawal
reactions (Greenblatt and Shader 1978). In addi tion to their
anxiolytic properties the benzodiazepines have been used as
anticonvulsants (Greenblatt et al 1981), as muscle relaxants in
preparation for major surgery for childbirth (Cree et al 1973), for
relief from acute dystonic spasms (Korczyn and Goldberg 1972). and
during alcohol withdrawal (Sellers et al 1983). However, it was
as hypnotics and anxiolytics that' benzodiazepines achieved their
greatest popularity <Greenblatt and Shader 1978).
3.2 Mechanism of Ren~orliazpninp Action
Ben z rid]a zepinps appear to intprac t with many npurotranc:;mi tter
systems (Redmond 1983). Thp primary interactions arp rpportpd to
be with the neurotransmitter gamma amino butyric acid (GABA) (Costa
1983). Intpractions with cholinergic, serotonprgic , dopaminergi~
and noradrenergic systems are regarded as secondary (Tallman et 031
1980). GABA receptors are widely distributed 'throughout the brain
and are believed to mediate the principal anxiolyti~, sedative,
muscle relaxant, and anticonvulsant properties of the
benzodiazepines (Costa 1983). There are reports suggesting the
existence of endogenous benzodiazepine-like compounds (Petursson
et a I 1982; C10w et a1 1983; Costa 1983), although the need for
further work to clarify their existence and role has been advocated
(Redmond 1983). Given the extremely broad range of actions of the
benzodiazepines, it has been assumed that these compounds act on
neural substrates for anxiety at multiple sites (Solomon 1976).
However excepting the benzodiazepine I GA8A receptor complex,
Redmond (1983) states that there is no compelling evidence that any
of the other neurotransmitter systems affected by benzodiazepines
are responsible for their anxio1ytic action. However the actions
of the benzodiazepi.nes are too broad to el iminate many. other
Possibilities. It appears that further research is required to
delineate the specific neurotransmitter systems involved in the
action of benzodiazepine anxiolytics.
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3.3 Extent of Llsrlqp.
From 1965 onw;:lrds usp of thp relatively hazardous
harbituratps began to decline while that of benzodiazepines rose
steadily~ In 1977 diazepam was the drug most commonly prescribed
by general practitioners in the United Kingdom, accounting for
4.3% of all prescriptions (Skegg et al 1977). Furthermore, in the
Un ited Kingdom, approximately 85% of all benzodiazepines are
prescribed by general practitioners (Rose 1983). In 1979 over
60,000,000 prescriptions for benzodiazepines were issued in the
United States (Rosenbaum 1982). In 1980 it was estimated that 40
billion doses of benzodiazepines were taken daily throughout the
world (Tyrer 1980). Within the British context 24,600,000
benzodiazepine prescriptions were issued by the family practitioner
service in 1974, rising to a peak of almost 31,000,000 in 1979.
By 1985 prescriptions had fallen to 26,000,000 (Taylor 1987).
However when prescriptions for benzodiazepine hypnotics are
separated from those classed as tranquillizers, two quite
different patterns emerge. In Britain benzodiazepine hypnotic
prescriptions rose steadily throughout the 1970's from under
5,000,000 at the start of the decade to 13,000,000 at the beginning
of the 1980s; the 1985 estimated total standing at some 14,000,000
prescriptions. By contrast, the number of benzodiazepine
tranqui 11izer prescriptions increased from around 10,000,000 in
1970 to a peak of 18,000,000 in 1978; the 1985 estimated total was
12,000,000 - one third down on the figure of seven years previously
(Taylor 1987).
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A cross-national study conducted by 8.3lter et a l (19A4)
provided comparable estim.3tes of past year prF.'valence use (the
proportion of the population who took anxiolytic/sedative
medications one or more times), and the duration of use (the
proportion of the population who took these medications d~ily fo~
various lengths of time). Rates for past-year prevalence of use
varied from 17.61. in Belgium to 7.41. in the Netherlands, with the
USA and UK being 12.91. and 11.21. respectively. There was wide
variation among countries in the prevalence of long-term and short-
term use, but regular daily use for 3 months or less was the
predominant pattern in 10 of the 11 countries surveyed. Past-year
prevalence rates were much higher for women than for men in every
country surveyed.
In Britain the rapid growth in benzodiazepine prescription
during the early lq70s has been referred to as the "benzodiazepine
bonanza" (Tyrer 1q74) J and led to fears of the total
Thetranquillisation of the ,population (Anonymous 1q73) •
ubiquitous nature of anxiety and overprescription raised concern
that benzodiazepi.nes were the new "opium of the masses" (Lader
1q78) • However growing criticism of the levels of use and abuse
of these drugs, together with concern about patient-led demand have
helped create a developing trend towards reduced prescribing. It
is estimated that similar trends are occurring in other countries
including the USA (Hollister lQ83). However significant demand
for-benzodiazepines in primary care still exists in Britain (Tyrer
1Q80) •
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3.4 Long- and Short-acting Benzodiazepines
As benzodiazepine usage rose the number of benzodiazepine
derivatives also increased. Marks C1983a) listed a total of 31
benzodiazepine compounds available in Germany, Italy, Japan, USA
and UK. The major differences between the numerous
benzodiazepines lie in their relative potency and pharmacokinetic
properties. The onset and duration of action after single oral
dose depends largely upon the absorption rate and the rate and
extent of distribution, whereas the rate and extent of accumUlation
during multiple dosage depends on elimination half-life and
clearance (Greenblatt et al 1981). The therapeutic implications
of half-life have been addressed by several authors (Cohn 1983;
Straw 1983). Compounds with shorter half-lives, which are less
likely to impair daytime function after a bedtime dose are more
rationally prescribed as hypnotics (Solomon et al 1979; Hindmarch
1980). Conversely where a~xiolytic activity is required drugs of
a longer duration of action are regarded as more suitable (Lader
1976). At present there are seven benzodiazepine compounds
available on National Health Service (NHS) prescription within
Britain. They can be classified as having either a long
<elimination half-life usually greater than 24 hours), intermediate
(half-life of 5 - 24 hours), or short (half-life of less than 5
hours) duration of action. Long-acting benzodiazepines prescribed
as - anxiolytics
Intermediate-acting
include chlordiazepoxide and diazepam.
benzodiazepines, some of which may be
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prescribed as anxiolytics or hypnotics, include lorazepam,
nitrazepam, oxazepam, and temazepam. The sole NHS available
short-acting benzodiazepine hypnotic is triazolam.
Looking at anxiolytic benzodiazepine usage by substance over the
period 1978 to 1985, the number of prescriptions containing long-
acting compounds fell by 12,5000,000 while those containing
intermed iate- and short-ac ting compounds increased by 5,500,000
(Taylor 1987). These results represent a significant shift in
the ba Iance of anx ioIytic usage towards produc ts wi th shorter
plasma half-lives.
3.5 Age I Sex Patterns of Usage
Within the context of basic consumption statistics the most
significant consumer variables associated with prescribing
benzodiazepines are age and sex.
Several of the early studies, both in the USA and Western
Europe, suggested that about one in ten males and one in five
females took tranquillizers or hypnotics, usually benzodiazepines,
during the course.of each year, two thirds of them for at least
one month at a time (Lader 1978; Balter et al 1974). World wide
female consumption rates are regarded as twice those of males.
It has been estimated that in Britain some 40 - 451. of
benzodiazepine prescriptions are supplied to patients aged over 65
(Taylor 1987).
In Britain 701. of both benzodiazepine hypnotics and
tranquillizers are dispensed to females, but the age breakdowns
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differ. In thp r::~c:;P of tr~nquillizF?rs, ronsLJmption rates in
females over 40 are high, and roughly equal between age groups.
It is estimated that the 13 mill ion British women aged over 40
receive almost 601. of all the benzodiazepine medicines prescribed
for the British population. For hypnotics there is a morE' even
increase in consumption with age: the five million British women
aged over 65 probably consume about 40'l.of all benzodiazepine
hypnotics prescribed, whereas the eight million aged between 40
and 65 take about 25'l.of the national total (Taylor 1987).
3.6 Dependency I Withdrawal
Some authors have suggested that the widespread use of
benzod ia zepines is 1arge 1y at tri butabl e to thei r ef fec tiveness
(Ba 11enger 1984). However, others (Rickels 1981a) state that
information on the extent of drug use tells us little about the
appropriateness of such use. In recent years the most p~rsistent
criticism concerning ber:'zodiazepines has focussed on the
development of dependence. The existence of such dependence is
suggested by a number of single and multiple case reports (see
Tables 3.1 and 3.2) including double-blind studies CTyrer et al
1981, Tyrer et al 1983). A wide range of wi thdrawa 1 symptoms
including anxiety, tremor, irritability, profUse sweating,
insomnia, nausea, vomiting, headache, muscular pains and stiffness,
and perceptual disturbances such as photophobia, paraesthesia, and
hypersensitivity to pain and touch have been described (see Tables
3.1 and 3.2). More serious symptoms such as epileptic fits
~1
(Hall ister et a l 1961), and psychotic reactions (Preskorn and
Denner 1977) have been noted. Estimates of the numbers of long-
term users who are affected by withdrawal symptoms vary widely,
with reports ranging from fifteen to forty-four per cent (Tyrer et
al 1983; Hallstrom and Lader 1982). Withdrawal symptoms typically
emerge in the first week after stopping the drug but may develop
after a reduction in dosage (Ashton 1984). The withdrawal syndrome
has been reported as lasting up to three months (Anonymous 1985),
but reports of withdrawal symptoms persisting for more than 6
months and in some cases for a year or more have been published
(Higgitt et al 1985) • Recent extensive publicity about
tranquillizers has led to increased consumer demand for medical
guidance about withdrawal (Lacey and Woodward 1985). Stopping
benzodiazepines abruptly is regarded as more likely to lead to
severe withdrawal symptoms such as fits or confusional states (Howe
1980; Tyrer et al 1981) than is graded withdrawaj~ As long-acting
benzodiazepines are assoc iated wi th 1ess pronounc:ed wi thdrawa 1
symptoms (Tyrer et al 1983; Rickels et al 1986) several researchers
recommend substituting long-acting for short-acting benzodiazepines
before withdrawal is begun (Petursson and Lader 1984; Ashton 1984).
However, other authors (Bowden and Fisher 1980; Laughren et al
1982) conclude that withdrawal from long-term diazepam use does not
result in any rapid recurrence of anxiety or prominent withdrawal
symptoms anyway, regardless of whether the withdrawal is rapid or
gradua 1•
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T"hlp 3.1. R~portc; of withrlrawal rPnrt'ion from hif)h rloc;nqe
henzodia7epinp tranf)lJillizprc:;.
Drug and ~
Range or Mean
dai Iv doc;e (!IIC])
Duration of
druquse
No of
patients
studied
!lain liithdralCcll
sylptoes
Holl ister et al
(19bl)
Chlordiazepoxide
3OO-bOO
1-7
IOIlths
II Psychosis, epi leptiforl convulsions
inSOlllia, anorpxia, agitation.
Slater (19bb) Chlordiazepoxide 4 years SllPating, abdOllinal cralps,
suocutanPOUScrawling sensations
Gordon 119b71 Diazepal bO I year Agitation, treaor, hypprhydrosis
Preskorn and Denner Diazepall bO-lbO b - 24 3 Anxiety, restlessness, treaor,
119m It othPr IOIlths organic psychosis I including
tranquillizers) auditory and visual hallucinationsl
A11guIander and Borg Chlorazepate 3 IOIlths Deliriua, confusion
119781
De Bard 119791 Diazepal 80 4 years Acute organic brain sY!ldroae
lincluding visual hallucinations,
disorientation, seizures and cOllaI
"iller and Neilsen Diazepaa bO-80 8 years Anxiety, eaotional lability,
11979) diahorrea, restlessness.
Stl!lCclrtet al Lorazepal20 honths Disorientation, nausea, stUlbI inggait.
119801
Ha lIs trOl and Lader Diazepal 135 3 - 14 4 Anxiety, sleep disturbance,
11981) lor PQuivalent) ypars intolerance to bright) ight and noise.
Table 3.2.
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Reports of withdrawal reactions from low dosage
(therapeutic U5e) henzodiazepines
Covi et al
(1973)
Bant 11975)
Vyas and Carney
(1975)
Rifkin et al
(1976)
Dysken and Chen
119771
Pevnick et a I
11979)
belen and Fisher
11980)
Einar'iOll 11980)
HoNe 11980)
Khan et al 119801
Winokur et al
(1980)
Drug and dose
range or llean
dai Iy dose IIIIQI
Chlordiazepoxide
:so - 40
Diazepaa 30
Diazepal 30
Diazepaa 30
Diazepal 15 - 30
l+alcol101 abusel
Diazepal 30 - 45
..;..."
Diazepall 31
Lorazepaa B - 12
Lorazepal 7.5
Lorazepa.
Diazepam
Oxazepa.
Diazepal 15 - 25
IXIration of drug
~
(mean or rangel
No 0 f
patients
studied
5 IOI1ths 39
t - 2 years 2
3 years
7 years
20 IOI1ths
1 - 7 years
I - 6 IOI1ths 4
4 - 7 years 2
3 - 10 year .. 4
2
2
6 year s
!lain withdra..al syaptOl5
Anxiety, treaor,
anorexia,dizziness
Severe trelOr
Confusion, grand ta I
seizures
Grand tal convulsions
Dysphoria, disorient-
ation, confusion,
psychosis with
'hypoaanic'presentation
Precipitous weight loss,
dysphori~, trl!llor
(no withdra..al reactions
but the suqqestion of
gradual anxiety recurrence)
Epileptic seizures
Panic, nocturnal tonic and
clonic seizures, ayoclonic
jerks.
Anxiety, irritability,
trelOr, vertigo, tinnitus,
palpitations, hyperacusia,
headaches
Depersonalisation states,
paresthesia .. , ataxia,
delirious withdrawal
psycho'ies or epileptifor.
crises.
!Tablp 3.1 Cmtd. I
Hallstro. and
lader (1981)
Peturs50n and
ladpr 11981 1
Schopf 1t'181)
lyrer et al 119811
laughren £It a 1
(1982)
lader and lader
and Petursson
11983)
lyrer et al 11983)
Ashton 11984)
Diazepall 20
lor PQuivalenl)
DiilzPpa. 10 - 30
lora7Ppail I - 7.5
Clobaz<lll 30
Various
benzodiazepines
Diazepa. 10
lorazepal 4
DicllP.paI 17
Diazepal 17
Other
benzodiazepines
Diazepall 5 - 20
Various
benzodiazl'pines
2 - 10 Yl'ars 6 Anxil'ty, slePp dislurbancl',
intolerance to bright light
and noise
I - 16 years 10
4
2
Anxiety, dysphoria,
perceptual changes,
unsteadiness, Neight loss
6.3 years 8 Visual sensory changes,
kinesthetic disturbances,
hypersensi ti vi ty and hypo-
sensitil'i ty, dpperson-
alisation, and
dereal ization
3.6 years 40 Anxiety, extn!le dysphoria,
perceptual ataxia, hyper-
sensitivity to sensory
stilUli, retching, IUscle
tllitching.
I - 12 years 24 INo prill inen t .ithdrallal
syndra.e but the suggestion
of gradual anxiety
recurrl'l1cel
1 - 16 years 17
10
Anxiety, tl'l1sion, sleep
disturbance, loss of
appetite, IIPta Illc taste,
hyper5Olnia, paresthesia,
sore eyes, photophobia.
41 Reduced sleep, depersonal-
isation, sadness,
derealisation, reduced
appetite, pe5si.iSl, poor
concentratioo, indecision.
Paresthesiae, depression,
poor ...ary, agorophobia,
panic attacks , ataxia,
headache, dizziness, speech
difficulty, hyper-
Sl'IlSit iv ity , inSOllflia,
flushing.
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lTable 3.2 Cmtd.)
Busto et al (1986)
Rickels et al
(1986)
Schweizer and
Rickels (1986)
Diazepal
Lorazepal
Oxazepal
Triazolaa
Flurazepal
Chlordiazepoxide
Nitrazepal
(Average dai Iy
dose = Is.g of
diazepaa or
equivalent)
Diazepaa 15.2
Chlorazepate 18.2
Lorazepal 3.9
Alprazolal2.7
Other
benzodiazepines
Diazepal
Lorazepal
Chlordiazepoxide
Clorazepate
Alprazolaa
(Average dai Iy
dose = 22119 of
diazepu or
equivalent)
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It
3
t
2
Persistent tinnitus,
involutary love.ents,
paresthesias, confusion,
perceptual changes.
(3 - <15 years 40
12
3b
6
16
II10re severe withdrawal
syndrtlllll!but the suggestion
of gradual anJiety
recurrence) •
10 years 6
•
2
2
I
!The addi tion of buspirone
did not lessen withdrawal
SYlllptOlS).
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Unfortun.=ltely inform.=ltion on op+ ima I withdrawal r>rnc:pdllrec;is
lacking - for relatively little systematic research has been none
on the treatment of benzodiazepine dependence. Studies that have
been published have had methodological limitations. For examr>le,
a significant number of studies investigating benzodiazepine
withdrawal have selected patients who previously e~perienced
difficulty discontinuing benzodiazepine medication (Busto et 031
1986; Hallstrom and Lader 1981). However Tyrer (1984b) reported
that fifty per cent of patients can cease benzodiazepine treatment
without experiencing withdrawal symptoms. Other studies
investigating benzodiazepine withdrawal used patients who had been
maintained within recommended doses for prolonged periods prior to
withdrawal (see Table 3.2) - although the recommended length of
benzodiazepine treatment was only eight to ten weeks (Committee on
Safety of Medicines 1980). Recommended treatment is currently
only two to four weeks (Committee on the Safety of Medicine~ 1988).
Other studies have used patients who have either been prescribed
or have self-administered high doses of benzodiazepines which were
well above the recommended level (see Table 3.1). In other stUdies
up to 33% of subjects continued to indulge in concomitant
"recreational drug use" during withdrawal from benzodiazepines
CRickels E't al 1986). In particular Rickels et 031 (1986) noted
that "Drugs primarily takp.n were marijuana, but to some extent also
QuaaludE', 'downers', amphetaminE's, LSD and cocaine", thereby making
intE'rpretation of their data rather difficult.
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With the exception nf two papers (Fontaine et al 1984; Murphy
et al 1984) controlled studies of benzodiazepine withdrawal after
the administration of short-term therapeutic doses are lacking.
Fontaine et al (1984) reported the results of a "double-blind,
placebo controlled study of four weeks of benzodiazepine" (diazepam
or bromazepam) treatment ,followed by 3 weeks placebo substitution.
Si xteen pa tients were wi thdrawn from ben zod iazepines abrupt Iy,
fourteen were withdrawn ~radually, and thirteen received placebo
throughout. Patients whose benzodiazepine was withdrawn abruptly
exhibited 'rebound' anxiety evidenced by increases of lOY. or more
above baseline total scores on both the Hamilton Rating Scale for
Anxiety (Hamilton 1959) and a Self Rating Symptom Scale (Guy 1976).
However there were no cases of rebound anxiety in patients whose
benzodiazepine was withdrawn gradually. In addition Fontaine et
al (1984) reported that fewer cases of rebound anxiety were seen
in patients who had received a long half-life benzodiazepine,
namely diazepam. The most common wi thdrawa I symptoms for both
gradua I and abrupt wi thdrawa I groups inc luded insomnia , gastric
problems, tremors, agitation, fearfulness, and muscle spasms.
Fontaine et al (1984) reported this study to illustrate rebound
anxiety and withdrawal symptoms after only four weeks
benzodiazepine treatment.
that negates such a claim.
However', there exists one major flaw
Thp.y noted that "immediately before
entering the wp.ek" placebo run-in period prior to double-blind
randomisation "20 patients had been treated continuously with
benzodiazepines (the majority with diazepam) for more than 1 year,
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17 for 3 months to 1 year, and 5 for less than 6 months; 6 were
untreated". It therefore appears wholly unwarranted to claim that
this study investigates rebound anx iety and withdrawa 1 symptoms
after "4 weeks of benzodiazepine treatment" given that 87.5'l.
patients had been receiving long-term drug therapy prior to study
inclusion. Fontaine et ~l (1984) assume that a one week placebo
run-in period in between long-term benzodiazepine consumption and
the start of the double-blind study was adequate. This approach
has been strongly criticised by Tyrer and Owen (1984) who note that
"A matter for concern in current drug trials is the
relative rarity of studies in which patients have been
on no drug treatment at the time of assessment. Most
patients are taking a benzodiazepine drug at this time
and it is often considered appropriate to have a washout
period of one week before starting a drug trial. This
., ;......
period is not adequate to allow for the resolution of
symptoms that are at least partly a consequence of
benzodiazepine withdrawa 1 (Petursson and Lader 1981;
Tyrer et al 1981; Tyrer et al 1983) and may be
preferentia 11y helped by a tria 1 benzodiazepine drug
because of cross tolerance between members of the
series". CTyrer and Owen 1984, p.78)
In addition it has been argued that the longer the course of
benzodiazepine treatment the greater the dependency and the more
marked the withdrawal symptoms (Marks 1983a). So Fontaine et aI's
~9
(1984) paper reportedly presenting withdraw?l results after 4 weeks
benzodiazepine treatment is in fact presenting withdrawal results
after a far longer period. It is unlikely that symptoms of
withdrawal would have been ameliorated in the one week placebo
run-in period given the reports that withdrawal effects may last
up to 6 - 12 months following the cessation of treatment CHiggitt
et al 1985) and that active metabolites of long-acting
benzodiazepine may persist in patients for as long as 200 hours
after benzodiazepine treatment is ended (Cohn 1983). In summary
Fontaine et aI's (1984) paper does not assess withdrawal after 4
weeks benzodiazepine treatment.
Murphy et al (1984) reported the results of forty patients
equally divided between four groups and receiving either diazepam
or buspirone in flexible dosage for a period of either 6 or 12
weeks, followed by placebo substitution up to a total study
duration period of 14 weeks. Patients were seen fortnightly for
the 14 weeks. At each assessment the investigators completed the
Comprehensive Psychopatholqgical Rating Scale (CPRS) (Asberg et al
1978) • Withdrawal of diazepam at 6 weeks from a mean daily dose
of 11.4 mg produced a significant increase in CPRS symptoms with
a subsequent fall over 4 weeks. A non-significant increase in CPRS
symptoms occurred on withdrawal after 12 weeks of diazepam
tre>atment, "although this was not as striking as the increase> after
withdrawal of diaze>pam afte>r 6 weeks". (There was no significant
increase in CPRS symptoms af ter wi thdrawa 1 from 6 or 12 we>eks
buspirone treatment). Murphy et al (1984) noted that it ~as
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difficult to he sure whether the CPRS increase in symptoms aftpr
stopping diazepam represented true withdrawal (indicative of
pharmacological dependence) or a return of pre-pxisting anxipty.
However they concluded that the symptoms exhibited after stopping
diazepam constituted true pharmacological dependence as they were
absent after abrupt withdrawal from buspirone - ..a finding that
contradicts the argument that such symptoms are a return to the
pre-drug state". Unfortunately this study has a number of
shortcomings. Firstly, there is no mention of patient diagnosis,
inclusion and exclusion criteria. Secondly, there is no
information concerning previous history of benzodiazepine treatment
or drug status in the period immediately prior to study inclusion.
Thirdly there is no actual assessment of withdrawal symptoms; the
increase in CPRS following abrupt termination of 6 weeks diazepam
treatment was regarded as synonymous with the experience of
,--,.,
withdrawal symptoms. Fourthly, there is no discussion as to why
there should be a significant increase of CPRS (indicative of
withdrawal symptoms) after 6 weeks diazepam treatment but not after
12 weeks diazepam treatment.
It therefore appears that these two controlled studies of
benzodiazepine withdrawal after administration of short - term
therapeutic doses are methodologically inadequate. Furthermore,
despite most anxiety disorders being treated in primary care
(Shepherd et 031 1966), and less than ten percent being referred to
psychiatrists in the United Kingdom (Goldberg and Huxley 1980),
studies of anxiolytic efficacy and subsequent withdrawal hitherto
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have been 1arge Iy based on skewed psyc h iatr ic ou tpa tien t groups
(Greenblatt and Shader 1974). These patients, are therefore an
atypical sample (Tyrer and Owen 1984).
The lack of adequately controlled studies investigating the
efficacy and subsequent withdrawal from short-term benzodiazepine
treatment, at the recommended dosage for GAD, in a primary care
setting, with patients who had not recently used or been dependent
on minor tranquillizers, suggested the need for research in this
neglected area.
3.7 Functional I Organic Impairment
In addition to increased concern about the volume of
prescribed benzodiazepines (Tyrer 1980) and associa~ed dependency
and withdrawal phenomena (Schopf 1983), there has been a growing
number of reports indicating that benzodiazepine treatment may be
associated with impairment of cognitive and psychomotor functioning
(Kleinknecht and Donaldson 1975; Hendler et al 1980; Hindmarch
1980; Johnson and Chernik 1982; Ghoneim et al 1984), including
driving performance (De Gier and Nelemans 1981; Moskowitz and
Smiley 1982), traffic accidents (8111et al 1974), and amnesia
(Dundee and Pandit 1972; Wolkowitz et al 1987). Furthermore
enlargement of cerebrospinal fluid spaces in low-dose (Lader et 031
1984) and high-doSF? (Schmauss and Kreig 1987) long-term
benzodiazepine USF?rs has been reported. Specific problems of
ben~odiazepine anxiolytics in relation to the elderly have also
been noted, for example, increased risks of falling (Linnola and
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Ellinwood 1982). Disadvantages are also associated with the long-
term use of benzndiazepine hypnotics in the elderly, such as
confusional states (Evans and Jarvis 1972), increased daytime
anxiety (Morgan and Oswald 1982), rebound insomnia (Oswald et al
1979), impaired daytime psychomotor performance (Morgan 19A5),Rnd
dependence (Higgit et al 1985). The type of ben;!odia;!epine
hypnotic influences the manifestation of side effects. Long-acting
drugs are more likely to accumulate and disrupt daytime activities
(Morgan 1985), while very short-acting drugs produce an earlier and
more severe rebound on withdrawal (Adam et al 1984).
With regard to cognitivE' and psychomotor impairment
associated with bE'nzodiazepine anxiolytics, research has usually
been conducted on patients who have recently been prescribed
benzodiazepines or on normal subjects after single doses (Linnoila
and Ellinwood 1982). However Golombok et al (1988) report that high-
dose, long-term benzodiazepine USE'rs perform poorly on tasks
involving visual-spatial ability and sustained attention and this
is consistent with deficits in posterior cortical cognitive
function. Unfortunately there are few studies investigating
cognitive and psychomotor performance during withdrawal from 10ng-
term benzodiazepine treatment (Lader and Petursson 1983) •
Petursson et al ( 1983) attempted
following
to assess psychological
benzodiazepine
They reported
functioning in patients long-term
treatmE'nt and thE'n during subsequent withdrawal.
long-term benzodiazepine use as having a differential impact on
Psychological performance, namely that cognitive skills such as
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attention, vigilance, and pure motor speed were not adversely
affected whereas tasks requiring combined use of sensory and fine
motor skills may be permanently impaired. Unfortunately Petursson
et aI's (1983) results are difficult to interpret due to the
con found ing impac t of prac tice ef +ec:ts and he iQhtened anKi ety
levels on test performance. Conversely Sakol and Power (1988)
using recently-developed computerised tests, which are less prone
to practice effects, suggest that cognitive skills such as
attention, vigilance and speed of information processing are
adversely affected by prolonged use of benzodiazepine anxiolytics,
whereas motor skills such as motor speed are not. Additionally,
during graded wi thdrawa I from long-term benzodiazepine use when
anxiety levels remain constant, Sakol and Power (1988) report
encouraging improvements in cognitive performance. In summary it
appears that long-term benzodiazepine users are at risk of
functional and possibly organic impairment, although replication
of the relatively small number of studies in this area is required,
and more attention should be directed towards investigating whether
possible impairments are reversible or permanent.
3.8 Characteristics of Long-Term Benzodiazepine Users in General
Practice.
The available data regarding extent of benzodiazepine use in
general and in specific age and sex groups cited earlier (3.3, 3.5)
fail to provide detailed information on the prevalence of long-term
Use in the community, and the characteristics of long-term users.
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Sincp thp mid-1970s thpre h~s
of benzodiazepines in most of
the exception
factor in this
hppn ~ decre~se in thp prpscribing
Western Europe and the USA (Marks
Italy (Williams et a1 1986). The1983a) ,
prime
being
decrease is most likely to h.-1ve been
reduction in new prescribing (ie. a decreasing rate Qf incid~nt
ben20diazepine use) rather than the wholesale discontinuation of
treatment by long-term consumers (Williams 1987). This suggests
that there is a cohort of long-term benzodiazepine users, created
during the "hayday" of benzodiazepine popularity in the mid 1970s,
from which members will slowly be lost (a small proportion will
discontinue treatment, others will die), and to which few new
members will be recruited, since a reduction in new prescribing
will inevitably lead to fewer people becoming long-term users
(Williams 1987).
Given the problems of possible dependency, withdrawal, and
functional and organic impairment it would seem important that the
characteristics of long-term benzodiazepine users be identified in
order that appropriate clinical management strategies be designed
and implemented. User characteristics may be considered as
predisposing to long-term use; alternatively they may be regarded
as characteristics which mitigate against discontinuation of
treatment, or a combination of both aspects.
A number of studies have investigated various features of
"Psychotropic" drug users. Woodcock (1970) carried out a
retrospective analysis of the medical records of 20 general
practitioners, and indicated that in 1967 2.81. of patients had been
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....eceiving a daily dosage of a psyc:hot....oo i c d ....LJg fa ....at least one
yea .....Fou ....-fifths of these long-te ....m consume ....s we....e aged 40 0....
ave.....and th ....ee qua ....te....s we ....e women. Pa....ish (1971) in a
....et ....ospective case note su ....vey of the wo ....k of 48 Birmingham general
practitioners, with a total list size of 13,2~9 Pdtientq~ repnrteQ
that 12.6% of the population had been prescribed p~yr.hQtrQpir. druQq
du ....ing a one year prevalence period; representing 17.1% of females
and 8% of males. Approximately 1.9 per cent of the population were
p....escribed a psychotropic continuously for a period of one year or
more. Eighty-three per cent of patients on prolonged therapy were
over the age of 40 years, and 54% of them.we ....e women over the age
of 45 years. Skegg et al (1977) repo ....ted the one yea ....p ...evalence
of psychotropic prescribing by 19 gene ....a I practi tioners to a
population of 36,280. During the year 9.7% of males and 21.0% of
females received at least one psychotropic drug. In every age
......
group a higher proportion of females than males received
psychotropic drugs. There was a sharp increase with age in the
proportion of patients receiving psychotropics. Among women it was
notably high in the 'middle aged' (33.0%) but the highest
proportion was found at 75 years or older (37.7%). Cooperstock
(1976;1978) analysed data based on the computerised reco ....ds of a
prescription insurance agency in southern Ontario. and reported
consistently higher proportions of female psychotropic use ....s than
male users (18% of males received one or mo ....e prescriptions for a
psychot ....opic drug in 1970-71, compa ....ed with almost 31% of females
in that year. while in 1973-74 the propo ....tions were 14.5% and
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almost 241. respectively). In addition, more females than males in
each period received multiple prescriptions. Mellinger et al (1978)
reported results from a cross-sectional nationwide survey of 2,552
adults in the USA. 'Regular' psychotropic drug users (defined as
anyone who had used psychotropic drugs during the past Year, and
who also at some time had used the same drug daily or almost daily
for two months or longer) were compared with those who had used
psychotropic drugs anytime in the year prior to interview. 80th
measures of psychotherapeutic drug use were "clearly and strongly
related to level of psychic distress" as assessed by a shortened
version of the Hopkins Symptom Checklist (HSCL) (Oerogatis et al
1974) • Mellinger et al (1978) concluded that their findings
suggested an "i llness behaviour model" for the use of psychotropics
in outpatient practice, lending little support to a "self-indulgent
consumer" interpretation.
Murray et a I (1981) from a survey designed pr imar i 1y to
investigate the effects of aircraft noise on health in West London
in 1977, reported the 2 week prevalence of drug consumption in a
sampl e of 5,904 peopl eli v ing wi thin an area close to Hea throw
Airport, as 10.91.. For every age group the rate of psychotropic
drug consumption was twice,as high in wome~ as in men. For both
sexes the proportion of drug users increased with "worsening self-
assessment of health". The relationship between General Health
Questionnaire (GHQ) 30 - i tE'm (Goldberg 1972) score, drug
consumption, and sex (ignoring the effect of age) was analysed.
They reported that "171. of the male high GHQ scores and 271. of the
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female high scorers consumed psychotropic drugs. In contrast to
these figures, only 5% of the male and 10% of the female low GHQ
Scores consumed these drugs". Murray (1981) conducted a postal
survey of 261 (presumably female) "Womans Own" magazine readers,
183 of whom were classified as "present" psychotropic users and 78
as "past" psychotropic users. Murray (1981) reported a high
prevalence of self-reported psychiatric symptoms among both present
users (83%) and past users (55%), as measured by the 30-Item
Symptom Rating Test (Kellner and Sheffield 1973). Widespread
physical impairment as measured by a modified verison of the Belloc
Physical status Inventory (Belloc et al 1971) was also noted.
Williams et a] (1982> reported a longitudinal study of 153
(95 females; 58 males> general practice patients beginning a new
course of psychotropic drug treatment. The group of patients was
characterised by high physical morbidity at time of prescribing.
Twenty-three (40%) of the males and 34 (36%) of the females had a
physical illness diagnosed by the GPs. Depression was cited as the
most common psychological complaint of females, whereas it was
sleep disturbance in males. For the majority of patients
Psychotropic drug treatment was short-term. Approximately 20% were
still receiving psychotropic drugs six months later, and this
prolonged treatment was associated with increased age, previous
psychotropic drug use, higher levels of psychological morbidity at
the inception of treatment, and for the women only, with social
problems as perceived by the GPs. The presence of physical illness
was not related to the duration of psychotropic treatment
4A
(Willi;tms 1983).
More recently Catalan et al (1988) identified the 3.61.
(males = 83; females = 235; total n = 318) of patients on long-term
Psychotropic drugs (as defined by receiving at least one
psychotropic prescription in each quarter of a 12-month period) in
one general practice. Of the 318 patients 511. were aged 60 or over,
as against 121. of the practice population. None of the long-term
user population was aged under 30 as against 511. of the practice
population. A subsample of 70 index patients was randomly selected
from the 318 patients and matched for age and sex with a control
group. All index and control patients were interviewd. Index
patients had higher levels of psychiatric morbidity as shown by the
Present State Examination (PSE) (Wing et al 1974), history of
specialist psychiatric treatment, and previous drug overdoses.
Apart from a higher rate of referral to general hospital outpatient
clinics in the preceding 12 months "there was little evidence that
index patients had more problems with physical health than
controls".
Although the above studies provide some interesting
information a number of
relevance with regard
methodological features limit their
to characteristics of long-term
benzodiazepine users. Firstly, all of the aforementioned studies
have investigatE'd "psyc:hotropi.c drug" use in a heterogE'neous group
of antidepressants, major and minor tranquillizers, and hypnotics.
Secondly, somE' of the studies also include stimulants and appetite
Suppressants within the "psychotropic" category (Parish 1971; Skegg
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Pt al 1977). Thirdly, the earlier studies were conducted when thp
barbiturates constituted the predominant anxiolytic drug (Woodcock
1970; Parish 1971). Fourthly, the composition of the index group
was often skewed (Murray 1981), and a lack of matched age and sex
controls predominated, with one exception (Catalan et al 1988).
Finally, none of the above studies investigated the characteristics
of benzodiazepine users in particular.
Two papers by Me 11inger et a I (1984; 1984a) have reported
characteristics associated with anxiolytic users (predominantly,
but not exclusively of benzodiazepines). Three papers, by Gabe and
Lipshitz-Phillips (1982), Salinsky and Dore (1987), and Rodrigo et
al (1988) have investigated the features of benzodiazepine
anxiolytic users alone, while Morgan et al (1988) have investigated
characteristics of elderly hypnotic (mainly benzodiazepine) users.
Mellinger et al (1984; 1984a) presented results of a cross
sectional 1979 survey of 3161 adults in the USA. Eleven percent
en = 387) of the total sample reported using a medically prescribed
anxiolytic one or more times in the 12 months prior to the survey.
Benzodiazepines accounted for 84Y. of the anxiolytics mentioned.
Long-term use (defined as regular daily use for a year or longer)
was relatively rare (n = 68) occurring among 15Y.of all anxiolytic
users. The most common pattern of use was occasional use, never
more than a day or two at a time. More than 81% of the occasional
users reported using the medication on fewer than 30 days during
the entire year. For 80Y. of the anxiolytic users, the longest
daily use was less than 4 months. Comparing 68 long-term regular
users > 12 months regular use), 319 other users
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( 12 months
use) and 2,774 non-users, Mellinger et al (1984; 1984a) concluded
that long-term regular users tended to be older, with high levels
of emotional distress, chronic somatic health problems, reported
more visits to a physician, and were preponderantly female.
Unfortunately the control group was not matched for age and sew.
Mellinger et al (1984) only noted that "controlling for age reduced
the magn itude of differences in number of hea Ith prob Iems", and
although no actual results were presented they state that the
"differences remained strong". It is difficult to determine the
significance of the reported differences between the three
unmatched groups as how much variance the age factor may have
accounted for is unknown. In addition it should be remembered that
16% of the anxiolytic group were in fact consuming non-
benzodiazepine anxiolytics. Furthermore it is not known whether
these American findings would apply to patients on benzodiazepines
in general practice in Britain.
Gabe and Lipshitz-Phillips (1982) assessed the demographic
features of 7 "high benzodiazepine users" (who had received at
least 10 prescriptions, in at least 5 of the previous 10 years>,
10 "intermittent benzodiazepine users" (who had prescriptions over
less than 5 years and on fewer occasions),and "non-users" who had
not been prescribed a benzodiazepine throughout the previous
dE'cade. All subjects were white, working-class females from an
east- end of London genera I prac tice. The only sociodemographic
factor that distinguished the groups was age. The "high" and "non-
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users" wpre younger than the "intermittent" IJsprs. Although this
study attempted primarily to assess "the meaning of benzodiazepine
use for women patients from one general practice", it is difficult
to attribute any significance to the results given the p.~ceedingly
sma 11 sample size, skewed composition, and generally ponr
methodology.
Salinsky and Dore (1987) from a total of approximately 6,000
patients in a north-west London general practice identified 96
long-term ( > 1 year) daytime benzodiazepine users of whom 79 (82%)
were aged over 45 years, and 66 (69%) over 55 years; 78 (81%) w&re
female. Seventy-two (75%) of the long-term benzodiazepine users
responded to a postal questionnaire assessing demographic features,
attitudes towards, and use of tranquillizers, and assessing
psychiatric morbidity by means of the Crown-Crisp Index (1979).
For each benzodiazepine patient two controls matched for age and
..~.,..
sex were selected from the practice register. Controls completed
the same postal questionnaires with the exception of the
benzodiazepine-related questions. Salinsky and Dore (1987)
concluded that long-term benzodiazepine users had significantly
higher scores for anxiety and other neurotic traits, but their
personal histories showed few significant differences from those
of controls. However, detailed examination of the paper indicates
that a significantly larger proportion of the benzodiazepine users
reported "suffering from chronic physical illness" in comp.:lrison
to controls. Unfortunately this was not verified by .:Inyformal
diagnostic procedure, or by case-note inspection, or analysed in
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any further detail. While this is the only rurrently available
report investigating long-term benzodiazepine users that has
incorporated a matched age and sex rontrol group, it nevertheless
has a number of shortcomings. Firstly, patients were rerruited
from a single general practice. It is therefore difficult to
generalise as the prescribing pattern of the GPs, and the
sociodemographic characteristics of the patient population may not
reflect the national pattern. Secondly, the sample size of the
benzodiazepine group was relatively small. Thirdly, although
Salinsky and Dore (1987) stated that they included only daytime
long-term benzodiazepine users it appears that 42% of the
benzodiazepine group were taking "sleeping tablets" as were 14% of
the control group.
Rodrigo et al (1988> identified 82 long-term > 1 year)
benzodiazepine users from the 1985 age sex register of one south
London general practice. These patients comprised 2.2% of the
practice population. Sixty-four benzodiazepine users agreed to
take part, and were interviewed at home using three ·schedules'.
Firstly, patients were asked questions about their past and present
Use of medicines using a schedule modified by Murray (1981).
Second 1y, the CU.n ica 1 Interview Schedu Ie (CIS) (Gol dberg et a I
1970) was administered to identify and quantify psychological ill-
health as well as information about self-reporte>d physical ill-
health. Thirdly, each patient was asked to complete the Kellne>r
and She>ffie>ld (1973) Symptom Rating Test (SRT) to measure>
psychological symptoms during the preceding week. Of the 64
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patients interviewed 16 were male and 48 female, only 5 were under
40 years of age and 26 were 70 years or over. The median duration
of trea tmen t wi th ben zod iazepines was 5 years, (range - 25
years). Altogether nine different ben7.odiazepines were being
prescribed, the most common being temazepam (25 patients),
diazepam (14), nitrazepam (12), and lorazepam (11). Fifty-four
patients completed the SRT. The proportion of patients scoring >12
on the SRT was substantially lower than that found by Murray (1981)
in her self-selected sample of long-term psychotropic users, and
that obtained by Wi 11iams et al (1982) in their study of new
recipients of psychotropics in general practice. Thirty-four per
cent of the patients en = 22) were classified as CIS cases.
Nineteen of these twenty-two cases were allotted an ICD diagnosis
relating to depression, but only one patient was allotted an
anxiety-related diagnosis. Just over half of the males and just
Over a third of the females reported a current physical illness.
Gastrointestinal, musculoskeletal, and cardiovascular disorders
were predominant.
While this is the most detailed published paper concerning
characteristics of long-term benzodiazepine users, a number of
methodological shortcomings exist. Rodrigo et al (1988) themselves
note .that the resul ts are derived from one general practice "so
the findings may not be generalisable to other settings".
Secondly, they also note that "much of the information is based on
recall and self report" although they did attempt. to gain
information on physical ill-health from GP records. Thirdly, t.hey
!'l4
appeared to group together bp.n~odia7p.pinp. hypnotic and anxiolytic
users. While this is acceptable in that the delineation between
an anxiolytic and hypnotic is not absolute in pharmacological terms
(Committee on the Review of Medicines 1980) or, with regard to how
the drug is administered, it would nevertheless have been u6eful
to note whether there existed any difference between the hypnotic
and anxiolytic benzodiazepine groups. Fourthly, their sample size
was relatively small. Fifthly and most importantly, they failed
to include a control group matched for age and sex. This is
especially important when the benzodiazepine group under study is
predominantly elderly and an asssessment of the incidence of
physical ill-health is being undertaken.
A number of studies representing a variety of methodologies
and designs have attempted to identify characteristics of sedative-
hypnotic users. Morgan (1983) in his review concluded that rates
of sedative-hypnotic prescribing and / or usage tended to increase
with the minimum age of the sample studied. Use of sleeping drugs
is generally reported to be higher among elderly females than among
elderly males (sex differences being less clearly defined among the
young and middle aged). Benzodiazepine hypnotics, particularly
nitrazepam and flurazepam appear to be common in all age groups,
although a growing trend for the use of triazolam and temazepam
(Morgan et 031 1982) may hav~ developed. More recently Morgan et
031 (1988) have reiterated their estimate that approximately 10 -
15% of the UK elderly population take a hypnotic each night over
prolonged periods, often over five years. However the Committee
on the Review of Medicines (1980) st.-1tpdthat "most hypnotics tend
to lose their sleep promoting properties within 3 to 14 days of
c:ontinuous use", and should only be prescribed "for short periods
of time and only after c:areful c:onsideration", especially in the
elderly.
Unfortunately a number of methodologic:al inadequacies exist
with regard to studies investigating hypnotic:-sedative drug use.
Firstly, virtually all studies encompass a variety of drugs under
the sedative-hypnotic label, for example the amalgamation of
antidepressants, barbi.turates, and benzodiazepines in Morgan et
aI's (1988) most recent article. Secondly, much of the information
is derived from hospital-based surveys, and may therefore not be
representative of the bulk of prescriptions whic:h emanate from
general practice (Saltzman and Van der Kolk 1980; Christopher et
al 1978). Thirdly, the relationship between physical health status
.~.,..
and hypnotic drug use has not been thoroughly investigated (Morgan
1983), and therefore differences between the sexes in sedat;.ve-
hYpnotic use in the elderly may reflect differences in health
status.
Cooperstock and Parnell (1982) reviewing methodologies and
findings in psyc:hotropic drug usage studies, conclude "distinctions
Should be made between drug types within large classes of drugs".
Unfortunately this has not been adhered to in the vast amount of
research to date and therefore littlE> is known of the
Characteristic.s of long-term benzodiazepine anxiolytic and hypnotic
users in comparison to matched age and sex controls.
3.9 Summary
The present chapter discussed the introduction of
ben7odiazepines. In addition the extent of lIsage, characteristics
of long - term· users, proh 1ems of long - term use, dependency and
associated withdrawal reactions were also highlighted.
From the review three specific areas requiring further
research are discernable.
Firstly, the paucity of well-controlled studies concerning the
relative efficacy and subsequent withdrawal of short - term
benzodiazepine treatment, at the recommended dosage, for
generalised anxiety, in a primary care setting, wi th patients
who have not recently used or been dependent on minor
tranquillizers merits further investigation.
Secondly, the lack of information concerning the characteristics
of long-term benzodiazepine users, from more than one general
practice, in comparison to matched age and sex controls, with
specific regard to differences between benzodiazepine hypnotic
Users, anxiolytic users, and hypnotic plus anxiolytic users
requires attention.
Thirdly, there is a lack of information concerning patients'
attitudes to benzodiazepi.ne use and withdrawal among long-term
benzodiazepine users.
These three issues are addressed in the studies conducted by
the present author, which are presented in the following chapters.
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CHAPTER 4 : ANXIOLYTIC AND PSYCHOLOGICAL TREATMENTS OF ANXIETY
STATES AND GENERALISED ANXIETY DISORDER.
4.1 Anxiolytic Treatment of Anxiety States and Generalised Anxiety
Disorder - Controlled Comparisons
Several reviews have surveyed clinical trials of
benzodiazepines and most concur in confirming the effectiveness of
this c I ass of compounds as anx io 1yt ics <Greenblatt and Shader
1987; Rickels et al 1978; Rosenbaum 1982). In one of the most
often quoted early reviews of benzodiazepines as treatments for a
wide range of anxiety disorders, Greenblatt and Shader (1978) noted
"most clinicians and investigators seem to agree that
benzodiazepine derivatives are more consistently effective than
placebo in well controlled, short term trials of anxiolytic drug
therapy" • Of 25 such trials reviewed, 18 showed strong
benzodiazepine placebo differences, 4 a trend, and 3 no
difference. However dissentient voices have been raised. Solomon
and Hart (1978) in their more comprehensive review of 78 double-
blind studies comparing benzodiazepines and placebo in a wide
variety of often unspecified anxiety disorders concluded that all
studies were "so poorly designed and executed as to be meaningless,
the efficacy of the entire group of drugs as antianxiety agents
must be questioned". Klein et al (1983) have conducted one of the
most recent comprehensive reviews of the pharmacological treatments
of specific anxiety disorders. They separately reviewed
Pharmacological treatment for ..obsessional-compulsive disorders,
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agoraphobia with or without panic, simple anrl social phobias, anrl
generalised anxiety disorder. Included in Klein et aI's (1983)
review of the pharmacological treatment of GAD are studies in which
patients were classified simply as "anxiety neurosis" or "chronic
anxiety disorders". They apparently assumed that the use Qf su~h
categories is synonymous with the DSM-III GAD classification.
While this may be true in some cases one cannot presume with any
certainty that the diagnostic characteristics of GAD are equivalent
to the more loose inclusion criteria of "anxiety states" used in
many studies.
Klein et al (1983) cited 32 studies, some of which had
placebo groups, in which the efficacy of at least two active drugs
was compared. In none of these studies was the diagnostic
characteristic of the sample described in detail. The presence or
primacy of additional symptoms was not noted in most studies,
although some studies reported concom,ttant depression. "These 32
studies were organised into three groups based on drug class : 6
involved comparisons of two different types of anxiolytics; 18
Compared anxiolytics and neurolepticsj and 8 compared anxiolytics
and antidepressants. On the basis of their review Klein et al
(1983) stated that as regards treatment outcome "remarkably few
Positive conclusions can be drawn". In addition they also noted
that "no single drug class emerges as consistently superior to any
other" in the -treatmen t of anx iety sta tt,s. However since the
present study is primarily concerned with the efficacy of
benzodiazepine anxiolytics, studies involving the comparison of
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two or more anxiolytics in the treatment of anxiety states will be
presented in more detail' \. In addition Klein et aI's (1983) review
requires updating. The results of 13 papers comparing anxiolytic
medicati.on in the treatment of patients suffering from various
"anxiety states", "anxiety neurosis", or "anxiety disorder" are
presented in Table 4.1. Of the 13 papers, 6 were previously
reviewed by Klein et al (1983). Overall most of the trials show
a statistically significant superiority of benzodiazepine in
comparison to placebo with no pronounced difference between
anxiolytics in terms of who responds or the degree of improvement.
Klein et a1 (1983) iden tified on 1y 4 comparative publ ished
clinical trials in which patients were specifically selected to
fulfil DSM-III criteria for GAD, namely; Rickels (1981b), Feigher
et e l (1982), Goldberg and Finnerty (1982) and Rickels et al
(1982) • There has since been a further 7 recent comparative
studies in which GAD patients alone comprised the subject
population, namely; Lapierre et al (1982), Fontaine et al (1983),
Ansseau et al (1985), Elie and Lamontagne (1984), Ceulemans et al
(1985), Buchsbaum et al (1985) and Jacobson et al (1985).
Furthermore there are an additional 3 comparative studies in
which formally diagnosed GAD patients have comprised part of the
patient population (Chouinard et al 1982; Tyrer and Owen 1984;
Dunner et al 1986). However, it is difficult to assess the impact
'Although there are a number of earlier, less well controlled
papers comparing the efficacy of a single anxiolytic with placebo,
these will not be reviewed far the sake of brevity: see Greenblatt
and Shader (1978); Solomon and Hart (1978) for reviews.
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of anxiolytic trpatment on GAD in these 3 studies due to t.hp
amalgamation of the various diagnostic groupings during analysis.
All the above studies are presented in Table 4.2.
Solomon and Hart's (1978) previously noted scathing attack on
the inadequacies in the design and implementation of benzodiazepine
anxiolytic research hopefully would have prompted improvements in
study methodology. Unfortunately however each of the 6 studies
concerning anxiolytic treatment of GAD patients alone listed in
Table 4.2 has major shortcomings.
Firstly, no study provides any
only one study (Rickels et al 1982)
follow-up data. Secondly,
assesses patients one week
after withdrawal from study medication; the remainder of the
studies provide no withdrawal data. Thirdly, information
Concerning patients' drug status prior to study inclusion is absent
in all but 6 studies, namely Fontaine et al (1983), Ansseau et al
(1985), Elie and Lamontagne (1984); Ceulemans et al (1985),
Buchsbaum et al (1985) and Jacobson et al (1985).
Jacobson et al (1985) stated that patients were excluded "if
they were receiving any other psychotropic drugs", and Buchsbaum
et e l (1985) note that "all patients were off psychoactive
medication for a period of 3 weeks prior to the study". Ceulemans
et a I (1985) stated that "six patients were being treated at the
start of the trial (mainly with benzodiazepines)" but "that
previous medication was stopped at the start of the trial" and "no
wash-out period was observed".
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Table 4.1 : Reports comparing at least 2 benzodiazepine anxiolytics
in the treatment of anxiety neurosis I anxiety states
.Rick!!ls et al
1974
lad!!r !!t al 1974
Sonn!! and Hoi_
1975
Fabr!! and I!clendon
1979
'Aden and Thein
1980
.Ma letsky 1980
Cohn 1981
'Allin 1981
.Wheatley 1982
.6oldberg and
Fiooprty 1982
Diagnosis; N
anxious, nE'Urotic
outpat ients,
N = 154
free-floa t ing
anxiety
outpatients,
N = 30
anxiety nE'Urosis
outpatients
N = 30
lOderate to severe
psychoneurotic
anxious
outpatients
N = 144
_oderately or
severely anxiM
outpatients
N = 235
lOderate to severe
anxiety,
N = lib
IOdera te to severe
anxiety,
N = 845
neurotic, anxious
general practice
patients,
N = 44
anxious
outpatients
N = 131
lOderate anxiety
N = 129
Drug [ond i t ioos
chlorll'zanonp.
chlordiazppoxide
placebo
lOdazepal
diazepa_
chlordiazppoxide
a.ylobarbi tone
sodiUl
placebo
diazepal
brOlazepa.
diazepal
alprazola.
placebo
diazppal
alprazolal
placebo
diazl!pal
alprazola.
placebo
diazepal
alprazolal
placpbo
diazepal
ch Iorll'zanone
diazl!pal
buspirone
placebo
buspirone
chlorazepate
Treahent
Duration
b lll'eks
2 - 4 Weeks
4 lll!eks
4 lll!eks
4 III!I!ks
4 III!I!ks
3 III!I!ks
4 IlePks
£kItcOll! : Evaluation Re :
Differential Drug Effects
both drugs> placebo
chlorll'zanone =
chlordiazppoxide
all benzodiazepines >
placebo, alyl. sod.
brOlazepa. > diazepal
both drugs ) placebo
alprazolal = diazepal
both drugs > placebo
alprazolcll = diazl!pal
alprazolal > diazepal
diazepa. = placebo
alprazolal ) diazl!pal
both drugs ) placebo
alprazolal = diazepal
equal efficacy
both drugs) placebo
buspirone = diazppal
!!QuaI efficacy
1,7
Hable 4.1 cootdl
Jacobson et al a n x i 0 u s diazepam 4 Nl'l'ks both drugc; ) plarebo
1983 outpatil'l1ts, c10bazam diazppall = clobazam
N = 144 placebo
John et .11 1983 anxiety nairotir diilZPpall 6 Nl'l'ks di.1zppam = clobaz.1'
outpatil'l1ts, c10bazal
N = 60
Doongaji Pt al anxipty nl'Urosis di.1zppall 6 Nl'l'ks diazppal = clobaz.1ll
1985 outpatil'l1ts, clobazal
N = as
= Rl'ViMd by Klpin et .11 11983)
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Table 4.2 : Repo~ts compa~ing the efficacy of anxiolytics in the
t~eatment of fo~mally diagnosed BAD.
Diagn()<jisj
Cri teriaj N
Drug Condit ions Treat.ent
Duration
OutCOle : Evidence Re :
Differential Drug Effects
.Rickels 1981b SAD; 1l51'1-111;
N = Ib4
alprazolaa
diazepa.
placebo
4 !leeks both drugs } placebo
alprazola. = diazepaa
'Feighner et al
1982
SAD; 051'1-1II ;
N = 100
buspirone
diazepaa
4 lEeks buspirone = diazepa.
.Goldberg and SADi IlSlI-l I i buspirone 4 !leeks both drugs) placebo
Finnerty 1982 N = 54 diazepal buspirone = diazepaa
placebo
.Rickels et al SAD; DSII-lIJ; buspirone • !leeks both drugs ) placebo
1982 N = 240 diazepaa buspirone : diazepal
placebo
Lapierre et al SAD; IlSK-IIl j dobazal 4 !leeks C lobazal : diazepa.
1982 N : 40 placebo
Fontaine et al SAD; 1lSK-1Il; brOlclzepaa • !leeks both drugs ) placebo
19BJ N = 48 diazepaa brOlclZepai ) diazepal
placebo
frtsseau et al 1985 GAD;ROC; Il'thylc lonazepal 8 - 18 days both drugs ) placebo
N = 18 lorazepaa lethylclonazepal ) diazepaa
placebo
Elie and SAD; 1lSK-1Il; alprazolaa • !leeks diazepaa ) alprazolal
LUIOntagne 1984 N = 4B diazepal
r.euIt'IaIIS et al SAD; IlSK-lIJ; ritan'>l!rin 2 !leeks both druqs ) placebo
1985 N = 13 lorazepa. ritanserin = lorazepa.
placebo
8uchsbau. et al GAD;DSII-lIJ; clorazepate 2 Neeks clorazepate > placebo
1985 N = 20 placebo
(-,4
(Table 4.2 [mtdl
Jacobsm et .I I
1985
flAD j D5I1-1I1 j
N = 39
buspirmp
diillPpiltII
placebo
both drug .. > placebo
buspirone = rlidlepaa
Chouinard et .II BADi POi ROC; alprazola. 8 Wl'l'ks alpralolaa ) placebo
1982 N = SO placebo
Tyn>r and ~ 6 AD; P D i buspirone 3 Wl'l'ks buspirone = diazepaa =
1984 Agoraphobia + PDi diazepaa placebo
DSH-Ill i N = 3b placebo
Dunner et a 1 198b SAD; P D i alprazolal 10 weeks both drugs> placebo
Agoraphobia + PD; diazepal diazl'paa = alprazolaa
DSII-1II i N = 48 placebo
• = RevieNed by Klein et al 119831
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Elie et al (1984) reported that of 48 p~tients, 24 were being
treated with oxazepam, and thirteen with lorazepam before entering
a one week single-blind washout period. However Fontaine et al
(1983) stated that "immediately before entering the study 20
pa tients had been trea ted wi th ben zod iazepinf-'s for morf-' than 1
year; 17 for 3 months to 1 year; and 5 for less than 3 mcn t ha"
prior to one week placebo washout, and thereafter random allocation
to bromazepam, diazepam, or placebo. Ansseau et al (1985) stated
that· patients were inc luded "wi th a minimum 1 year history of
regular daily intake of high doses of tranquillizers" with no wash-
out period prior to random allocation to anxiolytics or placebo.
As previously noted, Tyrer and Owen (1984) stated that rapid
withdrawal from long-term benzodiazepine treatment followed by a
one week placebo period is methodologically inadequate and does not
allow for the resolution of symptoms that are at least partly a
consequence of benzodiazepine withdrawal. Additionally withdrawal
may be preferentially helped by a trial benzodiazepine drug because
of cross tolerance between benzodiazepine derivatives. Thus lack
of placebo efficacy in some of the above studies may be partly
attributable to patients experiencing benzodiazepine withdrawal
symptoms during the study period. One may only speculate as to
whether the other 4 studies which failed to report details of drug
status prior to study inclusion are subject to such criticism.
Fourthly, although studies may produce statistically significant
drug vs. placebo differences and/or reductions in anxiety rating
prior to and following benzodiazepine treatment, this .does not
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necessarily imply significant clinical improvement. Virtually all
clinical trials, including those listed in Table 4.2, use the
Hamilton Anxiety Scale (HAM-A)(Hamilton 1959) as the main outcome
measure. The HAM-A observer rating scale is so well established
that it is employed routinely in anxiolytic studies in the USA and
UK. Reductions from an initial score of between 25 to 30 at the
beginning of a study to an end point of between 15 to 20 wi 11
generally produce statistically significant results. Lader (1985)
in his review of double-blind placebo controlled studies published
between 1977 and 1982 that used the HAM-A, stated that such
reductions are the norm for those on benzodiazepine treatments
(while placebo treatments tend to produce lesser reductions, with
end-points between 20 to 25). In addition Lader (1985) stated that
these benzodiazepine reductions on the HAM-A do not lead us to
conclude that patients are "cured", as they are still experiencing
clinically significant symptomatology. Furthermore Lader (1985)
noted that benzodiazepines "seem less effective compared with
placebo when self-ratings are used than when a trained observer
rates the patient". The studies listed in Table 4.2 fit such a
pattern. In particular patients' and referring physicians' ratings
of degree of cl inica I improvement are sometimes not inc Iuded
,
(Ansseau et al 1985; Lapierre et al 1982); or patients rating of
clinical improvement is restricted to oversimplified choices, e.g.
improved v , unimproved (Rickels et al 1982); or patients and
,
physicians ratings of clinical improvement contradict the
statistically significant results achieved on the HAM-A (Feighner
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et a 1 1982) . Feighner et al (1982) achieved statistically
significant reductions on the HAM-A following anxiolytic treatment,
but 57 - 601. of patients rated themselves as experiencing "no
change or worse" as did 57 - 621. of the respective referring
physicians.
In summary, despite the methodological limitations of the
above studies, it is sti 11 widely accepted that "for GAD the
benzodiazepines are the drugs of first choice" (Woods and Charney
1988) , although there is no persuasive evidence that any
benzodiazepine is more effective than any other (Greenblatt and
Shader 1974; Klein et al 1980; Mavissakalion 1982; Rosenbaum 1982;,
Ballenger 1984).
Unfortunately it appears that Solomon and Hart's (1978)
request for improved study methodology has not been wholly
successful and there remains a need for properly controlled
clinical trials of anxiolytics with particular regard to drug free
status at time of stuc:tyinclusion, continued assessment during
withdrawal, long-term follow-up, and the use of a wider range of
assessment measures including patients'and referring physicians'
assessment of degree of clinical improvement/unimprovement.
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4.2 Psychological Treatment of Anxiety States and Generalised
Anxiety Disorder - Controlled Comparisons.
At present there is no adequate review of the psychological
treatments of anxiety states and generalised anxiety disorder. So
studies investigating the efficacy of psychological approaches with
this clinical population will be presented in some detail. A
summary of the relevant literature is displayed in Table 4.3.
Raskin et al (1973) reported the results of 10 "chronically
anxious" ex-inpatients whose treatment comprised 25 minutes of
daily hospital-based frontalis muscle EMG biofeedback for a period
of 8 weeks. Anxiety was assessed using a 65-item mood checklist
filled out by the patient (Raskin et al 1972),and therapists rated
patients' "appearance and complaints". Outcome resul ts were given
as ; 6 patients improved, 3 moderately improved, and 1 markedl~
improved. Unfortunately a number of confounding variables exist.
Firstly, the 8 week "treatment period" was preceded by an EMG
training phase ranging from 2 weeks to 3 months. Secondly, 5 of
the 10 patients were on "moderate doses of chlordiapazide
hydrochloride (40 - 80 mg per day)" throughout the study. No
follow-up data were presented and no control or comparison group
was included.
Canter et al (1975) reported the results of a group of 28
in/outpatients suffering from anxiety neurosis, half of whom
received frontalis muscle EMG biofeedback, the remainder a
modified version of Jacobson's progressive relaxation (Jacobson
1938). The number of treatment sessions ranged from 10 to 25 over
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Table 4.3 : RPports coeparinq psyrhological treatlP.nts of anxiety states and generalised anxiety disorder.
Diagnosis;
Criteria; N
T rea t • e n t
Conditions
TreatlllPllt
Duratioo
Outcome : Evaluation Re:
Differential TreatlllPllt Effect
Raskin et al 1973 Chronically 100 8 Iftks 6 patients uni.proved
anxious; 3 patients lOderately
N = 10 i.proved
I patient aarkedly i.proved
Canter et al 1975 fwlxiety neurosis; 100 10 - 25 00 ) Progressive relaxation
N = 28 2 Progressive sessions
relaxation
Townsend et al Chronic anxiety; 100 4 !leeks 00 ) Group psychotherapy
1975 N = 30 2 Group
psychotherapy
Lavallee et al Free floating I 00 + Diazepal 4 !leeks No differPll(e bet..een
1976 anxiety; 2 placebo 00 + treataent groups
N = 40 diazepal
3 00 + placebo
4 placebo 00 +
placebo
.,!!atheNs and ShaN General anxiety; 1 Thought stopping 8 Meeks Thought stopping = Cognitive
1m N = 10 2 Cogn i tiVI! dPSPnsi tiza tion
dPSPnsi tization
Benson et al 1978 fwlxiety neurosis; _ I Self hy",osis 8 !leeks Self hy~is = lleditational
N = 32 2 lledi tational relaxation
relaxation
Lehrer 1978 fwlxiety neurosis; 1 Progressi VI! 3 !leeks Progressi VI! relaxation >
N = 20 relaxation llaiting list
2 Waiting list
Leboeu f and Lodge Chronic anxiety; 100 12 14 00 = Progressive rel<1xatioo
1978 N = 26 2 Progressive !leeks
relaxatioo
Rask in et al 1980 fwlxiety neurosis; Iat; 6 !leeks 00 = Progresc;ive relaxation
DSII III; 2 Progressive = Tran5Cendental aeditation
N = 55 relaxation
3 Tran5Cendental
lII'ditatioo
!Tahlp 4.3 roollll
WoodNardand Jones
1980
Hutchings et al
1980
RaM et al 1981
Jannoun et .11 1982
last et at 1983
Barlow et al 1984
Genl'ral anxil'tYi
N : 27
6I'nl'ral anxiety;
N" 70
Frel'-floating
anxiety;
N" 12
Generalized
anxiety;
H = 2b
Generalized
anxiety;
N = 1
SAD; PD; D5I! III;
N = 20
1 Cogni tive
restructuring
2 Hodi fied
systematic
desensitization
3 Cognitive
behaviour
lIIOdification
4 Waiting list
I Anxiety
aanagl'llll!flt
training
2 Applied
relaxation
training
3 Relaxation only
4 Placebo
5 Waiting list
1 Positive-
anxiety
.anagl!1lll!llt
training
2 Negative-
anxiety
aanagl'llll!flt
training
IAnxiety
aanagement
training after:
2a 4 lII!eks Nait
2b b lII!eks Nait
2c 9 lII!eks Nai t
1 Coping sel f-
statl!1lll!llts
2 Paradoxical
intention
t BMS + cognitive
behaviour ther •
+ progressive
relaxation
2 Waiting list
b weeks
b weeks
b weeks
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Cognitivl'
lIIOdification
behaviour
> Hodified
systematic dl".iP.llc;itization )
Cogni tivl' restructuring :
Waiting list
Anxiety IaIlagl'llll!flt training
> Applied relaxation training
= Relaxation only: Placebo
} Waiting list
Positive-anxiety lIclfIaqeIP.Ilt
training = Negative-anxiety
.anaql!1lll!llt training
Anxiety IIcl!IaqeIP.Ilt training
) Waiting
Coping self statl!llP.llts =
Paradoxical intention
Elt3 + cognitive behaviour
therapy + progressive
relaxation> Waiting list
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ITdblp 4.3 ronM).
Iarr ier and I!.lin 6enl.'ra I i zed J Appl isd 6 Nl?Pks Appl ied rplaxation training
1986 anxiety; relaxation > Waiting list
N = 50 training
a Participant
dP1llOl1st rat i00
b Written
ins truc t ions
e Taped
instructions
d Part icipant
dP1llOl1stration t
written
instructions t
taped
ins true tiros
2 Waiting list
Durhal and Turvey Generalized 1 BehavilXtr 6 IIIOIlths Behaviour therapy = CoqnitiVl!
1987 anxiety; therapy therapy
N = 40 2 CoqnitiVl!
therapy
lindsay eta I 1987 Generalized I CoqnitiVl! 4 Nl?Pks CoqnitiVl! behaviour therapy
anxiety behaviour ) Anxiety latlagPlPOt training
N = 40 therapy ) lormpal > Waiting Jist
2 Anxiety
IIaIla(jPlllPllt
training
3 lorazpPclll
4 Waiting list
1 Anxiety
.,.~
Butler et al 1987a SAD; ROC; 12 IIPPks Anxiety IatlagPIPOt ) Waiting
N = 45 latlaqt'lPll t list
2 Waiting list
BIOIIers et al 1987 SAD; DSI! III; 1 Anxiety 10 IIPPks Anxiety aanagI.'IIeIlt training
N = bb aanagPlllPllt = Non directiVl! counselling
training > Waiting list
2 Non;firectiVl!
counselling
3 Waiting list
a variable time period.
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Outcome was determined by patients and
therapists rating major an)(iety symptoms as having "decreased",
"increased" or "not changed". EMG was regarded as superior in
producing relief from anxiety symptoms. Of the 14 EMG patients, 12
were rated as "improved" and 2 as "riochange" by both patient and
therapist. Of the ·14 progressive rela)(ation patients 7 rated
themselves as "improved" and 7 reported "no change" - the therapist
ratings were 6 and 8 respectively. Unfortunately results may have
been confounded by 5 of the 28 patients being on unspecified
tranquillizers or sedatives on a p.r.n. basis. No follow-up data
were presented.
Townsend et al (1975) reported the treatment results of 8
chronic an)(iety inpatients who received group Psychotherapy in
Comparison to 10 chronic anxiety inpatients who received frontalis
EMG feedback. Group psychotherapy comprised 16 sessions of 60
minutes duration spread over a 4-week period. Thematic Apperception
Test (Murray 1943) picture cards were presented to groups of 4 _
5 patients to promote discussion of anxiety provoking aspects of
the Pictures followed by intermember support and interaction, and
POSsible methods to cope with anxiety. EMG biofeedback consisted
of 9 sessions of 20 minutes duration spread over a 4-week period.
Assessment measures comprised the State-Trait Anxiety Inventory
(STAI) (Speilberger et al 1970), and the Profile of Mood States
(POMS) (McNair and Lorr 1964). Overall "patient improvement was
arbitrarily defined ".resulting in 4 of 10 EMG patients.rated as
"improved" and none of the group psychotherapy patients achieving
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this status.
psychotherapy.
It was concluded that EMG was supp.rior to group
Unfortunately this study has a number of major
shortcomings. Firstly, a rather high drop-out rate e~isted with
only 18 patients from an original total of 30 completing the study.
Secondly, of the 18, 2 stopped medication, 2 increased medication,
6 had their medication changed, and 8 continued medication
unchanged. Thirdly, a range of psychotropics were used throughout
the study including chlorpromazine, diazepam, trifluorperazine
hydrochloride, and thiordiazpine, all dispensed in varying
dosages. Fourthly, patients classified as receiving EMG treatment
also "practised deep muscle relaxation for one-half hour each day
Using tape recorded instructions". Fifthly, only 2 EMG patients
were available for 6-month follow-up, and Townsend et al <1975)
admitted that only "anecdotal" follow-up impressions could be made.
Lavallee et al C1976>investigated 40 free-floating anxiety
outpatients' response to EMG frontalis biofeedback and diazepam in
a variety of controlled comparisons. Patients were equally
distributed between one of four treatments, including EMG +
diazepam, EMG + placebo diazepam, placebo EMG + diazepam, and
Placebo EMG + placebo diazepam. EMG treatment consisted of
30-minute sessions, twice per week for a period of 4 weeks.
Placebo EMG consisted of the same procedure except that no auditory
feedback tone was heard by the pat)ent. Diazepam treatment
consisted of 5 mgs t.i.d., or placebo diazepam, according to
treatment group. Patients were assessed using the Hamilton Anxiety
Scale CHAM-A) <Hamilton 1959>, the Institute of Personality and
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Ability Testing Scale (tPAT) (Cattell and Scheier 1958), and the
de Sonic Trait-State Anxiety Scale (de Sonic 1973). Due to
inadequate statistical analysis the results are reported in a
somewhat confusing and contradictory manner. Following the
treatment period there was a statistically significant reduction
in anxiety, as assgssed by the HAM-A, for all groups apart from the
placebo EMG + placebo diazepam group. However scrutiny of the data
did not reveal any actual differences between groups following
treatment. At 3 and 6-month follow-up the authors concluded that
"it was only the feedback (EMG + placebo diazepam) group who
maintained a significant anxiety reduction". However further
inspection of the data revealed that at follow-up the placebo EMG
+ placebo diazepam group did equally as well, if not better. Other
major flaws include: firstly, the conclusion that "EMG feedback
treatment without diazepam had a more prolonged therapeutic effect
..' ~'.."
for chronic anxious patients" has to be tempered by the fact that
placebo EMG + placebo diazepam produce similar results. Secondly,
the authors noted that "most patients were taking different drugs
before the experiment, usually diazepam or chlordiazepoxide. One
week before treatment they were asked to stop taking their usual
medication and were put on a schedule of diazepam placebo three
times per day, constituting a wash-out period". Unsurprisingly"21
Patients dropped out at this stage and were replaced by other
SUbjects". Lavallee et al (1976) do not mention reason~ for such
a high drop-out rate but it is likely that such patients were
eXperiencing benzodiazepine withdrawal symptoms as perhaps were a
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number of patients in the actual study. Thirdly, follow-up results
may have been confounded by all patients being routinely placed on
diazepam p.r.n. after, treatment, although differences in
consumption
significant.
Mathews and Shaw (1977) reported the results of 10 general
levels between groups at follow-up were not
anxiety psychiatric outpatients, from an original total of 14,
treated with 8 weekly sessions of thought-stopping or cognitive
desensitisation. In thought-stopping patients were instructed to
relax for 5 minutes, and then to begin concentrating on a
designated anxiety thought~ the presence of which was to be
signalled by the patient as soon as a clear image was obtained.
At this point the therapist shouted "stop" and instructed the
patients to substi tute a pre-arranged aIternative thought. In
Cognitive desensitisation the procedure applied was identical until
the point at which the patient signalled that a thought was clear.
Then they were not instructed to stop it but instead to tolerate
it and allow it to remain for as long as it seemed clear.
Clinical ratings of severity were made by an assessor (using a 5-
POint scale). Patients' self-report comprised a weekly mood scale
(McNair and Lorr 1964), and a diary of anxious mood (using a 0 -
10 scale) completed every three hours through the day. Mathews and
Shaw (1977) reported that "i,nterms of changes in cl inica11y rated
anxiety, all patients except one were rated to have improved in
varying degrees, although only two could be judged virtually
symptom free on (1 month) follow-up, and the average rated change
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was small (0.8 points on the assessors five point anxiety scale),
and the patients average self-rating of improvement was just above
'slightly better"! Unfortunately this study provides somewhat
scant information and outcome data. Secondly, it is not clear how
many patients comprised each treatment Qrowp. ThiralYJ a~ r~~QrdQ
drug status the paper only notes that patients "were not receiving
any treatment other than maintenance medication".
Benson et al (1978) report resul ts of 32 anxiety neurosis
outpatients equally allocated to meditational relaxation or self-
hypnosis relaxation. Meditational relaxation was learned by
patients adhering to a standard list of instructions comprising
sitting quietly with eyes closed, muscles relaxed, and ignoring
distracting thoughts for periods of 20 minutes once or twice
daily over an 8~week period. Self-hypnosis relaxation was taught
by a psychiatrist who repeated individualised instructions in a
soothing monotone characteristic of hypnotic induction procedures,
for example; relax and imagine you are floating, drifting, or
gliding. Patients were directed to practice the techniques for
10 - 15 minutes three times per day for the first 3 days and
thereafter twice daily for the 8-week study period. There was no
significant difference between the two treatments. Clinical
assessment was conducted by means of the Hamilton Anxiety Scale
(HAM-A) (Hami Iton 1959). Overall 34% of patients were rated as
"improved" on the HAM-A, and approximately 631. of patients "felt
improved" on self-rating questionnaires. A number of
methodological inadequacies exist in this study. Firstly, there
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is no mention of the criteria used to determine improvement /
unimprovement. Secondly, there is no mention of the possible
significance of 37 of the original 69 patients dropping out.
Thirdly, there is no follow-up, and fourthly, no mention of drug
status.
Lehrer (1978»)in a rather complicated design,compared the
effects of progressive relaxation in anxiety neurotic patients with
progressive relaxation and alpha feedback in nonpatients. Ten
anxiety neurotic patients were given four or five sessions of
individual, abbreviated Jacobsonian progressive relaxation
(Jacobson 1938) over a three-week period (and were told to practise
at home for one hour da i1y), and lOan xiety neurot ic patien ts
served as waiting-list controls. Ten nonpatients were assigned to
each of the same conditions and an additional 10 nonpatients were
given four sessions of alpha feedback. Regarding the patient
.~'."
groups alone Lehrer (1978) noted that reported anxiety, as measured
by the state anxiety scale of the State-Trait Anxiety Inventory
(STAI) (Speilberger et al 1970), "decreases significantly more in
the relaxation group than in the control group". Lehrer (1978)
addressed one of the major limitations of the study by stating that
"it is possible that the effect in the present study was also due
to drug intake in the patient group, since most of the patients in
the sample had histories of taking tra~quillizers". Furthermore,
no follow-up was conducted.
Leboeuf and Lodge (1980) selected 26 chronic anxiety
Outpatients and assigned them non-randomly to either frontalis EMG,
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or slightly-modified Jacobson's progressive relaxation (Jacobson
1938). Over a 12 - 14 week period both groups received 16 sessions
each lasting approximattly 30 minutes. Both groups showed
statistically significant decreases in anxiety during treatment but
there was no difference between groups in magnitude as assessed by
the STAY and the Taylor Manifest Anxiety Scale (TMAS) (Taylor
1953). Changes in anx iety symptoms were rated by the referring
psychiatrist using the Hami Iton Anxiety Scale (HAM-A) (Hamil ton
1959), and a 7-point 'clinical improvement scale', pre, post, and
at 3 months follow-up. Using these measures only 3 of 13 in the
progressive relaxation group, and 2 of 13 in the EMG group achieved
moderate improvement, and 6 and 5 respectively achieved slight
improvement. These results were maintained at follow-up. No
patients demonstrated marked improvement, and Leboeuf and Lodge
(1980) conclude that their success rate "was quite typical of the
response of anxiety neurotics to placebo drugs". Furthermore they
noted that "a decrease on an anxiety questionnaire while valid may
not be clinically significant" as "few patients in each group
showed more than marginal improvementR• In conclusion they noted
that EMG biofeedback was unlikely to be a successful treatment for
anxiety "since there is an increasing awareness that anxiety
neurosis consists of many dimensions of behaviour other than
Physiological ones and that each aspect of the patients problem
may need to be treated using a variety of techniques". While this
Paper addressed some of the issues neglected in previous studies
it has one major" drawback in that "most of the patients were on
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various trNnquilli7.p.rmedicNtionc:;".
Raskin et al (1980) report the results of 55 anxiety neurosis
volunteers of whom 31 completed a 6-week baseline period (during
which psychological, social, and physiological data were obtained),
followed by a 6-week treatment period, and a 6-week post-treatment
period in which data comparable to the baseline data were
collected. Patients were followed up at 3 to 18 months. Three
treatment groups were compared, namely; (a) EMG frontalis feedback
- conducted for 1 hourly sessions, 3 times per week, for 6 weeks;
Cb) modified progressive relaxation - conducted according to the
same schedulei (c) transcendental meditation - involving individual
instruction and lectures over 4 consecutive days, followed by
"weekly checking by the transcendental meditation trainer~ and 20
minutes practice, twice daily, over the six-week study period.
Outcome results suggested that "there were no differences between
...'~
treatments with respect~to treatment efficacy". Forty per cent of
the subjects were rated as having clinically significant decreases
in their anxiety as defined by scores on the Taylor Manifest
Anxiety Scale (TMAS) (Taylor 1953), and the Current Mood Checklist
(CMCL) (Raskin et al 1972). These improvements were usually
maintained at follow-up. However Raskin et al conclude that
"relaxation therapies as a sole treatment appear to have a limited
Place in the treatment of chronic anxiety" In discussing the
limitations of the study Raskin et al (1980) noted that their
SUbjects were a self-selected group of highly motivated individuals
recruited via public advertisements. Secondly, "subjects taking
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p~esc~iption medications to ~elieve anxiety we~e also included".
Woodwa~d and Jones (1980) selected 27 gene~al anxiety
outpatients f~om a hospital waiting list. Subjects we~e randomly
assigned to one of fou~ groups. a ,) Seven patients recei ved
"cognitive restructuring" involving the identification ef amdaty
-p~oducing ir~ational beliefs, followed by the production of more
adaptive self-statements. In addition patients were directed to
cognitively rehea~se self-inst~uctional ways of handling anxiety
and coping in imagination du~ing t~eatment sessions. b s ) Seven
patients received "modified systematic desensitization" ~epo~ted
as being identical to that of the cognitive restructuring g~oup,
the only diffe~ence being that relaxation was the method of coping
employed. In addition subjects p~acticed relaxation at home using
taped instructions. c.> Six patients ~eceived "cognitive behaviou~
modification"
~estructuring"
p~esented as a combination of "cognitive
and "modified systematic desensitazation" as
outlined by Meichenbaum (1974>. In the initial sessions cognitive
restructuring was emphasised while in the latte~ relaxation
t~aining was promoted. d.> Seven patients comprised a waiting list
no-treatment cont~ol group and we~e assessed at initial inte~view
and two months late~. The th~ee active t~eatments consisted of 8
g~ouP sessions (one per week) each lasting app~oximately 1 hou~ and
15 minutes. A numbe~ of assessment measu~es we~e used p~e- and
Post-t~eatment including the Zung Self Rating Anxiety Scale (Zung
1971), the Fea~ Survey Schedule (FSS) (Wolpe and Lang 1964), and
the Inte~nal and Exte~nal Con t r-ol Scale (IE) (Rotte~ 1966). The
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combined treatment "cognitive bp.haviour modifiCAtion" proved to
be statistically superior to the other two active treatment groups
and the waiting list group on the Fear Survey Schedule (FSS) (Wolpe
and Lang 1964). Cognitive behaviour modification also resulted in
a significant decrease in subjective anwiety measured by patients'
diary score in comparison to cognitive restructuring alone. In
fact, cognitive restructuring failed to result in any apparent
improvement on the dependent variables mentioned. Woodward and
Jones (1980) concluded their results demonstrate that " a
multidimensional approach to treatment, for example cognitive
behaviour modification, is more likely to succeed with this type
of patient than treatments comprising one element only, as does
cognitive restructuring".
While this is the first paper to propose and evaluate a more
pragmatic approach to the managment of generalised anxiety, namely
that of cognitive behaviour modification, it is unfortunate that
no information regarding patients' drug status was available, and
no patients' or referring physicians' assessment of level of
clinical improvement was reported. Furthermore a follow-up of more
than 1 month would have been useful.
Hutchings et al (1980) screened approximately 800 general
psychology students at the University of Kansas, and selected 70
students, scoring in the upper 151. of both the short form of the
Taylor Manifest Anxiety Scale (Bendig 1956), and the neuroticism
scale of the Eysenck Personality Inventory EPI (Eysenck and Eysenck
1968), as suffering from general anxiety. Subjects were randomly
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allocated in equal numbers of 15 per group, to one of 5
experimental conditions as follows :- a) "Anxiety Management
Training" CAMT) based on Suinn (1977), introduced with a self-
control rationale followed by progressive relaxation. Structured
rehearsal involved subjects visualising an anxiety provoking scene
from their past and then switching off the anxiety and practising
"relaxing away the anxiety". Subjects were instructed to practise
relaxation at home twice daily. b) "Applied Relaxation
Training"(ART) utilized the same self-control rationale, homework
assignments, and application instructions as AMT. However the ART
procedure omitted structured rehearsal, and substituted more
elaborate and varied relaxation instructions. Six different
audiotaped relaxation instructions were prepared for this purpose,
each tape introducing a new variation (eg. autogenic exercises,
gUided imagery). c) "Relaxation Only" (RO) employed the same
six audiotaped relaxation instructions and the same homework
schedule used in ART. RO differed in that subjects received a
"passive rationale" which suggested that relaxation would
automatically "supplant anxiety". There was no mention of self-
Control or instructions concerning the application of relaxation
in anx iety-provok ing situations. d) "Placebo" received a
Passive rationale similar to that used in the RO condition which
Suggested that anxiety would dissipate as they continued in
treatment. To this end subjects were shown six 1 hour videos with
tOPics related to psychology (eg. depression, sex roles,
aggression). Vaguely distinguishable impressions of people's
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faces, blurred movement, fire etc. were superimposed on the film
for random intervals of 1 - 15 seconds in order to "unconsciously
extinguish" subjects' anxiety. e) "No-treatment" waiting list
controls completed pre- and post- test assessments with no
intervening treatment.
All "active" treatments (ie a,b,c,d) were conducted in group
settings of 5 - 7 subjects who met once per week for a period of
6 weeks, each session lasting 1 hour and 15 minutes. Treatment
outcome was assessed by a number of state-trait anxiety
questionnaires including the State-Trait Anxiety inventory (STAI)
(Speilberger et al 1970), the Anxiety Symptom Checklist adapted
from Nicoletti (1972), the short form of the Taylor Manifest
Anxiety Scale (TMAS) (Bendig 1956), and the neuroticism Scale from
the Eysenck Personality Inventory (EPI) (Eysenck and Eysenck 1968).
In summary, on six of the eight measures of state or trait anxiety
collected post-treatment, subjects in the AMT exhibited lower
levels of anxiety than no-treatment waiting list controls, and on
four of these measures subjects in the AMT condition also exhibited
less anxiety than RO, and placebo subjects. ART was consistently
less effective than AMT. Subjects in the ART condition differed
from no-treatment waiting list controls on only four of the eight
measures collected at post-treatment and never differed from RO or
Placebo subjects. Twelve-month follow-up was conducted by postal
qUestionniare with a 60Y.return rate which provided inadequate data
for detailed analysis. This paper has a number of major
limitations. Firstly, the possible unrepresentative nature of the
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sample population. Secondly, the unusual method of subject
recruitment and diagnostic criteria. Thirdly, a lack of any
subjects' or referring agents' assessment of degree of clinical
improvement or unimprovement. Fourthly, lack of information
concerning level of prescribed medication. Fifthly, although
Hutchings et al (1980) stated that from the 70 selected subjects,
7 dropped out, post-treatment results are presented for only 58
subjects.
Ramm et al (1981) selected 12 free-floating anxiety
outpatients and randomly allocated them in equal numbers to either
anxiety management with positive self-instruction (P-AMT), or
anxiety management with negative self-instruction (N-AMT). All
patients had six sessions, presumably individually, each lasting
one hour. Patients attended twice during the first week and weekly
thereafter for four weeks. All patients were told that they would
be "taught to deal with anxiety by learning appropriate self-
instructional methods". Treatment sessions were divided into three
main parts discussion, rehearsal, and homework setting.
"Discussion" entailed eliciting patients' coping strategies,
.Checking that treatment instructions were being adhered to, and
discussing any difficulties that had arisen between sessions.
"Homework setting" entailed selecting anxiety-provoking situations
which patients should confront, and ensuring that they kept a diary
Of how anxious they felt in such situations. Both "discus<5ion" and
"homework setting" parts of treatment were similar for both P-AMT
and N-AMT patients. "Rehearsa I" of the use of se If-instruc tiona I
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cue cards was the main differentiating feature between treatment
conditions, the self-instructions on the cue card were "positive"
or "negative". Nine statements were on the positive cue card, for
example; 1. I can learn to control my behaviour, 2. I can cope
with these feelings, 3. These awful things don't mean anything
dreadful will happen to me, 4. These terrible feelings will pass
eventually. Nine statements were also on the negative cue card,
for example; 1.I'm really going crazy, 2. These feelings are out
of my control, 3. I seem to be getting steadi ly worse, 4. I' m
gOing to make a fool of myself. All patients within each treatment
condition used the same cue card.
their card with them at all times,
Patients were asked to carry
and to read it three times,
aloud if possible, when they experienced any anxiety~ If they did
not experience anxiety during a day, they were asked to read it
before going to bed at night! During rehearsal, the therapist asked
patients to imagine themselves in a difficult situation, and
prompted patients with positive or negative self-statements for
respective treatment conditions. Patients were assessed pre- and
post-treatment and at 3 and 6-month follow-up. Assessment measures
Comprised the Wakefield Depression Questionnaire (Snaith et al
1971), the Fear Questionnaire <Marks and Mathews 1979), and 5
Likert-style anxiety questions and 4 Likert-style target problems
designed by the authors. Ramm et al (1981) concluded that "overall
~hanges in anx iety states wi th ei ther form of AMT were not
impressive. Any slight gains that did exist at the end of
treatment were no longer present by one month follow-up.
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Unsurprisingly too few patients attended for six-month follow-up
to warrant analysis. This study also has serious shortcomings.
Firstly, and most importantly, the ethical issue of the entire
"negative sel f-instruction" component of the N-AMT whereby patients
are instructed to rehearse such statements as "I'm really going
crazy". A treatment approach such as this may potentially worsen
a patient's condition. Secondly, a rather small sample size.
Thirdly, a lack of any information on concomitant drug treatment.
Jannoun et a 1 (1982) randomly allocated 26 generalised
anxiety psychiatric outpatients to one of three groups which
differed only in length of time patients waited for treatment.
Group 1 waited for 4 weeks, group 2 had a 6-week wait, and group
3 had an 8-week wai t. All patients received five treatment
sessions over a 6-week period, and one "booster" session 6 weeks
after the end of treatment. Trea tmen twas presen ted to all
patients as a self-help programme modified from Suinn and
Richardson's Anxiety Management Training (AMT) (Suinn 1977). The
main treatment components listed by Jannoun et al (1982) were a)
"self monitoring" patients kept a daily record of anxiety level
and drug intake, b) "instruction booklets" explained the
treatment plan, and provided information about the psychophysiology
of anxiety, and described the uses and limitations of anxiolytic
drugs, c) "muscle relaxation" 'learned from audio-taped
and d) "cognitive control" -instructions and practised at home,
Patients were taught to evoke anxiety-provoking images, and engage
in positive self-talk. Patients were assessed pre- and post-
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treatment, and at follow-up 4 weeks and 10 weeks thereafter.
Outcome was assessed using the Hamilton Anxiety Scale (HAM-
A)(Hamilton 1959), the Hamilton Depression Scale (HAM-D)(Hamilton
1967), the Leeds Self-Assessment for Anxiety and Depression Scale
(LSAA, LSAD) (Snaith et al 1976), and the State-Trait AnKiety
Inventory (STAI) (Speilberger et al 1970). All the anxiety and
depression measures showed a signi ficant reduction from pre- to
post- treatment, and these improvments were maintained at follow-
up. There were no significant changes in anxiety during any of the
waiting periods prior to treatment. Although this study claimed
to report the effectiveness of a brief, time-limited, cost-
effective treatment approach it nevertheless has a number of
limitations. Firstly, when referred for treatment "22 of the 26
patients were using anxiolytic drugs regularly and 3 of them were
also using antidepressants". At the end of treatment, "5 patients
were abstaining, 6 showed a decrease in drug intake whi 1e 5
remained the same". While reduction in drug dependency is to be
commended it is uncertain how this may have influenced the overall
results. Secondly, although the study achieved statistically
significant results there was no assessment of patient or referring
agents' rating of degree of clinical improvement.
Last et al (1983), following from the results of Beck et al
(1974), suggested that generalised anxiety patients exhibit
"catastrophic cognitions". Last et al (1983) investigated the
,:"elativeeffectiveness of two cognitive strategies namely "coping
self-statements" (Meichenbaum 1977), and "paradoxical intention"
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(see Ascher 1980; Chambless and Goldstein 1980, for detailed review
of this technique) in an individual with generalised anxiety
disorder. The patient was treated within a small group of
individuals with other anxiety disorders, mostly phobias.
Treatment consisted of 11 weekly sessions that were 1 hour to 1
hour and 30 minutes long. During session 3,5,6, and 8 the strategy
for "paradoxical intention" was utilized; during sessions 4,7,9,
and 11 the strategy of "coping self-statements" was used. A fear
questionnaire (Marks and Mathews 1979) was completed at pre- mid-
and post-treatment and at 12-month follow-up. In addition each of
5 anxiety-provoking situations were rated both for degree of f.ar
and degree of avoidance using a 9 -point scale (Watson and Marks
1971) pre-, during-, post-treatment, and at follow-up. No
statistical technique was used to analyse the data although they
were presented graphically and some raw data scores provided. Last
.,;.."
et al (1983) noted thai their results "do not point clearly to a
differential treatment effect for the two cognitive strategies"
although the patient reported a preference for the "coping self-
statement" strategy. It is also interesting to note that reduction
in symptomatology did not actually occur during the two treatment
Phases, but occurred after treatment had ceased "primarily during
the follow-up phase of the study". Last et al (1983) also stated
that their single case study could "in no way provide an adequate
test for the efficacy of this treatment approach" (ie. "coping
Self-statements").
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Barlow et a l (1984) report the results of p.leven patients
meeting DSM-III criteria for panic disorder (PO), and nine meeting
the criteria for generalized anxiety disorder (GAD). Five GAD and
five PO patients were treated, with the remainder assigned to a
wai ting-l ist control group. All treated subjects were given
progressive relaxation training and frontalis EMG biofeedback
combined with cognitive behaviour therapy (CBT) during 18 sessions,
Over a 14-week period. The relaxation training was adapted from
Bernstein and Borkovec (1973), and consisted of tension-relaxation
exercises in addition to cue-controlled relaxation associated with
the subvoca Iized word "re Iax" • Subjects received 12 clinic
relaxation training sessions, and were required to practise
relaxation at home at least once per day. Subjects also received
a total of 8 EMG biofeedback sessions. The cognitive -behavioural
Component of treatment was based on Meichenbaum and Turk's (1973)
. ~.<.
stress innoculation trai'ning, and Beck and Emery's (1979) cognitive
therapy for anxiety disorders. The strategies taught included
COping self-statements and cognitive restructuring of anxiety-
prOvoking thoughts. Subjects received 12 sessions of CBT.
Waiting-list control subjects remained untreated for 14 weeks, and
completed the assessment measures at the beginning and end of this
Period. A wide range of assessment measures were used pre- and
Post-treatment, and included the State-Trait Anxiety Inventory
(STAn (Speilberger et al 1970), the Beck Depression Inventory
(801) (Beck et al 1961), the Psychosomatic Symptom Checklist (Cox
1975), and at pre-treatment only the Cognitive Somatic Anxiety
Questionnaire (eSAQ) (SchwL'irtzet al 1978).
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In addition, all
subjects were required to self-monitor their anxiety levels in a
daily diary using a 0 - 8 scale. Pre- and pos t-trea tmen t two
clinicians rated each subject independently on a 0 - 8 clinical
severity scale. Patients were followed up at least 3 months post-
treatment (range 3 months to 1 year). Barlow et al (1984)
concluded that their results "indicate a 'clear effect for
Psychological treatment of anxiety states (in comparison to no
treatment controls) with further improvement noted in most cases
at follow-up". Furthermore they noted that "this change was
pervasive and broad based" with effects evident on daily self-
monitored diary measures, questionnaire measures, and overall
clinical ratings of severity. Interestingly there were no
significant differences in outcome between GAD and PD. Despite the
generally positive pattern of results, changes in clinical ratings
of improvement were nof correlated at any point with reduction in
EMG. In general Barlow et 091 (1984) presented a relatively well-
controlled study incorporating specific treatment approaches
deSigned to alleviate the cognitive and somatic components of GAD.
Unfortunately there was no mention of the drug status of patients,
and the number of GAD patients was rather small.
Tarrier and Main (1986) randomly allocated fifty consecutive
"generalized anxiety" patients, referred to a district psychology
department, to one of four Applied Relaxation Training (ART)
Conditions, or a waiting-list control group.
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The four ART treatment groups were each instructed by diffprent
methods (a) handout (written instructions), (b) tape (taped
instructions), (c) participant demonstration (verbal instruction
and practice), and (d) combined methods (written and taped
instructions to take home, with verbal instruction and practice
dur ing trea tmen t sessions). The ART method had the following
components a) self-monitoring of anxiety levels, b) correct
breathing, c) progressive muscle relaxation, and d) positive
mental imagery. Assessment measures conducted pre-and post-
treatment comprised the Symptom Rating Test (SRT) (Kellner and
Sheffield 1973), and the Epstein-Fenz Anxiety Scale (EFAS) (Fenz
and Epstein 1965). At post-treatment patients rated the benefit
of treatment on a three-point scale (0 = none or minimal benefit,
1 = beneficial, 2 = very beneficial>. No significa~t reductions
in total SRT and EFAS scores between pre- and post-treatment
_ emerged for the the four individual ART treatment groups and the
waiting-list group. Similarly no significant reductions in SRT
subscales pre- and post-treatment for individual ART treatment
groups emerged. Three of the individual ART treatment groups
showed a significant pre- post-treatment reduction on only one
subscale of the EFAS, whi Ie the remaining ART group showed a
significant reduction on two EFAS subscales. Subsequently all four
ART results were amalgamated, producing significant pre- post-
treatment reductions of the EFAS total and the three subscales as
well as on the SRT total and one of three subscales. Tarrier and
Main (1986) report that "approximately 70% of the treated groups
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reported at least some benefit". However this result should be
regarded wi th some caution as it was "considered that 601. of
subj ec ts were in need of further trea tmen t"• This study has a
number of limitations. Firstly, only 301. of those who received
Some form of ART were not taking psychotropic m~dication.
Secondly, no actual follow-up data are presented. Thirdly, Tarrier
and Main (1986) concluded that "all four methods proved superior
to a waiting-list control". However this superiority was only
marginal when the four ART conditions are regarded separately and
it was only by combining ART treatments that slightly more
respectable degrees of significance were achieved.
Durham and Turvey (1987), from an initial sample of 68
generalised anxiety outpatients provisionally accepted for study
inclusion, reported outcome data on 40 patients randomly assigned
to either behaviour therapy CBT) or cognitive therapy CCT). The
-two trea tmen t cond itions' fo11owed a protoco 1 based on Bec k and
Emery's (1979) unpublished treatment manual. All patients received
a maximum of 16 hours individual therapy over a maximum of 6
months. For most patients treatment consisted of 1 hour weekly
sessions. There was no difference in the mean amount of therapy
given to patients in each of the treatment groups. Durham and
Turvey (1987) note that BT and CT had the "same style but differed
in content". Assessment measures included a modified lung Anxiety
Status Inventory (ASY) (lung 1971), the Beck Depression Inventory
(BDI> (Beck et· al 1961), the Modified Somatic Perception
Questionnaire (MSPQ) (Main 1983) , the Automatic Thoughts
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Questionnaire (ATD) (Hollon and Kendall 1980), and the modified
Dysfunctional Attitude Scale (DAS) (Burns 1980). In addition up
to five specific problems and goals were rated on a 9-point scale
at initial assessment, discharge, and follow-up, by the patien t,
the therapist, the patient's spouse or close relative, and an
independent assessor. Patients also kept a daily diary recording
their maximum severity of anxiety each morning, afternoon, and
evening on a 9 point scale. At discharge and 6-month follow-up
patients and the independent assessor made a global assessment of
patien ts' sa tisfac tion wi th trea tmen t, on a 9 point scale.
Durham and Turvey (1987) concluded that" at the end of treatment
there was no difference between CT and BT in the amount of
improvement observed". The clinical significance of the effects
of treatment suggested that at post-treatment 251. "of patients
showed slight or no change, 201. were moderately improved, and 541.
-had markedly or completely improved. However at 6-month follow-up
there was a significant trend for the CT patients to maintain or
improve upon their post-treatment gains, and for the BT patients
to revert back to their mid-therapy scores. By follow-up 621. of
eT patients were still rated as markedly or completely improved
While only about 301. of BT patients were rated as such. This study
prOvides one of the most thorough reports to date in terms of
number and range of assessmen t measures. Unfortunately it is
flawed in that 651. of patients were taking "medLca t Lori" at the
start of the trial, and "patients were encouraged to reduce
medication if possible but therapists made no specific attempts to
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help achieve this !Joal". Furthermore a Ithough CT and BT are
presented as being different in content "the eT condition included
behavioural techniques when appropriate". In addition the BT
condition while employing behavioural strategies such as
relaxation, distraction, and graded exposure also included "the use
of positive self-statements and general problem-solving strategies
when appropriate". As such the differences between BT and CT may
have at times been more apparent than real.
Lindsay et al (1987) reported the results of 40 generalized
anxiety outpatients randomly assigned in equal numbers to one of
four conditions, a) cognitive -behaviour therapy and relaxation
(CST) , b) anxiety management training (AMT), c) lorazepam CSZ),
d) waiting-list, - no treatment (WL). The CST groups received
treatment based on that described by Seck and Emery (1979), Beck
et al (1979), and Meichenbaum (1974). Treatment focussed on
..:.., ....
-anxiety-related self-statements and underlying assumptions about
self, and included challenging automatic thoughts and substituting
rational alternatives. Treatment sessions of one hour duration
were arranged twice a week over four weeks. Subjects were also
given a relaxation tape. The AMT group received treatment based
on the work of Suinn and Richardson (1971). The structure of AMT
treatment was as similar to the CST group as possible although the
"content and procedures of treatment were extremely different".
During treatment subjects were taught relaxation exercises and
given a relaxation tape based on Bernstein and 8orkovec's (1973)
approach. "Anxiety was explained to the patient in terms of
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physica 1 symptoms ann the emphas is of trea tmen t was a 1ways on
physical relaxation". The BZ group were prescribed lorazepam 1 mg
t.i.d.for 10 days, lmg b.d.for a further 10 days, and 1 mg nocte
for the remaining 10 days, and were seen "for a few minutes only".
The WL groups were seem for initiaI assessmen t and four weeks
thereafter. A three-month follow-up was conducted on the CBT and
AMT groups. Assessment measures comprised a) the General Health
Questionnaire - 28 items (GHQ) (Goldberg 1978), b) the Zung Self-
rating Anxiety Scale (Zung 1971>, c) the Modified Automatic
Perception Questionniare (MAPQ)(Main 1983), and d) the Cognitive
Anxiety Questionnaire (CAQ) an unpublished scale designed by
Lindsay and Hood (1982) to assess automatic thoughts in relation
to feelings of anxiety. In addition patients completed a daily
diary assessing anxiety level and frequency of anxiety related
cognitions, each rated on 15cm lines. Overall the most immediate
and greatest reductions in anxiety occurred in the BZ group.
However the initial BZ improvements in clinical status diminished
during the course of the trial period and were minimal at the end
of therapy. As such no follow-up data were available for the BZ
group as over half showed little sustained improvement and were
reluctant to discontinue drug treatment for the three months
follow-up period in the absence of alternative treatment. Both
Psychological treatment groups improved as the trial progressed,
with the most significant and consistent changes seen in the CBT
group. However, at follow-up there was no difference between CBT
and AMT groups. While this study has to be commended in attempting
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to compare pharmacoloQicnl and psychological approaches to anxiety
management and ensuring that all patients were drug-free for a
significant period (6 weeks) prior to study entry, it nevertheless
has a few minor limitations. Unfortunately there was no attempt
to balance between groups for the degree of therapist-patient
contact. It could be argued that the improvements in AMT and CST
groups, in comparison to SZ and WL, were solely due to the amount
of psychologist attention patients received as opposed to the
specific techniques of CST and AMT themselves. Indeed this
criticism applies to a number of studies previously reviewed in
this chapter and requires consideration in future studies comparing
pharmacological and psychological interventions. Secondly, Lindsay
et al (1987) quoted the Committee on the Review of Medicines'
(1980) Report that "benzodiazepine therapy be withdrawn
and that prescriptions be limited to short termgradually ....
Use". However, their use of lorazepam Img t.i.d. for 10 days prior
to graded withdrawal may be regarded as a rather short period of
therapy considering the recent more restrictive 1988 guidelines for
benzodiazepine prescription recommending treatment periods of 2 to
4 weeks only (Committee on Safety of Medicines 1988). Thirdly,
although Lindsay et al (1987) rightly implemented a graded
withdrawal programme, it would have been advantageous if this had
been a "placebo substitution" withdrawal programme. Use of the
latter would have determined whether the increase in anxiety
symptoms during graded reduction of medication was due to reduction
of SZ per se, or simp Iy a resu It of reduced tab Iet intake.
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Fourthly, it has been noted that withdrawal symptoms from short-
acting benzodiazepines such as lorazepam are more pronounced than
those from long-acting benzodiazepines (Rickels et al 1986).
Therefore it would have been more efficacious to use a
benzodiazepine such as diazepam which is long-acting, and which is
regarded as the standard comparative ben20diazepine of choice in
clinical trials (Rickels 1978).
Butler et al (1987a) reported on 45 patients (from a total
of 63; 18 of whom failed to attend or preferred other treatment)
with generalised anxiety disorder (GAD) as defined by Spitzer et
aI's (1978) Research Diagnostic Criteria. Twenty-two patients were
randomly allocated to an Anxiety Management (AM) treatment
condition, the remaining twenty-three to a Waiting-List (WL)
control group. AM treatment was described to patients in a booklet
and presented as a form of self-help. The patient booklet provided
information on the nature of anxiety, its common manifestation and
precipitants. Methods of eliminating anxiety, for example
relaxation, distraction, and identifying and challenging irrational
thoughts were also presented in the booklet. Patients were
encouraged to reduce avoidance using graded exposure. Taped
instructions for progressive muscular relaxation, which was to be
practised at home, were provided. Individual treatment sessions,
up to one hour in length ranged from 4 - 12. "Booster sessions"
were given 2 and 6 weeks after the end of treatment. A post-
treatment assessment was carried out 3 months after the start of
treatment, and follow-up assessments were conducted 3 and 6 months
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latp.r. Assessmp.nt measures included the Hami.lton Anxiety Scale
(HAM-A) (Hamilton 1959), the Hamilton Depression Scale (HAM-D)
(Hamilton 1967), the State-Trait An~iety Inventory (STAI)
(Speil berger et a 1 1970), the Leeds Scales (Sn~~ith et a l 1976),
the Present State Examination (PSE) (Wing et al 1974), and the
General Health Questionnaire (GHQ) (Goldberg and Hillier 1979).
Expectations about outcome, suitability of treatment, and anxiety
level were rated by patients on a 0 - 8 scale. In summary Butler
et al (1987) reported that highly-significant reductions in anxiety
and depression occurred in the AM group. In addition these changes
were replicated when the WL group also eventually received AM
treatment after the comparative study period. Treatment gains were
maintained by both groups at 6-month follow-up. Butler et al
(1987a) concluded that AM was suitable for treating GAD in primary
care as it was "readily understood by patients" and "as well as
-including procedures for controlling symptoms it deals with anxious
cognitions and avoidance behaviour, both of which appear to
contribute to the maintenance of anxiety disorders".
study Butler et al (1987a) have applied
In their
pragmatic,a
multidimensional, and mixed treatment approach to GAD. This
reflects the need to develop therapeutic techniques which address
the three main components, namely somatic. cognitive, and
behavioural aspects. Unfortunately a major limitation of this
study is that at initial assessment 46% of the patients were taking
regular medication. Of the prescriptions 73% were for anxiolytics,
14% for hypnotics, and the remainder for antidepressants and
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combined preparations. Se~ondly, of the 36 patients included at
6-month follow-up, "3 were given anxiolytic medication to help with
particular stressors •••• and another 9 had received more extensivE'
treatment for anxiety, including taking regular medication •••• 7
of these had also received antidepressant medication". So follow-
up results may have been confounded by the subsequen t
pharmacological treatment effects. Thirdly, although Butler et al
(1987a) described ~he patient group as suffering from GAD, it also
appears that "patients meeting the criteria for panic disorder as
well as GAD were included provided the GAD was the primary
disorder". However it was a Iso noted tha t "using the PSE
definition of panic attacks, 13 patients fulfilled the criteria for
panic disorder". Given these statements there appears to be a
degree of ambiguity c:onc:erning the diagnostic: features of the
patient population.
Blowers et al (1987) out of an original 95 GAD outpatients
(diagnosed ac:c:ordingto DSM III c:riteria) presented results on 66
patients randomly alloc:ated to anxiety management training (AMT),
non-direc:tive c:ounselling (NDC), or a waiting-list c:ontrol (WL).
Twenty patients rec:eived AMT and were given a booklet entitled
"Coping with An><iety", whic:h provided a treatment rationale that
"anxiety c:ould be c:ontrolled using rela)(ation and the modific:ation
of upsetting thoughts". Patients were taught a brief form of
rela)(ation based on· that described by Bernstein and Borkovec:
(1973) • Cue-c:ontrolled rela)(ation was emphasised and regular
homework practice was enc:ouraged. The c:ognitive c:omponent of
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treatment w~s an abbreviaten form of that descrihed hy Beck ann
Emery (1985). During treatment, time was devoted to identification
of patients' anxiety provoking thoughts, and methods of challenging
the validity of these cognitions. Blowers et al (1987) also noted
that "therapists searched for homework tasks that would throw light
on the validity of the thought content being discussed" but for
some unexplained reason "avoided giving instructions that might be
interpreted as encouraging systematic and regular exposure to
anxiety provoking situations". Twenty-two patients received NDC
and were ,given a booklet entitled "Understanding Anxiety" which
offered a rationale to the effect that patients could be helped by
"becoming aware of and understanding their own thoughts and
feelings". Therapists offered a non-directive approach based on
that described by Rogers (1957>. No relaxation instrDctions were
given, nor was any direct advice concerning anxiety management.
-Instead, therapists used reflection as their primary technique.
Twenty-four WL patients were assessed at time of acceptance into
the trial, and again 10 weeks later. AMT and NDC were given 8
sessions of individual treatment each lasting approximately 45
minutes, over a 10-week period. Assessments were conducted pre-
and post-treatment and at 6-month follow-up. Assessment measures
included the Clinical Anxiety Scale (Snaith et al 1982), the
Hospital Anxiety and Depression Scale (Zigmond and Snaith 1983),
the Speilberger Trait Anxiety Scale (Speilberger et al 1970), and
the St. Georges Anxiety Questionnaire (for which no reference was
provided>. In summary, AMT was significantly more effective than
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the WL condition, but there were surprisingly few significant
differences in outcome between AMT and NDC either at post-treatment
or at 6-month follow-up. Blowers et al (1987) concluded that AMT
was effective "but that its superiority to a less structured and
less directive alternative remains to be proven". With reference
to the modest clinical change reported in the AMT group, Blowers
et al (1987) noted that "real life exposure practise was
deliberately eliminated so that the effects,of brief training in
relaxation and cognitive coping could be evaluated in isolation".
However Mathews (1984) has argued that anxiety arousal may be a
crucial feature in successful treatment, perhaps because it exposes
patients to relevant anxiety-evoking stimuli, whether internal or
external in nature. Blowers et al (1987) admit that in the absence
of exposure, "relaxation and cognitive methods may be on'lyslightly
more potent than are relatively non-directive and non-structured
..~.....
methods of psychological counselling". They therefore suggested
that their results "can be used to argue for treatment involving
a combination of exposure to anxiety-arousing situations and
simu Itaneous prac tice in cogni tive coping methods". In other words,
they suggested that treatment should address cognitive,
behavioural, and somatic manifestations of anxiety as opposed to
the purely cognitive and somatic approach adopted in the AMT
programme. Unfortunately, Blowers et aI's (1987) results are
compromised by the fact that an unspecified number of patients were
taking "tranquillizers", and that approximately 30'1.of the original
sample dropped out. No further information being presented on
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either of these factors.
4.3 Summary
The efficacy of pharmacological and psychological techniques
in the management of GAD is presently inconclusive. Poor
methodological design has contributed to the apparent indeterminate
nature of outcome results. Ost (1982) attributes lack of efficacy
of psychological techniques to the oversimplified passive manner
in which anxiety reduction has been managed. For example, the
emphasis in the majority of studies to date on techniques such as
EMG feedback and progressive relaxation training, without enabling
patients to actively develop alternative cognitive"and behavioural
coping strategies for the management of generalised anxiety in
everyday situations: As a consequence multidimension.l and mixed
treatment approaches have been advocated (Mathews 1985) and more
recently adopted. Unfortunately with the exception of Lindsay et
aI's (1987) study, the efficacy of multidimensional treatments of
generalised anxiety has yet to be adequately compared with widely
used pharmacological alternatives.
The majority of studies investigating the efficacy of
Psychological treatments have included patients who were already
taking benzodiazepines. This practice is also methodologically
Unsound. The effect that benzodiazepines may have on the efficacy
of behaviour therapy for phobic anxiety has been reviewed by
Sartory (1983). Sartory (1983) concluded that the concurrent
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administration of benzodiazepines has little effect on the outcome
of behaviour therapy although it is possible that, at follow-u~
gains made whilst under the influence of the drug are less stable
than those made during a non-drug state. This relates to research
on state dependent learning where behaviour established under one
drug state may not transfer· so readi Iy to another drug state
(Overton 1966). In addition, other mechanisms, such as who or what
the therapeutic success is attributed to has important
ramifications. Sartory (1983) suggested that if patients "learn
to tolerate fear inducing situations because they trust in the
anxiolytic effect of a drug rather than their own clinical
improvement,
relapse".
discontinuation of the medication may lead to
Sartory (1983) recommended that "the use of
benzodiazepines in behavioural treatment is at best redundant and
at worst detrimental" and should therefore be discouraged.
Miller (1986) has highlighted that concurrent taking of
benzodiazepines during psychological treatment can misleadingly
distort the nature of the patients presenting problem. For
example, benzodiazepines may reduce the severity of anxiety
symptoms thereby enhancing the apparent efficacy of psychological
treatment. Alternatively, irregular medication consumption,
especially of short-acting benzodiazepines, when patients fail to
take medication as prescribed, may lead to temporary oversedation,
fOllowed by episodic withdrawal symptoms with heightened anxiety.
Unfortunately these issues have not been addressed in studies
which assume that concomitant benzodiazepine treatment is
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equivalent to psychological treatment alone.
From this review the specific area requiring further research
is evident. In particular a controlled comparison of the efficacy
of pharmacological and psychological treatment, each alone and in
combination, in the treatment of GAD.
10~
CHAPTER 5 : AIMS OF PRESENT RESEARCH
The present research consists of a sequence of studies each
conducted to meet a series of experimental aims which were derived
from the literature reviewed in Chapters 2,3, and 4.
The Pilot Study is divided into two partially-overlapping
sections (La , Ib); followed by the Main Study (II); a Secondary
Study (III); and a Subsidiary Study (IV).
la) PILOT STUDY
A controlled comparison of withdrawal symptoms and anxiety
recurrence following six weeks double-bi inr:!diazepam or placebo
treatment, for GAD in primary care.
Ib) PILOT STUDY
A controlled comparison of cognitive-behaviour therapy, diazepam,
and placebo in the management of GAD in primary care.
II) MAIN STUDY
A controlled comparison of the efficacy of diazepam, placebo,
cognitive-behaviour therapy, diazepam plus cognitive-behaviour
therapy, and placebo plus cognitive-behaviour therapy in the
management of GAD in primary care.
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III) SECONDARY STUDY
A controlled comparison of the characteristics of long-term
benzodiazepine users in primary care.
IV) SUBSIDIARY STUDY
Psychological ill-health and attitude to benzodiazepine use and
withdrawal among long-term benzodiazepine users.
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CHAPTER 6 : PILOT STUDY la and Ih.
6.1 la) Pilot Study
A Cnn tcro I l_ed Com par isnn 0 f _~~...:.t::..;h-,-d=--:...r-=a::..;w-,-a;:;__:l__ S~y__;_m"-Jpo;:_;::t_;::o,-,-m;_:_s.::;___ ...:.a;;_;n,-,-=d;___;A;__;_;_;n__;_x;_;l=-·P;;;_. ; t:.J...Y
Rprurrpncp Following Six Weeks Double-Blind Diazepam or Placebo
Treatment for Gp.nerali~pd ~nxiety Disorder in Primary Care.
As previously mentioned in the introductory chapters
bpn7.odiazepines arp gpneral1y acceptp.d to be the treatment of
choice in anxiety states, and sllperior to placebo (Greenblatt and
Shader 1974) • However many studies may be criticised on
methodological grounds (Solomon and Hart 1978). Furthermore a
number of studies have even suggested that placebo may be as
effective as anxiolytic medication, especially for patients with
low to moderate levels of anxiety (Johnstone et al 1980; Shapiro
et a I 1983). The existence of benzodiazepine dependence is now
incontrovertible (Petursson and Lader 1981; Marks 1983a; Tyrer et
a I 1983), a Ithough estimates of the numbers of users who are
affected by withdrawal symptoms vary widely (Hallstrom and Lader
1982) • Apart from a s ingu Iar notabl e except ion (Murphy et 031
1984), controlled studies of benzodiazepine withdrawal after the
administration of short-term therapeutic doses are lacking. In
addition, despite approximat~ly 85% of 0311 benzodiazepines being
prescribed by GPs (Rose 1983), and most anxiety disorders being
treated in primary care, wi th Iess than 10% being referred to
psychiatrists (Shepherd Pt. 031 1966), the efficacy of anxiolyticc;
has hitherto larlJely heen hased on -s t uriie-s with
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highly c;kpwed
psychiatric outpatient groups (Greenhlatt and Shadp.r 1974). The
lack of adequatp.ly controlled studies investigating the efficacy
and subsequp.nt withdrawal of short-tp.rm hp.nzodiazepine tre.3tmp.nt,
at the recommended dosage for GAD, in a primary c~rs s~tting! with
patip.nts who had not recently used or be~n d~p~ndsnt on minor
tranquillizers, prompted the first of this series'of studies.
This section of the pilot study aims to compare the
effectiveness of diazepam versus placebo in the management of GAD
over a six-week double-blind period in a primary care sp.tting.
ThE' ef fec t of pIaCE'bo on anx iety IevE'I was assessed dur ing one
WE'E'k singlE'-blind treatment with placebo before double-blind
treatment was started. Withdrawal reactions from diazepam were
investigated during a two-week withdrawal period, when ~ingle-hlind
placE'bo was substitutE'd for the double-blind active trE'atment•
.. ;'."'"
6.1.1 Subjects
Patients prE'senting to general practitioners (GPs) with a GAD,
who were thought suitable for pharmacological or psychological
treat.ment were referred for study Iriclusion. Following GP
assessment of morhidity the present author then assessed patient
characteristics, presE'nt mental 'State, and severity of illnes'S.
Patients werE' ~onc:;ideredsuitable for study inclusion if they met
the following criteria during detailed asses'Sm~nt :-
a primary diagnosis of GAD according to Pre'Sent State Examination
(PSE)(Wing et al 1973), DSM III (1980), and Research Diagnostic
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Criteria (Spitzer Pt al 1978); a minimum c;r.orpnf 15 on thE>
Hamilton Rating Scale for Anxipty (HAM-A) (Hamilton 1959) ;
c;ymptoms that had lasted for at least onE'month; no continuous and
prolonged use of benzodiazepines in thE'past 12 months; not taken
psychotropic drugs at timE'of initial a66e~5ment or in the previeus
three weeks; aged 18 to 65 years of eithE'r sex; and having given
written consent.
Patients were excluded if they met any of the following
criteria :- known to have a history of hypersensitivity reaction
tn, or abuse of, or dependence upnn benzodiazepines; exhibiting
any evidence of epilepsy, organic brain disease, or other
neurological deficits; exhibiting any significant cardiovascular,
hepatic, renal, respiratory, or endocrinological disease;
considered to have a high risk of suicide; evidence "o+ alcohol
abuse; if female, patients pregnant or lactating; if female,
patients not using contraceptive though required; previously
included in the present study; patients attending other therapists,
either professional or lay therapists. Patients with primary phobic
.or depressive disorders were specifically e~cluded, although
patients with minor secondary phobic or depressivE' features were
eligible for study inclusion.
A total of thirty-seven patients were referred by GPs for
study inc1us ion. ThreE' pa t jents wen'"not inc 1uded as thei r an)( i.ety
state was not of adequate severity tn meet entry criteria. One
pat ient was not admi ttE"d to the stlldy dUI=>to inabi 1ity to meet
diagnostic criteria; a primary depressive disorder was present.
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One patient was withdr-awn fr-om the study following the IJSP of nnn-
pr-escr-ibed benzodiazepines, and one patient dropped out pr-ior- to
commencement of active ther-apy. Thirty-one patients were included
in the pilot study.
6.1.2 Treatments
The thirty-one patients r-eceived one of thr-ee treatments
diazepam t n= t 0) , placebo (n=11), or- cognitive-behaviour- therapy
(CST) (n=10). The main demographic details of patients included
in the pilot study are shown in Table 6.1. Infor-mation concerning
pat ients' previous benzodiazepine pr-escr-iption, and pr-evious
episodes of anxiety wer-e supplied by GPs fr-om pr-actice r-ecor-ds.
The results of the diazepam and placebo gr-oups alone will be
pr-esented in this section as these gr-oups under-went a mor-e detailed
assessment with regard to treatment pr-ocess measur-es and withdrawal
symptoms. (A comparison of the relative efficacy of tr-eatment
outcome and follow-up for- diazepam vs. placebo vs. CST will be
presented separately in a following section of the pilot study
r-esults - PILOT STUDY Tb>.
All patients under-went a one-week single-blind placebo wash-
in per-iod, dur-ing which patients were unawar-e of their- dr-ug status.
Then diazepam and placebo tr-e.:ltment gr-Ollp5 r-eceived either- 5mg
d ia ze pam thr-ep timet;; daily or- p lac abo thr-ee timet;; daily dnuble-
blind for- a six-week per-iod. Following this per-iod,both gr-oups
r-eceived a fllr-ther-two weeks single-blind placebo per-iod, dur-ing
which patients wer-e unaW.:lr-eof their- dr-ug status, in or-der- to
1 1 1
Assess phArmacological withdrawal symptoms after cessation of
ben20diazepine treatment. All drugs were dispensed in identical
capsules packaged in dosettes, which were returned to the present
author at each asspssment to check comp lt anc e , On 1Y enouqh
medication to last to the next scheduled appointment was dispensed
at anyone time.
6.1.3 Procedure
Following initial GP and the present author's baseline
as<;=;pssmpnts,which together lastpd approximately one hour and
forty-five minutps, patients were randomly allocated to treatment
groups.
Over the six-week double-blind drug period the diazepam and
placebo patients were seen individually on four occasions by the
present author, and twice by their respective GPs. To compare the
impact of diazepam and placebo on cognitive and psychomotor
functions (to be reported separately) all patients completed a
battery of computerised cognitive and psychomotor tests, as well
as drug compliance assee::;sments.;:lndadvere::;ee::;ymptomchecklists
during each appointment with the present author.
For diazepam and pl03cebo patient<;=;the pre'5ent author also
-inquired about response to treatment in a non-directive manner so
ae::;to avoid makfng e::;uggestion'5of a therapeutic nature. E'ach
patient received approximately thrE"p.hours and twenty minutes
contact with thE" present author, and thirty minutes GP a'5'5ese::;ment
contact.
1 t?
Tab1 p 6.1 • Dpmof)raphir Fpaturpc; of Pi 1ot ~tlJr1y GAD _Pat ipnt':?_~
CRT P1Clcpho---,---
(0 = 10) (0 = 10) (n=ll)
Mean age (yrs) 3~.5 31.R 36.9
Se)( 1M, 9F 2M, SF 1M, tOF
Duration o~ symptoms 3.2 4.9 3.2
(months)
Nos with history of S 6 to
an)(iety
Nos prey ious 1Y 7 7 7
prescribed
benzodiazepines
1 1~
6.1.4 Menc;.!Jr-e~
Thr-ee pr-imar-y me~C;lJr-esof tr-eatment pr-ocess and outcome wer-e
ue;ed in this section of the pilot study.
a.) The Hamilton (19~9) Rating Scale for- Anxiety (HAM-A)
(Appendix 1) Wc'\S used by thE' pr-pspnt author- a's thF? main tr-patment
pr-ocpss and outcome mpasur-e to dpt.er-mine pat iE'nte;' anxipty
symptoms.
The HAM-A was dE'signed to aSSF?SS thE' sever-ity of symptoms in
patients suffpr-ing from anxiety npurosis. The HAM-A consists of
14 itF?ms, each rated on a fivp-point (0 - 4) scale. Under- each
itpm a number- of symptoms and signs are listed, which indicate the
range of phenomena to be considered when scoring. The 14 items
include anxious mood, tension, fears, insomnia, difficulties in
concentration and memory, depressed mood, general somatic symptoms
(muscular), general somatic symptoms (sensory), cardiovascular
.~....
symptoms, respiratory symptoms, gastrointestinal symptoms, genito-
urinary symptoms, autonomic symptoms, and behaviour at interview.
The items can be totalled to produce a general factor of anxiety,
or divided to produce a bipolar factor contrasting 'psychic' with
'somatic' symptom'S. Hamilton (1959) ref10rted reliability
Correlations as varying between +0.83 to 0.95. The evaluation of
presence and inten'Sity of the various items is based on an
intervipwer's assessment of the patjpnt's condition at the time of
interview. Few of the 14 items are c1inical signs to be directly
Observed during interview. The maj or-i ty of items are c;ymptoms
(i.e. patient complaints), and therefor-e the assessment is based
1 1 4
on thp (1<'ltipnt'e:;rnnrlition durin!) thp (1rpvinus d.=lYs<'le:;rer:ommpnrlprl
by Hamilton (1986). Throughout the present spries of studies
HAM-A asspssments covered the 7 - day period prior to interview.
A more detailed and structured scorinq system based on specific
assessment of the frequency, severity and duration of symptoms, was
introduced at initial entry asspssment and used consic:;tently
thereafter (Hamilton Anxiety Glossary - Power et al 1985; Appendix
2). The Hamilton Anxiety Glossary (HAM-G) (Power et al 1985) was
developed to improve inter-rater reliability of the HAM-A and is
similar in structure and intention to the glossary developed by
Williams (1984) for the Hamilton (1960) rating scale for depression
(HAM-D) •
The HAM-G was evaluated by 16 clinical pychologists during
anxiety assessment training using pre-recorded ~ videotaped
interviews with GAD patients. Prior to HAM-G training the standard
deviation of the 16 psychologists' HAM-A scores was 4.61. When
rating the same interview using the HAM-G~the standard deviation
was 1.86, thereby illustrating a statistically significant
improvement in reliability (t = 3.427, df = 14, p < 0.05) (Snedecor
and Cochran 1967). In the above training session the HAM-G also
significantly reduced the HAM-A scores from a mean of 32 (range 25
- 39) prior to use, to a mean of 22.37 (rang"" 19 - 25) whpn
adhered to (t = 7.06, df = 15, p < 0.01).
that the HAM-G enhances reliability and "produces more
conservative HAM-A score.
With the exception of the initial GP assessment (day -7),
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undertaken before the placebo wash-in period began, the HAM-A was
completed at each assessment interview by the present author, that
is, at the end of the placebo wash-in period but immediately before
the active treatment period (day 0), and on days 7, 14, 28, and
42 of the si~-week double-blind active treatment period. A final
assessment was conducted at the end of the two-week withdrawal
period (day 56).
b). The Kellner and Sheffield (1973) Symptom Rating Test (SRT)
(Appendi~ 3), designed to measure changes in symptoms of distress
in neurotic patients participating in therapeutics such as drug
trials, was the main self-report treatment process and outcome
measure used.
The SRT cons ists of a check -1 ist of 38 symptoms; 15 are
somatic, and 23 psychological, and the patient rates each symptom
on a four-point scale. Kellner and Sheffield (1973) report test-
retest reliability correlations as varying between +0.92 to 0.94.
Split-half reliability of changes on the SRT score in neurotic
outpatients after one month was .+0.89. In a number of validation
studies the SRT discriminated significantly between patients and
normals. In drug trials the SRT was found to be effective in
,.
discriminating between responses to psychotropic drugs and to
placebo. Kellner and Sheffield (1973) report the SRT to be a
valid and reliable measure of distress. The SRT was completed by
the patient at the GP's initial assessment before the placebo wash-
in period began. Thereafter the SRT was administered by the
Current author and completed by the patient to the same schedule
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as the HAM-A.
c) Adverse reactions to the druC) regimen were recorded by the
present author at each assessment interview by means of an open
ended interview and check-list of adverse symptoms (Appendix 4).
6.1.5 Results
One-way analysis of variance produced no significant
difference on subjects' demographic variables i.e. age and duration
of symptoms. No significant difference in mean scores was seen
between diazepam and placebo groups on initial HAM-A (day 0)
(t = 1.23, df = 19), and initial SRT (day -7) (t = 0.062,
df = 19). Mean ratings and standard deviations for diazepam and
placebo groups on the HAM-A during active double-blind treatment
)
(days 7, 14, 28 and 42), and at the end of the s'ingle-blind
withdrawal period (day 56) are presented in Table 6.2 and
-illustrated in Figure 1.
Mean ratings and standard deviations for both groups on the
SRT, at day -7 and on the same schedule as the HAM-A ratings are
presented in Table 6.3 and illustrated in Figure 2.
Effects of treatment were investigated by computing repeated
measures analysis of variance (MANOVA) with treatment group as the
between subjects factor and time of assessment as the within
subjects factor.
a). HAM-A ratings The between-group analysis revealed a
significant time (F (5,95) = 12.76 P {0.001) and interaction
effect (F(5,95) = 3.09 p <0.05) with no significant group effect.
t 17
Trlh)p /-,.7. HAM-A merln"'!___~~n e;tannrlrn npvirlt~one; (SO) fo_r Oj~zp.R.am
rlnn PI rlceho grollpe; rlt Prlch rlsspssment stagp nlJri.ng trprltmpnt.
Plarpho
HAM-A (SO) x (SO)
Day 0 18.9 (3.7) 16.7 ( 1. 1)
Oay 7 12.1 (6.6) 13.5 (4.8)
Day 14 10.1 (6.7) 12.8 (5.6)
Day 28 11.0 (7.3) 12.7 (6.3)
Day 42 9.9 (6.3) 12.6 (6.3)
Day 56 14.8 (6.1 ) 12.1 (6.6)
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Table 6.3. SRT means anrl standarrl rleviatinns (SO) for Oiazepam anrl
EJacebo groupe:; at each assessment st~e rlllring tn"atment.
Tli,,!~~a'!!. ~ac:_~bo
SRT X (SO) X (SO)
Day -7 38.5 (13.0) 35.0 (12.6)
Day 0 37.1 (20.0) 34.7 ( 9.7)
Day 7 28.2 (13.9) 27.3 (12.8)
Day 14 24.3 (18.1) 27.2 (13.1)
Day 28 30.4 (18.0) 28.3 (16.0)
Day 42 26.1 (17.3) 27.1 (16.6)
.~....'
-Day 56 38.0 (21.4) 25.8 (17.4)
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To assess the simple effects of time within each group a repeated
measures within-group MAN OVA was performed, which revealed
significant changes over the six assessment sessions in both the
placebo (F(5,95) = 3.11, p <0.05), and diazepam (F(5,95) = 12.30,
P <0.005) groups.
Within-group treatment response revealed that there was a
significant reduction in HAM-A scores for the diazepam patients,
during the first week (day 0 - day 7) of active double-blind
treatment, (t = 3.11, df = 9, P <0.05). This was maintained at
the end of active treatment, comparing day 0 to day 42, (t = 5.76,
d f = 9, P <0•0005) • However fo 11ow ing sing Ie-b 1ind placebo
substitution withdrawal (day 56) there was a significant increase
in HAM-A scores in comparison to the end of active double-blind
treatment (day 42) (t = 3.01, df = 9, p <0.05). Despi te such
increases in HAM-A following withdrawal, the diazepam group as a
whole were still assessed to be less anxious at day 56 in
comparison to the beginning of douqle-blind active treatment (day
0) (t = 2.50, df = 9, P <0.05).
Simi larly wi thin-group treatment response for the placebo
patients revealed a significant reduction in HAM-A scores, during
the first week of active double-blind treatment, from day 0 to day
7, (t = 2.48, df = 10, p <0.05) which was maintained at the end
of active treatment, comparing day 0 to day 42. (t = 2.30, df = 10,
P <0.05). However, unlike the diazepam group, the placebo group
did not exhibit a significant increase in HAM-A scores following
single-blind placebo substitution withdrawal (day 56) when compared
122
to the end of double-blind treatment (day 42) (t = 1.46, df = 10).
At the end of the single-blind withdrawal period (day 56) the
placebo group were also assessed on the HAM-A to be less anxious
than at the beginning of double-blind active treatment (day 0)
(t = 2.44, df = 10, P <0.05). There was no significant diff~r~nc~
between the treatment groups on any of the individual assessment
days.
b) SRT ratings The SRT ratings revealed a significant time
effect (F(6,114) = 3.48, p <0.005), and no significant group or
interaction effect. To assess the simple effects of time within
each treatment group a repeated measures within-group MANOVA was
performed, showing that only the diazepam group changed
significantly during treatment over the seven assessment sessions
(F(6,114 = 3.08, p <0.001).
Within-group treatment response comparing initial SRT scores
-before entry to the study (day -7) and following single-bl ind
placebo wash-in treatment (day 0) failed to show any significant
reduction for either the diazepam Ct = 0.33, df = 9), or placebo
(t = 0.18, df = 10) groups. Al though a number of within-group
trends e)(isted there were no significant changes in SRT scores
between individual assessment days for both treatment groups. In
particular there was no significant reduction in SRT scores at the
end of the active double-blind treatment period (day 42), in
Comparison to the beginning of double-blind active treatment
(day 0) for ei ther group. The increase in SRT scores for the
diazepam group following single-blind placebo .substitution
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withdrawal (day 56) in comparison to the end of active double-blind
treatment (day 42) failed to achieve statistical significance.
There was no significant difference between the treatment groups
on any of the,individual assessment days on the SRT.
6.1.5.3 Withdrawal
Adverse withdrawal reactionsat the end of the two-week placebo
withdrawal period (day 56) were considered to have occurred if
(i) there was a quantitative increase in the severity of symptoms
from that reported at the end of the double-blind period (day 42),
or (ii) new symptoms had emerQed that had not previously been
reported. Table 6.4 shows increases in previously-occurring
symptoms, and the appearance of new symptoms. No patient may have
a score in both columns for anyone symptom. The diazepam group
reported a significantly greater number of both types of withdrawal
.;;'.~,
-symptoms for each patient (t = 8.91, df = 19, P (0.005; t = 3.69,
df = 19, p <0.05) than the placebo group.
6.1.6 Discussion
A significant reduction in anxiety ratings as assessed by
HAM-A scores was found in patients who had taken diazepam, and to
a lesser extent also in those who had taken placebo. Both drugs
were most effective during the first week of double-blind
treatment, a result similar to that found by Shapiro et al (1983).
The efficacy of both drugs as assessed by the SRT, was .less
noticeable and few significant results emerged, although the trend
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was similar in direction to HAM-A scores. This discrepancy between
self-ratings and observer-ratings is in accord with Lader's (1985)
suggestion that sel f- report data provide a more conservative
assessment of drug efficacy in comparison to trained observer
ratings. In addition large standard deviation qcorss on SAT ratin96
by both groups (Table 6.3) illustrate the wide range of patients'
self-reported anxiety symptoms throughout the study period.
No significant reduction in SRT scores was seen in either
group during the initial placebo wash-in period. The reduction in
anxiety ratings during the first week of double-blind treatment may
have been partly due to factors other than double-blind medication
for example, the introduction of the clinical psychologist
assessor, whose sole concern was assessment of efficacy, and who
purposely did not provide any direct psychological treatment but,
nevertheless, provided increased contact with the patients. This
Suggests that factors such as amount of contact wi th patients
during drug trials may playa substantial role in determining the
outcome of treatment.
A number of problems exist
after the end of anxiolytic
in defining withdrawal symptoms
treatment. A small number of
withdrawal scales exist but are either unvalidated (Lader, personal
communication 1985), or validated on subjects during withdrawal
from long-term, high-dose benzodiazepine abuse (Sellers et al 1987,
unpublished report). Owen and Tyrer (1983) ,suggested that the
first symptoms experienced during withdrawal are similar to those
Of anxiety. Whether these symptoms are a recurrence of clinical
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anxiety, or a drug withdrawal reaction is difficult to determine.
The emergence of new symptoms during withdrawal however, is less
likely to be due to anxiety recurrence. Owen and Tyrer (1983)
therefore suggested that the presentation of new symptoms, and a
temporary increase in pre-existing symptoms may indicate a
withdrawa I syndrome.·
The results of the present pilot study suggest that withdrawal
from diazepam after a short period of treatment by substitution
with single-blind placebo leads to an increase in both anxiety and
withdrawal symptoms. Graded withdrawal may reduce the number and
severity of symptoms, and this will be assessed in the main study
to follow (Chapter 7). Nevertheless the results of single-blind
placebo withdrawal treatment indicated that the symptoms reported
were not reactions that occurred due to the cessation of tablet
consumption but were specifically due to the termination of
., ;,..~.
-diazepam treatment.
However, not all patients receiving benzodiazepines experience
withdrawal symptoms and I or increases in anxiety during withdrawal
(Laughren et al 1982). Tyrer (1984b) suggests that over 50% of
long-term users can abruptly stop benzodiazepines without any
problems occurring. Similarly in the present pilot study only half
of the diazepam group exhibited significant increases (defined as
increases of ~ 100% of day 42 HAM-A score at day 56) in anxiety
dUring withdrawal. The finding that withdrawal.symptoms can occur,
after a relatively short period of treatment in a significant
percentage of patients, has important implications for management.
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The current trend advocates a reduction in the duration of
treatment. However the above study suggests that the use of
diazepam at normal therapeutic doses, and for what has hitherto
been regarded as a safe length of treatment, may result in
withdrawal symptoms. During withdrawal many patient~ a~e likely
to interpret any minor physical or psychological change either as
evidence of anxiety recurrence,or evidence of withdrawal problems,
thereby magnifying their self-perceived dependency. Furthermore,
the expectancy of severe withdrawal reactions that has been
highlighted by some sections of the popular press may inadvertently
focus patients' attention, and thereby enhance withdrawal effects
in patients with suggestible personalities. It is important that
such misconceptions are all ayed prior to the commencemen t of
withdrawa 1.
The results of this section of the Pilot Study were published
- by Power et al (1985).
Although the sample size of this section of the pilot study
is relatively small, the results suggest that a reassessment of
benzodiapine use may be required, with graded withdrawal being
introduced as standard c:1inic:aI prac tice even af ter very short
periods of use. The efficacy of graded withdrawal will be assessed
in the main study to follow.
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6.2 I b) PILOT STUDY
~ Controlled ComparisQ!l.._of Cqq~it_iye-Rphaviour Thp.rc"i~_nia7p.(1am
~.~d PI acg_Q.Q__J.Q_J ~_S'._fI.CiD.(~.g~mf?nt .of Ge=>npr.a.J_ispd Ar:.~i..~.ty_D isordpr_~
Pr imary l.arE'~.
As previously noted in thE' introductory chapters, the efficacy
of psychological techniqup.s in the managempnt of GAD has heen
inconclusive, outcome results producing small improvements which
are seldomly clinically significant COst 1982). As a consequence
multidimensional and mixed-treatment approac:hes have been advocated
(Mathews 1985) and recently adopted (Lindsay et al 1987; Blowers
et al 1987; Butler et al 1987). Unfortunately, with the exception
of Lindsay et aI's (1987) study, the efficacy of multidimensional
psychological treatments of GAD has yet to be adequately compared
with widely used pharmacological alternatives.
In the present section of the pilot study a preliminary
comparison of the relative effectiveness of CBT vs. diazepam vs.
placebo in the management of GAD in a primary care setting was
undertaken.
6.2.1 Subjects
The patient sample was as descrihed in 6.1.1.
6.2.2 Trea tm2!!.t~
Diazepam and placebo treatment groups were as descrihed in
section 6.1.2 and all patients were seen on an individual basis.
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The CRT group received cognitive therapy based on Beck and Fmery's
(1979) approach which was specifically concerned with the
elicitation and modification of automatic: t hourjht e and irration."ll
assumptions. Written handouts explaining the rationale and
management techniques of cognitive therapy were given tn patientq
(Append ix 5). In conjunction with the handouts,patients were also
trained in progressive relaxation using a procedure adapted from
Jacobson (1938). Patients were supplied with taped relaxation
training instructions to be followed dai lye Individual behavioural
targets, such as graded exposure, were also set where necessary.
The CBT approach used in the present study was simi 1ar to the
"Anxiety Management" approach adopted by Butler et al (1987b) for
the treatment of persistent generalised anxiety. Patients in the
CBT group did not receive any concomitant psychotropic medication •
..~..~
6.2.3 Procedure
All patients completed the initial GP baseline assessments,
as outlined in section 6.1.3, before being randomly allocated to
treatment groups. The procedure for diazepam and placebo treatment
groups was as outlined in section 6~1.3. Patients allocated to the
CBT group were seen for therapy on four occasions by the current
author, who was not involved in the assessment of end of treatment
outcome for the CBT group. Each CBT appointment for therapy lasted
approximately fifty minutes. In addition. eBT patients also
received two fifteen-minute GP assessment appointments, and two
psychologist assessor appointments,each conducted both prior to and
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following trpatment. CAr was providec1 ovpr a six-week pprioc1,
equivalent to the length of time d i azepam and placebo patients
recpived 'active' double-blind treatment. Following initial GP
assessment, thE? diazepam and placebo groups received .::1 one-wef-ll<
single-blind placebo wash-in period.
pharmacological treatment was given to the eBT group during this
week.
The present author admi.nistered medi.cation, and conducted
treatment process and outcome assessments on the pharmacologically-
treated patients and was certainly unaware of the drug status of
the double-blind diazep~m and placebo groups. Because the current
author conducted the eBT it was thought methodologically
unsatisfactory that he also should be responsible for asssessing
treatment outcome for this group. 80 a psychologist assessor who
was unaware of the n~ture of the study was asked to assess
,';'."
treatment outcome for the eBT group. However if informed by the
patient the psychologist assessor could have concluded that a
patient had been allocated to the eBT group. One therefore cannot
presume that the psychologist assessor was completely blind when
conducting outcome measures on the eBT group.
The psychologist assessor was trained in the administration
of the HAM-A by the current author. prior to the commencement of
this study. A sample of four non-study an)(iety patients were
independently rated on the HAM-A by the current author and the
Psychologist assessor. A high level of agreement on HAM-A scores
Was achieved (Pearson r = 0.91. p < 0.01).
1 ~ 1
6.2.4 Mprlc;ur-pc;
Four- pr-imar-y mPMSIJr-PS of t r-patmpn t pr-OCE'SC;and outcome wer-p
used in this section of the pilot study.
a.) It is obviously not possible to deter-mine how anxious patients
in this study wer-e in compar-ison to those r-epor-ted in other- studies
given the pr-obable var-iability in HAM-A scor-es between studies due
to lack of specific sever-ity criter-ia. In the pr-esent study GPs
r-ated patients' sever-ity of illness on a 7 - point scale at initial
assessment and at the end of the active tr-eatment per-iod.
point sever-ity r-ating scale had four- anchor- points
1 - nor-mal; not at all ill, absence of symptoms
3 mild; symptoms definitely pr-esent but no significant impair-ment
The 7-
of function
5 moder-ate; a definite degr-ee of impair-ment
7 sever-e; an incapacitating condition.
b.) The Hamilton (1959) Rating Scale for- Anxiety (HAM-A) and the
Hamilton Anxiety Glossar-y (HAG) (Power- et al 1985) wer-e used as
described in section 6.1.4 a). The HAM-A ratings were compared, for
all thr-ee groups, at baseline pre-treatment (Day 0), one month
following baseline (Day 28), and at the end of the active treatment
period (Day 42).
c.) The Kellner and Sheffield (1973) Symptom Rating Test (SRT) was
administered as described in section 6:1:4 b).
d.) Overall symptom change at the end of active treatment was
assessed in all patients by GPs; for the diazepam and placebo
groups by the cur-rent author; and for the CST group by the
137
Psycholooist Assessor. Patients were rated on a 7-point srale of
overall symptom change, ranging from 1 - 'very much improved', 2
'much improved', 3 - 'minimally improved', 4 'no r:hanQe', 5 -
'minimally worse', 6 - 'much worse' to 7 - 'very much worse'.
e) Finally, pa t t en t s WP.rf':' seen at 12-month follow-up, and GP
records were examined to assess subsequent post-study psychotropic
medication usage, and psychological or psychiatric treatment. The
clinical assessment at follow-up is not reported, as it was
impossible to ascertain what factors were responsible for clinical
status given the possible confounding influence of subsequent post-
study treatment.
6.2.5 Results
Of the patients assessed by GPs at initial inteview, on the
1 7 severity scale, 16% were given a rating of 3 (mild); 21%
- a rating of 4; 58% a rating of 5 (moderate>; and 5% a rating of b.
There were no significant differences between treatment groups in
terms of GP initial severity ratings.
One-way analyses of variance were performed between groups on
the pre-treatment SRT and HAM-A ratings, and also on the subjects'
demographic variables, ie. age and duration of symptoms (see
Table 6.1). No significant re~ults were obtained, suggesting that
the thrf?e trf?atment groups were compe reble prior to treatment.
Table 6.5 gives the means and standard devi-3tions for each group
at each assessment on the SRT and the HAM-A.
Effects of treatment were investigated by computing repeated
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measures analyses of variance (MANOVA) with treatment group as the
between-subjects factor and time of assessment as the within-group
factor.
a. ) HAM-A ratings The between-g roup ana lyses revea Ied a
significant time (F(2,56) = 82.3, P (0.05) and interaction effect
(F(4,56) = 7.2, p (0.05), with no significant group effect.
Within-group repeated measures MANOVA over the three assessment
sessions showed significant c~ange during treatment for the placebo
(F(2,20) = 5.21, p (0.05), diazepam (F(2,18) = 22.07, P (0.0005),
and CST (F(2,18) = 185.02, p (0.0005) groups. The only significant
difference between treatment groups was at the end of active
treatment (day 42) (F(2,28) = 5.16, P (0.05). A post-hoc Scheffe
test indicated a significant difference between CST and placebo
groups at the 0.05 level.
b.) SRT ratings: A between-group analysis produced a significant
_ time effect (F(2,56) = 13.6, P (0.05) with no significant group or
interaction effect. Wi thin-group repeated measures MANOVA over
the three assessment sessions showed that only the CST group
changed significantly during treatment (F(2,18) = 31.35, p
<0.0005), but no significant differences between treatment groups
occurred on any of the individual assessment days.
c.) Overall symptom change While the above results establish
levels of statistical significance in group comparisons using
specific anxiety measures, an assessment by BP and psychologist
assessors, of symptom change at the end of active treatment period
(day 42) illustrates clinically-rated change. Table 6.6 shows
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patip.nts' symptom changp at day 42 in compa r t son to study pntry, and
also reveals the h iqh Ip.vel of betwE'p.n GP and
psychologist assessors (Pp.arson r = 0.89, P (0.005).
d.) Follow-up: Recent studies have noted an inability to collect
adequate follow-up data as patients often require subsequent
treatment between the end of the active study period and the
deSignated follow-up date (Tarrier and Main 1986; Lindsay et al
1987). Bellack and Hersen (1984) recommend the use of 'unobtrusive
measures' at follow-up to extend the external validity of research
findings, and to reduce contamination effects of subsequent
treatment. Table 6.7 illustrates post-study psychotropic
prescription and lor psychological treatment at twelve months
follow-up.
T~ble 6.5. Me~n~ and ~tanrlarrldpviation~ (SO) for each group at
each a~~essment se~5ion during treatment on the HAM-A ~nd ART.
CRT !2_i a ~~n.~m. Plac:p.ho
-HAM-A X (SO) X (SO) X (SD)
Day 0 18. 1 (2.5) 18.9 (3.7) 16.7 (1. 1 )
Day 28 7.8 (4 •1) 11.0 (7.3) 12.7 (6.3)
Day 42 4.5 (4.6) 9.9 (6.3) 12.6 (6.3)
SRT
Day 0 31 .0 (9.3) 37.1 (12.0) 34.7 (9.7)
Day 28 17.0 (to.3) 30.4 (t8.0) 28.3 (16.0)
Day 42 14.4 <12.1> 26.1 (17.3) 27. 1 (16.6)
..~'.~
'_i.!..
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Table 6.6. GP ann 11c;y:chologic;tass~c;c;or CPA) ratings of ov~ra 11
sy:mptom change at end of active treatment p~riod.
Si:mptom £3FI PA
Change
CRT DZ PL CBT DZ PL
Very rruch 6 2 6 2 2
improved
M..tch
improved 4 4 5 3 4 4
Minimally 3 2 1 2 1
improved
f\b change 2 1 1
Minimally 1 1 1~ 1worse
- t1.Jchworse 1 1
Very much
WOrse
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Table 6.7. SubsPQIJPnt psychological and / or psychotropic
treatment at 12 mont.hs follow-up.
CAT Diazepam Placebo
(N = 10) (N = 10) (n = 11>
Psychological 3 4
Psychotropic 3 2 1
Psychological 2 1
+
Psychotropic
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1->.2.1-> Disruc;si.nn---.-.----- ..-.-
Using the mnre rpc;trirtprinumbpr nf L-Ji.thin-grolJpasspsc;mentc;
over timE>, (in rompAric;nn to Pilnt Sturiy 1a), results of thp
HAM-A r-atinqs surror-t a significant treatment effect for all threp
gr-oups. The pnri of trPAtment CRT scores wpre significantly low~r
than placebo, but no such differencp existed between diazepam and
placebo groups. Results of the SRT scores suggest a significant
impr-ovement over time for the CBT group alone, although therp were
no significant diffprences between trpatment groups on any of the
individual asc;essmpnt days. A non-significant trend for a
reduction in self-report symptoms was evident in the diazepam and
placebo groups. Large standard deviation in the SRT ratings of all
three groups (Table 6.3) illustrate the wide range of patients'
self-report anxiety symptoms prior to and following treatment.
End of therapy assessments were conducted prior to diazepam
-withdrawa I so that outcome r-esuIts were not confounded by the
withdrawal symptoms or anxiety recurrence that may develop
following cessation of benzodiazepine treatment (Pilot Study 1a>.
In general therp pxisted close agreement between the GP and
psychological assessment of the proportion of patients in each
category of symptom change following treatment. For both GPs and
psychological assessor there existed a grpater spread of treatment
response for diazepam and placebo groups than for the CRT group.
This may reflect the greater range of SRT and HAM-A ratings at the
end of treatment "for diazepam and plac~bo groups than for the CRT
group. Some researchers note the need for further treatment of
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f1Atients following the f?nrlof sturly trp.Atmpnt f1p.riorl(TArrier anrl
Main 1986), and others st<3te that virtually no f1Atients are
symptom-free at follow-up (Durharn .~nc1TurVf:OY1987). At twelve
months follow-up three of ten CST patip.ntc;hac1 rp.ceiven subsequent
psychotropic medication. This may suggp.st that the study period
was too short and amount of CST inadequate. The treatment period
has therefore been extended in the main study to follow. Seven of
ten diazepam patients received subsequent psychotropic and lor
psychological treatment. This high proportion may have been
inadvertently inflated by placebo substitution withdrawal from
diazepam and the subsequent recurrence of anxiety or withdrawal
symptoms, or a lack of satisfaction with the degree of improvement
during diazepam treatment. In order to minimize the impact of
withdrawal symptoms at treatment outcome and follow-up, placebo
sUbstitution graded withdrawal, will be adopted in the main study
-to follow. At the end of active treatment the placebo group
achieved the smallest degree of symptom improvement on both the
HAM-A and SRT ratings and unsurprisingly six of eleven patients
received subsequent treatment.
It is important to note that there was no formal assessment
of C8T content or skill of the current author as therapist. The
degree of contact involved in assessing cognitive and psychomotor
performance of the diazepam and placebo groups was the same as that
given to the C8T group. This reduces the possibility that the
comparatively greater improvement in the C8T group at the end of
active treatment could be attributed to the amount of psychologist
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Attention patients received. This factor w~s seldom control led for
in other studies. However since the diazepam and placebo groups
received no direct form of counselling, it would be inappropriate
to claim that the superiority of CBT was related to the technique
itself rather than to it simply being a structured fQrm Qf
counselling intervention. Furthermore the psychomotor assessments
conducted on the diazepam and placebo groups could possibly have
had an adverse impact on treatment outcome. So in the main study
to follow, patient groups will continue to be balanced for overall
amount of psychologist contact but the patients receiving diazepam
alone and placebo alone will not undergo psychomotor assessment,
but wi 11 simply receive enquiries about response to treatment,
conducted in a non-directive manner,
suggestions of a therapeutic nature.
It could be argued that in the absence of a waiting-list
so as to avoid mak iog
- control group, it is not possible to be certain that change over
time was attributable to treatment per se. However, Lindsay et al
(1987), Blowers et al (1987), and in particular Butler et al
(1987a) all reported the superiority of a form of psychological
treatment similar to that adopted in the present study, in
comparison to waiting-list controls.
Although the pilot studies suggest the superiority of CST over
diazepam '"and placebo as trea tmen t for GAD, the resu 1ts do not
PE'rmit a wholl y adequate comparison of treatment efficacy at
follow-up. In addition there was no combined psychological and
pharmacological treatment group, and the number of outcome
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meaSlJreS, and sample size merit exp~nsinn.
Results of this section of the Pilot Study are currently in
press (Power et al. 1989).
The main study attempts to redress most of the pilot study
inadequacies, and to extend the area of inquiry •
."~
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CHAPTER 7 : MAIN STUDY
7.1 A Controlled Comparison of the Efficacy of Diazepam,
Placebo, Cognitive-Behaviour Therapy. Diazepam plus Cognitive-
Behaviour Therapy. and Placebo plus Cognitive-Behaviour
Therapy in the Management of Generalised Anxiety Disorder in
Primary Care.
This main study attempts to redress many of the methodological
inadequacies of previous studies, cited in the introductory
chapters, that investigated the efficacy of pharmacological
treatments and/or psychological approaches in the management of
GAD. In addition lessons from the Pilot Study (Chapter 6) have
also been incorporated in the design and method of the main study.
This study attempts to compare the efficacy of diazepam (DZ) vs •
.• ';",W
-placebo (PL) vs. cognitive behaviour therapy (CBT) vs. diazepam
plus cognitive-behaviour therapy (DZ+CBT) vs. placebo plus
cognitive-behaviour therapy (PL+CBT) in the management of primary
care GAD patients who are drug-free at time of referral, and who
are not using non-study concomitant psychotropic medication during
the course of study treatment.
7.1.1 Subjects~'
Patients presenting to general practitioners (GP) with GAD who
were thought suitable for pharmacological and/or psychological
treatment were referred for study inclusion. Following GP
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asspssment of psychologir.al mor-bidi.ty thp pr-pspnt author- thpn
assessed patient char-acter-istics, pr-esent mental state, and
sevpr-ity of illness. Patients wer-e consider-ed suitable for- study
inclusion if they met the same detailed er-iter-ia outlined in thE'
Pi]ot Study (section 6.1.1.>. A t o t a l of 113 patients Wel'"f;:I
r-efer-r-edby GPs for- study inclusion. One patient was not included
as their- anxiety state was not of adequate sever-ity to meet entr-y
cr-iter-ia. One patient was not admitted to the study following the
use of concomitant non-study pr-escr-ibed benzodiazepines. Two
patients failed to attend for- initial psychological assessment.
A fur-ther- five pat ien ts dr-opped-out after- in it ia 1 psycho log ica 1
assessment, and the attendance of 3 other- patients was so spor-adic
that few r-elevant data wer-e available, and so they wer-e excluded
fr-om ana Iysi s. A total of 101 patiE:>nts wer-e included in the
study.
..~-:-.
7.1.2 Tr-eatments
The 101 patients r-eceived one of five tr-eatments: diazepam
(OZ) (n = 22), placebo CPL) Cn = 19), cognitive-behaviour- ther-apy
(CST) Cn = 21), diazepam plus cognitive-behaviour- ther-apy COZ +
CST) (n = 21), placebo plus cognitive-behaviour- ther-apy CPL + CST)
Cn = 18). All patients wpr-e tr-eated on an individual basis by the
,~.
pr-esent author-.
7.1.2.1 Diazp.pam Ther-apy COZ>
a) Wash-In: Patients wer-e initially placed on one-week, single-
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blind, placebo, three times daily.
b) Active-Treatment: Following wash-in patients received six
weeks double-blind diazepam, three times daily (5mg + 5mg + 5mg).
c) Graded-Withdrawal: At the end of active-treatment patients
received one-week, double-blind diazepam plus placebo substitution
three times daily (5mg + placebo + 5mg), followed by another one-
week double-blind diazepam plus placebo substitut.ion (placebo +
placebo + Smg). Patients were then continued single blind on
placebo three times daily for a final one-week period.
7.1.2.2 Placebo Therapy (PL)
a.) Wash-In' : Patients were initially placed on one-week
single-blind placebo three times daily (as in section 7.1.2.1.(a».
b.) Active-Treatment: Following wash-in, patie~ts received
six weeks double-blind placebo, three times daily.
c v ) Graded-Withdrawal :';''Atthe end of active-treatment,
patients received two weeks double-blind placebo three times daily.
Patients were then continued single-blind on placebo three times
daily for a final one-week period.
7.1.2.3 Cognitive-Behaviour Therapy (CBT)
All patients received a maximum of seven CBT treatment
sessions which uti 1ized the same methods as the Pi lot Study
(section 6.2.2). CBT treatment sessions were provided over a nine-
week period equivalent to the length of time DZ and PL groups
received double-blind active-treatment and graded withdrawal.
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a) Wash-In: Ac; in sec tion 7. 1.2.1.(a )•
b) Active-Treatment: Six weekc; douhle-blind diazepam
C5mg t.i.d) as in section 7.1.2.1.Cb). Patients also received a
maximum of seven CBT sessions as in section 7.1.2.3. (OVf-'1'"thf-'
equivalent nine weeks encompassing activp.-treatmf-'ntand gradf-'d-
withdrawal periods).
c) Graded-Withdrawal: As in sec tion 7. 1.2.1•(c)•
7.1.2.5 Placebo plus Cognitive-Behaviour Therapy (PL + CBT)
a.) Wash-In: As in section 7.1.2.1.(a).
b.) Active-Treatment: Six weeks double-blind placebo (t.i.d)
as in section 7.1.2.Z.(b). Patients also received a maximum of
seven CBT sessions as in section 7.1.2.3 (over the equivalent nine
weeks encompassing active-trea tment and graded-wi thdrawa 1 periods).
c.) Graded-Withdrawal: As in section 7.1.2.2.(c).
7.1.3 Procedure
Following the initial GP aS5essment (day - 7), patients were
randomly allocated to treatment groups. After completion of the
one-week wash-in period, or equivalent for the CST alone group, all
patients completed baseline p5ychological assessment (day 0),
conducted by the present author. Thereafter all drugs, packaged
in identical bubble-packs, were dispensed by-the present author.
Only enough medication to last to the next scheduled appointment
was dispensed at anyone time, and bubble-packs were returned at
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each assessment to rherk com~lianrp.
Over the six-week r1ouble-blinrl druq fJF.'rior1thF.'DZ and PL
patients werF.'seen individually on five occ~5inns hy the present
author (days 0, 7, 14, 28, 42,). At the end of ac t i ve douhle-
blind treatment OZ and PL patients continued double-blind gr~ded-
withdrawal and were again seen by the present author at the end of
this two-week period (day 56). Patients then completed graded-
withdrawal with one-week single-blind placebo and were assessed by
the present author at the end of this period (day 63). Finally
one week after ceasing all medication (day 70) patients were
assessed by the present author and their respective GPs. In total
patients were seen on eight occasions by the current author and
twice by their GPs. For OZ and PL patients the present author
assessed drug compliance, adverse symptoms, and inquired about
response to treatment in a non-directive manner so as to avoid
-making suggestions of a therapeutic nature (as in section 6.1.3).
Consequently each OZ and PL patient received approximately 5 hours
and 40 minutes contact with the present author and 30 minutes GP
assessment contact.
Patients allocated to CBT alone were seen individually for
therapy by the current author according to the same time schedule
as the DZ and PL patients. Each CST appointment for therapy
lasted a~proximately 40 minutes. In addition CBT patients also
received two 15-minute GP assessments. The CBT group received no
psychotropic medication at any time during the study period. The
DZ + CBT group, and the PL + CST grOIJP both reel?ived 'psychotrop ic'
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medication <"lndind iv i r+ua l thpr;~f1Y!ariminic;tprpriby thp rlJrrpnt
author, according to the samp time schedulp as the DZ, PL, and CAT
alone groups. All groups rprp.ived approxim,-:ltelythp.same amount of
contact with the current author and their respective GPs.
7.1.4 Measures
Seven primary mpasures of treatment process and outcome were
used in this main study.
a) The Hamilton (1959) Rating Scale for Anxiety (HAM-A) with
the Hamilton Anxiety Glossary (HAM-G) (Power et al 1985) as
described in section 6.1.4.(a). The HAM-A was completed for all
groups on Days 0, 7, 14, 28, 42" 56, 63 and 70.
b) The Kellner and Sheffield (1973) Symptom Rating Test (SRT)
as described in section 6.1.4.b. The SRT was -completed by
patients on Days -7, 0, 7, 14, 28, 42, 56, 63 and 70.
c) The General Health Ouestionnaire (Goldberg 1972)
(Appendix 6) is a well-known and extensively validated screening
method for the identification of psychiatric illness in general
pract.icE'. It has been tested and va 1idated in a number of
cultures and languages (eg. Harding 1976; Munoz et al 1978; Chan
and Chan 1983). The version of the GHQ used in this study
consisted of 60 items with four response categories each.
Conventionally each item is scored by setting codes 1 and 2 to 0,
and 3 and 4 to 1. Johnstone and Goldberg (t976) suggested that
respondents with scores ef between 12 and 19 tend to remit with
time, even without treatment; but these with scores of 20 or more
14R
tend to improve only if offered treatment. The GHQ W~5 cnmpletprl
by patients at Days 0 and 70.
d) A 10cm 'Tense-Relaxed' visual analogue scale (Appendix 7),
relating to the previous week, and anchored at end points
o = Relaxed, 10 = Tense, was completed by patients according to the
same schedule as the SRT in section 7.1.4.(b).
e) At Day 0 patients were asked what symptom particularly
bothered them. There were no preconditions or restrictions on the
patients' reply and their anSWE'r was regarded as thE'ir persona l
main 'Target Symptom'. Patients were subsequently asked to
complete a 10cm 'Target Symptom' visual analogue scale
(Appendix 8), relating to the previous week and anchored at end
points 0 = Not at all bothered; 10 = Extremely bad, could not be
worse. The Target Symptom visual analogue scale was completed
according to the same schedule as the HAM-A in section 7.1.4.(03)
..;...,~
f) Severity of Illness was rated on a 7 - point scale, as
described in section 6.2.4.(03), by GPs at Day -7 and Day 70. The
current author also rated Severity of Illness on the same 7 point
scale, according to the same schedule as the HAM-A in section
7.1.4.(a)~
g) Overall Symptom Change was assessed on a 7 - point scale,
as described in section 6.2.4.(d)., by BPs at Day 70. Patients
a 1so rated OVl?ra11 Symptom Change on the same 7 - point sca le,
according to the same schedule as the HAM-A in section 7.1.4.(03).
The current author also completed the same 7 point scale for each
patient on Days 7, 14, 28, 42, 56, 63 and 70.
149
h) In additinn .=:lnvprserpar:tinne; tn thp drug rel)imen wprp
recornpd by the prpsent authnr at each ae;e;pc;smentinterview by
means of an open-ended interview and check~ist of adverse symptoms
ae; in 6.1.4.(c).
i.) Finally p.=:ltientswere seen at 6 months follow-up and GP
records were examined to assess subsequent post-study psychotropic
medication usage and psychological or psychiatric treatment. In
addition patients completed the SRT, GHQ, 'Tense-Relaxed', and
'Target Symptom' visual analogues, and self-reported Overall
Symptom Change. The current author also completed the HAM-A,
Severity of Illness and Overall Symptom Change.
7. 1.5. Resul ts
The main demographic detai Is of pat ients included in this
study are as shown in Table 7.1 •
.~.,''''
One-way analyses of variance between groups failed to produce
any significant differences with regard to age (F (4,96) = 0.823
p = 0.513); duration of symptoms (F(4,96) = 0.028, p = 0.998);
Day -7 SRT (F (4,96) = 0.11, p = 0.976); Day 0 HAM-A (F (4,96) =
0.33, p = 0.856); Day -7 'Tense-Relaxed' visual analogue (F (4,96)
= 0.31, P = 0.864); Day 0 'Target Symptom' visual analogue
(F (4,96) = 0.74, P = 0.561); and Day 0 GHQ (F (4,96) = 0.31,
p = O. 86A) ; therf:>bysllggesting that the groups were comparable
prior to active treatment.
Effects of treatment were investigated by computing repeated
measures analyses of variance (MANOVA) with treatment group as the
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DZ A... CAT Dl-tCRT A ..+r:RT
(n=22) (n=19) (n=21) (n=71) (n=lA)
Mean Age (yrs) 39.77 42.57 41.47 36.3..~ 42.38
Sex bM,16F 3M, IF BM,13F 7M,14F 5M,131='
Duratjan of 3.36 3.31 3.19 3.28 3.27symptoms
(mths)
I\bs patients 17 16 19 16 10previously
prescribed
benzo-
diazepines
I\bs patients 5 6 7 5 6previously ~.".
- referred for
psycho logica 1
or psychiatric
treatment
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between-subjects factor and time of assessment as the within-group
factor. Tests for simple effects were then carried out with a
priori or post-hoc comparisons where appropriate.
a) HAM-A rating: Tab 1e 7.2 presen ts the HAM-A means and
standard deviations for each treatment group at each assessment
stage during treatment and Figure 3 illustrates the data
graphically.
The between-group analysis revealed a significant group
(F (4,96) = 4.75, P < 0.005), time (F (7,672) = 180.48, P < 0.001)
and interaction effect (F (28,672) = 7.78, P < 0.001), indicating
differential changes across groups. An analysis of F tests for
simple effects was carried out for each time of assessment, with
post - hoc Scheffe tests to illustra te spec ific between group
differences and the results are to be found summarised in
Table 7.3. No significant between-group HAM-A differences emerged
.~.."
- until Day 28 when PL and DZ + eBT groups were the first to
significantly differ. This difference was maintained throughout
the remainder of the study period. On Day 42 a significant
difference between DZ and DZ + CST, and between PL and CST groups
emerged and was again maintained at subsequent assessments. At
Day 63 DZ and CST groups differed for a singular occasion as did
PL and PL + CST on Day 70. At no time did CST, DZ + CST and PL +
CBT groups differ from each other. Similarly, at no time were DZ
and PL groups, or DZ and PL + CST groups significantly different.
The above results illustrate differences between the treatment
groups in the rate of change. Within-group analysis revealed a
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Table 7.2 HAM-A mpanG and Gtandard dpviatinnG (SO) for trpatmpnt
HAM-A 07 Eh CAT DZ+CAT PL+CBT
Day 0 18.7 17.B lB.5 18.9 17.9
(3.7) (2.4) (3. 1) (5. 1) (2.6)
Day 7 12.9 14.5 14.5 12.5 15.3
(5.0) (4.9) (3.7) (4.0) (3.3)
Day 14 11•1 13.3 11.4 8.9 11 .4
(6.2) (5.9) (4.5) (4.7) (5.3)
Day 28 10.3 13.0 9.0 7.0 10.0
(5.8) (6 •1) (5.0) (4.2) (5.8)
Day 42 10.9 13.4 7.6 5.1 7.8
(7.5) (5.7) (5.0) (3.3) (5.5)
Day 56 10.5 13.0 5.7 4.3 7.3
(7.0) (6.2> (4.4) (3.2) (5.4)
Day 63 10.6 12.8 5. 1 4.4 7.1
(7.0) (6.2) (4.7) (4.2) (5.5)
Day 70 10.5 12.9 5.2 4.0 7.0
(7.0) (6.2) (4.8) (4.2) (5.4)
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FIG.3 Mean Hamilton Anxiety Scale scores for treatment groups
at each assessment stage during treatment:
I:> DZ; .PL; .CBT; oDZ+CBT; OPL+CBT.
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Table 7.3 Analysis of variance and simple effects on Hami Iton
Anxiety Scale Scores at each assessment stage during treatment.
(f) TII\Ofactor fHJVA with repeated df F p
measures en B.
Factor A (treatment grc:up) 4,96 4.75 0.002**
Factor B (time of assessment) 7,672 180.48 0.000***
Interaction A X B 28,672 7.78 ' 0.000***
(if) Simple effects (SS, Factor A)
df F p Scheffe
Day 0 4,96 0.33 0.856
Day 7 4,96 1.59 0.181
Day 14 4,96 1.72 0.150
Day 28 4,96 3.25 0.015* 2-4*
Day 42 4,96 6.b3 O.OOOU:U: 1-4*, 2-3*,2-4***
Day 56 4,96 8.39 0.00001;(" 1-4*, 2-3** ,2-4***
Day b3 4,96 8.16 O.OOOOIU 1-3*,1-4*,2-3**,2-4***
Day 70 4,96 8.71 O.OOOO.t:t;t: ~*,1-4**,2-3**,2-4***
(iii) Simple Effects (SS, Factors>
DZ 7,672 23.94 o.ooo rxs
PL. 7,672 7.35 0.0001.U:
CBT 7,672 66.08 O.OOOlt1(
DZ + CBT 7,672 75.89 O.OOO*~ *
PL. + CBT 7,672 41.20 0.000*'1:1'..
* p <0.05; ** p <0.01; *** p < 0.001
K~y : Post-hoc Sch~ff~ tr~atl~nt group cOlparisons :- I = DZ; 2 = PL; 3 = CBT; • = DZ + CBT; 5 • PL + CBT
"ot~ : Groups s~parat~d by a hyphen differ significantly frol each other. .
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significant reduction in HAM-A scores for all groups during the
course of treatment (see Table 7.3).
There was no significant increase in HAM-A scores for the DZ
and DZ + CST groups during the course of graded-withdrawal from Day
42 to 63 (t = 1.10, df = 21, P = 0.284; t = 0.91, df = 20, p =
0.373), or following cessation of all tablet consumption between
Days 63 and 70 (t = 0.38, df = 21, p = 0.704; t = 1.57, df = 20,
P = 0.131). The absence of an increase in HAM-A scores during or
after graded-withdrawal is of major clinical importance.
Comparison of pre- (Day 0) and post-treatment (Day 70) HAM-A scores
revealed a significant reduction for DZ (t = 5.93, d f = 21, P <
0.001), CST (t = 13.97, df = 20, P < 0.001), DZ + CST (t = 11.01,
df = 20, p < 0.001), PL + CST (t = 8.34, df = 17, P < 0.001) groups
and to a less extent the PL group (t = 3.83, df = 18, P < 0.005).
b) SRT ratings Table 7.4 presents the SRT means and
Standard deviations for each treatment group at each assessment
stage during treatment and Figure 4 illustrates the data
graphically. The between-group analysis (Table 7.5) revealed a
significant group (F (4,96) = 2.79, P < 0.05), time (F (8,768) =
103.04, P < 0.001), and interaction effect (F (32,768) = 4.73,
P < 0.001) indicating differential changes across groups. F tests
for simple effects and post-hoc Scheffe tests revealed no
Significant between group differences until Day 42 when PL and DZ
+ CST were the first to significantly differ., This difference was
maintained throughout the remainder of the study. On Day 56 and
thereafter significant differences between DZ and DZ + CST, and
15A
Tahlp. 7.4 SRT mpanc; and c; tancJa_I""r!.__!1Pv i.!!.t i nn"!.._( SO ~__fnr::__!_~_<"l_tmpD_t
groups at Pilch ac;c;pc;c;mpnt c;t~_«J~rj~.!l_!I.:!",a!=m~~.t '.
SRT DZ PL CST 127+CBT PL.+CAT
Day -7 39.3 40.2 39.4 39.7 41 .7
(14.4) ( 8. 1) (15.0) (13.3) (10.0)
Day 0 36.6 38.1 39.9 39.7 39.4
(13.6) ( 8.5) (15.8) (13.4) (10.4)
Day 7 28.0 32.8 32.5 27.4 34.1
(12.8) (15.4) (16.6) (11.5) (12.2)
Day 14 25.5 31.5 25.6 19.6 26.0
(13.2) (16.7) (15.0) (10.7) (18.3)
Day 28 24.8 30.3 20.9 18.6 22.3
(13.3) (18.0) (1.4.5) (13.8) (14.0)
Day 42 26.3 30.4 18.0 13:6 19.6
(15.7) (17.5) (13.9) (10.5) (14.9)
.~'.~
Day 56 25.6 30.3 13.3 11.9 17.7
(14.6) (18.0) (11.5) ( 9.4) (11.9)
Day 63 24.8 29.5 12.6 10.3 17.4
(15.2) (18.4) (12.6) (10.7) (12.5)
Day 70 24.8 30.0 12.5 9.9 16.8
(15.7) (18.4) (13.9) (10.4) (1.1.7),
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Table 7.5 Analysis of variance anrl simple effects on Kellner and
Sheffield (SRT) scores at each assessment stage during treatment.
(i) Two-factor ftC.JA with repeated
measures en B.
Factor A (treatment graJp)
Factor 8 (time of assessment)
Interaction A X B
(ii) Simple effects ($,Factor A)
df F
Day -7 4,96 0.11
DayO 4,96 0.24
Day7 4,96 0.97
Day 14 4,96 1.58
Day 28 4,96 1.81
Day 42 4,96 4.20
Day 56 4,96 7.12
Day 63 4,96 6.63
Day 70 4,96 6.98
df F p
4,96 2.79 0.031*
8,768 103.24 0.000***
I
32,768 4.73 i 0.000***
p Scheffe
0.976
0.913
0.427
0.184
0.132
0.0001~t)j: 1-4*,2-3**,2-4**
(fii) Simple effects ($,Factor B)
DZ 8,768 10.05 0.000 ~ t '.f
A.. 8,768 4.29 0.000)j:It
C8T 8,768 38.64 o.ooo r 1: t
DZ + CST 8,768 43.92 0.000,*t '(
A.. + C8T 8,768 25.98 0.0001 1 ~
* p < 0.05; ** p < 0.01; *** p < 0.001
K!y : Post-hoc 5ch!ff! tr!~t.!nt group co.p~risons :- I = Dl; 2 = Pl; 3 = CBT; , = D1 + CBT; 5 = Pl + CBT
Not! : Groups s!parat!d by • hyph!n diff!r significantly fro. !ach oth!r.
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FIG.4 Mean Kellner and Sheffield (SRT) scores for treatment
groups at each assessment stage during treatment:
l> DZ; • Pl; • CST; 0 DZ+CST; 0 Pl+CST.
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bptween Pt. .=lndCRT groLJJlswerp evident. There were no other
bptween - group d j fferenr:es. Table 7.5 .=llso i 111Jc;tr.=ltpsthe
significant redLJr:tionin SRT sr:ores for all treatment groups during
the study period. Within-group analysis also revealed that only the
PL group showed a significant reduction in symptoms during thf'l
initial single-blind placebo wash-in pp-riod r t = 2.26, df = 18,
p < 0.05). There was no significant increase' in SRT scores for
the DZ and DZ + CBT groups during the course of graded-withdrawal
from Day 42 to 63 Ct = 1.82, df = 21, p = 0.084; t = 1.33, df =
20, p = 0.197) or following cessation of all tablet consumption
between Days 63 and 70 et = 0.00, df = 21, p = 1.000; t = 0.38,
df = 20, p = 0.710). Comparison of pre (Day -7) and post (Day 70)
SRT scores revealed a significant reduction for DZ (t = 4.21,
df = 21. p < 0.001), CST ct = 8.57, df = 20, p < 0~~01), DZ + CBT
Ct = 8.27, df = 20, p < 0.001), PL + CST Ct = 6.89, df = 17, P <
0':'·001) groups, and to a less extent the PL group (t = 2.65, df =
18, p < 0.05) •
c) GHQ ratings: Table 7.6 presents GHQ total and subscale
means and standard deviations for each treatment group prior to
active treatment at Day 0, and post-treatment at Day 70.
In order to assess the significance of GHO change displayed.
by the groups over time, paired t-tests were conducted. The results
of these are shown jn Table 7.7.
As can be seen the PL group stands nut as the one group that
made no significant changes between the two testing'S on the GHQ-
Total,and only showed a significant change on the AnwietY/lnsomnia
lAO
TOlhle 7.6. RHO TntOll Olnci Suhc;rOllp mpOlnc; Olnci c;tOlnciOlrcinpviOltinnc:;
(SO) for trpOltment f]rn.!!QC.L!!.tOOly_Q.~.nr!_!?!!y_Z9_~
D1 Pl CBT D1+CBT Pl+CBT
-• ISD) -• ISD) -• ISD) -• ISO) -• ISD)
Day 0 39.401 B.74) 39.891 9.86) 39.bIlI0.16) 38.23112.071 36.SOI12.30)
Day 70 27.00(16.46) 31.94117.25) 11.38116.82) 7.95112.44) 16.11I15.911
!ioIatie
Sy.ptOllS
DayO 5.IBI 1.B4) 5.2tf I.m '.951 2.08) 4.951 1.98) 4.S01 'l.14)
Day 70 3.541 2.57) 4.001 2.47) 1.281 1.76) 0.901 1.721 2.001 2.30)
Anxiety +
In50lllllia
Day 0 6.451 0.b7) b.361 0.7b) b.041 1.111 b.331 0.96) b.331 1.08)
Day 70 5.091 2.24) 5.211 'l.34) 1.951 2.571 1.b6I··h90) 2.941 2.411
Social
!tis fune tion
Day 0 4.IBI 1.40) 4.421 1.53) '.851 I.m 4.711 1.m 4.lbl 1.94)
Day 70 'Z.6BI2.'l3) 3.571 2.31) 1.471 2.33) 0.7tf 1.73) 'l.001 2.24)
SeVl're
J)pprl'5Sion
Day 0 2.S01 2.04) 2.731 1.85) 2.951 2.90) 2.381 2.34) 2.271 2.32)
Day 70 1.041 2.10) 1.941 2.171 0.85( 2.05) 0.38( 1.531 1.051 2.151
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Tahlp 7.7. GHllTotrl) rlon SuhscrI)p Pri i rpri t-tpsts rlt r>rly_q_~on
nrly 70 for trerltmpot groups.
Pl Pl CBT Dl+CBT Pl+CBT
df = 21 df = 18 df = 20 df = 20 df : 17
BHIl t t t !. t
Total 4.08" 2.10 8.33"1 9.29"1 5.46".
SOlatic Sy.ptoas 3.12" 2.00 6.90". 7.67." 3.86"
Anxiety + Insoania 2.92" 2.32. 7.54"1 9.63." 5.7511.
Social Dysfunction 3.71" 1.49 7.35." 8.74". 4.65".
Severe Depression 3.4211 1.97 3.74" 4.191$1 1.95
..;....
• p (0.05; •• p (0.01; ••• p { 0.001
1A7
Suhsr:ale. The Pt. + CRT qr-Ollflae-hieverl c:;il]nifie-antlylower- scor-pc:;
on thp GHQ Total and two nf the slJhsr.:llec:;. However- the nz, CAT,
and nz + CAT gr-oups pxhihited consistently lower- scar-ps on a] 1
measur-es. The magnitude of the differ-ence hetween t.he day 0 and
day 70 tended to be qr-eater- for- the CRT and DZ + CST gr-oups.
There was no significant differ-ence in GHQ Total and Subscale
scor-es hetween tr-eatment gr-oups at Day 0 as illustr-ated in
Table 7.8. However at Day 70 the GHQ Total differ-ed
significantly between DZ and CST, PL and CST, DZ and DZ +CRT, and
PL and DZ + CST gr-oups. These differ-ences wer-e also pr-esent for-
Somatic Symptoms, and Anxiety and Insomnia Subscales. The Social
Dysfunction Subscale r-evealed a significant differ-ence only he tween
PL and DZ + CaT gr-oups.
d) 'Tense-Relaxed' visual analogue_. Table 7.9 pr-esents the
'Tense-Relaxed' visual analogue means and standar-d deviations for-
each tr-eatment gr-oup at each assessment stage dur-ing treatment.
The between-gr-oup analysis revealed a significant gr-oup (F
(4,96) = 6.35, p < 0.001), time (F (8,768) = 68.80, p < 0.001) and
inter-action effect (F (32,768) = 4..81, P < 0.001) indicating
differ-ential changes acr-oss groups. Significant differ-ences
between groups first emer-geodoat Day 14 when PL differed fr-om both
CST and DZ + CST groups.
dur-ation of the study per-iod.
This differ-encp persisted for- thp
At Day 56 and ther-eafter- PL and PL
+ CST groups differ-ed. DZ and CST gr-oups differ-ed at Day 63 and
Day 70. The above 'Tense-Rp.l axed' r-esu1ts are iII ustr-ated in
Table 7.10.
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Table 7.8. One-way analysis of variance on GHQ Total and Subscales
at Day 0 and Day 70 for treatment groups.
p.
GHQ Total ',96 0.31 0.868
SOlatic SYlptols ',96 0.39 0.811
Anxiety + Insolnia ',96 0.57 0.683
Social Dysfunction ',96 0.72 0.578
Severe Depression ',96 0.34 0.846
Day 70
GHO Total ',96 8.47 0.0000U11:. 1-3',2-3",1-"',2-""
SOlatic SYlptols 4,96 7.95 0.0000'f(~~ 1-3',2-3",l-4",2-'"
Anxiety + Insolnia 4,96 11.11 O.OOOO'ut 1-3",2-3",1-4"',2-4'"
., ;....~
Social Dysfunction 4,96 5.12· 0.OOO9UJt 2-411
Severe Depression 4,96 t .57 0.187
• p (0.05; •• p (0.01; .1. p ( 0.001.
Key I Post-hoc Scheffe treatlent group cOlparisons :- t = DZ; 2= PL; 3 = CST; • = DZ + CST; 5 = PL + CST
Note: Sroups separated by a hyphen differ significantly frol each other.
1A4
•Tilhlp 7.9. Tpnc;~:::_t:!.~l~_~~d__y.t~.'_J_~l___i!!!~JCl!1,~g~t:'c...i!!l2_ __~_l}rl_....5 ....tc'!~rl~rrl
rlpv.liltionc; (SO) for trp.:Itmpnt grOlJ[!c; .:It Pilch ilsc;pc;c;mpnt st.:lge
tJ_l)__ri.n.!)._!rp~tmp~ t .
Tf?nsp.-R~axP.d
visual _1::>7 _PL __£AT D7+CAI Pl.+CBT
analngue
Day -7 7.72 7.89 8.09 7.76 8.16
(2.25) (1.32) (1.3.~) (1.33) (1.15)
Day 0 6.77 7.78 7.57 7.81 8.05
(2.34) (1.39) (2.37) (1.40) (1.25)
Day 7 5.40 6.31 6.04 5.61 7.83
(2.17) (2.68) (2.17) (2.73) ( 1.68)
Day 14 4.90 7.00 4.61 4.33 6.05
(2.50) (2.21) (2.20) (2.10) <1.95)
Day 28 4.72 6.94 3.76 4.04- 5.38
(2.22) (2.52) (2.46) (2.50) (1.85)
Day 42 5.04 6.89 3.61 3.42 4.94
(2.31) <2.5..) (2.55) (2.39) (2.01)
Day 56 5.00 6.89 3.33 3.47 4.22
(2.39) (2.49) (2.49) (2.48) (2.07)
Day 6.3 5.45 6.6.."T, 2.90 3.42 3.94
(2.11> <2.56) (2.73) (2.73) (1.95)
Day 70 5.50 6.52 2.76 3.33 3.8.."T,
(7.74) (?71 ) (7.46) (7.47) (7.09)
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Table 7.10. Analysis of variance and simple effects on
'Tense-Relaxed" visual analogue scores at each assessment stage
during treatment.
(i) Two factor fH:NA with
repeated measures D1 B df F .
Factor A (treatment group) 4,96
Factor 8 (time of assessment) 8,768
Interaction, A X8 32,768
6.35
68.80
4.81
p
0.000*>1:.>1:.
0.000>1:.**
0.000*"*~
(ii) Simple effects rss, Factor A)
df F p
Day -7 4,96 0.31 0.864
DayO 4,96 1.47 0.214
Day 7 4,96 2.16 0.079
Day 14 4,96 4.99 0.0011 J(X
Day 28 4,96 5.81 O.OOO3~tt
Day 42 4,96 6.77 0.0001u:~
Day 56 4,96 7.21 O.OOOOJUX
Day63 4,96 7.88 O.OOOOl't. "It
Day 70 4,96 8.54 O.OOOO1(:4(;l
(iii) Simple effects rss, Factor B)
DZ 8,768 8,14 0.000 lkt r.
PI.. 8,768 2.03 0.040~
CST 8,768 32.03 0.000)1('f.:f.
DZ + C8T 8,768 26.58 O.OOO:Ki:l:.
PI.. + CBT 8,768 20.12 O.OOO*t':f
Scheffe
2-3**,2-4**
2-3**,2-4***
1-3*,2-5*,2-4**,2-3***. ;.~
* p < 0.05; ** p < 0.01; *** P < 0.001
K~y I Post-hoc Sch~ffr trrat.~nt group cO'parisons :- I s DZ. 2 • PL; 3 s eBT; 4 = DZ + eBT; 5 = PL + eBT
Hotr : Groups s~parat~d by a hyph~n diff~r significantly fro. ~ach other.
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All treatment groups showed a significant within-group shift from
'Tense' to 'Relaxed' anchor points on the visual analogue at the
p < 0.001 level, apart from the PL group which achieved a
significant result at the p < 0.005 level. In keeping with HAM-A
and SRT resu Its there was no evidence of a shift towards thE?'
'Tense' end of the continuum during graded-withdrawal for the 02
and DZ + CBT groups (t = 1.18, df = 21, P = 0.0250; t = 0.00, df
= 20, P = 1.000) or following cessation of all tablet consumption
between Days 63 and 70 (t = 0.37, df = 21, P = 0.715; t = 0.27,
df = 20, P = 0.793). Comparison of pre (Day -7) and post (Day 70)
'Tense-Relaxed' visual analogue scores revealed a significant
reduction for CBT (t = 9.15, df = 20, p < 0.001), DZ + CST (t =
6.94, df = 20, P < 0.001), PL + CST (t = 7.24, df = 17 P < 0.001)
groups, and to a lesser extent DZ (t = 3,29, df = 21, P < 0.005)
and PL (t = 2.31, df = 18, p< 0.05) groups.
e) 'Target-Symptom' visual analogue. Table 7.11 presents
the 'Target-Symptom' visual analogue means and standard deviations
for each treatment group at each assessment stage during treatment.
The between-group analysis revealed a significa~t group (F (4,96)
= 5.20, P < 0.005), time (F(7,672) = 82.27, P < 0.001) and
interaction effect (F (28,672) = 5.29, P < 0.001) indicating
differential changes across groups. At Day 28 significant
differencE's between PL and both CST and DZ + CST groups emerged
and were maintained throughout the study period. At Day 63 and
Day 70, DZ and CST groups differed. DZ and DZ + CST groups only
differed at Day 70. These results are presented in Table 7.12.
1n7
,Tablp 7.11. TrI....get-S~m~tnm vi C;IJ.:ll.:l')~J.nr:.l~~m_!:'~n 2_.._..~_nr1 c;t.:lnda....r1
geviations (SD) fo ....t ....ea tmen t___g....ou~c; at Pnch ac;c;pc;c::;mpnt c;tngp
du ....ing treatment.
I{l:cm:..t-Svmptnm
Visual QI ~?L. G~I DZ.:tG..~ EL-+£BT
analogue
Day 0 7.59 7.6..> 8.09 7.85 8.38
(1.70) (2.14) (1.54) (1.38) ( 1.65)
Day 7 5.09 6.57 6.04 5.71 7.11
(2.56) (2.16) (2.39) (1.92) (2.02)
Day 14 4.59 6.26 4.66 4.52 5.72
(2.36) (2.64) (2.41) Cl.94) (2.39)
Day 28 4.63 6.63 3.52 3.61 5.50
(2.46) (2.24) (2.48) (2.15) (2.64)
Day 42 4.72 6.47 3.28 2.95 4.11
(2.54) (2.75) <2.43) (1.74) (1.99)
Day 56 4.72 6.10 2.76 3.09 3.94
(2.79) (2.76) (2.43) Cl.81> (2.53)
Day 03 5.04 5.84 2.42 2.71 3.44
(2.64) (2.89) (2.3,3) (2.05) (2.25)
Day 70 5.40 5.84 2.52 2.M 3.72
(2.53) (2.87) (2.62) (2.12) (2.44)
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Table 7.12 Analysis of variance and simple effects on 'Target-
Symptom" Visual Analogue scores at each assessment stage during
treat.ment.
(i) TlIIQ-factorPtVJA with repeated
measures D1 B. df F P
Factor A (treatment group) 4,96 5.20 0.001**
Factor S (time of assessment) 7,672 82.27 0.000***
Interaction A X S 28,672 5.29 0.000***
(ii) Simple effects (SS, Factor A)
df F P SctP.ffe
Day 0 4,96 0.74 0.561
Day 7 4,96 2.40 0.055
Day 14 4,96 2.22 0.072
Day 28 4,96 5.49 o •0005 xx t 2-3** ,2-4**
Day 42 4,96 7.11 O.OOOOtn .. 2-3** ,2-4***
Day 56 4,96 5.90 0.0003)j(~l. 2-3**,2-4**
..;~.."
Day 63 4,96 7.45 O.OOOO'f~ * 1-3*,2-3**,2-4**
Day 70 4,96 7.53 O.OOOO*t*, 1-3*,1-4*,2-3**,2-4**
Uii) Simple effects (SS, Factor B>
DZ 7,672 9.44 0.000 ~X~
PI.. 7,672 2.75 0.008:i~
CST 7,672 36.57 0.000)(.*,1:
DZ + CST 7,672 30.47 0.000'* ~t
PI.. + CST 7,672 24.69 o.ooor 1( ~
* p < 0.05; ** p < 0.01; *** p < 0.001 ., .
Key : Post-hoc ScheHe treiltll'ntgroup cOlpilrisORs :- t = Dl; 2 = Pl; 3 = CBT; , = DZ + CBT; 5 = Pl + CBT
Note: Sroups sl'pilriltl'dby iI hyphen differ significantly frol each other.
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All treatment groups showed a significant within-group shift
for their individual 'Target-Symptom' from 'extremely nad , !:t:luld
not be worse,' to 'not at all bothered'; at the p < 0.001 level J
apart from the PL group which achieved a significant result at the
p < 0.01 1eve 1• In parallel with other results there was no
evidence of a shift from the 'not at all bothered' end of the
continuum during graded-withdrawal for the DZ and DZ + CST groups
(t = 0.78, df = 21, p = 0.444; t = 0.61, df = 20, p = 0.548) or
following cessation of all tablet consumption between Day 63 and
70 (t = 1.40, d f = 21, P = O. 176; t = 0.29, df = 20, p = 0.771).
Comparison of pre (Day 0) and post (Day 70) Target-Symptom visual
analogue scores revealed a significant reduction for DZ (t = 4.45,
df = 21, p < 0.001), CBT (t = 9.29, df = 20, p < 0.001), DZ + CBT
(t = 9.08, df = 20, p < 0.001), PL + CBT (t = 7.11; df = 17, P <
0.001) groups, and to a lesser extent the PL group (t. = 3.54, df
= 18, p < 0.005).
f)
establish
Sever ity of GAD The previously mentioned results
the statistically significant changes in group
comparisons over time using specific assessment scales. However it
is regarded as important to assess overall clinical ratings of
change.
i.) GP Severity Ratings :Table 7.13 presents GPs' assessments
of Severity of GAD at study entry (Day -7) and at the end of the
study period (Day 70). At Day -7 there· was no significant
difference in the proportion of patients allocated by referring GPs
to the various categories of symptom severity for each of the
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Table 7.t~. GP rating~ of ~everit~ of patj~nt~· GAD_p.re-(D~-=7)
ann po~t-(.I?~y __70~_ treatment.
~
~mpto. Severity
01
nil I
I - Normal
2
3113.61
4 4118.21
5 - l10derate 9140.91
6 5112.71
7 • Severe II 4.51
IChi square = 7.45, df = 16, p = 0.9631
Day 70
SYlptOI Severity
I - Norlal II 4.51
2 21 9.11
9140.91
4 3113.6 I
5 - l10derate 4118.21
6 21 9.11
7 - Severe II 4.51
IChi square = 43.59, df= 24, P = 0.0081
~
nlll
11 5.31
4121.11
11157.91
3115.81
115.31
2110.51
2110.5)
5126.31
7136.8)
2110.5)
CBT
nlll
21 9.5)
5123.8)
9142.9)
3114.3)
21 9.5)
4119.0)
7133.3)
6128.b)
21 9.5)
21 9.5)
Dl+CBT
nlll
4119.0)
3114.3)
8138.1 )
5123.8)
11 4.8)
10147.6)
5123.8)
4119.0)
11 4.8)
11 4.8)
Pl+CBT
nil)
2111.11
2122.2)
9150.0)
3116.7)
4122.2)
6133.3)
3116.7)
3116.7)
II S.bl
II S.b)
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treatment groups (X2 = 7.45, df = 16, p = 0.963). For each
treatment group the largest single severity category on the 1 - 7
scale was '5 - moderate severity;' and the majority of patients
fell in the 'moderate' to 'severe' categories. However, at Day 70
the proportion of patients allocated to each category differed
between groups (X2 = 43.59; df = 24, P < 0.01). The largest
single category for each of the treatment groups was as follows;
DZ - (mild); PL - (moderate); CST - (mild/moderate); DZ + CST
(normal); PL + CST - (mild/moderate).
ii) Psychologist Severity Ratings: Table 7.14 illustrates
the current author's assessment of patients' severity of GAD at
Day 0 and Day 70. At Day 0 there was no significant difference
bet,ween groups in the proportion of patients allocated to the
2'various categories of symptom severity (X = 16.74, df = 16, P =
0.402). At Day 0, in agreement with the referring GPs, the current
author placed a majority of patients in each group in the moderate
severity category~ At Day 70 the proportion of patients allocated
by the current author to each category differed between treatment
groups ()(2 = 41.84, df = 24, P <0.05).
Although the referring GPs and the current author carried out
independent assessments of patient severity without prior
collaboration there was nevertheless a satisfactory level of
agreement at Day 0 (Pearson r = 0.41, P < 0.001) and especially at
Day 70 (Pearson r = 0.854, p <0.001).
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Table 7.14. P5yrhnlogi5t ratings of severity of patients' GAD pre-
(Day -7) and pnst-(Day 70) treatment.
Day -7
SYlptom Severity
D1
nm
I - Norul
2
3 - "ild
4 II 4.51
5 - "odl'rate 15169.21
6 5122.71
7 - Sl'vl're I I 4.51
IChi ~Quare = 16.74, df = 16, p = 0.4021
Dav 70
SYlptol Sevl'rity
I - Norlal 11 4.51
2 4119.21
3 - "ild 3113.61
4 6127.31
5 - "oderate 6127.31
6 21 9.11
7 - Sevl're
Pl
nlll
CBr
nlll
3114.31
15178.91 12157.11
4121. II 5123.BI
, - II 4.81
II 5.31 3114.31
11 5.31 11152.41
4121.11 21 9.51
3115.81 II 4.81
7136.81 4119.01
3115.81
IChi square = 41.94, dE: 24, p = 0.013141.84, df = 24, P ( 0.051.
II 4.8)
12157.11
6(28.61
2( 9.51
6(28.61
10147.61
3114.31
II 4.81
11 4.81
15183.31
2111.1 I
115.61
2111 .11
. 5127.8)
4122.21
3116.71
3116.71
II 5.6)
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g) Overall Symptom Change: Overall symptom change at Day 70,
from Day -7 (for GPs) and Day 0 (for the current author), are
presented in Tables 7.15 and 7.16 respectively. Table 7.17 shows
patients' self-assessment of their overall symptom change from Day
-7 to Day 70. All assessors indicated that overall symptom change
at Day 70 differed between treatment groups; GPs (X2 = 53.32, df =
16, p < 0.001); -the current author ()(2 = 38.47, df = 16, P <
0.005); patients' self-rating (~2 = 36.66, df = 20, p < 0.05).
Arbitrarily taking the categories of 'very much improved' and
'much improved' as indicative of significant clinical improvement,
GPs regarded 45% of DZ; 36% of PL; 86% of CST; 87% of DZ + CST
and 72% of PL + CST groups as achieving this status (Table 7.15).
In general, similarly proportioned representations of significant
clinica1 improvement were noted by the current ,author and by
patients own self-report (Tables 7.16 and 7.17). High levels of
agreement regarding overall symptom change existed between GP and
psychologist (Pearson r = 0.93, P < 0.001), GP and patient
(Pearson r = 0.89, p < 0.001), and psychologist and patient
(Pearson r = 0.94, P < 0.001).
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Tahle 7.15. GP Rat_.inCJ.2_of~v~ral1_~~ptom ~hangp. post-treatment
(Day 70).
Day 70
Sy.ptoa Changp.
• Very auch
iaproved
4118.21 3115.81 14166.71 16176.21 9150.0)
2 - Much iaproved 6127.31 2110.51 4119.0) 21 9.5) 4(22.2)
3 - Miniaally 8136.41 2110.51 II 4.81 3114.31 2111.11
iaproved
4 - No change 3113.6) 12163.2) 21 9.51 2( I1.11
5 - Miniaally worse II 4.51 II 5.6)
6 - Much worse
7 - Very .urh worse
(Chi square = 53.32, df = 16, p = 0.000)
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Table 7.16. Ps~chologist Ratings of overall s~m~tom change ~nst-
treatment (Da~ 70) •
Day 70 DZ Pl CBT DZ+CBT ~Sy.pto. Change nil) nlll nlll nil) nil)
- Very luch 7131.8) 3115.8) 16176.2) 16176.2) 9150.0)
ilproved
2 - "uch ilproved 5122.7) 3115.8) 21 9.5) 3114.3) 5127.8)
3 - "ini.ally
ilproved
6127.3) 4121.11 21 9.5) 21 9.5) II 5.61
4 - No change 21 9. II 8142.11 II 4.81 2111.11
5 - "ini.ally Norse 21 9.11 II 5.3) II 5.61
6 - "uch Norse
7 - Very luch Norse
(Chi square = 53.32, df: 16, p : 0.0013)
17A
Tahlp 7.17. P.:Itipnts , SP 1f - r.:lt i ng of ovpr.:Jl1 s~m~tom change ~oc:;t-
trpatmpnt (_Day 70)•
Day 70 DZ Pl CBT Dl+CBT Pl+C8T
Sy_ptolllChange nlll nlll nlll nm n(%! .
- Very lIIuch 6127.3) 4121.1) 16176.2) 15171.4) 11161.1)
i_proved
2 - Much i_proved 5122.7) . 3115.8) 3114.3) 21 9.5) 2111.11
3 - Mioieally
i.proved
4( IB.2) 2110.5) I I 4.81 4(19.0) 2111.1l
4 - No change 5122.71 8142.11 II 4.8) 2111. II
5 - Mini_ally worse 219.11 II 5.3)
6 - Much worse 11 5.3) 115.6)
7 - Very auch worse
IChi square = 36.66, df = 20, p = 0.0128)
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h) Treatment Outcome: Jacobson et al (1984) highlighted the
inadequacies of treatment efficacy results which were based solely
on statistical comparisons between two or more treatment
conditions. They noted that such comparisons have two conventional
properties which limit their usefulness in outcome research.
Firstly, "that they are based on the average improvement score for
all subjects and thus provide no information on the effects of
therapy for individual clients". Secondly "that the 'significance
test' itself imposes a criterion for determining a treatment effect
which often has little clinical relevance".
While the above presentation of Severity Ratings and Overall
Symptom Change assessments may partially accommodate such
criticisms, Jacobson et al (1984) recommended a number of formulae
for computing clinically significant change. Lindspy et al (1987)
stated that the most stringent of these is to assess whether a
patient's outcome response falls outside the range of the
dysfunctional population by two standard deviations from the
pretreatment mean of that population, in the direction of
functionality. Table 7.18 illustrates the number of patients
achieving this criterion at Day 70 on'the HAM-A, SRT, GHQ, 'Tense-
Relaxed' visual analogue, and 'Target-Symptom visual analogue.
On all the measures the DZ + CST group consistently has the
largest percentage of patients showing 'clinically significant
change' • The CST group shows a similarly consistent pattern of
improvement, although the magnitude of the effect is less
pronounced.
17A
Tahlp 7.1A. Nllm~~r anrt_._t~J....__o!_1?i:ltipnts in p.ar~Q!!I!._who no, or
do not, ac hi eve •Cl in i ca l_!_Y_E_!.!lf)_if i C <:int_f:.h_angp·, a_!;_!2.-:!y_zQ_!",
'Clinically Significant Change'
YI.'S No YI.'5 No
15 7
(68.21 (31.81
7 12
(3b.811b3.21
SlIT 7 15
(31.8) 168.2)
5 14
126.31173.71
7 15 5 14
126.31173.7)131.81168.2)
8 14
13b.4) 1b3.6)
3 16
115.8) 184.2)
'hrql.'t.
SYlJltOl'
8 14
(3b.411b3.6)
6 13
(31.6) (bB.4)
VI.'5 No
18 3
185.71114.3)
16 5
176.21123.8)
15 6
171.41128.61
16 5
176.2)123.8)
16 5
176.2) 123.8)
VI.'5 No
1_9 2
190.511 9.5)
18 3
185.7)( 14.3)
19 2
190.511 9.5)
15 6
(71.41128.6)
17 4
181.01119.0)
VI.'5 No
15 3
(83.31 I16.7)
9 9
ISO.OI (SO.OI
13 5
172.2)127.8)
II 7
161.11138.9)
13 5
172.21127 .81
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With the exception of SRT results the PL + CAT group also reveal
a similar pattern of the majority of patients reporting 'clinic~lly
significant change', although to ~ lesser ewtent th~n the CaT and
OZ + CST groups. With the exception of the HAM-A re~ultq, the
majority of the OZ patients failed to achieve 'clinic~lly
significant change'. The PL group consistently showed the lowest
number of patients achieving 'clinically significant change' on all
anxiety measures.
Follow-Up: As mentioned in the Pilot Study, adequate
follow-up data are often difficul t to collect and evaluate as
patients may require subsequent treatment between the end of the
study period and the designated follow-up date. To circumvent
this difficulty collation of 'unobtrusive measures' at follow-up
has been recommended by Sellack and Hersen CI984)~ Table 7.19
illustrates the number of patients in each group who received
Psychological or psychiatric referral, or psychotropic medication
during the 6 months period post-study. The number of patients who
received subsequent treatment differed between groups (~2 = 17.96,
df = 4, P < 0.005). The majority of OZ and PL patients received
Subsequent treatment, while most of the CST, OZ + CBT, and PL + CBT
patients did not.
Analysis of the numbers of patients who received psychotropic
medication in the six months post-study period revealed no
Significant difference between groups ()('2= 8.57, df = 4, P =
0.072) as illustrated in Table 7.20.
However there was a significant difference between groups in
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T.:.hlp 7.19 • Numhp.r arid ('":.~_p~t!pnts _r:p.cPlvin._gpsychologic.:.l,
or psychiatric rpfprr.:.l.1~c;ychotr.~[1ir. mpnir..:.tiondurin!] " month
~rion poc:;t-c;tun.~
SuhseguE>nt !!1. e:;. CAT Qf+GBT B:,.+CBITreatlTlE'l"lt
YP.<; 12 17 4 :-s 5
(57.1> (70.6) (21•1) <15.8) (27.8)
f\b 9 5 15 16 13
(42.9) (29.4) (78.9) (84.2) (72.2)
(Chi ~lIarE' = 17.96, df = 4, P = 0.0013)
Tahlp 7.70 Numhpr and (7.) of R.!!.tipnt1!._Prec:;crihpr:lsychotropic:
medicat.ion during " month period post-st.udy.
Psychntronic:s DZ Ft. CRT DZ+CBT A_.+CBT
Yes 7 9 3 2 5
(3.3.3) (52.9) (15.8) (10.5) (27.8)
No 14 8 16 17 13
(66.7) (47.1) (84.2) (89.5) (72.2)
(Chi square = 8.57, df = 4, P = 0.072)
Table 7.21. Numbpr ann (7.) of patipntc; rpceiving psychological or
psychiatri.c rE'ferral during b month pprind post-study.
PsycholQJical/ DZ A.... CBT DZ+CBT PL+CBT
Esychiatric
refE>rral
Yes 12 6 2 3 1
(57.1.) (35.3) ( 10.5) (15.8) ( 5.6)
9 1t 17 16 17
(47..9) (f,4.7) (89.5) <84.2) (94.4)
(Chi squarE' = 19.08, df = 4, P = 0.0008)
1 A 1
the number of patients who received psychologir.al or psychiatric
referrals from their GP in the 6 months post-study period
( )(2 = 19 • 08 , d f = 4 , P < 0 • 001 ) • Table 7.21 shows that the
overwhelming majority of C8T, DZ + C8T, and PL + CBT pat.ients
recei ved no such referra 1s. A minor ity of PL patients recei ved
subsequent referrals. Only in the DZ Group were the majority of
patients referred for psychological or psychiatric treatment during
the 6 months post-study period.
All patients were asked to attend for a six-month follow-up
appointment. Table 7.22 illustrates that, with the exception of
the PL group, the vast majority of all patients attended for this
follow-up assessment. Of the 3 non-attenders from the DZ group,
1 had changed both address and GP and was therefore untraceable,
the remaining 2 simply failed to attend without providing
explanation. The 2 CBT non-at tenders had also changed both address
.0"-.'"
and GP and therefore could not be contacted. Two CBT + DZ
patients had also moved house and changed GP, and a further 2
simply failed to attend. For the PL + CBT group 2 patients also
failed to appear for follow-up assessment. However from the PL
group only 8 of 19 patients attended for follow-up. Of the
remaining 11 non-attender PL patients; 1 had died, 1 had'
emigrated, 1 had moved house and changed GP, and 8 failed to attend
without explanation.
Given the confounding inf luence of post-study treatment on
status at follow-up the results in Table 7.22 are only for
attenders at follow-up who had received no psychotropic,
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Table 7.27. Number and (7.) of p_ati~nts with no su bsegtJI:mt ~ost-
stud~ treatment who achievp 'cl inical1~ significant changp' at
6 month follow-up assessment.
Dl Pl CBT Dl+CBT Pl+CBT
n = 22 n = 19 n = 21 n = 21 n = 18
niX) niX) nlll nil) niX)
No of follow-up 19 8 19 17 16
attenders IB6,4) 142.11 190.5) IBI.O) IBB.9)
No of follow-up 9 5 15 16 13
attenders with no 140.9) 126.3) 171.41 176.2) 172.2)
subsequent treat.ent
No of follow-up
attenders with no
subsequent treat.ent
who achieve
'clinically
5igni ficant change'
on :-
,;...,;
HAH-A 9 4 15 15 12
140.9) 121.0) 171.4) 171.4) 166.71
5RT 5 3 II 14 9
122.71 115.8) 152.4) 166.71 150.0)
GHQ 6 3 13 15 9
127.3) 115.B) 161.9) 171.4J 150.0)
'Tense-relaxed' 5 3 14 14 9
122.71 115.8) 166.7) 166.7) 150.0)
'Target 5y.ptol' B ~ 15 14 B
136.4) 115.B) 171.41 166.71 144.41
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psychological or psychiatric subsequent treatment.
The majority of CST, DZ + CBT, and PL + CBT attenders had not
received treatment post study. However only a minority of the oz,
and PL attenders had received no treatment -post-study. At si)f
months follow-up assessment the DZ + C8T, and C8T group had
main tained in it ia 1 trea tmen t ga ins. This is evident by the
majority of patients in both groups showing 'clinically significant
change' on the anxiety measures without recourse to any subsequent
post-study treatment. At Day 70 the PL + C8T groups had shown the
third greatest reduction in anxiety, this relative rank was also
seen at follow-up when approximately 50% of PL + CST patients
exhibited 'clinically significant change'. The DZ group had the
second lowest number of patients achieving clinically significant
change at follow-up. The PL group contained the lowest number of
patients achieving clinically significant change at follow-up.
However in this PL group only 42% of patient~~~ttended for follow-
up, whereas all other groups achieved at least an 80% attendance
rate. The 8 patients from the PL group who simply failed,without
explanation, to attend for follow-up were characterised by poor
response to treatment. In particular, at Day 70, these 8 PL
patients all failed to achieve 'clinically significant change',
status on the HAM-A, and only 1 of the 8 patients achieved such
status on the SRT. For these 8 patients comparison of Day ° and
Day 70 on the HAM-A, and Day -7 and Day 70 on the SRT failed to
produce any significant reduction in symptoms et = 1.57, df = 7,
n.s. ; t = 1.38, df = 7, n.s.>. So they were a group which failed
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to respond to treatment, and this lack of therapeutic impact may
have made them reluctant to attend for follow-up.
DISCUSSION
At Day 70 all treatment groups had improved to a greater or
lesser extent on the HAM-A, SRT, Tense-Relaxed and Target-Symptom
measures. All groups apart from PL showed significant GHQ
reductions.
Differences between groups in the rate of symptom reduction
first emerged at Day 14 on the Tense-Relaxed visual analogue,
followed at Day 28 by the HAM-A and the Target-Symptom visual
analogue. Between-group differences on the SRT did not emerge
unti 1 Day 42. On the above measures these early differences
favoured DZ + eBT and/or eBT over PL. Differences in favour of
DZ + eBT in comparison to DZ emerged atNa similar stage on the
HA~A and SRT but at a later stage on the Target Symptom measure.
Differences in favour of eBT in comparison to DZ eventually
occurred on the HAM-A, Tense-Relaxed, and Target-Symptom measures.
The HAM-A and Tense-Relaxed measures also showed differences in
favour of PL + eBT in comparison to PL. At Day 70 the GHQ showed
differences in favour of DZ·+ CBT, and CBT in comparison to PL and
DZ. At no point did CBT, DZ + CET, and PL + CST groups diffpr.
Similarly at no point did DZ and PL groups differ. Few between-
group differences emerged in the first two weeks of the study, all
groups seemed to he improvi.ng at a similar rate. However, at:
lA~
Hpp~oximat~ly nay 14 to Day 7.8, PL anrl D7 t~PAtmpnt gAins bpgan
to p la t eau , whilp. CBT, DZ + CBT, anrl PL + CBT continul?p.d to
imp~ove.
The p~ec;;p.ntstudy pp.~mits compa~ison of stati.stically
significant. change on specific anxiety measu~es vs. clinically
~ated change as assessed by psychologist and GP seve~ity ~atings;
psychologist, GP, and patient self-~epo~ts of ove~all symptom
change; and Jacobson et aI's (1984) fo~mulae fo~ 'clinically
significant change'.
The PL qroup pr-oducad small but statistically significant
~eductions on most of the anx iety measu~es during treatment.
Howeve~ the clinical significance of these changes for the PL group
was fa~ less imp~essive, and 70% of patients requi~ed subsequent
treatment in the 6 months post-study period. It is not su~p~ising
-that few PL patients attended fo~ follow-up if they regarded the
treatment they received in the study as lacking efficacy.
As a group the DZ patients appeared to respond well if one
looks at pre and post-study statistically significant reductions
on the specific anxiety measures. However, at Day 70, only a
minority of the DZ patients achieved 'clinically significant
change' on the anxiety measures, except the HAM-A where a majo~ity
of DZ patients did achieve such status. Although the majority of
DZ patients we~e ~ated as 'minimally' o~ 'much' imp~oved by the
cu~~ent alJtho~, GP, and self-report at Day 70, this treatment gain
was not of adequate magnitude or permanence"to p~event 57% of them
requi~ing subsequent treatment in the 6 months post-study period.
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CAT, Dl + CAT, and Pl + CAT group~ all achieved pre and
pos t+wt udv statistically significant rertuct Lon s on thF:'specific
anxiety measures. Tn addition at Day 70 both referring GP and the
current author rated a larger percentage of the CST, DZ + CST and
PL + CST groups as veering towards an absence of symptoms. on the
severity rating, in comparison to DZ and PL groups. This trend
was also reflected by the majority of CST, and DZ + CST patients
being rated as 'very much improved' by GPs, the current author and
patients self-report. After treatment on Day 70 the D1 + CST in
particular, followed by the CST group consistently produced the
largest percentage of patients achieving 'clinically significant
change'. Follow-up revealed a low rate of subsequent treatment and
a high rate of maintained improvement for the DZ + CST and CST
groups. Although the PL + CST group did not differ from CST and
DZ + CST groups on statistical analysis of the specific anxiety
measures during treatment, there was a tendency for the magnitude
of PL + CST symptom reduction to be less impressive. This pattern
of results was reinforced at Day 70, with only 501.of the PL + CST
group rated by GP, and the current author as 'very much improved'.
Similarly, smaller percentages of ·the PL + CST group achieved
'clinically significant change', at Day 70 on the SRT and 'Tense-
Rela~ed' measures in comparison to CBT and DZ + CBT groups. At
follow-up slightly fewer PL + CBT patients maintained 'clinically
significant change' on the HAM-A in comparison to CBT and DZ + CBT
groups. Similarly at follow-up only 501. of the PL + CBT achieved
'clinically significant change' on the SRT, GHQ and Tense-Relaxed
1A7
mp.:isurps. Ovpr.:ill,thp dpgrpp of 'clinical ly si~nificant chan~p.'
achieved by the PL + CRT tended to he }pse; th.:inthat attained by
the CBT and DZ + CBT groups. However this did not }pad to any
major differences in the number of PL + CBT patients receiving post-
study treatment in comparison to CBT and DZ + CBT groups.
The effect that benzodiazepines may have on the efficacy of
psychological treatment was discussed in Chapter 4. It has been
argued that concurrent benzodiazepine use may diminish or enhance
the effectiveness of psychological treatment CMiller 1986).
Furthermore, withdrawal of concurrent benzodiazepines may lead to
relapse if patients attribute clinical improvement to the
anxiolytic effect of medication (Sartory 1983). These points are
relevant to the present research. In particular, if patients in
the DZ group attributed treatment gains solely to the drug, then
discontinuation of the medication may indeed lead to relapse.
This phenomenon may explain the high rate of subsequent treatment
received by the DZ group, and even those in the Pl group, who had
responded positively during treatment. However, this does not
appear to apply to the DZ + CBT group which, although not
significantly different from the CBT and Pl + CBT groups,
exhibited the greatest reductions on specific anxiety measures, and
attained the highest percentage of patients achieving 'clinically
significant change' at Day 70 and at follow-up. Diazepam in
combination wi th cogni tive-behaviour therapy did not appear to
impede psycho logica I trea tmen t or Iead to re Iapse in DZ + CBT
patients. Rather diazepam may have had a beneficial impact on
1RR
tr-eatmE"nt outcomp. and follow-up in thp DZ + r::STQroup. This may
bp. r-esponsible for thE" DZ + CRT qr-oup consistently beina one of the
fir-st gr-oups to show early treatment gains compared to PL controls.
The lese:;impressive r-esults of PL + CST in comparison to CST and
DZ + CST may be explained by patient expectations regarding the
benefit of placebo medication not being met. Patients in the PL
+ CST gr-oup may thus have expected the placebo medication to
partially ame Li or-at e their anx f e t v s t a t e , (as o La zepam may havE'
done for- the DZ + CST gr-oup). Ther-efore PL + CST patients may
have applied cognitivE'-behaviour therapy techniquE'S with less
vigour- and greater- passivity than those in the CST alone gr-oup.
ThE' unfulfilled expectation of placebo efficacy, coupled with
diminished levels of cognitive behaviour- ther-apy application, may
have impair-ed the effectiveness of PL + C8T tr-eatment and reduced
thE' percE'ntagE' of patiE'nts achieving clinically si~nificant changE'
at Day 70, and follow-up.
Anxiety r-E'duction in thE' CST group was sE'cond to that in thE'
DZ + C8T gr-oup but these groups wer-e not significantly differ-ent.
The prE'sE'nt study therefore shows that C8T is a viable method of
anxiety management which has lasting r-esults at follow-up.
Although thE' PL and to a lE'ssE'r E'xtE'nt thE' DZ groups failE'd
to attain and maintain the levels of anxiety reduction achieved by
thE' C8T, DZ + C8T, and PL + C8T qroups, it is nE'verthelE'ss
impor-tant to note that a sma] I but significant propor-tion of DZ
patiE'nts did achieve'clinically significant change' status at Day
70, and ther-eafter- at follow-up without subsequent post study
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treatment. Tn th~ Pilot Study (Chapter h) 70% of diazepam patients
required some form of treatment in the 12-month period post-study.
Tn the present study, albeit only a 6-month follow-up, only 57X of
OZ patients required subsequent treatment. The reduction in the
number of DZ patients requiring post-study treatment in the present
study, in comparison to the Pilot Study, may be due to the
implementation of a graded-withdrawal programme for both the DZ and
DZ + CST groups. Nei ther OZ nor OZ + CST patients showed any
significant elevations of HAM-A, SRT, Tense-Relaxed, and Target-
Symptom measures during graded - wi thdrawal. As previously
mentioned in the Pilot Study, Owen and Tyrer (1983) suggested that
a temporary increase in pre-existing symptoms and the presentation
of new symptoms may indicate a withdrawal syndrome. The Main
Study did not reveal an increase in pre-existing symptoms for the
DZ and DZ + CST groups during graded -wi thdrawa 1, nei ther were
major withdrawal symptoms experienced. A few patients from the
DZ, and DZ + CST groups complained of mild agitation, an increase
in the vividness of dreams, and some disturbed sleep, during and
immediately following graded-withdrawal. However these symptoms
were mild and of no major concern to the patients. The Pi lot
Study suggested that a reappraisal of the use of benzodiazepines
was necessary and advocated graded-withdrawal. The present study
suggests that although diazepam appears less effective than
cognitive-behaviour therapy for the management of GAD, the
pharmacological approach should not be discarded completely. As
a first line of treatment diazepam produces clinically signi~icant
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results for a substAntial minority of patients. Although these
results are not wholly mAintained at follow-up the introduction of
a placebo substitution I]r.'3ded-withdrawal programme, after a
relatively short course of treatment, maximizes initial gains and
limits withdrawal symptoms, thereby possibly reducing sl-lbsequl='nt
dependence.
A number of criticisms pertaining to the Pilot Study also
apply to the Main Study. There was no formal assessment of CST
or skill of the current author as sole therapist. Unfortunately
this was beyond the scope of the present study. Although CST was
administered according to structured guidelines presented in
section 6.2.2, the particular emphasis placed on the amelioration
of cognitive, behavioural, and somatic components varied according
to patients' specific presenting problems. The superiority of CST
whether alone or in combination cannot be attributed solely to the
" .,.~
amount of psychologist attention patients received. DZ and PL
groups received a similar amount of attention during which the
current author conducted enquiries about response to treatment in
a non-directive manner so as to avoid making suggestions of a
therapeutic nature. Thus, certain components of cognitive-
behaviour therapy, apart from the amount of non-directive
counselling the patient rec~ives, are likely to be responsible for
treatment gains and maintained improvement at follow-up. At
present one can only speculate as to which ~omponents of cognitive-
behaviour therapy are important. However from a patient's
viewpoint the fact that they themselves feel that they can control
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their symptoms and that their worst fears will not be realized may
enhance long-term treatment gains. Cognitive-behaviour therapy
also teaches patients that they are responsible for treatment gains
and alleviates their central fear that they will' lose control' in
some manner or other. Cognitive-behaviour therapy is a more
active and directive form of anx r e t v management, than the more
passive form of long-term benzodiazepine use.
In summary, the present study suggests that short-term diazepam
with graded-withdrawal is still a treatment strategy worth
pursuing given the substantial minority of patients who respond
positively to it, and the often long waiting-list for psychological
treatment. However treatment gains with diazepam are not always
well maintained. Alternatively cognitive-behaviour therapy
produces long standing an)(iety reduction for the ~ajority of the
patients. Diazepam in conjunction with cognitive-behaviour therapy
results in early treatment gains and this combined treatment may
be most appropriate for patients suffering from severe GAD.
Additional,ly the current study also suggests that benzodiazepines
if used judiciously need not lead to a withdrawal syndrome and
subsequent dependence. Given the growing demands from the 1ay
press and the current recommendations of the Committee for Safety
of Medicines that patiemts be wi thdrawn from long-term
benzodiazepine use, the characteristics of a long-term user
population will be investigated in the next chapter.
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CHAPTFR A : SECONDARY STImy
8.1.1 A controlled comparison of characteristics of long-term
be~zodiazepine users in general ~ractice.
As mentioned in the introductory chapters, long-term use of
benzodiazepines is no longer recommended (Committee on the Review
of Medicines 1980). The popularity of these drugs (Tyrer 1974;
Lader 1978), and subsequent problems of dependency and withdrawal
(Murphy et al; Power et al 1985) have led to various estimates of
the number of patients on long-term repeat prescription (Balter et
a11984; Mellings:>ret al 1984). Growing concern about the number
of patients on long-term benzodiazepine maintenance has been
reflected both in medical journals (Drury 1985;
1987) and the lay press (Cohen 1983).
Although numerous articles have been published concerning ths:>
l'yrer and Murphy
characteristics of heterogeneous groups of psychotropic drug users
(Parish 1971; Skegg et al 1977; Cooperstock 1978; Murray et al
1981), there is a paucity of papers, especially in the United
Kingdom, concerned with benzodiazepine users in particular. Of
two recently published papers, concerned with characteristics of
long-term benzodiazepine users (Salinsky and Dore 1987; Rodrigo et
al 1988), only one (Salinsky and Dore 1987) incorporated a matched
age and sex control group. Both studies were carried out in
single general practices and each had a sample si Ze of
approximately 70 subjects. These fac tors comprom i se the general
193
applicability of thp ~esults. In one of these sturlies, patients
on eithpr benzorliazppine anxiolyticc; or hypnotics wprp apparently
included (Rodrigo et 031 1988), while in the othpr study patients
on an anxiolytic alone, or an anxiolytic plus hypnotic were
included (Salinsky and Dore 1987). However neither study assessed
the similarities or differences between anxiolytic and/or hypnotic
users.
Studies of hypnotic users have often included non-
ben20diazepine hypnotic drugs (Morgan et 031 1988), been limited to
the elderly (Morgan 1983), or to those in hospital or residential
care settings (Cook et 031 1983) • Little is known of
benzodiazepine hypnotic users in the community.
The current study reports on the characteristics of a large
group of long-term benzodiazepine anxiolytic. and hypnotic users
from three general practices in comparison with matched age and sex
controls. As previously noted, the boundary between
benzodiazepine anxiolytic and hypnotic is not absolute
a
in
pharmacological terms (Committee on the Review of Medicines 1980)
or with regard to how the drug is administered. Nevertheless
in the present study it was also decided to investigate differences
in those receiving prescriptions for hypnotics alone, anxiolytics
alone, and anxiolytics plus hypnotics, as this has not previously
been addressed in the literature.
8.1.2 Subjects
The study was conducted, with the consent of the eleven
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principal GPs, in thrp-p practicps of the Forth V~lley GP Rese~rch
Group during December 1987 - Febru~ry 1988. The three practices
comprised approximately 17,000 patient~ from three main and two
branch surgeries in suburban and village environments surrounding
Stirling town. One was a dispensing practice. Two were training
practices at the time of the study, and the third had just been
approved for training. The record systems were A4 with summary
sheets which included prescription summaries. All three practices
had computerised repeat prescription using the Scottish G-Pass
system which enabled an accurate and readily-available list of
patients receiving repeat prescription benzodiazepines to be
examined.
A total of 445 patients, currently prescribed
benzodiazepines. were identified in the three study practices as
having received 3 or more consecutive prescriptions of one or more
benzodiazepines.
8.1.3 Procedure
A random sub-sample of 205 patients was selected and matched
from the age sex register with controls. Two non-medical research
assistants ECS and MH8 were trained by the present author td
conduct a initial review of all patients· case notes. The data
collected from case notes were subsequently checked by a principal
in general practice (RJS) who was not working in any of the three
practices being studied.
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8.1.4 MF'aC:;IJrec:;
The rhararteristicc:; of the bpn7ndiazepine group which were
noted included age and sex distribution, number of years nn
benzodiazepines, age at first prescription and current
benzodiazepine medication.
Information was also collected for both benzodiazepine users
and matched controls on the frequency of consultations and all
prescribed medication over the past 10 years where the prescription
had been repeated more than once. In addition an analysis was
prepared, for both groups, of illnesses in each body system. Any
illness recorded on the medical summary or which required
specialist referral, or repeat prescription was included. Illness
was graded into major and minor episodes (excluding trivial
illnesses) and was done blind (between users and controls) by the
principal in general practice (RJS).
8.1.5 Results
8.1.5.1 Extent of Use:
The rate for three or more repeat presriptions in the three
study practices (17,000 patients) was 26 per 1000 or 2.6%. If
extrapolated this would provide an estimate of 133,120 on long-term
benzodiazepine medication in Scotland. Whilst no national rate
of benzodiazepine prescribing for Scotland is available, the Common
Services Agency (Information and Statistics Division) reported 1.78
million hypnotic prescriptions and 1.39 million sedative and
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tranqu illizp,r presc r.iptions NS hNV i nq been i ssuerl in 1986 to a
Scottish population of 5.123 million.
Table 8.1, adapted from Rodrigo et 031 (1988), shows the
results of some other recent studies that estimated the extent of
long-term general 'tranquillizer use' or benzodiazepine use. The
results are not directly comparable, in that different groups of
drugs are compared between studies. Furthermore other studies
have assessed the extent of drug use for more than one year,
whereas the present study assessed the frequencY'of three or more
consecutive repeat prescriptions. However 92% of the present
study population had received repeat prescriptions for more than
one year. Notwi thstanding these issues the various estimates
provide a valuable insight into the ex tent of regular
benzodiazepine use.
8.1.5.2 Benzodiazepine Patient Characteristics.
The benzodiazepine group comprised 48 (23%) males and 157
(77%) fema 1es. The mean age of the benzodiazepine group was 64
years (S.D. = 14 years, range = 27 - 90 years). The mean male age
was 59 years (S.D. = 15 years, .range 29 - 90 years). The mean
female age was 65 years (S.D. = 13 years, range 27 - 88 years).
Table 8.2 shows that only a minority (approximately 18%) were
currently aged 4~ years or below and that the majority of patients
(66%) first received a benzodiazepine prescription while aged
between 40 and 69 years. These results are illustrated graphically
in Figures 5 and 6.
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Tablp A.l. Ecotimatpri p)(tpnt of lnng-tprm lJ5P of 'tranguil1i7prco'
or benzodiazppines in recent coturiieco.
Stroll and lader 1984
Com=unitySurvey
"Use of tranqui 11izers for one yPar or
lOre"
Mellinger and Balter 1981
COIDIIIUIIi ty Survey USA
"Use of anti-anxiety agmts for 12
IOflths or we'
Balter et al 1984
COIIIUIli ty Survey
5Pveral Countries
'Regular daily use of anti-anxietyl
sedative drugs for 12 I!Jlths or lOre'
Sa I insky and Dore 1987
General Practice, England
'Taking benzodiazepines regularly
during the day for we than oneyPar'
Rodrigo et al 1988
General Practice, England
'Prescription for benzodiazepines for
one year or -are'
Present Study
General Practice, Scotland
"Three or .ore consecutive
benzodiazepine prescriptions'
1.51 of men
1.6l of population
lJ( : 3.ll of population
USA: 1.8%of population
Europe: 1.6l of population
1.6 1of registered patimts
2.2% of registered patimts
2.6l of registered patimts
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Table 8.2. Illustrating current age distribution of 8Z users and
distribution of age at which first prescribed 8Zs.
Aqe Distritutic:nof BZ Distributic:nof age at
Users which first [2rescribed
BZs
Age (Years) r-.b ('Yo) r-.b ('Yo)
20-29 2 (1) 11 (5.5)
30 - 39 9 (4.5) 31 (15)
40 - 49 24 (12) 38 (19)
50 - 59 32 (15) 64 (31)
60 - 69 61 (30) 33 <16)
70 - 79 54 (26) .25 (12)
80-89 22 (11 ) 2 ( 1>
90-99 1 <0.5) 1 (0.5)
40
30
Cl)
C)
ca-; 20
o
"-
Cl)a.
10
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age (years)
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Fig.5. Percentage age distribution of benzodiazepine
users (N = 205; 26 per 1000; 2.6% practice pop.)
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Cl)
Clca-c 20
Cl)
o....
Cl)
a.
o
20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Age (years)
Fig.6. Percentage distribution of age at which first
prescribed benzodiazepines (N = 205; 26 per 1000; 2.6%
practice pop.)
•
201
The menn length of time bn repeat prescription
benzodiazepines was approximately 8 years (S.D. = 6 years,
range = 1 mon th - 23 years). Table 8.3 shows that of the 201
benzodiazepine users for whom the length of time on repeat
prescr iption cou 1d be ascerta ined, over ha 1f (58%) had been in
receipt of benzodiazepines for more than 6 years. These results are
illustrated graphically in Figure 7.
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!.?hlp A.3 Dic;trih_lItion_n.f_lp~!l!!t of_tJ_mp. on rpppat prpc;r.ri..I!!i_Qn R7~
TimE' (YE'ar~l. No JI.) o~ Bl users
0-1 16 (8)
1 - 5 68 (34)
6 - 10 57 (28)
11 - 15 22 (11)
16 - 20 32 (16)
21 - 25 b ( 3)
TOTAL 201 (100)
30
Cl)
C)
ca- 20c:
Cl)
0~
Cl)
C.
10
203
40
o
0-1 1-5 6-10 11-15 16-20 21-25
Time (years)
Fig.7. Percentage distribution of length of time on
repeat prescription benzodiazepines (N = 201)
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8.1.5.3 8enzodiA7.epine PAtients vs. Controls
Systemic Illness Histor~
Table 8.4 shows that only 181. of benzodiazepine users in
comparison to 371. of controls had no history of major systemic
illness. Forty per cent of benzodiazepine users had a history of
three or more systemic illnesses in comparison to 241.of controls.
A similar trend was evident with regard to minor systemic illness,
although to a lesser eKtent, with 151.of benzodiazepine users in
comparison to 241. of control s with no recorded minor systemic
illness.
Although. the differences between the groups are less clear
when major and minor systemic illnesses are combined, nevertheless
481. of the benzodiazepine group in comparison with 341. of the
control group suffered seven or more major pIu",!minor recorded
illnesses.
Table 8.5 illustrates the frequency of previous episodes
of major and minor illness in specific systems in benzodiazepine
patients and controls. Benzodiazepine patients eKhibited
significantly more episodes of major cardiovascular illness et =
3.81, df = 408. P < 0.001), major and minor gastro-intestinal
illness et = 3.02, df = 408, P < 0.005; t = 3.55, df = 408,
P < 0.001), major and mindr genito-urinary illness et = 2.65, df
= 408, P < 0.01; t = 2.14, df = 408, P < 0.05), major respiratory
j] lnec;s (t = 3.50, df = 408, P < 0.01), major central nervouc;
system illnesc; (t = 2.17, df = 408, P < 0.05) and minor ear noc;e
and throat illnec;s et = 2.08, df = 408, P < 0.05).
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T~blp. 8.4 - Distrihution .~_!_nt!~h!"_c_t?_f_r>rp'vjous m~jor, min~ ~nri
~~jor + minor sy:stp.mir: i_11np.ssps in 1?_~1J.?_.Q.r:ti~7'p.pi"-p.(AZ) users ~nri
controls from GP rp.corris.
Hajnr Svsteeic Illness Hinor Sysh'lIIic Kajor + Hinnr Svsteeic Illness
Illness
Numb!.'r of NoIII of 81 No IX ) of Ho!4l of 81 No IX ) of NoIX) ·of 8l No IX) of
R!.'cord!.'d Users controls Users controls IJsI.'rs Controls
T1lnesSl'S
24 (12)
None 3b liB) 76 cm 31 115) 49 124) 7113)
1 - 2 85 142) 79 139) Bl (40) B7 142) 42 1211 62 (30)
3 - 4 56 127) 40 119) 46 (22) 44 (22) S7 (28) S2 125)
S-6 IS I 7) 8 I 4) 21 110) 11 I S) 33llbl 35 117)
7-8 11 IS) 2 ( 11 16 I 8) 8 I 4) 2S (12) 16 ( 8)
9 - 10 2 I 1) 6 I 3) 6 I 3) 20 ItO) 6 ( 3)
11 - 12 4 I 2) 7 1 3) 9 14.S)
13 + 14 I 7) I 10.5)
TOTIl 205 1100) 205 1100) 205 1100) 205 1100) 205 1100) 205 (100)
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Tabll' 8.5. Total nuabPr of prpyioos speri fir ppio;odpc; of IIiJjor and .inor o;ystPlir i Ilnpo;c;po; in bPnlodi~lPpillP (81) Ir;pf'S and rmtro!
groops fro. liP rPCords.
Minor Systl'llic IIlnl'5S Maior SvstP.lllic Il\nl'55
Naturl' of Hlness Ho III of 81 No 11) of Ho 11) of 81 Ho 11) of
UsPr .. Control s UsPr .. Control ..
Cardiova'iCular 55 I 9) 47 (10) 145 (29) bS (23)
Sa.. trointl'5tinal 102 (17) 50 III) 88 (18) 4b (15)
BPni tourinary 104 (17) 70 lIb) 70 (14) 41 114)
Rl"ipiratory 17 I 3) 13 I 3) 30 I b) 8 I 3)
Skin 45 I 7) 4b (10) 10 I 2) 13 I 4)
Cl'ntral Nt>rvous Systl'll II I 2) 12 I 3) Ib I 3) 5 I 2)
Hal'llatoloqy Ib I 3) 9 I 2) 5(1) 5 I 2)
Endocrinl' 12 I 2) 10 I 2) 30 I b) 15 I 5)
"
locOlllOtor 139 (22) 111 (25) bSll4l b5 (22)
Ear/Hasp/Throat bl (10) 39 I 9) 19 I 4) 14 I 5)
Opthallic 39 I b) 30 I 7) 12 I 2) 13 (14)
Othl'r 15 I 2) 14 I 3) 3 I Il 4 I Il
TOTrt. MJ11lEROF bIb (100) 449 (100) 49b (100) 297 (100)
REClJlDEDIllNfSS£S
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Thus the benzodiazepine group had experienced significantly more
episodes of major and minor systemic illness than the control group
(t = 5.14, df = 40~, P < 0.001; t = 3.33. df = 408, P < 0.01).
8.1.5.4 Consultation Rates.
For each of the last five years benzodiazepine patients
Consistently consulted their GP at a significantly higher rate than
Controls, as illustrated in Table 8.6.
8.1.5.5 Psychotropic Medication and Psychiatric Referral
Over the last ten years, benzodiazepine users had received a
Significantly greater variety of antidepressants et = 4.87, df =
408, p < 0.001), major tranquillizers (t = 2.50, df = 408, p <
0.05), benzodiazepine anxiolytics et = 6.11, df = 408, P < 0.001',
benzodiazepine hypnotics (t = 3.95, df = 408, p < 0.001), and other
DSYchotropics (t = 3.77, df = 408, p < 0.001), although the overall
frequencies were relatively low. Over the same period the mean
number of pharmacologically distinct non-psychotropics prescribed
on at least one occasion for the benzodiazepine group was 11.41 (SD
:::9.56), compared with 7.29 (SD = 6.00) for the control group,
reflecting a significant difference between groups et = 4.73, df
:::408, p (0.001).
Benzodiazepine patients were also currently receiving more
antidepressants and non-psychotropic drugs Lt = 4.75, df = 408,
D < 0.001; t = 8.01, df = 408. p « 0.001), both of which hSl.tfbeE'n
Prescribed for a significantly great~r length of time jn comparjson
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Table B.6. Comparison of average number of GP consultations by
year for 8Z users and controls (df = 40B)
EZ Users Controls
Year Mean (SD) Mea.!!..._lSD) t 12.<
1983 5.40 2.79 5.14 0.001
(6.06) (3.99)
1984 6.45 3.24 5.96 0.001
(6.43) (4.26)
1985 6.89 3.52 6.35 0.001
(6.18) (4.43)
1986 6.60 4.05 4.71 0.001
(6.12) (4.73)
1987 6.53 3.65 5.64 0.001
(5.83) (4.38)
.........,
1983 -
1987
32.03
(25.76)
17.34
(16.87)
6.83 0.001
to controls (t = 3.30, of = 408, P < 0.01;
7.09
t = 4.52, of = 408, p
< 0.001).
Within the bp.nzodjazepine group, 75 (36.5%) patients had
previously received a psychiatrir referral and 5 (2.4%) patients
a psychological referral, in comparison with 1.3 (6.3%) patients
and 1 (0.5%) patient respectively in the control group.
8.1.5.6 Se~ Differences.
Within the benzodiazepine group the mean male age of 59 years
(S.D. = 15 years, range = 29 - 90 years) was significantly lower
than that of the mean female age of 65 years (S.D. = 13 years,
range = 27 - 88 years) Ct = 2.83, df = 203, p < 0.01). The only
other differences between the se~es in benzodiazepine users were
the greater overall number of previous major systemic illnesses
et = 2.15, df = 203, P < 0.05), minor respiratory illnesses Ct =
2.87, df = 203, p < 0.01), and minor c:entral nervous system
illnesses et = 2.31, df = 203, p < 0.05) in males, and the greater
variety of previously prescribed anxiolytic:s for males et = 2.01,
d f = 203, p < 0 •05) • Female benzodiazepine users suffered more
previous episodes of minor genito-urinary illness et = 2.10, df =
203, P < 0.05) than male counterparts.
Within the control group a similar age difference existl?d
between the sexes given the matching of subjects. However, female
controls had received, during the previous ten years,
signific:antly greater variety of antidepressants et = 2.43, df =
203, p <0.016), benzodiazepine anxiolytics et = 2.41, df = 203,
p < 0.017)
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and non-psychotropics et = 2.04, df = 203, p < 0.043)
than the male counterparts. FF?males also suffF?red fpwpr episodps
of major locomotor illness (t = 2.51, df = 203, p (0.013).
8.1.5.7. 8F?nzodiazepine Anxiolytics and Hypnotics
Table 8.7 illustrates the current distr.ibution of
benzodiazepine anxiolytic and hypnotic presciption. A total of 79
(38%) patients received 'anxiolytic' medication alone; 98 (48%)
received 'hypnotic' medication alone, and 28 (14%) received
'anxiolytic plus hypnotic' medication. The total sample of 205
patients included two receiving repeat prescriptions concurrently
for two different hypnotics, and three receiving two different
anxiolytics.
One-way analysis of variance with post-hoc Sc~effe comparisons
was used to illustrate significant between group differences.
Table 8.8 summarises the mean scores of variables that differed
Significantly between groups and presents the results of the
statistical analysis.
Table 8.8 shows that patients currently receiving
benzodiazepine hypnotic alone' were significantly older and had
received their first benzodiazepine prescription at a later age
than patients currently "receiving a benzodiazepine anxiolytic
alone, or a benzodiazF?pine anxiolytic plus hypnotic.
21 ]
Tahlp 8.7. Oistrihution of current presc r i pt i. on
henzodia7p.pines
Hypnotics An )(j_9J-ytic 05
Generic Name No ( 'l. ) of Generic Name No ('l.) of
Patients Patients
Temazepam 59 (46) Dia7.epam 56 (51 )
Nitrazepam 57 (44) Oxazepam 34 (31 )
Triazolam 11 ( 9) Lorazepam 13 (12)
Lormetazepam 1 ( 1 1 ) Chlordiaze- 7 ( 6)
poxide
--------- ---------
TOTAL 128 ( 100) 110 (100)
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T~ble 8.B. Means (SD) and summ~ry of diffprpnrps bptwppn
benzodiazepine (AZ) hypnotic ~lone, anxinlytic ~lnnp, and
~nxiolytic + hypnotic groups (rtf= 2,202).
Group 1 Group 2 Group 3
Variable Hypnotic Anxiolytic Anxiolytic F P< Schl'ffe
+ Hypnotic
In = 981 . In = 791 In = 791
Patient age
Iyrs)
68.93
112.271
58.68
113.161
60.93
112.901
14.39 0.001 1-2,1-3
Ag! BZ first 57.02 47.68 4B.04 12.23 0.001 1-2,1-3
presc r ibed Iyrs I 113.051 114.071 112.16)
Ho. previous lajor + 6.02 4,42 b.IB 4.67 0.01 1-2
linor systuic I 4.02) I 3.12) I 4.301
illnesses
Ho. previoos lajor 2.79 I.Bb 2.68 4.B4·;·':' 0.01 1-2
systeaic illnesses I 2.22) I 1.751 ( 2.lb)
No. pr!viously 12.70 9.05 13.57 4.14 0.01 1-2
pr!scribed non- I 9.44) I 9.b41 ( B.65)
psychotropic
medications
No. previously 0.52 0.39 0.86 4.65 0.01 2-3
prescribed hypnotic! I 0.691 I 0.721 I 0.751
No. currently 3.82 3.67 4.82 4.39 0.01 2-3
prescr i bed I 2.351 I 2.121 I 2.141
lledications
Key: Post-hoc SchPffe treatllll'Ot group cDllparisons : I = HypnotiC; 2 = AnxiolytiC; 3 = Anxiolytic + Hypnotic. - ' .
Noh' : Groups Sl'parat~ by cl hyphPo differ significantly frOlll each othPr,t<'O,O~:
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Furthermore, patients receiving a benzodiazepine hypnotic
alone, when compared with the anxiolytic alone group had suffe~ed
a significantly greater number of majo~ plus mino~ systemic
illnesses, especially major, and had also received a significantly
greater variety of non-psychotropic medications. The amdol ytic
plus hypnotic group revealed similar scores to those of the
hypnotic alone group on these three variables. The differences
which emerged between the anxiolytic alone and the anxiolytic plus
hypnotic groups were not significant, possibly due to the
comparatively small size of the latter group.
Finally, the anxiolytic plus hypnotic group had previously
received a greater variety of hypnotics and was currently receiving
a greater overall number of medications than the anxiolytic alone
group.
nature
This result can perhaps be
of benzodiazepine prescription for
explained by the dual
the anxiolytic plus
hypnotic group. However, no such differences emerged between the
hypnotic alone and anxiolytic plus hypnotic groups.
8.1.6 Discussion.
The data for the present study were gathered from GP records
and are therefore somewhat restricted in that information derived
from personal interview and standardised assessment of patients is
not reported. However an assessment of psychological ill-health,
attitude towards benzodiazepine use, and "willingness to stop or
alter benzodiazepine medication was collected for a subsample of
the benzodiazepine group and wi 11 be reported in Chapter 9.
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Np.vprtheless the finrlings of the present study i lLu-st ra t e .=I numbp.r
of important features of benzodiazepine users.
The data obtained from the three study practices confirm
estim."Ites of other researchers of extensive long-term use of
benzodiazepines. The level of 26 long-term benzodiazepine users
per 1000 patients, concentrated in the older age group, provides
a substantial challenge to primary care.
The age and sex distribution of the benzodiazepine group is
similar to that reported in previous studies (Salinsky and Dare
1987; Rodrigo et al 1988). However this is the first controlled
study to report significantly greater specific systemic illness in
,
what is the largest United Kingdom benzodiazepine group yet
studied. Former studies have lacked controls or reported general
levels of illness in single practices with sampl~ sizes of about
70 SUbjects. The individual categories of disease that presented
.....'~
significantly more often in benzodiazepine users in the current
study may repay more detailed investigation.
Benzodiazepine users exhibit higher rates of cardiovascular,
respiratory, central nervous system, gastro-intestinal,
gen ito-ur inary, and to a 1esser degree, ear, nose and throa t
illnesses than matched controls.
ExpJanations for such an excess could be the parallel
treatment of discomfort or anxiety accompanying somatic pathology,
or the presence of specific organic system vulnerability or
weakness underlying the most commonly expressed symptoms of a given
anx iety disorder as suggested by Ma Imo and Shagass (1949).
7t~
Another explanation may hR that majnr systemic illness exacerbates
the development of anxiety symptoms leading to a subsequent demand
for benzodiazepine medication in patients with an~iF-ty p~one
personalities. Alternatively doctors may experience difficulty
helping patients to cope with a chronic physical ccmp t a in t , and
therefore prescribe benzodiazepines to try to alle~iate the ~n~iety
and/or despondency that the complaint engenders in the patient, and
possibly in the doctors themselves. Further detailed interview
and establishment of the precise sequence of physical illness,
psychiatric sequelae, and subsequent prescription will be needed
to clarify these alternatives.
The higher level of consultation in the benzodiazepine group
may simply reflect attendance for repeat benzodiazepine
prescription, although during the period studied repeat
prescription could easily be obtained without GP consultation.
Alternatively more frequent consultation could be related to the
higher level of somatic morbidity rather than a lower tolerance of
disease. However the benzodiazepine group also received a greater
variety of psychotropic medication, which may reflect a higher
incidence of psychiatric morbidity, or drug dependency, or poor
alternative coping resources for both patients and doctors.
Male benzodiazepine _users had suffered a greater overall
number of previous major systemic illness than female
benzodiazepine users. These sex differences were not present in
the matched controls, so the sex difference in the benzodiazepine
group cannot be wholly explained by the higher incidence of
21l;,
~ystemic illnessps in m~les in gener~l. However this conclusion
should be treated with caution given the relatively sm,'111nl.Jmbflr
of m~les in the present study.
A major finding of the present study is that significant
differences exist between patients currently receiving ~ hypnotic
alone, an anxiolytic alone, or an anxiolytic plus hypnotic.
The hypnotic alone users are the oldest group, and have
suffered more previous systemic illnesses than those prescribed an
anxi0Iytic a Ione • These resul ts suggest that benzodiazepine
hypnotics may be prescribed if patients' sleep is disrupted by
serious illness, the process of ageing, or both.
The characteristics of long-term benzodiazepine users, in the
present study, reflect a picture of ill-health in a predominantly
aged population. It is interesting to note that the mean age of
patients receiving their first benzodiazepine prescription was 47
years, which is arguably older than the suggested age of onset for
the anxiety disorders, which are predominantly regarded as
Occurring in early adulthood.
It is currently accepted that long-term benzodiazepine use
is not recommended for the treatme~t of anxiety states or insomnia
(Committee on the Review of Medicines 1980), and there is growing
pressure for patients to be withdrawn from long-term use. Howevl?r
issues affecting first-time prescription must be distinguished from
the approach to currpnt long-term USE'rs. The present study
highlights the confounding influence of major somatic morbidity in
a population of long-term users. The need for further
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investigation of the interrelationship between benzodiazepine
prescribing and physical illness is required and may need to be
addressed separately from the issues surrounding long-term use in
an)(iety states. Furthermore the implementation of graded-
withdrawal programmes for long-term benzodiazepine users must
attempt to address such issues, as different management strategies
may be necessary for those long-term benzodiazepine users
characterised by chronic physical illness, as opposed to those who
are in relatively good health. The balance of benefit and risks
between steady-state moderate long-term use of hypnotics in
physically ill older patients also needs to be addressed separately
from that of users who are young and free Ifrom such somatic
problems.
The challenge which long-term use of benzodiazepines presents
to the medical professions and patients is large and real.
However:~ the response should be a careful and measured one.
Patients should not be stressed by ill-prepared abrupt withdrawal,
Carried out as a response to media and legal pressure, in the
absence of adequate support strategies • Further research into
the use of alternative graded-withdrawal programmes in primary care
settings will be required before clear guidelines can be formulated
on the best form of management of these patients.
Whilst GP records have provided clear evidence with regard to
Physical morbidity there is a lack of clarity relating to
Psychological ill-health and willingness to reduce or alter
ben20diazepine intake.
21A
An attempt to gather such information is
presented in the following chapter.
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CHAPTER 9 : TERTIARY STUDY
9. 1 • 1 Psycholqgical ill-heal th .:!nrlattittJrleto ben7orlia7E'pinE'
USE' and withdraw.:!lamong 10ng-tE'rm benzodiazepine users.
Rodrigo et al (1988) stated th.:!ttheir one Qp.neral practice,
sixty-four patient sample, was the first study of "long-term
benzodiazepine USE'rs in which a standard assessment of psychiatric
morbidity has been carriE'd out ... They u5ed the Clinical Interview
Schedule (CIS) (Goldberg E't al 1970), the Kellner and Sheffield
(1973) Symptom Rating Test (SRT), asked patients questions about
their past and present use of medicines, and extracted information
on physical ill-health from GP records. Although this study has
methodological limitations, it is to be commended in attempting to
interview long - term benzodiazepine users to assess formal
psychiatric diagnosis according to ICD criteria using the CIS.
However only 2 of 16 male subjects and 20 of 48 female subjects
were able to be classified as CIS cases, the most common diagnoSis
being 'neurotic depression', accounting for 1 male and 16 female
Subjects. WhilE' this study reported SRT scores no other anxiety
Although the prescribing of benzodiazepines has
Or depression measure of psychological ill-health was reported.
reportE'dly associated with social problems CKerlw.:!rd1969;
CoopE'r 1972; Cooper and Sylph 1973; Cooperstock and Lennard 1979)
systematic research has fai led to evaluate the specific social
difficulties that characterise such patients. Furthermore the>
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lpvp] of social problpms pxpprienced hy hpn2'odL"17Ppine tJsp.rsin
comparison to other relevant groups has not been assessed.
Current high level media coverage has presented a negative
view of benzodiazepines by highlighting dependence and rpcommendinQ
withdraw.31. While some groups of benzodiazepine patients are
presently taking legal action against the prescribers and
manufacturers of such drugs, there has been little systematic
research on the attitudes of patients who are currently on long-
term medication. In an attempt to clarify some of these issues
the psychological ill-health and attitude to benzodiazepine use and
withdrawal among long-term benzodiazepine users was investigated
in more detail.
9.1.2 Sublects
From the sample of 445 benzodiazepine anxiolytic and/or
..~..,.
hypnotic users described in section 8.1.2, a random sample of 145
patients was contacted. They were sent a letter on practice
notepaper, signed by a research administrator (VS) on behalf of
their GP, inviting them to attend their own health centre to
discuss their treatment on benzodiazepines. The invitation in no
Way suggested that attendance would result in their being withdrawn
Two research assistants (ECS and DS) were trained by the
from benzodiazepinp medication (Appendix 9).
9.1.3 PrOCE'dure
CUrrE'nt author to conduct a semi-structured interview and to
administE'r a number of standard assessment measures to each patient
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who attended for a forty-five minute assessment session.
9.1.4 MeNsures
Three primary self-report qlJestionnaires of psychological ill-
health were used:
a) The Kellner and Sheffield (1973) Symptom Rating Test (SRT)
as used in sections 6.1.4, 6.2.4, and 7.1.4 ••
b) The General Health Questionnaire (60-item) (GHQ) (Goldberg
1972) as used in section 7.1.4 ••
c) The Beck Depression Inventory (BDI) (Beck et al 1961) was
used to assess behavioural manifestations of depression. The BDI
consists of 21 categories of symptoms and attitudes. Each·category
describes a specific behavioural manifestation of depression and
consists of a graded series of self-evaluative statements (Appendix
10). 8eck et al (1961) reported a split-half reliability of +0.86
..~
for the inventory, and high degrees of validity when compared with
diagnostic judgements of clinicians.
In addition one interviewer/assessor questionnaire of
Psychological ill-health was used:
d) The Hamilton Anxiety Scale (HAM-A) (Hamilton 1959) as used
sections 6.1.4, 6.2.4,and 7.2.4 ••
In addition patients completed three other questionnaires:
e) The Social Problems Questionnaire (gPO) (Corney and Clare
1985). Designed to measure the presence/absence of social
problems, the questionnaire covers housing, occupation, finance,
social and leisure activities, child/parent and marital
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rp.lationships, rp.lationships with rp.lativps, friends, neighbours
and workmates, and legal problems (Appendix 11).
f ) A 'Ben7odiazepine Dependency OuestionnairE" (BZDO)
constructE'd by thE' presE'nt author to assE'SS patients' attitudE's to
thE'ir current benzodiazepine medication, for example, willingnE'ss
to stop or change medication, concern at being on medication,
appropriateness of current dosage etc. (see Appendix 12).
9.1.5 Results
From a total of 48 patients who attended for interview, 44 (31
female, 13 male) completed all the assessment measures. Of this
sample, 10 were receiving 'anxiolytic + hypnotic' medication; 16
WE're receiving an 'anxiolytic alone', and 18 were receiving a
'hypnotic alone'. A significant between-group difference existed
..~.•~ for age (F(2,43) = 3.56, p < 0.05), as illustrated in Table 9.1.,
although no two groups differed significantly at the 0.05 post-hoc
Scheffe level. Length of time on repeat prescription
benzod ia zepines d id not d iffer between ben zod iazepine subgroups
CF C'2•43) = 1.31, p = 0.278). Males and females did not differ
with respect to age Ct = 0.55, df = 42, P = 0.588) or length of
time on repeat prescription benzodiazepines Ct = 0.70, df = 42,p
= 0.491).
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Table 9.1 Means, standard deviations, (SO) and one-way analysis
of variance between hypnotic alone, anxiolytic alone, and
anxiolytic + hypnotic groups (df = 2,41).
Anxiol~tic
Hypnotic Anxiol~tic + Hypnotic
Variabll' IN = IBI IN = Ibl IN = 10) _F_ P
Agl' bO.bl 52.50 62.30 3.56 0.031*
112.99) I 9.93) I 7.60)
ll'ngth of 139.22 93.97 107.20 1.31 0.279
tilt' on 1119.41l 185.73) I 66.36)
bl'nlodiaa-
pines
I.ths)
HAI1-A 9.77 9.25 8.20 0.18 0.830
I 6.76) 16.32) 16.52)
SRT 15.55 14.81 13.20 0.10 0.903
113.72) 113.541 (13.991
GHD 8.05 6.00 8.40 0.15 0.857
114.92) 18.731 113.25)
BDI 7.61 4.97 5.60 0.82 0.444
17.381 15.35) 15.921
* p <0.05
Y.E'Y : Post-hoc SchE'ffl' treatmpnt group cOlllparisons :- 1 = HypnotiC; 2 = AnxiolytiC; 3 = Anxiolytic + Hypnotic,
Note: Groups SE'parated by a hyphen differ significantly frOlt each othE'r ,:
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a) Psychological TIl-Hpalth: Table 9.1 also p~espnts the HAM-A,
GHQ, and BOT sco~es fo~ thE> 'an)(iolytic + hypnotic', "anx io iv ti c
alone' and 'hypnotic alone' q~oups. No significant batween-gre~p
diffe~ences on these variables were found by ons-way analysis ef
variance.
Given that the benzodiazepine treatment subC)~oups fai led to
diffe~ on the measures of psychological ill-health (Table 9.1), and
that no significant se)( differences e)(isted (see Table 9.2), the
remainder of tbe results section will presE>nt data for the
benzodiazepine group as a whole. Table 9.3 presents the overall
group means and standard deviations an the HAM-A, SRT, GHQ, and
BDI.
From the total sample of 44 patients interviewed, only 11 (25%)
scored ~ 15 on the HAM-A and were therefore within the range
required to satisfy the HAM-A entry criterion which operated in the
main study (Chapter 7).
12 on the SRT was 43%.
The proportion of patients who scored >
This is similar to Rodrigo et aI's (1988)
figure of 50% for their sample of 64 long -term benzodiazepine
users. In the present st.udy only 5 pati.E'nts (11%) achieved a
Score of ) 19 on the GHQ, a level at which it is suggestE'd that
patients wi 11 only improve if offered treat.ment LJohnstone and
Goldberg 1976>.
All measures of psychological ill-health showed significant
positive correlations with one another a~' shown in Table 9.4.
b ) Social Proble>ms: Table 9.5 gives the> results of the
present study and other relevant work (Corney and Clare 1985) for
22~
Table 9.2 t-tests between ma]e and female ben7odia7epine patient~
on HAM-A, SR"I:...2___!_:J.!-IQ_~nrt_BR._!__(df = 42)
"ale Fpule
(N = 13) (N = 31)
Variable "pan ISO) "ean (SO) p
HA"-A 9.15 (6.74) 9.25 16.40) 0.05 0.962
5RT 6.38(13.26) 1.80(12.15) 0.34 0.132
6HD 13.23(15.011 15.06112.93) 0.41 0.684
BDI 5.30 11.30) b.51 Ib.OIl 0.57 0.511
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Table 9.3 Means and standard deviations (SD) on HAM-A, SRT, RHQ,
and BDI for all repeat prescription benzodiazepine interviewees
(n = 44).
Variable
HAM-A 9.22 6.43
SRT 14.52 13.43
GHQ 7.38 12.35
BDI 6.15 6.36
.~....
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Tab) EO 9.4. Pparson Corrp) C!!__i_Q~flf'f_f._i!- i'pnts___f_Q-,= __~J_l__ r-_5)~<:t_t
prEOsc r!...Rt i on hpn zod i a "en inp in terv i ewppc; o'l_ HAM-~~§RT -L__fitLfb_
and BDI (df = 44).
HAM-A 0.873* 0.593* 0.711lk
SRT 0.669* 0.807*
GHQ 0.804*
EDI
(lkP <0.001)
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Tablp 9.5. Numhpr~ of diffprpnt typps of SPO proh1pms ppr pprson
by samp]p.
NUll b l'r o f .SaIlQIl' frOll GP .GP Attl'lldm
diffl'rent tYQl'Sof lic;t
aajor probll'll'lper ""Ie (I) FP.tIaIl'(I) Outer lonjoo III Inner loodoo III
person (n=bIl) (n=90) (n=BI) (n=94)
None 70.b 63.3 53.1 41.5
One 14.7 IB.9 21.0 23.4
TNO 10.3 10.0 17.3 13.B
Three 1.5 4.4 4.9 10.b
Four+ 2.9 3.3 3.b 9.5
Nu. b e r o f .Psychiatric rut- .Social Worker Prl'Sent Study (I)
different ty~ of ~tient'l III rl'fl'rral'lIII
major QroblP.15 per (n=27) (n=65) (n=44)
!1erson
None 40.7 3.1 79.5
One 14.8 24.b 11.4
TNO 14.8 27.7 2.3
Three IB.S 20.0 4.S
Four+ II.I 24.6 2.3
.(CornpY and Clarl' 1985)
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comparison. ThE' reped t prE's!:ription ben zod iazepi ne patients
showed a similar SPQ profile to that exhLbLted by Corn13Y ~nQ
Clare's (1985) random sample from a 8P li~t. SCII:ial work
referrals, psychiatric out-patients, and GP attenders all fihnw13Q
higher levels of major social problems than repeat prescl'"'iption
benzodiazepine users. The most common problem identified by the
benzodiazepine users was interpersonal relationship problems (9.0/.).1
followed by work (7.0/.),and marital (7.0/.) difficulties. However
in general the SPQ data did not support the notion that those
repeat prescription benzodiazepine users who attended for
assessment interview suffered from unusually high levels of social
problems.
c:) Attitude to Benzodiazepine Use: Table 9.6 shows the
repl ies of patients to the BZOO. Over' SO/. of patients regarded
their medic:ation as being vital/essential or very important in
helping them c:ope. Only a minority of patients (tt/. approx.) were
definitely, or very muc:hc:onc:ernedabout being on benzodiazepines,
and over 70/. thought that it would be fairly, or very diffic:ult to
stop medic:ation. Over SO/. thought that their c:urrent
benzodiazepine dosage was just about right. Given the above
pic:ture it may seem surprising that approximately 40/.of patients
stated that they were fairly or very willing to stop their
medic:ation. However it must be remembered that the remaining
60/. were fairly or very unwilling to' c:ease benzodiazepine
medic:ation. Similarly, approximately 68/. expressed some degree
of c:oncern if their medic:ation were to be changed. It therefore
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Tahle 9.6. Responses to 'Ben7odiazepin~ ()epenopnry Ollec;tinnnairp'
(n = 44)
Ouestion 1 ..
How import ..:mt is your medi.c.ationin helping you cope?
Response
Vital/essenti.al
Very important
A little important
Not important
34.1
47.7
1.3.7
4.5
Question 2 :
Does being on your medic.ation concern you at all?
Response
Not concerned at all
A little concerned
Definitely concerned
Very much concerned /
worried
54.5
34.1
9.1
2.3
Question 3 :
How easy do you think it would be to stop your medication?
Response
Very easy
Fairly easy
Fairly difficult
Very difficult
(Don't know
4.5
22.7
29.5
40.9
2.3)
Ouest ion 4 :
What. do you think about your c.urrent medic.ation dosage?
Responc;e
Extremely high
A little high
Just about right
Extremely low
o
9.1
81.R
9.1
?31
Tablp. 9.6 Rp«;ponsp.«;to .Apn7oni.'l7Ppinp. Opppnnp.nry Oupc;tionnairp.·
(contd)
OUE'stion 5 :
How willi.ng would you be to stop your mprtic.ation ?
Responsp.
Very willing
Faj.rly willing
Fairly unwilling
Very unwilling
13.6
27.3
40.9
18.2
OIJPst.ion b :
How do you think YOll would feel if your medication was changed?
Response
Not concerned at all
A little concerned
Definitely concerned
Very much concerned I
worriE'd
31.8
36.4
25.0
6.8
Quest.ion 7 :
How do you think YOll would feel if your medication was stopped ?
Response
Not concernE'd at all
A little concerned
Definitely concerned
Very much concerned I
worried
(Dont know
6.8
13.6
36.4
40.9
2.3)
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seems consistent that abnut 811.r-epor-terisome dpgr-f?1?of concer-n if
their medication wer-e to be stopped.
9.1.6Discussi.on
Unfortunately only 44 patients, r-epr-esent.ing30.31. of the
or-iginal 145 invited patients, attended for int.erview; so any
generalisations from the present study should be treated with
caution. A number of factors may have contributed to the poor
response rate in this study. Although the invitation letter
(Appendi~ 9) deliberately did not suggest that attendanc.e would
result in patients being withdrawn from medication, patients may
have feared that attendance would result in benzodiazepine
withdrawal, and therefore have decided not to attend. If this is
so then the figures on benzodiazepine dependency, willingness to
modify or stop medication, etc. may present an over-optimistic
picture as those who failed to attend may be more heavily
benzodiazepine dependent.
Mellinger et al (1984) suggested that long-term, predominantly
benzodiazepine an xLolv t Lc users e)(hibit high levels of psychic
distress, in particular an)(iety and depression. Murray (1981)
from her'Woman's Own' postal survey reported that 83 I. of self-
selected psychotropic drug users scor-ed) 12 on the SRT:
Similarly, Williams et al (1982) repor-ted that 84 I. of male and
91 I. of female, newly prescribed psychotropic drug users scored
) 12 on the SRT and were therefore 'classified as "probable
psychiatric cases". The number of patients achieving this
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cut-off on thp SRT in thp pr-esent sturly was substantially lowpr-
than the figur-es cited by Mur-r-ay (1981) and Williams et al (1982),
The tr-end towar-ds a low per-centaqe of psyr.hiatric Qr p~y~hQ1Qgl~Ql
'caseness' in the pr-psent study was fur-ther strenqthened by the
relatively low HAM-A and GHQ scores. The lQW nwmber of patit?nt~
achieving 'caseness' scor-es on the var-ious assessment measures may
suggest that long-ter-m benzodiazepine use is functional in reducing
anxiety-r-elated symptoms. Alter-natively, if (as suggested in
Chapter 8) long-ter-m benzodiazepine US!? is associated pr-imar-ily
with a history of major- systemic illness, it may be that the gr-oup
of long-ter-m user-s in this study has never- shown exceptionally high
levels of psychiatr-ic and psychological mor-bidity. Fur-ther- work
is needed to clar-ify whether-, in this long-ter-m benzodiazepine
gr-oup, the original benzodiazepine pr-escr-iption was aimed at pur-ely
psychological, physiological, or- a combination of pr-esenting
symptoms.
Appr-oximately 80X of the pr-esent study population r-epor-ted no
major- social pr-oblems. This finding is at odds with the popular-
ster-eotype of the long-t.er-m benzodiazepine user-, but pr-obably
concur-s with the data pr-esented in Chapter- 8, which show
benzodiazepine user-s char-acter-ised as .3 pr-edominantly elderly
population with a histor-y of major- systemic illness. However the
high per-centage of patients who failed to attend for- inter-view may
be evp.n mor-e hp..3viIy benzodi.3zepine dependent than the study
sample. Similarly, non-attendance may have been higher- in
patients with gr-eater- psychiatr-ic morbidity and major social
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problE'ms. Indeed these characteristics may predispose towards
non-attendance in such studies.
The picture presented by patients' replies to the BZDQ
suggests a dependence on and concern about alteration or cessation
of a level of benzodiazepine usage that is regarded as 'just about
right'. Forty per cent of the sample were fairly or very willing
to stop benzodiazepine medication, but ironical ly 77"1. expressed
concern if their medication were to be stopped. This may suggest
that a substantial number of benzodiazepine users, while regarding
themselves as dependent on their medication, and worried about how
they would cope without such medication, would still consider some
form of graded, structured, and medically supervised withdrawal
package. Although not presented, the patient group exhibited a
level of benzodiazepine intake that was usually below the
originally prescribed dosage. As such they did not appear as a
long-term, high-dosage, benzodiazepine abusing group. Rather they
appeared to have altered their dosage to the lowest, most
appropriate, level. The results of this study, and the
data presented in Chapter 8, may have implications for the
implementation of withdrawal· programmes that are currently
receiving support and attention. This will be discussed in more
detail in the following final chapter.
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CHAPTER 10 : DISCUSSION
A thorough review of the literature highlighted specific g~ps
in our knowledge of pharmacological and psychological aspects of
anxiety managemE'nt. The work undertaken for this thesis was
designed to redress the situation with a series of studies aimed
at answering specific questions in the hope that the answers would
have clinical relevance to anxiety management.
The results of the Pilot Study la suggested that anxiety
recurrence and withdrawal symptoms occur in a significant
proportion of patients after a relatively short period of
benzodiazepine treatment. The potential for dependence on
benzodiazepines may be explained by these phenomena. However it
is not just the occurrence of withdrawal symptoms and the
recurrence of anxiety that may lead to pharmacological dependence.
It has been suggested that the best predictor of susceptibility to
drug dependence and subsequent withdrawal symptoms is a passive and
dependent personality (Tyrer et al 1983). Such traits are likely
to be prevalent in anxiety patients thereby increasing their
propensity to drug dependency. Furthermore patients'
interpretation of the significance of somatic changes during, or
following, benzodiazepine withdrawal .is also an important factor
influencing drug dependence. Following the reduction or cessation
of a successful anxiolytic compound some patients may interpret any
minor withdrClwCllsymptoms and/or sI ight increases in anxiety as
evidence of an exacerbation of their original ~nxipty state.
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They
may then revert to pharmacological treatment by requesting renewed
prescription, as their only method of al leviating an~i~ty symptoms.
This is likely to lead to feelings of inability to cope without
medication and may further exaggerate any feelings of h~lpl~ssn~ss
and dependency. If however withdrawal symptoms ar~ r~gard~d as
temporary, independent of anxiety state, and part of the process
of the body readjusting to functioning without an active
anxiolytic, then this is less likely to foster dependency.
However following a limited treatment period with diazepam,
wi thdrawa 1 symptoms and anx iety recurrence can be minimi zed by
withdrawing the drug in a gradual manner as was shown in the Main
Study. Since it is not easy to identify which patients are at
risk of suffering wi thdrawal symptoms and poss ible dependency
problems, graded-withdrawal should be a standard procedure for all
patients. Using graded-withdrawal enhances the effectiveness of
benzodiazepine treatment and diminishes the risk of dependency.
There has been an increasing preference for using short half-
life benzodiazepines. This decision may be premature and
unwarranted if ongoing research substantiates the viewpoint that
benzod iazepines with shorter ha 1f-l ifes are assoc iated wi th greater
dependency - their withdrawal symptoms occur earlier, and are often
more severe - than longer-acting alternatives CTyrer and Murphy
1987) • Consequently it may be judicious, in some cases, for
patients to be changed from short- to long-acting benzodiazepines
prior to graded-withdrawal. Nevertheless there will be a
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substantial number of patients for whom withdrawal effects and/or
psychological dependence are either very severe or have such an
intense personal impact that it would be unethical to prl?ssurise
them into stopping medication. The results of such action may bl?
worse than the original condition. Jenner (1985) stated that "we
should not fighttco hard to stop patients taking the tablets they
believe in". Another option should be available for those patients
who are able to stop regular consumption but find it difficult to
cope without the occasional tablet, that of maintenance on
flexible, intermittent low dosage. This option may be
particularly applicable to the long-term benzodiazepine users
(especially of hypnotics) in the older age group and characterised
by a high incidence of previous major systemic illness, who
comprised a large proportion ,of the study group reported in Chapter
8. To impose a blanket withdrawal programme for-all such p~tients
may be impractical and unethical. As an alternative, long-term
benzodiazepine patients should be screened in order to assess self-
motivation and suitability for graded-withdrawal. In Chapter 9
it was suggested that although patients are concerned about their
benzodiazepine medication being stopped a significant minority
would nonetheless be willing to consider ceasing medication,
presuming some form of structured graded-withdrawal programme we~e
operative.
The development of alternative coping strategies and anxiety
management techniques may prove useful prior to and during
withdrawal programmes. For example, individual patients may
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benefit from relaxtion t ra i rif nq prior to withdrawal. However
Cormack and Sinnott (1983) sUl)l)est that these techniques are not
hel pful as methods of reducing dependency when used in group
settings. In addition relaxation training alone is unlikely to
suffice as an adequate coping strategy. Cognitive strategies -
teaching the patient to reappraise and alter their perception of
the significance of withdrawal symptoms - should be incorporated
as a major treatment component of any withdrawal package.
Patients should be prevented from spectating on themselves for
withdrawal symptoms and should refrain from exaggerating or
catastrophising the significance of any minor somatic change. In
patients with specific anxiety problems, as well as withdrawal
difficulties, formal -psychological treatment may be necessary.
However the effectiveness of psychological inte'rventions during
withdrawal have yet to be fully evaluated.
An increasing number of reports point to the efficacy of anti-
depressants for the treatment of anxiety states (Klein et al 1983;
TeIch et al 1985; Michelson and Mavissakalion 1985). However the
efficacy of anti-depressants during withdrawal from long-term
benzodiazepines has not been published. Recent evidence (reported
by K. Rickels at the British Association of Psychopharmacology in
December 1987) sUQgests that long-term benzodiazepine users whose
withdrawal is covered by parallel anti-depressant therapy are more
likely to remain benzodiazepinp abstinant at 6 to 12 months follow-
up. Tyrer·(1985) has also suggested that anti-depressants may be
useful during benzodiazepine wi thdrawal . Controlled
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investigations of thp efficacy of different types of psychologiral
support, and anti-tiF?pressantand placebo covpred withdrawal, during
graded-withdrawal
process of being
colleagues.
This series of studies was commenced prior to publication of
from long-term benzodiazepine
implemented by the current author and his
DSM tII-R, and hence the DSM-ttt definition of GAD was used
throughout. However patients included in the present studies
would in ~act have met all but one of DSM ItI-R GAD criteria.
DSM ttI-R GAD diagnosis states that "unrealistic or excessive
anxiety and worry" be present for at least a 6-month period. This
contrasts with the minimum one month recommendation for DSM-Ilt GAD
symptoms. In all treatment groups in the present studies the
average minimum duration of symptoms was> 3 months. So the GAD
patients studied were not experiencing transitory, episodic
symptoms of anxiety, but were a group of patients with a chronicity
of symptoms greater than that necessary to meet DSM-III criteria.
This study suggests that on average GAD patients attempt to cope
wi th their anx iety symptoms for approx imate1 y 3 months before
seeking medical assistance. To expect. GAD patients to suffer
these symptoms for up to 6 months, without some form 6f
pharmacological or psychological treatment, in order to meet DSM
ITT-R GAD criteria, seems unethical. Tf DSM TIT-R criteria had
been implemented it would have been difficult to recruit the number
of patients, drug-free at st.udy inclusion and who had not been
us ing ben zod i Cl zepi.nes for prot rae ted per iods prior to referra 1,
necessary for the present studies.
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It therefore seems that the
DSM III-R GAD definition imposes an excessively long time criterion
for a disorder that is both prevalent and disablino in the short-
and long-term.
The present series of studies has also shown that a
prescription for benzodiazepines is not the only form of management
for GAD patients. The 'Cognitive-Behaviour Therapy' (CBT) used
in the present series of studies was similar to Butler et aI's
(1987a) 'Anxiety Management' (AM) treatment. Butler et 031 (198703)
stated that this form of treatment is "brief and simple" and is
"clearly suitable for patients with persistent GAD, who are
commonly seen in general practice for whom prolonged drug treatment
is unsatisfactory". These authors also regard this treatment
approach as easy to teach to therapists and read~ly understood by
patients. They note that it has a sound rationale "because, as
well as including procedures for control Iing symptoms, it deals
with anxious cognitions and avoidance behaviour, both of which
contribute to the maintenance of anxiety disorders". It seems
reasonable to expect that a treatment approach that addresses the
three main components of anxiety (L~ng 1971) would produce greater
and more stable degrees of clinical improvement than techniques
that are aimed at purely cognitive (Beck and Emery 1979), primarily
Soma tt c (Lehrer 1978), or ma in1y behav ioura 1 (Durham and Turvey
1987) aspects of GAD management. Whether or not the most
appropriate term for this p.clecti.C'and pragmatic: psychological
treatment approach for GAD is 'Anxiety Management' or 'Cognjtive-
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Behaviour Therapy' is debatab]p. ThE> mnst important factor is
that this treatment approach is effectivE>.
The CBT approaches used in thE> present series of studies were
morE> effective than the pharmacological alternatives at the end of
the study period and at follow-up. However the superiority of CST
techniques did not become evident until approximately 28 days after
the initiation of treatment. It therefore appears that GAD
patients initially wi 11 do equally well whether inert or active
pharmacological treat~ent, or psychological treatment is offered.
If CST techniques involve patients actively learning to control
their anxiety symptoms and to develop new adaptive coping
strategies, then it is hardly surprising that this is not achieved
overnight. Although the benefits of CST require time to become
manifest they are well maintained at fol low+u p ,> It is planned
that the 101 patients included in Chapter 7 will be followed-up for
longer than the 6-month period already reported.
The current series of studies did not investigate prognostic
indicators of treatment outcome. Butler and Anastasiades (1988)
have very recently suggested that the response of GAD patients to
'Anxiety Management' was better if patients were less anxious and
relatively less demoralised prior to treatment. They regarded
'demoralisation' as low self-esteem and failure to cope with
symptoms. They also noted that demoralisation may impair
treatment progress more than mi Id depression, especially if a
pa tien t 's rE'SOLlrCes for cop ing are Iimi ted or under-used. The
24?
CAT administer~d In the present serie~ of studies may be effective
not only because it alleviates the immedi."Itesornat Ic , cognitive,and
behavioural symptoms of GAD, but also becausp- it enhances patients'
feelings that they can cope, and thereby improves their self-
esteem.
The present studies have assessed in detai 1 the relative
effectiveness of different treatment approaches in the management
of GAD. Further research should concentrate on the identification
of clusters of symptoms, or patient characteristics, which
preferentially predispose to positive treatment outcome with
differing pharmacological and psychological treatment approaches.
This would allow identification of the significant minority of
patients who respond positively to benzodiazepine medication. As
psychological treatment in the form of CBT is not always available
nor always necessary, differential treatment based on reliable
prognostic assessment would allow better use of G.P. and
psychologist time and National Health Service resources.
Previous studies have attempted to determine the relative
efficacy of cognitive and behavioural approaches in the management
of GAD (Durham and Turvey 1987). Thl? present research has
deliberately avoided such comparisons, and instead addressed the
basic question of how pharmacological and.psychological treatments
Compare. It is hoped that this study has made some contribution
t.o our understandi.ng of the psychological and pharmacl"JlogicAI
treatment optinns for the management· of GAD, and that
24~
the
information derived from this research will lead to more effectivp
management of anxiety disorders in primary care.
244
REFERENCES
Adam K Oswald I Sha~jro C (1984) Fffect~ of lo~razolam and of
triazolam on sleep and overnight urinary cortisol.
Psychopharmacology 87, 389 - 394
Aden GC Thein SG (1980) Alprazolam compared to
~laceho in the treatment of anxiety.
Clinical Psychiatry, 41, 245 - 248.
diazepam and
Journal of
Allgulander C Borg S (1978) A case report: a delirious abstinence
syndrome associat.ed with chlorazepate. (Tranxilene).
British Journal of Addiction 73, 175 - 177.
Allin DM (1981> Successful treatment of anxiety with a single
night-time dose of chlormezanone: double-blind
comparison with diazepam. Current Medical Research
and Opinion 8, 33 - 38.
Anderson DJ Noyes R Crowe RR (1984) A comparison of panic
disorder and generalised anxiety disorder. American
Journal of Psychiatry 141,572 - 575.
Anonymous (1973) Lancet, 1, pg 1101.
Anonymous (1985) Some problems with the benzodiazepines.
Therapy Bulletin 23, 21 - 23.
Drug
Ansseau M Doumont A Thiry D von Frenckell R Collard J (1985)
Initial study of methylclonazepam in generalised
anxiety disorder. Psychopharmacology 3, 80 - 87.
Asberg M Montgomery SA Perris C Schalling D Sedval G (1978).
A comprehensive psychopathological rating scale.
Acta Psychiatrica Scandinavica 271 (suppl) 5 - 27.
Ascher'L M (1980) Paradoxical
(Eds) Handbook
clinical guide.
Intention. In A Goldstein EB Foa
of Behavioural Intervention a
New York: Wiley 266 - 321.
Ashton H (1984) Renzodiazepine withdrawal
British Medical Journal 288,
an unfinished story.
I 135 - 1140.
Ballenger JC (1984) Psychopharmacology of the anxiety disorders.
Psychiatric Clinics of North America, 7, 757 - 771.
8alter M8 Levine J Manheimer DI (1974) Cross-national study of
the pxtent of anti-anxiety / sedative drug USE'.
New England Journal of Medicinp 290, 769 - 774.
74:')
Balter MB Manheimer 01 Mellinger GD Uhlenhuth EH (1984)
A cross-national comparison of anti-anxiety I
sedative drug use. Current Medical Research and
Opinion. 1984, 8, 5 - 20.
Bant W (1975) Diazepam withdrawal symptoms. British Medical
Journal 4, pg 285.
Barlow OH (1985) Dimensions of anxiety disorders. In :
AH Tuma and JD Maser (Eds). Anxiety and the Anxiety
Disorders. Hillsdale, NJ : L Erlbaum Associates.
Barlow DH Blanchard EB Vermilyea JA Vermilyea BB DiNardo PA
(1986) Generalized anxiety and generalized anxiety
disorder description and reconceptualization.
American Journal of Psychiatry, 143, 40 - 44.
Barlow OH Cohen AS Waddell MT
Blanchard EB
Vermilyea BB Klosko JS
DiNardo P (1984) Panic and
andgeneralized
treatment.
anxiety disorders nature
Behavior Therapy 15, 431 - 449.
Beard GM (1869) Neurasthenia or nervous exhaustion. Boston Medical
Surgery Journal 3, 217-220
Beck AT Emery G (1979) Cognitive Therapy of Anxiety and Phobic
Disorders. Unpublished treatment manual of the
Center for Cognitive Therapy, 133 South 36th St.
Philadelphia, P.A. 19104.
Beck AT Laude R Bohnert M (1974) Ideational components of anxiety
neurosis. Archives of General Psychiatry 31, 319 -
325.
Beck AT Rush AJ Shaw BF Emery G (1979) Cognitive Therapy of
Depression. New York: Guilford.
Beck AT Ward CH Mendelson M Mock J Erbaugh J (1961> An
inventory for measuring depression. Archives of
General Psychiatry 4, 561 - 571.
Bellack AS Hersen M _(1984) Research Methods in Clinical
Psychology. Pergamon Press Inc.
Belloc NB Breslow L Hochstim JR (1971) Measurement of physical
health in a general population survey. American
Journal of Epidemiology 93. 328 - 336.
Bendig AW (1956) The development of a short form of the manifest
anxiety scale. Journal of Consulting Psychology 20,
384.
24h
Benson H Franke] FH Aptel R Daniels MD Schniewind HE Nemiah
JC Sifneos PE Crasswe}ler KD Greenwood MM Kotch
JB Arns PA Rosner B (1978) Treatment of anxiety
: a comparison of the usefulness of self-hypnosis
and a meditational relaxation tpchninup.
Psychotherapy and Psychosomatics, 30, 229 - 242.
Bernstein DA Borkovec TD (1973) 'Progressive Relaxation Training.
Champaign, IL : Research Press.
Blazer D Hughes D George LK (1987) Stressful life events and the
onset of a generalized anxiety syndrome. American
Journal of Psychiatry 144, 1178 - 1183.
Blowers C Cobb J Mathews A (1987) Generalized anxiety a
controlled treatment study. Behaviour Research and
Therapy 25, 493 - 502.
B0 0 Haffner JFW Langard 0 Trumpy JH Bredesen JE Lunde PKM
(1974) Ethanol and diazepam as causative agents in
road traffic accidents. In: Proceedings of the 6th
International Conference on Alcohol, Drugs and
Driving. Toronto, Canada.
Bowden CL Fisher JG (1980) Sa fety and ef ficacy of long-term
diazepam therapy. Southern Medical Journal 73, 1581
1584.
Breir A Charney DS Heninger GR (1985) The diagnostic validity
of anxiety di~;-orders and their relationship to
depressive illness. American Journal of Psychiatry
142, 787 - 797.
BUChsbaum MS Hazlett E Sicotte N Stein M Wu J Zetin M (1985)
Topographic EEG changes with benzodiazepine
administration in generalized anxiety disorder.
Biological Psychiatry 20, 832 - 842.
Burns 0(1980) Feeling Good: The New Mood Therapy. William Morrow:
New York.
Busto U Sellers EM Naranjo CA Cappell H Sanchez-Craig M
Sykora K (1986). Withdrawal reaction after 10nq-
ter-m therapeu tie: use of ben zod iazep j nes. The New
England Journal of Medicine 315, 845 - 859.
Butler G (1985) Exposure as a treatment40r sorial phobia: some
instructive difficulties. Behaviour Research and
Ther-apy, 23, 651 - 657.
247
Butler G Anastisiades P (1988) Predicting response to anxiety
management in patients with generalised anxiety
disorders. Behaviour Research and Therapy 26,
531 - 534.
Butler G Cullington A Hibbert G Klimes I Gelder M (1987a)
Anxiety management for persistent generalised
anxiety. British Journal of Psychiatry, 151,
535 - 542.
Butler G Gelder M Hibbert G Cullington A Klimes I (1987b)
Anxiety management developing effective
strategies. Behaviour Research and Therapy 25,
517 - 522.
Butler G Mathews A (1983) Cognitive processes in anxiety.
Advances in Behaviour Research and Therapy 5,
51 - 62.
Cameron OG Thyer BA Nesse RM Curtis GC (1986) Symptom profiles
of patients with OSM-I II anxiety disorders. American
Journal of Psychiatry 143, 1132 - 1137.
Canter A Kondo CY Knott JR (1975) A Comparison of EMG feedback
and progressive muscle relaxation training in
anxiety neurosis. British Journa'l of Psychiatry
127, 470 - 477.
Catalan J Gath OH Bond A Edmonds G Martin P Ennis J (1988)
General practice patients on long-term psychotropic
drugs: a controlled investigation. British Journal
of Psychiatry, 152 399 - 405.
Cattell RB Scheier IH (1958) The nature of anxiety: a review of
thirteen multivariate analyses comprising 814
variables. Psychol Rep. 4, 351 - 388
Cerny JA Himadi WG Barlow OH (1984) Issues in diagnosing anxiety
disorders. Journal of Behavioural Assessment 6,
301 - 329.
Ceulemans OLS Hoppenbrouwers MLJA Gelders YG Reyntjens AJM
(1985) The influence of ritanserin, a serotonin
antagonist in anxiety disorders: a double-blind
placebo-controlled study versus lorazepam.
Pharmacopsychiat 18, 303 - 305.
Chamb less OL GoIdstein AJ (1981) ClinicaI treatment of
agoraphobia. In:M Mavissakalion DH Barlow (Eds)
Phobia : Psychological and Pharmacological
Treatment. New York: Guildford, 103 - 144.
?4A
Chan DW Chan TSC <19A3) Reliability, va.lf d i t v and thp c;trurture
of the General Health Questionnaire in a Chinpse
context. Psychological Medicinp, 13, 363 - 371.
Chouinard G Annablf? L Fontainf? R Solyom L (1982) Alpr.3201.'lmin
thf? treatmpnt of genpra]ised anxiety and panic
disorders: a double-b) ind placebo control led study.
Psychopharmacoloqy 77 229 - 233.
Christopher LJ Ba 11 inger BR Shephf?rd AMM Ramsay A
(1978) Drug prescribing patterns in the
a cross sectional study of in-patients.
Ageing 7, 74 - 82.
er-ooks G
elderly
Agf? and
Clare A (1987) Introductory remarks. In: The Benzodiazepines in
Current Clinical Practice. CEds) H Freeman Y Rue.
Royal Society of Medicine Services Limited. London
pg 1.
Clow A Glover V Armando I Sandler M (1983) New endogenous
bf?nzodiazepine receptor I igand in human urine
identity with endogenous monoamine oxidaze
inhibitor. Life Sciences 33, 735 - 741.
Cohen S (1983) Current attitudes about benzodiazepines trial by
media. Journal of Psychoactive Drugs 15, 109 - 113.
Cohn JB (1981) Multicentre double-blind efficacy and
comparing alprazolam, diazepam,_ and
clinically anxious patients. Journal
Clinical Psychiatry 42, 347 - 351 •...'~
safety study
placebo in
of
Cohn JB (1983) Long- and short-acting benzodiazepines - a review
of the role of benzodiazepines. In: Benzodiazepines
Divided (ed) MR Trimble. John Wiley and Sons 229 -
236.
Committee on thp Review of Medicines (1980) Systematic review
of the benzodiazepines. British Medical Journal,
280, 910 - 912.
Commjttee on the Safety of Medicines (1988)
Dependence and withdrawal
ProbIp-m.,;No. 21.
Benzodiazepines,
symptoms. Current
Cook PJ Huggett A Graham-Pole R Savage IT James 1M (1983)
Hypnotic accumulation and hangover in elderly
inpat.ients a controlled double-bl ind study of
temazepam and nitrazepam. British Medical Journal
286, 100 - 102.
749
Cooper A (1972) Clinical and soci~l aspects of chronic neurosis.
Proceedings of the Royal Society of Medicine 65,
509 - 512.
Cooper B Sylph J (1973) Life events and the onset of neurotic
illness. Psychological Medicine 3, 421 - 435.
Cooperstock R (1976) Psychotropic drug use among women. Canadian
Medical Association 115, 760 - 763.
Cooperstock R (1978) Sex differences in psychotropic drug use.
Social Science and Medicine 128, 179 - 186
Cooperstock R Lennard HL (1979)
tranqui 11 izer use.
1, 331 347.
Some social meanings of
Sociology of Health and Illness,
Cooperstock R Parnell P (1982) Research on psychotropic drug use.
A review of findings and methods. Social Science
and Medicine 16, 1179 - 1196.
Cormack MA Sinnott A (1983) Psychological alternatives to long-
term benzodiazepine use. Journal of the College of
General Practitioners, 33, 279 - 281.
Corney RH Clare AW (1985) The construction, development and
testing of a self-report questionnaire to identify
social problems. Psychological Medicine 15, 637 -
649.
.~','"
Costa E (1983)Benzodiazepine - GABA i.nteractions a model to
invest iga te the neurobiology of an xiety. In
Anxiety and the Anxiety Disorders (eds ) AH Tuma
JD Maser New Jersey, Lawrence Erlbaum 27 - 52.
Covi L Lipman RS Pattison JA Deragatis LR Uhlenhuth EH (1973)
Length of treatment with an><iolytic sedatives and
response to their sudden withdrawal. Acta
Psychiatrica Scandinavica 49, 51 - 64.
Cox DJ Freundlich A Meyer BG (1975) Differential effectiveness
of electromyographic feedback, vE'rbal relaxation
instruc t.ions, and med ica t. ion placebo wi th t.ens1.on
headache. Journal of Consulting and Clinical
Psychology. 43, 892 - 898.
Cree JE Meyer J Hailey DM (1973) Dia~epam in labour: its
metabolism and effect on t~e clinical condit1.on and
thermogenesis of the nE'wborn. British Med1.cal
Journal. 4. 251 - 255.
250
Crowe RR Noyes R PnlJIs DL (1983) A fAmi 1y study
disorder. Archives of General Psychiatry,
1065 - 1069.
of pAn i c
40,
Crown S Crisp AH (1979) Manual of thE'Crown-Crisp Experimental
IndE'x. London: Hodder and Stoughton.
Cullen W (1784) First lines in the practice of physic. Volumes J -
IV. Edinburgh: C.Elliott and T.Caddell.
Da Costa JM (1871) On irritable heart a cl inical study of a
functional cardiac disorder and its consequences.
American Journal of Medical Science, 61, 17 - 52.
De Bard ML (1979) Diazepam withdrawal syndrome: a case of
psychosi s, sei z ure and coma. Amer i can Journa I of
Psychiatry, 136, 104 - 105.
De Bonic M (1973) Etude de l'anxiete par la methode des
Revue de Psychologie Appliquee 23,questionnaires.
15 - 47.
De Gier JJ Nelemans FA (1981) Driving performance of patients
receiving diazepam medication. In: Alcohol, Drugs
and Traffic Safety. (ed) L Goldberg. Stockholm.
Almarquist and Wiskell 1009 - 1023.
Derogatis LR Lipman RS Rickels K Uhlenhuth EH Covi L (1974)
The Hopkins Symptom Checklist (HCSL). In
Psychological Measurements in Psychopharmacology.
Modern Problems in Pharmacopsychiatry, Vol 7 (ed)
P Pichot, Basel, Karger.
Diagnostic and Statistical Manual of Mental Disorders: I. (1952)
American Psychiatric Association, Washington D.C.
Diagnostic and Statistical Manual of Mental Disorders: II. (1968)
American Psychiatric Association, Washington D.C.
Diagnostic and Statistical Manual of Mental Disorders: III. (1980)
American Psychiatric Association, Washington D.C:
Diagnostic and Statistical Manual of Mental Disorders: JII-R
(1987) Amer~can Psychiatric Association, Washington
D.C.
Di Nardo PA O'Brien GT Barlow DH Waddell MT Blanchard EB (19B3)
Reliability of DSM-III anxiety disorder categories
using a new structured interview. Archives of
Gpneral Psychiatry 40, 1070 - 1074.
751
Doongaji DR Sheth AS Ante JS Desai AA Vohara SA Dahholkar S
(1985> A comparative study of sinCJle and multiple
doses of clobazam vs. diazepam in anxiety neurosis.
Current Therapeutic Research 37, 398 - 405.
Downing RW Rickels (1985) Early treatment response in anxious out-
patients treated with diazepam. Acta Psychiatrica
Scandinavica 72, 522 - 528.
Drury VWM (1985> Ben:zodiazepinp.s a challenge
prescribing. Journal of the Royal
General Practitioners 35, 86 - 88.
to rational
CollegE' of
Dundee JW Pandit SK (1972) Anterograde amrie-sLc E'ffE'cts of
pethidine, hyoscinE' and dLa zepam in adults. British
Journal of Pharmacology 44, 140 - 144.
Dunn G (1983) Longitudinal rE'cords of anxiE'ty and deprE'ssion in
gE'nE'raI prac ticE' thE' second na tiona 1 morbi dity
survE'Y. Psychological ME'dicine 13, 879 - 906.
Dunner DL Ishiki D Avery OH Wilson LG Hyde TS (1986) Effect
of diazepam on anxiety and panic attacks in panic
disordE'r : a controllE'd study. Journal of Clinical
Psychiatry 47, 458 - 460.
Durham RC Turvey AA (1987) CognitivE' therapy vs. behaviour therapy
in the treatment of chronic qeneral anxiety.
Behaviour Research and ThE'rapy 25, 229 - 234 •
• <0 ....
Dysken MW Chan CH (1977) Diazepam withdrawal psychosis: a case
report. American Journal of Psychiatry 134, pg 573.
Elie R Lamontagne Y (1984) Alprazolam and diazepam in the
treatment of generalized anxiE'ty. Journal of
Clinical Psychopharmacology, 4, 125 - 129.
Einarson TR (1980) Lorazepam withdrawal seizures. LancE't 1, pg
15t.
Evans JG Jarvis EH (1972) Nitrazepam and the elderly. British
Medical Journal 4, pg 487.
Eysenck HJ Eysenck SAG (1968) Manual for the Fysenck Personality
Inventory. Educational and Industrial Testing
Service. San Diego: California.
Eysenck SBG Eysenck HJ (1975)
Questionnaire.
Manual of.the Eysenck Personality
London: Hodder and Stoughton.
252
Fabrp LF McLenrlnn OM (1979) A double-blinrl study comparing the
efficacy and safety of alprazolam with diazepam and
placebo in anxious out-patients. Current
Thprapeutic Research 25, 519 - 526.
Feighner J Merideth C Hendrikson G (1982) A double blind
comparison of bLJspirone and diazepam in out-patients
with generalized anxiety disorder. Jour-n.;!lof
Clinical Psychiatry 43, 103 - 107.
Fenz WD Epstein S (1965) Manifest anxiety: unifactorial or-
multifactorial composition. Perceptual and Motor
Skills 20, 773 - 780.
Fontaine R Annable L Chouinard G Ogilvie RI (1983)
and diazepam in general ized anxiety
control led study with measurement· of
concentrations. Journal of
Psychopharmacology 3, 80 - 87.
Bromazepam
a p lacebo
drug plasma
Clinical
Fontaine R Chouinard G .Annable L (1984) Rebound an xi e t v in
anxious patients after abrupt withdrawal of
benzodiazepine treatment. American Journal of
Psychiatry 141, 848 - 852.
Freud S (1894) The justification for detaching from neurasthenia
a particular syndrome The anxiety neurosis.
Collected Works Vol. I pp 76 - 106. Hogarth Press
and Institute of Psychoanalysis, London. Paper
reprinted in 1946.
Gabe J Lipshitz-Phillips S (1~82) Evil necessity? The meaning
of benzodiazepine use for women patients from one
general practice. Sociology of Health and Illness
4, 201 - 209.
George LK Hughes DC Blazer DG (1986) Urban I rural differences
in the prevalence of anxiety disorders. American
Journal of Social Psychiatry 6, 249 - 258.
Ghoneim MM Hinrichs JV Meweldt SP (1984) Dose response analysis
of the behavioural effects of diazepam :1. Learning
and Memory. Psychopharmacology 82, 291 - 295.
Goldberg DP (1972) The Dptection of Psychiatric Illness by
Monographs No.21 OxfordQuestionnaire. Maudsley
University Press: London.
Goldberg D (1978) General Health Questionnaire. Windsor
Nelson.
NFER -
75~
Goldberg D Cooper A Eastwood MR Kedward HA Shepherd M (1970)
A standardised psychiatric interview for use in·
community surveys. British Journal of PreventativE'
and Social Medicine 24. lA - 23.
Goldberg D Hi II fer VF (1979) A scaled version of the Gemp-ral
Health Questionnaire. Psychological Medicine 9, 139
- 145.
Goldberg D Huxley P (1980) Mental Illness in the Community:
The Pathway to Psychiatric Care. London Tavistock.
Goldberg HL Finnerty R (1982)
separate studies.
43, 87 - 91.
Comparison of buspirone in two
Journal of Clinical Psychiatry
Golombok S Moodley P Lader M (1988) Cognitive impairment in
long-term benzodiazepine users. Psychological
Medicine 18, 365 - 374.
Gordon EB (1967) Addiction to diazepam (Valium). British Medical
Journal 1 pg 112.
Greenblatt DJ Shader RI (1974) Benzodiazepines in Clinical
Practice. Raven Press ~ New York.
Greenblatt DJ Shader RI (1978) Dependence,
addiction to benzodiazepines-
pharmacokinetic considerations.
Reviews 8, 13 - 28.
tolerance and
clinical and
Drug Metabolism
Greenblatt OJ Shader RI (1987) Pharmacotherapy of anxiety with
benzodiazepines and B - adrenergic blockers. In:MA
Lipton A DiMascio AF Killam (Eds)
Psychopharmacology: A Generation of Progress. New
York, Raven Press.
Greenblatt DJ Shader RI Divoll M Harmatz JS (1981)
Benzodiazepines :. a summary of pharmacokinetic
properties. British Journal of Clinical
Pharmacology, 11, 115 - 165.
Guy G (1976) ECDEU Assessment Manual
rev ised Roc kvillE', Md •
Mental Health.
for Psychopharmacology,
National Institute of
Hallstrom C Lader M (1981) Benzodiazepine withdrawal phenomena.
International Pharmacopsychiatry 16,235 - 244.
7!'l4
Hallstrom C Lad~r M (1982) Th~ incidpnce nf hpnlodi~lPpin~
d~p~ndpnce j n 10nf)-term users. .Journa1 of
Psychiatric Treatm~nt and Fvaluation. 4, 293 - 296.
Hami 1ton M (1959) Th~ asspssment of arixie t v st."1tesby rating.
British Journal of Medical Psychology 32, 50 - 55.
Hamilton M (1967) Development of a rating scale for primary
depressive illness. British Journal of Medir.al
psychology 6, 278 - 296.
Hamilton M (1976) Hamilton Anxiety Scales (HAS) : Scoring
instructions and glossary definitions. Acta
Psychiatrica Scandinavica 73, 19 - 22.
Harding TW (1976) Validating a method of psyr.hiatric cas~
identification in Jamaica. Bulletin of the World
Health Organisation, 54, 225 - 231.
Hartshorne H (1864) Heart disease in the army. American Journal
of Medical Science 48, 89 - 90.
Hendler N Cinin C Terence M Long D (1980) A comparison of
cognitive impairment due to benzodiazepines and to
narcotics. American Journal of Psychiatry 137, 828
- 830.
Hibbert GA (1984) Ideational components of anxiety: their origin
and context. British Journal of Psychiatry 144,
618 624.
Higgitt AC Lader MH Fonagy P (1985) Clinical management of
benzodiazepine dependence. British Medical Journal
291, 688 - 691.
Hindmarch I (1980) Psychoactive function and psychoactive drugs.
British Journal of Clinical Pharmacology 10, 189-
209.
Hoehn-Saric R (1981) Characteristics of chronic anxiety patients.
In: DF Klein and J Rabkin (eds) Anxiety New
Research and Changing Concepts. New York Raven
Press.
Hoehn-Saric R (1982) Comparison of generalised anxiety disorder
wi th pan ic d isorde:>rpat ients. Psychopharmacology
Bulletin 18, 104 - 108.
Hollister L E Motzenbecker FP
reactions from
Psychopharmacologia,
Degan RO (1961)
chlordiazepoxide
2, 63 - 68.
Withdrawal
(Librium)
25:=;
Hollon SD Kendall PC (1980) Cognitive self-statements in
depression : development of an automatic thoughts
questionnaire. Cognitive Therapy and Research 4,
383 - 395.
Howe JG (1980) Lorazepam withdrawal seizures.
Journal 280, 1163 - 1164.
British Medical
Hutchings DF Denney DR Basgall J Houston BK (1980) Anxiety
management and applied relaxation in reducing
general anxiety. Behaviour Research and Therapy
18, 181 - 190.
Jablensky A (1985) Approaches to the definition and classification
of anxiety and related disorders in European
psychiatry. In:AH Tuma and JD Maser (eds) Anxiety
and the Anxiety Disorders (pp 577 - 589). Hillside,
NJ : Lawrence Erlbaum Associates
Jacobson AF Dominguez RA Goldstein BJ Steinbook RM (1985)
Comparison of buspirone and diazepam in generalised
anxiety disorder. Pharmacotherapy 5. 290 - 296.
Jacobson AF Goldstein BJ Dominguez RA Steinbook RM (1983)
A placebo-controlled double-blind comparison of
clobazam and diazepam in the treatment of anxiety.
Journal of Clinical Psychiatry 44, 296 - 300.
Jacobson E (1938) Progressive Relaxation. Chicag'o: University
of Chicago Press.
Jacobson NS Follette WC Revensdorf D (1984) Psychotherapy
outcome research: methods for reporting variabiIity
and evaluating clinical significance. Behaviour
Therapy, 15, 336 - 352.
Jannoun L Oppenheimer C Gelder M (1982) A self help treatment
programme for anxiety state patients. Behavior
Therapy 13, 103 - 111.
Jenner A (1985) Anxiety: the pharmacological and sociological
interface. Psychiatry in Practice (Anxiety Symposium
Supplement) pg 6.
John J Roy A Verghese A (1983) Clobazam and diazepam as
anxiolytics and their effect on motor coordination.
Current Therapeutic Research 33, 990 - 996.
Johnson LC Chernik DA (1982) Sedative hypnotics and human
performance. Psychopharmacology 76, 101- 103.
7511
Johnston~ A Goldb~rg DP (1976) Psychiatric scr~~ning in gpnpral
practice. Lancpt, i, h05 - 60A.
Johnston~ EC Ow~ns DCG Frith CD McPh~rson K Dowie C Ril~y G
Gold A (1980) N~urotic illness and its r~spons~ to
anxiolytic and antid~pr~ssant m~dication.
Psychological M~dication 10, 321 - 328.
K~dward H (1969) The outcome of neurotic illn~ss in the community.
Social Psychiatry 4, 1 - 4.
Kellner R Sh~ffield BF (1973) A self-rating scale of distr~ss.
Psychological Medicine 3, 88 - 100.
Khan AP Joyce P Jones AV (1980) B~nzodiaz~pine withdrawal
symptoms. New Z~aland Medical Journal 92, 94 - 96.
Klein DF (1964) Delineation of two drug responsive anxiety
syndromes. Psychopharmacologica 5, 397 - 408.
Klein DF (1981) Anxiety reconceptualized. In:DF Klein and J Rabkin
(eds) Anxiety - New Research and Changing Concepts.
New York • Raven Press.
Klein D Fink M (1962) Psychiatric reaction patterns to
imipramine. American Journal of Psychiatry
432 - 438.
119,
Klein DF Gittleman R Ritkin A Quitkin F (1980) Diagno~is and
Drug Treatments of Psychiatric Disorders. Baltimore
• Williams and Wilkins.
Klein DF Rabkin JG Gorman JM (1983) Etiological and patho-
physiological inferences from the pharmacological
treatment of anxiety. In: Anxiety and the Anxiety
Disorders (eds) AH Tuma JD Maser New Jersey,
Lawrence Erlbaum 501 - 532.
Klein DF Rabkin JG (1981) Anxiety: New Research and Changing
Concepts. New York. Raven Press.
Kleinknecht RA Donaldson D (1975) A review of the effects of
dia7epam on cognitive and psychomotor performance.
Journal of Nervous and Mental Disease 61, 399 -
411...
Korczyn AD Goldberg GJ (1972) Intravenous diazepam in drug-
induced dystonic reaction. British Journal of
Psychiatry 121, 75 - 77.
7~7
Kr.=lmprM SartorillC",N .1<"'lhlpn<;kyA Gulbin.=lt W (1979) The TCD-9
cl.=lssifir.=ltion of mpntal rlisorr:!ers. Act.=l
Psychiatric.=! Scanninavira 59, 241 - 262.
Lacey R Woor:!wardS (1985) That's Life Survey of Tranquillisers.
Lannon: BBC Publications.
Lader M (1972) The nahlrp of .=!nxiety.
Psychiatry, 171. 481 - 491.
British Journal of
Lader M (1975) The nature of clinical anl<ipty in modern socipty.
In~Strps5 anr:!Anl<iety Vol.T. CD Speilberger ann TB
Sarason (eds) Npw York, Halstead Press.
Lader M (1976) Anti.anxiety drugs clinical pharmacology and
therapeutic use. Drugs 12.1362 - 373.
Lader M (1978) Benzodiazepines the opium of the masses?
Neuroscience 3, 159 - 165.
Lader M (1983) DependE'nce on benzodiazepines. Journal of Clinical
Psychiatry 44, 121 - 127.
Lader M (1985) Bemzodiazepines, anxiety and catecholamines a
commentary. In: Anx iE'tyand the An)(iety Disorders.
AH Tuma and JD Maser (eds) Lawrence Erlbaum : New
Jersey.
Lader MH Bond AJ James DC (1974) C I inica I compar ison of
anxiolytic drug therapy. Psychological Medicine 4,
381 - 387.
Lader M Petursson H (1983) Long-term effects of benzodiazepines.
Neuropharmacology 22, 527 - 533.
Lader MH Ron M Petursson H (1984) Computed axial brain
tomography in long-term benzodiazepine users.
Psychological Medicine 14, 203 - 206.
Lang PJ (1971)The application of psychophysiological methods. In:
SL Garfield and AE Bergin <eds) Handbook of
Psychotherapy and Behavioural Change. New York
John Wiley and Sons.
Lapierre YD Tremblay A Gagnon A MonpremiE'r P Berliss H Oyewumi
LK (1982) A therapeutic and discontinuation study
of c:lobazepam and diazepam in an)(iety neurosis.
Journal of Clinical Psychiatry 43, 372 - 374.
258
last CG Barlow OH O'Brien T (1983) Comparison of two cognitive
strateg ies in treatment of a patient with
generalized anxiety disorder. Psychological Reports
53, 19 - 26.
Laughren TP Battey Y Greenblatt DJ Harrop OS (1982) A
controlled trial of diazepam withdrawal in
chronically anxious outpatients. Acta Psychiatrica
Scandinavica 65, 171 - 179.
Lavallee YJ Lamontagne Y Pinard G Annable L Tetrault L (1977)
Effects of EMG feedback, diazepam and their
combination on chronic anxiety. Journal of
Psychometric Research 21, 65 - 71.
Leboeuf A Lodge J (1980) A comparison of frontalis EMG feedback
training and progressive relaxation in the treatment
of chronic anxiety. British Journal of Psychiatry
137, 279 - 284.
Lehrer PM (1978) Psychophysiological effects of progressive
relaxation and alpha feedback in nonpatients.
Journal of Consulting and Clinical Psychology 46,
389 - 404.
Lewis T (1919) The Soldier's Heart and the Effort Syndrome. Shaw
London.
Lindsay WR Gamsu CV McLaughlin E Hood EM Espie CA (1987)
:';";Acontrolled trial .of treatments for general ised
anxiety. British Journal of Clinical Psychology 26,
3 - 15.
Lindsay WR Hood EH (1982) A cognitive anxiety questionnaire.
Unpub Iished.
Linnola M Ellinwood E (1982) Effects of benzodiazepines on
performance of healthy volunteers and anxious and
elderly patients. In Pharmacology of
8enzodiazepines (eds) E Usdin . P Skolnik.
MacMillan Press 601 607.
Lipshitz A (1988) Diagnosis and Classification of Anxiety
Disorders. In: Handbook of Anxiety Disorders (eds).
CG Last M Hersen. Pergamon Press 41 - 65.
McNair OM Lorr M (1964) An analysis of mood in neurotics. Journal
of Abnormal and Social Psychology 69, 620 - 627.
Main CJ (1983) The modified somatic perception questionnaire
(MSPO). Journal of Psychosomatic Research. 27,
503 - 514.
7.59
Maletzky BM (1980) Anxiolytic efficacy of alprazolam compared to
diazepam and plar:ebo. Journal of International
Medical Research 8, 139 - 143.
Malmo RB Shagass C (1949) Physiologic study of symptom mechanisms
in psychiatric patients under stress. Psychosomatic
Med ic ine , 1 1, 25 - 32.
Marks 1M Gelder MG Edwards G (1968) Hypnosis and desensitization
for phobias a controlled prospective trial.
British Journal of Psychiatry 114, 1263 - 1274.
Marks I Lader L (1973)
review.
156, 3
Anxiety States (anxiety neurosis) : a
The Journal of Nervous and Mental Disease
18.
Marks J (1983a) The benzodiazepines an international
perspective. Journal of Psychoactive Drugs 15,
137 - 149.
Marks J (1983b) The benzodiazepines - for good or evil.
Neuropsychobiology. 10, 115 - 126.
Mathews AM (1984) Anxiety and its management.
in Psychiatry. (eds) R Gaind
Spectrum Publications New York.
In Current Themes
8 Hudson Vol. 3
Mathews AM (1985) Anxiety States A Cognitive Behavioural
Approach. In: Psychological Application in
Psychiatry. BP Bradley and C Thomson (eds) John
Wiley and Sons Ltd.
Mathews AM Shaw P (1977) Cognitions related to anxiety: a pilot
study of treatment. Behaviour Research and Therapy
15, 503 - 505.
Mavissakalion M (1982)
disorders.
491.
Pharmaco Iog ic trea tmen t of an x iety
Journal of Clinical Psychiatry 43, 487 -
Meichenbaum D (1974) Therapist manual for cognitive
modification. Unpublished Manuscipt.
University of Waterloo. Ontario.
behaviour,
Meichenbaum DH Turk D (1973) Stress innoculation
training approach to anxiety management.
Unpublished Manuscript. University of
Ontario.
a skills
Waterloo.
260
Mellinger GD Balter MB (1981) Prevalence and patterns of use of
psychotherapeutic drugs results from a 1979
national survey of 'American adults. In:Tognoni G
Bellantuono C Lader M (eds) The Epidemiological
Impact of Psychotropic Drugs. Amsterdam: Elsevier.
Mellinger GO Balter M8 Manheimer Dr Cisin IH Parry HJ (1978)
Psychic distress, life crisis, and use of
psychotherapeutic medications. Archives of General
Psychiatry 35, 1045 - 1052.
Mellinger GO Balter MB Uhlenhuth EH (1984) Anti-an~iety agents
: duration of use and characteristics of the users
in the USA. Current Medical Research and Opinion
8, 21 - 36.
Mellinger GO Balter M8 Uhlenhuth EH (1984a) Prevalence and
correlates of the long-term regular use of
anxiolytics. Journal of the American Medical
Association 251, 375 - 379.
Michelson L Mavissakalion M (1985) Psychophysiological outcome of
behavioural and pharmacological treatments of
agoraphobia. Journal of Consulting and Clinical
Psychology, 53, 229 - 236.
Miles HWM Barrabee EL Finesinger JE (1951) Evaluation of
psychotherapy, with a follow~up'study of 62 cases
of anxiety neurosis. Psychosomatic Medicine 13,
83 - 105. ..-;......
Miller E (1986) Benzodiazepines and the behaviour therapist
managing withdrawal and the problems of concurrent
treatment with these drugs. Behavioural
Psychotherapy, 14. 1 - 12.
Miller F Neilson J (1979) Diazepam (Valium) detoxification.
Journal of Nervous and Mental Diseases 167, 637 -
638.
Morgan K (1985) Effects of repeated dose nitrazepam and
lormetazepam on psychomotor performance in the
elderly. Psychopharmacology 86, 209 - 211.
Morgan K (1983) Sedative-hypnotic drug use and ageing. Archives of
Gerontology and Geriatrics, 2, 181 - 199.
Morgan K Dallosso H Ebrahim S - Arie T Fentem PH (1988)
Preva lence, frequency, "and duration of hypnotic drug
use among the elderly living at home. British
Medical Journal 296, 601 - 602.
7nl
MorgAn K Gil1e."Ird C.) Reive A (1982) Hvpn o t t c tJs."Igein
residential homps for thp elderly: a prevalence and
l orrqi t.urt ina l analysis. Age ."IndAgeing 11, 229 -
234.
Morgan K Oc;~"aldT (19R2) Anxiety caused by a short I i.ofehY!"lnotic.
British Medical ,Journal 284,!"Iq 942.
Moskowitz H Smiley A (19R7) Efofects of chronically administered
buspirone and diazepam in driving-related ski t ls
performance. ,)ourna1 of C 1in i.ca1 Psyc hiatry 43,
45 - 55.
Munoz PE Vazquez JL Pastrana E Rodrigue7 F Oneca C (1978)
Study of the validity of Goldberg's 60-item GHQ in
its Spanish version. Social Psychiatry, 13,
99 - 104.
Murphy SM Owen RT Tyrer PJ (1984) Withdrawal symptoms after six
weeks treatment with diazepam. The Lancet 15,
pg 139R.
Murray HA (1943) Therapeutic Apperception Test Manual.
Mass. : Harvard University Press.
Cambridge
Murray J (1981) Long-term psychotropic drug-taking and the process
of withdrawal. PsychologicaL Medicine 11. 853 -
858.
Murray J Dunn G Williams P Tarnopolsky A (1981) Factors
affecting the consumption of psychotropic drugs.
Psychological Medicine 11, 551 - 560.
Nicoletti J (1972) Anxiety management training. Unpublished
doctoral dissertation. Colorado State University.
Fort Collins. Colorado.
Noyes R Clarkson C Crowe RR Vates WR McChesney CM (1987)
A family study of general ized anxiety disorder.
American Journal of Psychiatry 144, 1019 1024.
Oppenheimer BS Levine SA Morrison RA
St.Lawrence LoJ Wilson
Rothschild MA
FN (1918)
neurocirculatory
Military Surgery
asthen ia and
42, 409 - 426.
its
Report on
management.
Osler W (1912) The Principles and Prac~ice of Medicine. 8th Edition
New Vork, Appleton and Co.
262
Ost LG (19A2) Retep.ndeter.=!pi yid angec;tnPllrnc:-, en I?va1tJerandp
ovprc;ikt. Sc"mdin;:avian .lciurna I nf Rphi'lvinur Thprill"Y
11, 11~ - 134.
Oswald T Adam 1< Burrm'" S LdzLkow=sk i C (1979) The effpctc; of
two hypnotics on sleep, sLJhjPctive fppl inC]s and
ski lIed performance. In: Pharmacology of the StatF's
of Alertness (eds) P Passouant and I Oswald. Oxford
Pergamon Press.
Overton DA (1966) State-dependent learninq produced by depressant
and atropine-like drugs. Psychopharmacologica,
10, 6 - 13.
Owen RT Tyrer P (1983) Benzodiazepine dependence
the evidence. Drugs 25, 385 - 398.
a review of
Parish P (1971) The prescribing of psychotropic drugs in general
practice. Journal of the Royal College of General
Practitioners 21, Supplement 4, 1 - 77.
Petursson H Bhattacharga SK Glover V Sandler M Lader MH (1982)
Urinary monoamine oxidase inhibitor and
benzodiazepine withdrawal. British Journal of
Psychiatry 140, 7 - 10.
Petursson H Gudjonsson GH Lader MH (1983) Psychometric
performance dur ing wi thdra~a 1 from long-term
benzodiazepine treatment. Psychopharmacology 81,
345 - 349. .......
Petursson H Lader MH (1981) Withdrawal from long-term
British Medical Journalbenzodiazepine treatment.
283, 643 - 645.
Petursson H Lader M (1984) Benzodiazepine tolerance and
withdrawal syndrome. In Advances in Human
Psychopharmacology. GO Burrows JS Werry (eds).
Greenwich, Connecticut: JAI Press pg 89 - 119.
Pevnick JS Jasinski DR Haertzen CA (1978) Abrupt withdrawal from
therapeutically administered diazepam. Archives of
·General Psychiatry 35, 995 - 998.
Power KG ~lE."rromDWA Simpson RJ Mitchell M (1985) Controlled
study of wi thdrawa 1 symptoms and rebound anx iety
after six week coursE' of diazepam for generalised
anxiety. British Medical Journal 290, 1246 - 1248.
263
Power KG Jerrom DWA Simpson RJ Mitchell MJ Swanson V (1989)
A controlled comparison of cognitive-behaviour
therapy, diazepam and placebo in the management of
generalised anxiety. Behavioural Psychotherapy 17,
1 - 14,(In Press).
Power KG Mitchell MJ Jerrom DWA (1985)
Glossary. Unpublished Manual.
Hami Iton Anxiety
Preskorn H Denner J (1977) Benzodiazepines and withdrawal
psychosis : report of three cases. Journal of the
American Medical Association 237, 36 - 38.
Ramm E Marks 1M Yuksel S Stern RS (1981) Anxiety management
training for anxiety states positive compared
with negative self-statements. British Journal of
Psychiatry 140, 367 - 373.
Rapee RM (1985) Distinctions
generalized
presentation.
of Psychiatry
between panic disorder and
anxiety disorder clinical
Australian and New Zealand Journal
19, 227 - 232.
Raskin M Bali LR PeekeHV (1980) Muscle biofeedback and
transcendental meditation a controlled evaluation
of efficacy in the treatment of chronic anxiety.
Archives of General Psychiatry 37, 93 - 97.
Raskin M Johnson G Rondestvedt JW (1973) Chronic anxiety treated
by feedback-induced muscle relaxation. Archives of
General Psychiatry 28, 263 - 267.
Raskin M Peeke HVS Dickman W Pinsker H (1982) Panic and
general ised anxiety disorders. Archives of General
Psychiatry 40, 1085 - 1089.
Raskin M Rondesvedt JW Johnson G (1972) Anxiety in young adults
: a prognostic study. Journal of Nervous and Mental
Disease 154,_ 229 - 237.
Redmond DE (1983) Neurochemical basis for anxiety and anxiety
disorders: evidence from drugs which decrease human
fear oro anxiety. In Anxiety and the Anxiety
Disorders. (eds) AH Tuma JD Maser. New
Jersey,Erlbaum 533 555.
Rickels K (1981a) Benzodiazepines use and misuse. In: Anxiety
New Research and Changing Concepts. (eds) DF
Klein J Rabkin Raven Press New York 1 - 26.
Rickels K (1981b) Recent advances inanxiolytic therapy. Journal
of Clinical Psychiatry 42, 40 - 44.
2h4
Rickels K Case GW Winokur A Swenson C (1984) Long-term
benzodiazepine therapy: henefits and risks.
Pharmacology Bulletin, 20, 608 - 615.
Rickels K Case WG Schweizer EE Swenson C Fridman RB (1986)
Low-dose dependence in chronic benzodiazepine users
: a preliminary report on 119 patients. Psycho-
pharmacology Bulletin 22, 407 - 415.
Rickels K Downing RW Winokur A C1978) Antianxiety drugs
clinical use in psychiatry. In: LL Iverson
SD Iverson SH Snyder Ceds) Handbook of
Psychopharmacology (vol 13) New York Plenum.
Rickels K Pereira-Ogen J Case W Osolanos I Mirman M Nathanson
J Parish L (1974) Chlormezanone in anxiety: a drug
rediscovered? American Journal of Psychiatry 131,
592 - 595.
Rickels K Wiesman K Norstad N Singer M
Danton J (1982) Buspirone
a controlled study.
Psychiatry 43, 81 - 86.
Stoltz D Brown A
and diazepam in anxiety
Journal of Clinical
Rifkin A Quitkin F Klein DF (1976)
diazepam. Journa I
Association 236, 2172
Withdrawal reaction to
of the American MedicaI
2173. ~
Rodrigo EK King MB Williams P ~1988)
benzodiazepine users.
296, 603 -606.
Health of long-term
British Medical Journal
Rogers CR C1957) The necessary and sufficient conditions of
therapeutic personality change. Journal of
Consulting and Clinical Psychology. 21, 95 - 103.
Rose AJ (1983) Controversies in practice. In: Benzodiazepines
Divided. (ed) MR Trimble. John Wiley and Sons Ltd
pp 61 - 65.
Rosenbaum JF (1982) The drug treatment of anxiety. The New
England ~ournal of Medicine, 306, 401 - 404.
Rotter JB (1966) Generalised expectancies
external control of reinforcers.
Monographs 88, 1 - 28!
for interna I and
Psychological
Sakol MS Power KG (1988) The effects of long-term benzodiazepine
treatment and graded withdrawal on psychometric
performance. Psychopharmacology, 95, 135 - 138.
76~
Salinsky,lV Dore r::.l(19R7) r::har.'lctpric;ticc:;of long term bs=rizo>
rii.=l7PpinpIJsers in I]pnpr.=llpr.=lctirp. ..1oIJrn.=llof
thp College of Gpnpral Practitioners 37. 202 - 204.
Salt~man C Van der Knlk (1980) Psychot~opic d~ug p~~sc~iptions
for elde~ly p.'ltientsin Qene~al hospital. Jou~nal
of the American Geriatric Society 28, 18 - 22.
Sartory G (1983) Benzodiazepines and benav t our-al t~~atm~nt of
phobic anxiety. 8ehaviou~al Psychothe~apy 11,
204 - 217.
Schmauss C Kreig JC (1987) Enlargement of ce~ebrospinal fluid
spaces in long-term benzodiazepine abusers.
Psychological Medicine, 17, 869 - 873.
Schnur S (1939) Cardiac neurosis associated with organic heart
disease. American Heart Journal 18, 153 - 165.
SChopf J (1981) Unusual withdrawal symptoms after long-term
administration of benzodiazepines. Nervenarzt 52,
288 - 292.
Schopf J (1983) Withdrawal phenomena after long-term administration
of benzodiazepines. A review of recent findings.
Pharmacophychiat 16, 1 - 8.
Schwartz GE Davidson RJ Coleman DJ (1978) Patterning of
cognitive and somatic processes in the self-
regulation of anxiety: effects of medication versus
exercise. Psychosomatic Medicine 40, 321 - 328.
Schweizer E Rickels K (1986) Failure of
benzodiazepine withdrawal.
Psychiatry 143, 1590 - 1592.
buspl rone to manage
American Journal of
Sellers EM Busto U Sykora K (1987) Valid assessment of
benzodiazepine withdrawal. Unpublished report.
Sellers EM Naranjo CA Harrison M Devenyi P Roach C Sykora K
(1983) Diazepam loading: simplified treatment of
alcohol withdrawal. Clinical Pharmacology and
Therapeutics 34, 822 - 826.
Shapiro AK Struering El Shapiro E
How much better
Psychiatric Research
Milcarek BI (1983) Diazepam
than placebo. Journal of
17, 51 - 73.
Shepherd M Cooper B Brown AK Kalton GW
Illness in General Practice.
University Press.
(1966) Psychiatric
London. Oxford
7Mn
Skpgg DC Do 1 1 R Pprry .J
practice.
(1977) Usp of medicinE'S
British Medical Journal
in QPnpral
]. ]561 - 1563.
Slater J (]966) Suspec ted deppndpnce on ch lord ia zppox idp
hydrochloride (Librium). Canadian Mpdiral Journal
95, pg 416.
Snaith et al (1971) Wakefield Depression Questionnaire. Cited in:
Ramm E Marks 1M Stern RS Anxiety ManaQement
Training for anxiety states: positive compared with
negative self-statements. British Journal of
Psychiatry (1981) 367 - 373.
Snai th R Baugh S Clayden A Husain A
clinical anxiety scale.
Psychiatry ]41, 518 - 523.
Sipple M
British
(1982) The
Journa 1 of
Snaith R Bridge G Hamilton M (1976) The Leeds Scales for thE'
Self-assessment of Anxiety and Depression.
Barnstaple : Psychological Test Publications.
Snedecor GW Cochran WG (1967) Statistical Methods (6th ed) Ames,
Iowa Iowa State University Press.
Solomon K (1976) Benzodiazepines and neurotic anxiety. New York
State Journal of Medicine, 13, 2156 - 2164.
Solomon K Ha rt R (1978)
research on
placebo - a
Psychiatry
Pitfalls and prospects in clinical
antianxiety drugs: benzodiazepines and
research review. Journal of Clinical
39, 823 - 831.
Solomon F White CC Parron DL Mendelson WB (1979) Sleeping
pills, insomnia and medical practice. New England
Journal of Medicine 300, 803 - 808.
Sonne LM Holm P (1975) A comparison between bromazepam and
diazepam in anxiety neurosis. International
Journal of Psychopharmacology 10, 125 - 128.
Speilberger CD Gorsuch RL Luschene RE (1970) Manual for the
State-Trait Anxiety Inventory. Consulting
Psychologists Press, California.
Spi tzer RL Endicott J Robins E (1978) Research Diagnostic
Criteria for a Select Group of Functional Disorders
3rd edn. New York: StatE' Psychiatric Institute.
2/,7
Sternb~ch LH (1982) Thp dis~ovpry of eNS ~ctivp 1,4 - henzo-
rii.=lzepines (r:hpmic;try). Tn: Ph~rm~r:oloIJY of
Benzoriiazepinps (eric;) E Llsdin P Skolnick TF
Tallman 0 Greenhlatt SM Paul. McMillan Prpss.
7 - 13.
Stpwart RB Salem RA Springer PK (1980) A case report of
lorazppam withdrawal. Amerir.=ln .Journal of
Psychiatry 137, 1113 - 1114.
Stall M Lader M (1984) Unpublished Observations. citpd by
Petursson H Lader M. Dependence on Tranquillizers
London: Oxford University Press.
Straw RN (1983) J mp 1ica tions of ben zod ia zepine prescr ib inC]. In:
Benzodiazepines Divided (ed) MR Trimble. John
Wiley and Sons 67 - 77.
Suinn RM (1977) Manual - Anxiety Management Training.
Ft. Collins, Colorado.
RM Suinn
Suinn RM Richardson F (1971) Anxiety management training: a
non-spec if ic behav iour thera py prog ramme for an xiety
control. Behaviour Therapy, 2, 498 - 511.
Tallman JF Paul SM Skolnik P Gallagher OW
the age of anxiety. ScienCE>
(1980) Receptors for
207, 274 - 281.
Tarrier N Main CJ (1986) Applied relaxation training
generalised anxipty and panic attacks:
E>fficacy of a learnt coping strategy on
reports. British Journal of Psychiatry
330 - 336.
for
the
subjective
149,
Taylor D (1987) Current usage of benzodiazepines in Britain. In
The Benzodiazepines in Current Clinical Practice
(eds) H Frpeman Y Rue Royal Society of Medicine
Services Limited, London pp 13 - 18.
Taylor JA (1953) A personality scale of manifest anxiety. Journal
of Abnormal and Social Psychology 48, 285 - ,295.
TeIch MJ Agras WSM Barr Taylor CB Roth WT Gallen C (1985)
Combined pharmacological and behavioural treatment
for agoraphobia. Behaviour Research and Therapy,
23, 325 - 335.
Torgersen S (1983) Genetic factors In.·anxiety disorders. Archives
of General Psychiatry 39, 687 - 689.
2hB
Townsend RE Houc,p ,JF Add.=3rio f) (1975) A comf").=3risonof b i o+
feedh.=3r.k-medi.=3tedrelaxation and grollf')ther.=3py in
the treatment of chronic .~nxiety. Amerir:an .Irurr na l
of Psychiatry 132, 598 - 601.
Tyrer P (1974) The ben20dia2E'pine bonanza.
709 - 710.
t.anc e t , .Sept 2.1st,
Tyrer P (19BO) Dependence on benzodia2epines. British Journal of
Psychiatry 137, 576 - 577.
Tyrer P (1984a) Classification of anxiety.
Psychiatry 144, 78 - 83.
British Journal of
Tyrer P (1984b) Benzodiazepines on trial. British Medical Journal
288. 1 101 - 1 102.
Tyrer P (1985> Clinical management of benzodiazepine dependence.
British Medical Journal, 291, 1507.
Tyrer P (1986> Classification of Anxiety Disorders: a critique of
DSM Tri. Journal of Affective Disorders 11,
99 - 104.
Tyrer P Murphy S (1987) The place of benzodiazepines in
psychiatric practice. British Journal of Psychiatry
15, 719 - 723.
Tyrer P Owen R (1984) Anxiety in primary care is short-term
drug treatment appropriate? Journal of Psychiatric
Research 18, 73 - 78.
Tyrer P Owen R Dawling S (1983> Gradual withdrawal of diazepam
after long-term therapy. Lancet 1, 1402 - 1406.
Tyrer P Rutherford D Huggett T (1981) Benzodiazepine withdrawal
symptoms and propranolol. Lancet 1, 520 - 522.
Vyas 1 Carney MWP (1975) Diazepam withdrawal fits.
Medical Journal 4, pg 44.
British
Watson JP Marks IM (1971) Relevant and irrelavant fear in
flooding - a crossover study of phobic patients.
Behaviour .Therapy 2, 275 - 293.
Weissman MM (1985) The epidemiology of anxiety disorders: rates
risks and family patterns. In Anxiety and the
Anxiety Disorders. -AH Tuma JD Maser (eds>.
Hillsdale NJ, Lawrence Erlbaum Associates.
Wheatley D (1982> Buspirone : a multicenter efficacy study.
Journal of Clinical Psychiatry 43, 92 - 94.
269
Wheeler EO White PD Reed ItJEr:ohen ME (1950) Neurocirculatory
asthenia (anxiety neurosis. effort synrlrnme.
nelJr.'1sthenia). Journal of thp ArflPric:anMp-tiic:,"\l
Association 142, 878 - BRA.
Williams JMG (1984) The Psycholoqical Trpatmpnt of Depression
A Guide to the Theory and Practice of Coqnitive-
Behaviour Therapy • Croom Helm . London and
Canberra.
Williams P (1983) Factors influencing the duration of treatment
with psychotropic drugs in general practice: a
survival analysis approach. Psychological Medicine
13, 623 - 633.
Williams P (1987) Long-term benzodiazepine use in general practice
In: The BenzodiazE'pinE's in Current Clinical PracticE>
(eds) H Freeman Y Rue. Royal Society of Medicine
Services 19 23.
Williams P Bellantuono C Fiorio R Tansella M (1986)
Italy : national trends
Psychological Medicine
Psychotropic drug use in
and regional differences.
16, 841 - 850.
Wi 11 iams P Murray J Clare A (1982) A longitudinal study of
psychotropic drug prescription. Psychological
Medicine 12, 201 - 206.
Wing JK Cooper JE Sartorius N (1973) PrE'sent State Examination.
Cambridge. Cambridge University Press.
Winokur A Rickels K Greenblatt OJ Snyder PJ Schatz NJ (1980)
Withdrawal reaction from long-term low dosage
administration of diazepam. Archives of General
Psychiatry 37, 101 - 105.
Wolkowitz OM Weingartner H Thompson K Pickar 0 Paul SM
Hommer OW (1987) Diazepam-induced amnesia: a
neuropharmacological modp.1 of an "organic amnestic
syndrome". American Journal of Psychiatry 144,
25 - 29.
Wolpe J (1958) Psychotherapy by Reciprocal Inhibition.
Stanford University Press.
Stanford
Wolpe J Lang PJ (t964) A Fear Survey Schedule for use in
behaviour therapy. Behaviour Research and Therapy
2, 27 - 30.
270
Wood P (1941) Effort Syndrome.
767 - 772.
British Medical Journal 1,
Woodcock J (1970) Long-term consumers of psychotropic drugs. In
: Treatment or Diagnosis : A Study of Repeat
Prescriptions in General Practice. (eds) M Balint
M Marinker London Tavistock Publications 147-
176.
Woods SW Charney DS (1988) Benzodiazepines. A review of
benzodiazepine treatment of anxiety disorder:
pharmacology, efficacy and implications for patho-
physiology. In: Handbook of Anxiety Disorders.
(eds) CG Last M Hersen Pergamon Press. 413 - 444.
Woodward R Jones RB (1980) Cognitive restructuring treatment:
a controlled trial with anxious patients. Behaviour
Research and Therapy 18, 401 - 407.
World Health Organisation (1978) International classification of
diseases - clinical modification. (9th ed)' Ann
Arbor, MI : Edwards Brothers.
Zigmond AS Snaith RP (1983) The hospital anxiety and depression
scale. Acta Psychiatrica Scandinavica 67,
361 - 370.
Zitrin CM Klein DF Woerner MG Ross DC (1983) Treatment of
phobias. I. Comparison of imipramine hydrochloride
and placebo. Archives of General Psychiatry 40,
125 - 139.
Zung WWK (1971) A self-rating scale for anxiety. Psychosomatics
12, 371 - 384.
APPENDIX 1
HAMILTON RATING SCALE FOR ANXIETY
HAM-A
Hamilton Rating Scale for Anxiety
DArE OF EVALUAiION PT.NO.
INIT[ALS •.••• __
For each item check the one response which best characterizes the patient now.
o 2 3 4
Not Mild ~loderate Severe Very
present severe
ANXIOUS MOOD
Worries, anticipation of the worst,
fearful anticipation, irri tabil ity
TEr:sION
Feelings of tension,fatigability.
startle response, moved to tears
easily, trembling, feelings of
~stlessness, inability to relax
FEARS
Of dark, of strangers, of being left
alone, of animals, of traffic.
of crowds
I--.
INSOr~NlA
Difficulty ;n falling asleep. _.
brOken sleep, unsatisfying
sleep and fatigue on waking,
~eams, nightmares, night terrors
INTELLECTUAL
Difficulty in concentration
,
I
~
r-e_Oormemory I
DEPRESSED ~100D ..
~oss of interest. lack of pleasure IIn hobbies, depression, early~ing, diurnal swing
SOMATIC (Muscular)
Pains and aches, twitchings,
_. ISt~ffness, myoclonic jerks, ..~r'ndin9 of teeth, unsteady voice,
~creased muscular tone
Sor·'.ATIC(Seoscry)
!innitus, blurring of vision, InOt and cold flushes, feelingsOf weakness, pricking sensation
PT. NO . HAM-ACATE OF EVALU~T!ON
INITIALS.------~---.------
Not Mild Hodera te Severe Very. present severe,.._
CARDIOVASCULAR SYMPTOMS .
Tachycardia, palpitations,
pain in chest, throbbing of
vessels, fainting feelings,
~ghing, dyspnoea
RESPIRATORY SYMPTOMS
Pressure or constriction in chest.ChOking feelings, sighing,
~s.E_nea
GASTROINTESTINAL SYMPTOMS
Difficulty in swallowing, windabdominal pain, burning
sensations, abdominal full-
ness, nausea, vomiting,
borborygmi, looseness of
~s. loss of weight, constipation
GENITOURINARY SYMPTOMS
F'~equency of micturition, urgency "of
mlCturition, amenorrhea,
menOrrhagia, development of
f~igidity, premature
~Jaculation, loss of libido, .
~~~ence
AUTONOMIC SYMPTOMS
Dry mouth, flushing, pallor,
~endency to sweat, giddiness.
ens;on headache, raiSing
~hair ..
BEHAVIOUR AT INTERVIEW
;idgeting, restlessness or ,
ac;ng, -tremor of hands,
f 1f~rrowed brow, strained face,~lghing or rapid respiration,
aCial pallor, swallowin~, etc.
o 2 3 4
APPENDIX 2
HAMILTON ANXIETY GLOSSARY
ASSESSMENT OF ANXIETY STATES
GLOSSARY FOR USE WITH THE HAMILTON ANXIETY SCALE
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INTRODUCTION
The Hamilton Anxiety Scale and Glossary are intended for use with
patients already diagnosed as suffering from neurotic anxiety states,
and not for assessing anxiety in patients suffering from other
disorders.
A series of symptoms is assembled to form the fourteen items of the
scale, each of the items being defined in a series of brief statements
and headed by the name of the item.
Examples of questions co elicLL Lilt~~vzLityof,sJ~ptoms are written
into the glossary. In addition the examiner will usually wish to
ask other questions which are not written into the glossary, either
general probes or more specific questions, depending on the nature
of the patient's replies.
Assessments are made on a five point scale, examples of scoring
criteria for each grade being included. In practice, the last grade
is rarely used for out~watients, and serves more as a marker, a
method of delimiting the range, rather than as a grade of frequent
practical use.
The interviewer should introduce himself briefly, describe the
purpose of the interview and explain any recording equipment.
(1) Anxious Mood (0-4)
Anxious mood may be regerded as a continuous state of apprehension
pervading all situations.
part, by certain aspects of
It is important to remember
all sorts of ways. Useful
"tense", or "up-tight".
Milder anxious mood is relieved, at least in
the environment such as familiarity or company.
that patients interpret the word "anxious" in
common terms are "nerves", "jittery", "on edge"
" NOW, I WOULD LIKE TO ASK YOU ABOUT THE WAY YOU HAVE BEEN FEELING DURING
THE LAST WEEK. HAVE YOU BEEN ON EDGE, OR HAD TROUBLE WITH YOUR NERVES?
HAVE YOU BEEN FEELING ANXIOUS OR FRIGHTENED, AS THOUGH SOMETHING TERRIBLE
WERE ABOUT TO HAPPEf\~ TO YOU? HOW_OFI'EN? DOES IT COME AND GO? HOW
LONG DOES IT LAST? HOW BAD IS IT? HOW MUCH DOES IT TROUBLE YOU?
HAVE YOU BEEN IRRITABLE? HOW DO YOU SHOW IT?""
o = Absent
1 = Mild. Inappropriate apprehensions or worries which are
mild and present some of the time. a minor increase in
irritability which occurs occasionally.
2 = Moderate. Moderately severe symptoms, present much of
the time which are of concern to the patient and result
in minimal impairment to social functioning or work
.performance. Patient irritable much of the time.
3 = Severe. Severe symptoms which are present most of the
time or intermittent panic attacks impairing social
functioning or work performance. Irritable most of the
time and shows anger by shouting or quarelling.
4 = Very Severe. Persistent state of intense anxiety or
intermittent severe panic attacks causing marked
limitation of the patient's activities. Constantly
irritable with violent outbursts of temper, possibly
involving breaking objects or physical violence.
(2) Tension (O~4)
Patients may complain of tension in a variety of ways. They may
complain of feelings of tension, inability to relax, being startled
easily, weeping easily, trembling and shaking, and feeling restless.
" HAVE YOU FELT TENSE OR FOUND IT DIFFICULT TO RELAX DURING THE PAST
WEEK? HAVE YOU BEEN "JUMPY" OR "SHAKY" OR "FIDGETY" AND "RESTLESS"
DURING THE PAST WEEK? HAVE YOU BEEN MOVED TO TEARS DURING THE PAST
WEEK? HOW MUCH AND HOW OFTEN HAVE THESE SORTS OF THINGS BOTHERED
YOUf "
o = Absent.
i = Mild. Reporting a mild inability to relax on occasion.
However a change in environment or company tends to
relieve such tension.
2 = Moderate. Reporting a moderate inability to relax
and feelings of restlessness occurring much of the
time. Not alleviated by a change of environment or
company.
3 = Severe. Reporting a marked inability to relax and
feelings of restlessness present most of the time.
4 = Very severe. A cons t.mt feeling of needing to be on
the move. A total inability to relax. Patient·
rarely stays seated for more than a short period of
time.
(3) Fears (0-4)
Rate any specific fear that the patient reports e.g. fears of dark,
strangers, being left alone, large animals, traffic, crowds, etc.
Assess what restrictions the "fear" imposes on the patient.
" IS THERE ANY PLACE"SITUATION OR THING THAT YOU ARE AFRAID OF, THAT
YOU TEND TO AVOID IF POSSIBLE, OR THAT MAKES YOU FEEL ILL AT EASE. "
-o = 'Absent.
1 ~ Mild. An irrational fear or foreboding of situations
which are not avoided and can be approached with
apprehension.
2 = Moderate. A moderate fear of situations, sometimes
provoking panic. The patient prefers to avoid these
situations but can approach if accompanied or if the
situation demands.
3 = Severe. A severe fear of situations provoking panic
and is almost always avoided, unless accompanied or
unless sheer necessity requires that the situation be
approached.
4 = Very severe. A very severe fear of situations which
would produce total avoidance and which would produce
a severe panic reaction if it were encountered.
(4) Insomnia (0-4)
Sleep disturbance may manifest itself in differing forms. Insomnia may
present as:
difficulty falling asleep
broken or disturbed sleep (which is often difficult to assess)
early wakening
Patients may also complain of unsatisfactory sleep and fatigue on wakening,
nightmares, dreams, and restlessness. When insomnia is severe it generally
affects all phases of sleep and tends not to be relieved by hypnotics.
Insomnia should be assessed on the degree to which sleep is lost over the
course of the whole night compared with what may be normal for the popul-
ation and the age-group.
" WHAT HAS YOUR SLEEP BEEN LIKE OVER THE LAST WEEK? HAVE YOU BEEN TAKING
SLEEPING PILLS? WHAT TIME DO YOU GO TO BED? WHAT TIME DO YOU GO TO
SLEEP? WHEN YOU DO GET TO SLEEP DO YOU SLEEP WELL? WHAT TIME DO YOU
WAKEN IN THE MORNING? WHAT TIME DO YOU NEED TO GET UP? "
o = Absent.
1 = Mild. Sleep loss of one hour or less, causing only
minor concern to the patient.
2 = Moderate. Sleep loss of one to two hours, resulting
in a degree of impaired social functioning or work
performance that is of concern to the patient.
3 = Severe. Sleep loss of two to four hours, of much
concern to the patient, and significantly impairing
daily routine.
4 = Very severe. Sleep loss of greater than four hours
and sleep only occurring in brief exhausted snatches.
Severe functional impairment of daily routine tasks.
(5) Intellectual (cognitive) (0-4)
Intellectual and cogn~t~ve changes may manifest themselves as periods
of forgetfulness, or complaints of inability to concentrate adequately.
" HAVE YOU HAD ANY DIFFICULTY CONCENTRATING AT WORK, OR ON OTHER THINGS
YOU DO, E.G. HOBBIES, READING, WATCHING T.V., HOUSEWORK, DAILY CHORES.
HOW OFTEN? HOW BAD IS IT? WHAT IS YOUR MEMORY LIKE? HAVE YOU
NOTICED A CHANGE IN YOUR ABILITY TO REMEMBER THINGS?
o = Absent.
1 a Mild. A minor increase in forgetfulness or concentration
but not persistent and performance can be improved with
added effort. No significant impairment in performance.
2 = Moderate. An increase in forgetfulness or concentration
thereby impairing routine performance e.g. forgetting
telephone numbers, inability to concentrate fully on T.V.,
reading or work. Results in a minor degree of impairment.
3 = Severe. A marked reduction in the ability to concentrate
or remember, restricting the patient's daily performance.
Routine tasks may be lengthened or not completed. The
impairment is noticeable to others and unable to be
overcome by the patient.
4 = Very severe. Unable to perform any series of routine
tasks, or learn new information, due to a severe inability
to concentrate or remember new information. Severely
impaired.
(6) Depressed Mood (0-4)
Depressed mood may be characterized by a gloomy attitude, pess~m~sm
about the future.and feelings of hopelessness. Milder depressive
mood may be relieved, at least in part, by environmental change, such
as company or other forms of external stimulation. Patients may
interpret"depressed mood" in different ways. Useful common phrases
are" feeling down" or"feeling low':
" HAVE YOU BEEN FEELING REASONABLY CHEERFUL DURING THE PAST WEEK OR
HAVE YOU FELT DEPRESSED OR LOW SPIRITED? HOW WOULD YOU DESCRIBE IT?
DOES IT co~mAND GO? HAVE YOU LOST INTEREST IN THINGS? DO ANY
ACTIVITIES GIVE YOU PLEASURE? DO YOU FEEL ~~TTER OR WORSE AT ANY
TIMES OF THE DAY?
.....
o • Absent. Very mild or occasional feelings no worse
than the patient's normal experience when well.
I a Mild. Persistent feelings described as moody,
downhearted or dejected. More intense occasional
feelings may be relieved by company,or a change in
environment, or in a change in activity.
2 = Moderate. Persisting or frequent feelings of
depression, blueness, etc.; often feels like
crying, may cry occasionally, not easily relieved
by company or environmental change.
3 = Severe~ More-intense feelings; frequent bouts of
crying and feelings of despondency and helplessness
throughout the working day.
4 = Very severe. Persistent severe feelings, may b~
described as beyond tears, painful, no relief,
excruciating, agonising, persistent, unrelieved
feelings, suicidal.
(7) General somatic (muscular) (0-4)
This symptom consists of diffuse muscular aching or stiffness, ill-defined
and often difficult to locate, but frequently in the back and sometimes
in the limbs; these may also feel "heavy". Erratic muscular tone may
result in clonic jerks, twitchings, grinding of teeth and an unsteady
voice.
" HAVE YOU HAD ANY ACHES OR PAINS DURING THE LAST WEEK? HAVE YOUR LIMBS
FELT STIFF,TIGHT, TWITCHY OR JERKY? DOES YOUR VOICE FEEL UNSTEADY,
HAVE YOU BEEN GRINDING YOUR TEETH? HOW OFTEN? HOW BAD?
o = Absent.
1 = Mild. A slight increase in muscular tension, aches and
pains, but of no significant concern to the patient.
2 = Moderate. A noticeable increase in symptoms, of concern
to the patient but of a sporadic nature and able to be
relieved or brought under control by the patient to some
extent.
3 = Severe. A significant increase in symptoms being outwith
the patient's control and occurring with such severity and
regularity (on a daily basis) thereby causing the patient
concern and impairment. Periods of total relief from
symptoms being very infrequent.
4 = Very severe. Continuous and severe stiffness, pain or
clonic jerks. This results in a significant degree of
motor impairment and is therefore greatly inhibiting and
of much concern to the patient.
(8) General somatic (sensory) (0-4)
Autonomic overactivity may manifest itself as blurring of v~s~on,
tinnitus, hot and cold flushes, feelings of weakness, or prickling
sensations.
" HAVE YOU SUFFERED FROM ANY OF THE FOLLOWING RECENTLY: RINGING IN
YOUR EARS, BLURRED VISION, FLUSHES, PRICKLY SENSATIONS OR FEELING·_
WEAK? HOW OFTEN? HOW BAD? "
o = Absent.
1 = Mild. One or two definite symptoms of mild intensity
occurring once or twice per week, leading to only mild
interference with day to day activities.
2 = Moderate. Marked symptoms occurring more than twice
per week or continuous milder symptoms present most of
the week. Presence of symptoms significantly
upsetting daily routine; and while present, impairing
daily performance.
3 = Severe. Severe symptoms occurring at least daily or
severe sporadic episodes that totally incapacitate
while they last. Patient experiences difficulty in
getting going and only occasionally experiences respite
from symptoms. "
4 = Very severe. Patient experiences mUltiple severe
symptoms much of the time or frequent severe sporadic
episodes which totally incapacitate, resulting in
marked impairment and an inability to perform daily
tasks. Patient never totally symptom-free, symptoms
only periodically reducing in intensity.
(9) Cardiovascular symptoms (0-4)
Patients may experience cardiovascular irregularities such as tachy-
cardia, and various other arhythmias may be present. Patient may
attribute inappropriate degree of significance to minor abnormalities
or be fearful of the consequence of such abnormalities.
" HAVE YOU NOTICED RECENTLY ANY OF THE FOLLOWING: INCREASED HEART
RATE OR YOUR HEART SEEMING TO RACE OR RUN TOO FAST, PALPITATIONS,
PAINS IN YOUR CHEST, THROBBING OF BLOOD VESSELS OF YOUR HEART,
FEELING FAINT OR FEELING THAT YOUR HEART M1S~£S A BEAT? "
o = Absent.
1 = Mild. An increased awareness of heart rate or
heart beat irregularities that do not incapacitate
the.patient in any way; occurs infrequently,
usually not more than three times per week.
2 = Moderate. More persistent tachycardia, arhythmias,
angina, palpitations or faintness that are not,
according to the patient, under his/her control and
are a cause of concern, necessitating an adjustment
of the patient's daily routine; occuring frequently
almost daily.
3 = Severe.
fear of
cardiac
present
Patient may severely restrict·activity for
the consequences of tachycardia or irregular
activity and palpitations. Symptoms may be
most of the time.
4 = Very severe. Patient completely preoccupied with
cardiovascular symptoms. Severe impairment of
function. Symptoms continuously present.
(10) Respiratory symptoms (0-4)
Severe forms of these symptoms may result in hyperventilation and is
therefore easy to detect although less severe forms are often less
noticeable. The patient may complain of pressure or constriction in
chest, choking feelings, sighings, dyspnoea, tightness or gasping for
breath.
" HAVE YOU HAD ANY DIFFICULTY IN BREATHING RECENTLY?
HOW BAD? "
WHEN? HOW OFTEN?
o = Absent.
1 • Mild. Experience of mild respiratory symptoms, not
g~v~ng rise to undue concern and not restricting
patient's daily activities.
2 = Moderate. A more pronounced loss of regular breathing
control necessitating termination of activities in
order to regain control of breathing. (less than 5
mins. x2 per day).
3 = Severe. Patient feels he/she is unable to control
erratic breathing pattern, unable to regain breathing
control and unable to continue any task at hand when
breathing pattern becomes disturbed. (greater than
5-10 mins. x4 per day).
4 = Very severe. Frequent and intense respiratory
difficulty resulting in prolonged daily episodes of
hyperventilation (greater than 30 mins.), and possible
concomitant loss of consciousness.
(11) Gastro-intestinal symptoms (0-4)
A great variety of gastro-intestinal symptoms may exist ranging from
a very occasional difficulty in swallowing to a medically diagnosed
irritable bowel syndrome.
A check list of gastro-intestinal symptoms fol10ws:-
Difficulty in swallowing; wind; dyspepsia; pain before and
after meals, burning sensations, fullness, waterbrash, nausea,
vomiting, sinking feelings; "workirg"in abdomen; borborygmi;
looseness of bowels; loss of weight; constipation.
" HOW HAS YOUR APPETITE BEEN? HAVE YOU HAD ANY DIFFICULTY IN KEEPING
YOUR FOOD DOWN RECENTLY? HAVE YOU BEEN CONSTIPATED RECENTLY OR
HAVE YOUR·BOWELS BEEN AS REGULAR AS YOU WOULD NORMALLY EXPECT? HAVE
YOU HAD HEARTBURN RECENTLY? HAS YOUR STOMACH BEEN TROUBLING YOU AT
ALL?· HAVE YOU LOST ANY WEIGHT RECENTLY? "
o = Absent. No major gastro-intestinal upset of any
consequence in recent months.
1 = Mild. A minor degree of gastro-intestinal, or bowel
irregularity, resulting in a minor degree of irritation
and annoyance as opposed to incapacitation.
2 = Moderate. A moderate degree of gastro-intestinal or
bowel irregu1arity,-'resu1ting in a degree of incapacit-
ation that is of concern to the patient.
3 = Severe. A severe degree of gastro-intestinal or bowel
upset that is often unpredictable and uncontrollable
even if food intake is modified, resulting in significant
functional impairment.
4 = Very severe. Frequently painful and incapacitating
gastro-intestinal or bowel upset, possibly resulting in
markedly reduced and modified food intake with concomitant
loss of weight. Severe functional impairment.
(12) Genito-urinary symptoms (0-4)
Desire to micturate can reflect intense anxiety. Females may experience
various menstrual irregularities, whilst males and females may experience
a wide range of sexual dysfunctions. A check list of genito-urinary
symptoms fo11ows:-
Frequency of micturition)
Urgency of micturition )
Amenorrhea )
Menorrhagia )
Development of.frigidity)
in both males and females
in females alone
Ejacu1atio praecox)
Loss of erection ) in males alone
Impotence )
Patients need not experience symptoms from all the.above categories of
symptoms.
" HAS THERE BEEN ANY CHANGE IN THE NUMBER OF TIMES, OR URGENCY WITH WHICH
YOU HAVE TO GO TO THE TOILET TO URINATE? HAS THERE BEEN ANY CHANGE IN
YOUR LOVE LIFE, SEX LIFE, OR INTEREST IN SEX, RECENTLY? HAS THERE BEEN
ANY CHANGE IN THE REGULARITY OF YOUR PERIODS? (FEMALES ONLY). "
o = Absent.
1 = Mild. A noticeable increase in frequency or urgency of
micturition which can be alleviated by partially reducing
liquid intake and environmental change and is more of an
inconvenience than a handicap. A mild decrease in sexual
receptivity/performance/arousal etc. where such dysfunction
would not normally be present.
2 = Moderate. A marked increase in urgency or frequency of
micturition cannot be brought under control by patient.
Sexual dysfunction is evident on many occasions and is
therefore of concern to both patient and sexual partner.
Females may experience menstrual irregularity which is of
concern to them.
3 = Severe. Urgency and frequency of micturition is such
that patient organises daily routine around presence and
availability of toilets. Sexual dysfunction is evident
on most occasions. Marked menstrual 'irregularity in
female patients.
4 = Very severe. Fear of involuntary voiding is such that
patient needs to be constantly in reach of a toilet and is
therefore severely functionally impaired. Sexual
dysfunction" is evident on all occasions of attempted
sexual intercourse. Female patients are completely
amenorrheaic.
(13) Autonomic symptoms (0-4)
Autonomic accompaniments of anxiety may entail any of the fo1lowing:-
dry mouth; flushing; pallor; tendency to perspire heavily;
giddiness; tension headache; raising of hair.
Various combinations of the above check list may be present to a greater
or lesser degree.
" HAVE THERE BEEN TIMES RECENTLY WHEN YOU HAVE FELT ANy UfTHE FOLVi"WING;
GIDDY OR UNSTEADY, HAVE SWEATED A LOT, HAD A DRY MOUTH, FELT FAINT,
DIZZY, HEADACHES, PIAN AT THE BACK OF THE NECK, BUTTERFLIES. HOW
OFTEN? HOW BADLY? "
o ... Absent.
1 - Mild ., One or a few of the above symptoms havevbeen
present on occasion but were mild and did not cause
concern. Present on occasion (not more than twice per
week).
2 = Moderate. A number of the above symptoms have been
present on a number of occasions causing distress,
(greater than twice per week), or a single symptom
has been present on a regular basis.
3 = Severe. A number "of the above symptoms have been
present most of the time, resulting in some impairment
to function and marked concern to patient.
4 = Very severe. A number of the above symptoms have been
continually present, to the extent that this has
markedly impaired the patient carrying out daily routine
tasks. Virtually no relief from symptoms.
(14) Behaviour at interview (general) (0-4)
This is not based on the patient's subjective report but is based upon
the interviewer's observations of the patient's general appearance and
behaviour throughout the whole assessment interview.
Observe general anxiety checklist as fo11ows:-
Tense, not relaxed. Fidgeting: hands, picking fingers,
clenching, tics. Restlessness: pacing. Tremor of hands.
Furrowed brow. Strained face.or voice. Increased'
muscular tone. Sighing respirations. Facial pallor.
Swallowing , belching, sweating. Tremor and eye-lid
twitching.
o = Absent. Calm and relaxed.
1 a Mild. Exhibiting up to two of the above behaviours,
occasionally throughout the interview.
2 = Moderate. Intermittently exhibiting two to four of the
above behaviours or continually exhibiting up to two of
the above behaviours throughout the interview.
3 = Severe. Frequently exhibiting at least four of the
above behaviours or continually exhibiting less than
four of the above behaviours, resulting in slightly
impaired communicadon.
4 = Very severe. Continually exhibiting the majority of
the above behaviours to such an extent that communication
is extremely difficult.
APPENDIX 3
KELLNER AND SHEFFIELD SYMPTOM RATING TEST
SELF RATING SCALE
date -.
Describe how you have felt during the PAST WEEK.
If you' have not had the symptom at all make a check mark (V) in the box on the left like this.
Extremely,
....• A little A great deal, could not
Not at all slightly quite a bit have been
worse
I Headaches or head pains V
If you have had the symptom describe how much it has bothered you or troubled you, for
example, like this: .
Extremely,
A little A great deal, could not
Not at all slightly quite a bit have been
worse
I Headaches or head pains ·V
Please answer all questions.· Do not think long before answering.
·Extremely,
A little A great deal, could not
Not at all slightly quite a bit have been
worse
1 Feeling dizzy or faint
2 Feeling tired or lack of
energy
3 Nervous
4 Feelings of pressure or
a tightness in head or
body
5 Scared or frightened
6 Poor appetite
, .-
7 Heart beating quickly or
strongly without reason
(throbbing or pounding)
8 Feeling that there was
no hope
9 . Restless or jumpy
10 Poor memory
Self-rating scale
Extremely,
A little, A great deal, could not
Not at all slightly quite a bit have been
worse
11 Chest pains or breathin?
difficulties or feeling 0 .
not having enough air
12 Feeling. guilty
13 Worrying
14 Muscle pains or,aches,
or rheumatism
15 Feeling that people look
down on you or think
badly of you
16 Trembling or shaking
17 Difficulty in thinkin9
clearly or difficulty In
making up your mind
18 Feeling unworthy or a
failure
19 Feeling tense or
'wound up'
20 Feeling inferior to
other people
21 Parts of body feel numb
or tingling
22 Irritable
23 Thoughts which you
cannot push out of
your mind
24 Lost interest in most
things
25 Unhappy or depressed
26 Attacks of panic ,
27 Parts of your body
feeling weak
28 Cannot concentrate
29 It takes a long time to
fall asleep, or restless
sleep or nightmares
30 Awakening too early and
not being able to fall
asleep again
APPENDIX 4
ADVERSE EVENT RECORD AND WITHDRAWAL SYMPTOM CHECKLIST
FVGPaG AAER
Study No "',.,.,'
ADVERSE EVENT RECORD
I
Date of evaluat10n Pt, No •••••••••••.................. In1t1als ........
For the first evaluation please record the adverse events whicp have occurred during
the Erevious week. For all subsequent evaluations record the adverse events since
last evaluation, irrespective of whether you suspect the drug or not.
RECORD HERE'concurrent medical illness, injury, or adverse reaction which has been:
- spontaneously reported by patient
- observed by staff
- reported by patient on open questioning, i.e. "How do you feel? Have you felt
unwell? Has anything in particular been bothering you"?
RATE SEVERITY of the event using the following scale:
SEVERITY
1 = Mild - Does not hinder the patient's pretreatment functioning, but is an annoyance
2 = Moderate - Definite degree of impairment to functioning, uncomfortable or embarrassing
:5 = Severe - Definite hazard to well-being, significant impairment of functioning or
incapacitation
9 = Not assessed
ADVERSE EVENT SEVERITY CODE ACTION TAKEN i(Print) (Print) •
-'
..
INVESTIGATOR'S SIGNATURE
Study No •••••••••••
WITHDRAWAL SYMPTOM CHECK LIST
Current evaluation
tnrncrs .
I
I
!,~i ~ ~~ _
,::~:~I
I
I
.................. . Pt. No ...••.••••••••..
Date of evaluat10n
INSTRUCTIONS
For the first evaluation please record the symptoms reported to have occurred during
the previous week. For all subsequent evaluations describe the symptoms since last
/
I
evaluation, irrespective of whether you suspect the drug or not.
Check the presence or absence of each symptom on the list as REPORTED BY THE PATIENT ON
ACTIVE QUESTIONING, e.g. "Have you had a headache"? "Have you had dry mouth"? etc. If
symptom was reported on Adverse Event Record, check the box "REPORTED ON AAER"-.
RATE SEVERITY using the following scale:
SEVERITY
0 = Not Eresent
1 = Mild - Does not hinder the patient's pretreatment functioning, but is an annoyance
2 = Moderate - Definite degree of impairment to functioning, uncomfortable or embarrassing
:3 = Severe - Definite hazard to well-being, significant impairment of functioning orincapacitation
9 = Not assessed
SYr-1PTOM CODE REPORTED SEVERITY ACTION TAKEN/COMMENTSON AAER- (Print)
Difficulty getting to sleep
Disturbed sleep
Restlessness I
Tremor
Hyperactivity " .-
Abdominal cramps
Sweating a lot
Convulsions
Confusion
Dysphoria
Anxiety I
Ioleakne'ss
Lack of energy
Numbness
Loss of appetite
Nausea
Apprehension
Over active
Headache - I..
Dizziness I
Faintness
APPENDIX 5
COPING WITH ANXIETY : A GUIDE TO COGNITIVE THERAPY
1.
",
COPING WITH ANXIETY: A GUIDE TO COGNITIVE THERAPY
To be'human is to have emotional problems. Sometimes we can deal with
these problems by ourselves or with the help of family and friends. '
However, we sometimes also benefit from professional help in overcoming
emotional prc~lems before they become so severe as to be disabling.
This booklet is designed to help you make the most of your experience
with Cognitive Therapy - a new and generally effective form of treatment
for people suffering from anxiety. Read it through several times and
discuss anything you're not clear about with your therapist.
SIGNS OF ANXIETY
"What if I fail this exam? My career will be ruined before it starts.
1 feel so sick just thinking about it that I can't study. But I have
to study or •••• ".
"Every time I leave the house I feel sick, I think I'm going to collapse
and have to go back home. I can't go anywhere unless someone's with me".
"When I have to talk'to strangers I start to swea.t and panic - I feel
trapped and can't think of anything to say" •
•"I sometimes feel very tense and uncomfortable, worrying about things
that I've got to do the next day, or even the next week or month. I can't
seem to get rid of these worrying thoughts no matter how hard I try".
Such are the thoughts and emotions that sweep over those who suffer from
anxiety and phobias. Since both anxiety and phobias are rooted in fear,
they both indicate the dread of some type of danger or threat to one's
wellbeing. This sense of threat is manifested by a wide range of physical
symptoms - anxiety's "body language" - which are distressing in themselves;
rapid breathing, accelerating heart rate, dizziness, nausea, headache,
sweating, dryness of mouth, tightening of throat, pain in various sets of
muscles. etc. When the state of anxiety is prolonged - or chronic -
these frightening or uncontrollable symptoms may take the form of what
seems to be a real disease or disability.
One of the most important facts for a severely anxious person to learn
- and to recall to mind at critical moments - is that the symptoms he is
experiencing are not dangerous. The racing pulse or pounding heart, the
dizziness or nausea, the desire to scream or cry or pound the table -
none of these physical or emotional reactions indicate that the person is
dangerously ill or "going crazy". They are unpleasant. They are
uncomfortable. ' But they can be tolerated until they go away. And they
will go away •-
NATURE OF fu\~IETY A~ID PHOBIAS
While phobias cause intense anxiety, accompanied by its various physical
and/
2.
and emotional symptoms, the phobic individual is reacting to a specific object
or situation which can to some extent and without great inconvenience, be '
avoided. As long as the feared event, object or situation is not an integral
part of the person's life, he can remain free from the anxiety effects of
phobia. For instance, someone who has in intense, phobic fear of flying, can
usually find ways of getting to places without having to go on an aeroplane.
The anxiety sufferer, however, cannot always pinpoint the source of his anxiety.
And even if he can identify the cause, he cannot avoid encountering it; either
the. demands-of his daily life force him to confront the feared circumstances,
or he has so completely internalized his fear that the source of it is within
himself •
Sometimes it is necessary for a person to experience fear in order to acknow-
ledge the threat of real danger and prepare himself to meet it. A certain
degree of anxiety may accompany such fear. But the person who suffers from
excessive anxiety or phobic reactions is not responding to the reality of his
situation. He may be anticipating a threat to his well-being when there is
little likelihood that it will occur. If he is facing a challenge of some
sort - an exam, or job interview, he will magnify the difficulties and dwell
on the horrors of a negative outcome. At the same time he will underestimate
overlook or discount his own ability to cope with whatever he fears. In
other words, he misinterprets and distorts reality so that he feels anxious
about dangers which either do not exist or which he could cope with effective~
if he were not so disabled by his own anxiety reactions.
To make matters worse, when the severely anxious person becomes aware of his.own
unpleasant physical and emotional reactions, he may begin to dread and fear the
symptoms themselves even more than the situation that triggers them. The more
upset he gets, the more exaggerated his symptoms become, and he is involved in
a self-perpetuating spiral of increasingly intense emotional and physical
suffering.
NEW UNDERSTANDING FROM RESEARCH
Since this form of anxiety is based on a m~s~nterpretation of reality, research
has revealed that certain thoughts and mental pictures automatically accompanYl
the experience of anxiety. ' These AUTOMATIC THOUGHTS or cognitions, ~re usualfY
focussed on the future: "I won't be able to do the job", "I'll lose control 0
myself and be humiliated", "I'll die from a heart attack", "If I go to the party
no-one will talk to me".
. eThe connection between these AUTOMATIC THOUGHTS and the experience of excesS1V ~e
anxiety, suggested to these people studying the problem that if the patient be~ tY
more aware of those thoughts and changed them to conform with reality, the an~1~y
would be very much less. Clinical experience with people who suffer from anX1e
has shown that this method can be very effective. The approach is called
COGNITIVE THERAPY.
COGNITIVE THERAPY IN PRACTICE
In the following anecdote you may recognise the way in which a person's anxious °
thoughts destroy his ability to function adequately. A lonely young man want~ ~s
ask a girl for a date, but every time he has the opportunity to do so the anx10•
thoughts rise up and he avoids asking ,her. The 'automatic thoughts' he has are·
"She'll think I'm stupid to be so nervous./
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nervous. She'll turn me down and I'll look pathetic.
yet again."
I'll have failed
How would Cognitive Therapy help someone whose anxious thoughts and
imaginings interfered with their ability to lead the kind of life that is
rewarding to them? First, by helping you to recognise the kind of errors
of reasoni~g in your thinking that cause you to feel upset. Secondly, by
helping you to correct these errors and substitute more reasonable and
rational thoughts that will not result in excessive, debilitating feelings
of nervousness and anxiety. Thirdly, by helping you to understand how
your own characteristic ways of looking at the world (what are called
UNDERLYING ASSt~PTIONS)may make you vulnerable to thinking in anxiety-
provoking ways.
During treatment, your therapist will help you to learn how to challenge
your irrational, automatic thoughts and to change maladaptive underlying-
assumptions. There are a variety of ways of doing this, and your therapist
will help you to find the particular ways that help you best. This can be
a slow and at times a painful process, and will involve you in taking some
risks in 'testing out' your beliefs and ideas to determine how realistic
they are. However, the rewards of learning how to control your anxiety
will almost certainly compensate more than adequately for the hard work
that may be involved. As you gradually eliminate the distortions and
inaccuracies in your own thinking you will develop an increasing confidence
in your ability to handle situations in your life that previously caused
you a lot of difficulty.
STEPS IN COGNITIVE THERAPY
(1) The first step is to recognise your own AUTOMATIC THOUGHTS whenever you
feel anxious. In order to help you recognise them, keep these
characteristics in mind:
(a) These thoughts,just seem to come out of nowhere, and flash through
your mind without you really being aware of them.
(b) They seem very plausible and reasonable to you at the time 'you are
experiencing them. In fact you accept them as a perfectly
reasonable way of thinking in the circumstances, just as you might
readily accept the truth of a realistic thought like "The phone is
ringing - I must answer it".
(c) These thoughts are, however, quite unreasonable and irrational as
you will realise when you learn to challenge them with reason and
facts.
(d) Automatic thoughts are the kind of thoughts most people would find
depressing or anxiety-provoking if they believed them.
(2)/
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(2) The second step is to learn how to challenge automatic thoughts with
reason and facts about how the world really is. A good way of doing
this is to consider all the various thoughts that you might have had
instead of the automatic thOughts. When you do this you will begin
to realise that the way you thought about the situation was only one
of a number of different interpretations. (It is very important to
remember that there are always lots of different ways of looking at
the same situation). Once you do this you will start to see that
the automatic thoughts that caused you to be anxious or upset contained
THINKING ERRORS. These errors tend to fall into the following
categories:
(a) ALL-OR-NONE THINKING:- Seeing things in black or white rather than
in shades of grey (e.g. you're either a total success or a total
failure).
(b) OVER-GENERALISING:- Imagining that one bad experience in a situation
means that you will always have a b~experience in such situations.
(e.g. thinking that you will always be anxious in social situations
just because you were extremely anxious at a party you went to
recently).
(c) CATASTROPHISING:- Assuming that the worst possible thing is bound to
happen in a situation that you find difficult (e.g. after an
argument with your boss, assuming that you'll probably lose your job,
have to sell your house, and won't ever be able to work again)~'
(d) EXAGGERATING:- Blowing things u? oct of proportion. Reaction to a
situation that is difficult or embarassing or irritating or upsetting,
as if it were a major disaster, (e.g. being extremely upset when a
neighbour you know slightly criticizes the behaviour of a friend of
yours).
(e) IGNORING THE POSITIVE:- Overlooking positive experiences and
positive aspects of a situation because they 'don't count' for som7reason. Dwelling exclusively on the negative aspects of a situatlOn
(e.g. thinking only of all your negative qualities and personal .
failings after you have been turned down for a job).
JUMPING TO CONCLUSIONS:- Coming to a quite arbitrary conclusion about
something in the absence of any definite facts to justify this, (e.g·
deciding that your new neighbour doesn't like you just because she
turned down your invitation to go to the local supermarket with her)·
(f)
'SHOULD'STATEMENTS:- This refers to automatic thoughts that cause
excessive anxiety or guilt because they inappropriately contain the
words 'should' or 'must' or 'always' or 'never'. People generallY
have these thoughts when they try to live by personal rules or d
standards that may in fact be excessively rigid and overdemanding an ~
have no real application to normal, everyday life, (e.g. I must alway
look my best or people won't like me).
Once you have learnt to identify your automatic thoughts and the thinking
errors they contain, the third step is to practice substituting RATIONALRESPONSES/
(g)
(3)
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RESPONSES for the automatic thoughts. Thus, instead of automatically
responding to the situation with a ser Les of negative, anxiety-provoking
thoughts, you will gradually learn to respond to situations in more
reasonable ways. For example: you will begin to realise that the
experience of acute anxiety is always limited in time and that you can
learn to control anxiety by not over-reacting to the symptoms. You will
also learn to test out your anxious thoughts and beliefs about what might
happen to you in'certain situations, by conducting PERSONAL EXPERIMENTS.
It very often happens that people are not as anxious as they imagined
they would be in certain situations. Remember that in nearly all anxiety-
provoking situations there are what we call RESCt~ FACTORS: these are
things that make the feared consequences of being anxious tolerable,
unlikely to ,happen, limited in time, etc.
(4) \Vhen you have practised going through the first three steps and learnt
how to control,your anxiety symptoms in your everyday life, the fourth
stage is to modify any UNDERLYING ASSUMPTIONS you may have that make you
vulnerable to being anxious. These are a little more difficult to
explain than automatic thoughts; they refer to the characteristic ways
in which you look at the world and think about yourself. For example
anxious people very often have excessive needs for love and approval from
other people, or beliefs that always.being very successful at work is of
vital importance to being a worthwhile person. They may have expectations
of life that are very unlikely to be satisfied or perhaps excessive
feelings of responsibility for other people. As therapy progresses you
will begin to learn about the kind of beliefs and assumptions that you
have that may make you vulnerable to further episodes of anxiety in the
future. Once these are identified you can work with your therapist to
try to change them so that you are less likely to experience any
recurrence of anxious thoughts and feelings.
The following statements are examples of maladaptive underlying
assumptions:
(ar In order to be happy I have to be successful in everything I do.
(b) I must be liked by people at all times.
(c) If I make a mistake it means I'm incompetent.
(d) I can't live without being loved.
(e) If somebody disagrees with me it must mean he doesn't like me.
(f) My value as a person mainly depends on what other people think of me.
GENERAL COMMENT ABOUT COGNITIVE THERAPY
(1) This type of therapy works best where there is a close working relation-
ship between you and your therapist. This relationship should be a
collaborative one in which you both work together as a team. It should
,be an open relationship in which you feel comfortable talking about any
doubts or anxieties that you may have about your progress, your personal
life, or the way, in which your therapist behaves.
(2)/
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(2) Throughout therapy you will be given HOMEWORK to do between therapy
sessions. This is a very important part of Cognitive Therapy and it
is important that you understand both what you have to do, and why.
It will almost certainly be useful to have: a notebook and pen handy
during therapy sessions so that you can take a note of anything you
need to remember.
(3) During your first few sessions of therapy, as part of the general.
assessment of your problems and present circumstances, it will be
useful to set certain TREATMENT GOALS. Setting goals gives impetus
to the process of treatment. If you have in your mind a clear
picture of how you would like to change and what you imagine your life
would be like if you were free of anxiety, you will know what you are
working toward. So share your ideas with your therapist so that he
can help you reach YQur goal.
(4) In addition to the steps in Cognitive Therapy outlined above, there
may well be other therapeutic techniques and approaches that you can
use to learn how to control your anxiety, or to put yourself in
situations that you have been afraid of, or to learn more effective
ways of behaving in social situations. For example, your therapist
may help y"()ulearn how to relax, or how to approach fearful situations
using a method called 'graded exposure', or how to become more
assertive using 'role-playing' techniques. It is not always clear at
the start of treatment which approach is most likely to be of m~st
benefit to you, and finding the right approach may involve some aegree
of trial and error.
CONCLUDING COMMENTS
This booklet has hopefully given you some idea of what is involved in
Cognitive Therapy. Remember that the purpose of this type of treatment is
to teach you skills that you can carryon using once therapy has ended.
Learning to be confident about overcoming anxiety symptoms may take quite
a while. It is something that you will probably need to work at on your
own whenever you come across situations in life that are stressful or
problematic in some way. No-one' s life is ever completely free. of anxiety
or depression - the important goal is to relieve yourself of excessive
anxiety that inhibits your ability to enjoy life and realise your potential.
Learning how to do this is never a smooth, straight-forward process - you
are bound to have some ups and downs and occasional setbacks. The important
thing is that with hard work and practice you will gradually become more and
more confident about doing things without anxiety that you had previously
thought were quite out of reach.
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APPENDIX 6
GENERAL HEALTH QUESTIONNAIRE
, Study Number .........
~ease read this carefully:
Date ..................
We should Uke to know it'you have had any .edical complaints, and how your health has
been in general, over the past t'ewweeks. Please answer ALL the questions on the
following pages si.ply by underlining the answer which you think most nearly applies to
1ou. Remember that we want to know about present and recent complaints, not those that
You had in the past.
It is important that you try to answer ALL the questions.
~ you very .uch for your co-operation.
YOU RECEN1'L Y :
1. Been feeling perfectly well
and in good heal ttl?.
Been feeling in ne~d of a
good tonic?
3. Been feeling run down
and out of sorts?
, 4. Felt that you are ill?
s. Been getting any pains
in your head?
6. Been getting a feeling
of tightness or pressure
in your head?
Been able to concentrate
on whatever you are doing?
8. Been afraid that you were
going to collapse in a
public place?
Been having hot or cold
spells?
to. Been perspiring
(sweating) a lot?
Found yourself waking early
and unable to get back to
sleep?
Been getting up feeling your
sleep has not refreshed you?
Been feeling to tired and
exhausted even to eat?
Lost much sleep over worry?
Been feeling mentally alert
and ·wide awake?
Better Same Worse Much worse
than usual as usual than usual than usual
Not No more Rather IIIOre Much IDOre
at all than usual than usual than usual
Not at No BOre Rl)ther JaOre Much more
all than usual than usual than usual
Not at No IItOre Rather DtOre Much IIIOre
all than usual than usual than usual
Not at No aaore Rather .-ore Much more
all than usual than usual than usual
Not at No more Rather more Much more
all than usual than usual than usual
.Better Same Less Much less
than usual as usual than usual than usual
Not at
all
Not at
all
Not at
all
Not at
all
Not at
all
Not at
all
Not at
all
Better
than usual
No more Rather more Much more
than usual than usual than usual
No more Rather more Much more
than usual than usual than usual
No more Rather more Much more
than usual than usual than usual
No more Rather more Much more
than usual than usual than usual
No more
than usual
No more
than usual
No more
than usual
Same
as usual
Rather more Much more -
than usual .than usual
Rather more Much more
than usual than usual
Rather more Much more
than usual than usual
Less alert Much less
than usual alert
16. -been feeling full of energy?
17. -had difficulty in getting
off to sleep?
IS. -had difficulty in staying
asleep once you are off?
19. -been having frightening or
unpleasant dre8.IDS?
20. -been having restless, dis-
turbed nights?
21. -been .anaging to keep your-
self busy and occupied?
22. -been taking longer over the
things you do?
23. -tended to lose interest in
your ordinary activities?
24. -been losing interest in
your personal appearance?
25. -been taking less trouble
with your clothes?
26. -been getting out of the
house as much ss usual?
27. -been zanaging as well as
most people would in your
shoes?
2S. -felt on the whole you were
doing things well?
29. -been late getting to work,
or getting started on your
housework?
Better
than usual
Not
at all
Not at
all
Not at
all
Not at
all
More 80
than usual
Quicker
than usual
Not at
all
Not at
all
More
trouble
Same
as usual
No DOre
than usual
No .ore
than usual
No acre
than usual
Ho acre
than usual
Same
as usual
Same
as usual
No DOre
than usual
No more
than usual
About sa.e
More Same
than usual as usual
Better
than IDOst
About
the same
Better About
than usual the same
Not at
all
30. -been satisfied with the way Moreyou've carried out your task? satisfied
No later
than usual
About same
as usual
-been able to feel warmth and Better
affection for those near to than usual
you?
About slUte
as usual31.
32. -been finding 1t·easy to get
on with other people?
33. -spent much time chatting
with people?
34. -kept fe,~ing afraid to say
anything to people in case
you made a fool of yourself?
35./
Better
than usual
More ti..e
than usual
Not at
all
About sa.e
as usual
About sa.e
as usual
No IIOre
than usual
Less energy
than usual
Rather more
than usual
Rather DOre
than usual
Rather DOre
than usual
Rather DOre
than usual
Rather less
than usual
Longer
than usua!
Rather IDOre
than usual
Bather .ore
than usual
Less
trouble
Less
than usual
Rather
less well
Less well
than usual
Much lees
energetic
Much .ore
than usual
Much ..ore
than usual
Much DOre
than usual
Much JDC)re
than \.UIual
Much lesS
than usual
Much longer
than usual
Much more
than' usual
Much more
than usual
Much lesS
Much lesS
than usual
Much
less wel1
Much
less well ::1>
Rather later Much later
than usual than usuSl,.
Less satis-
fied than
usual
Less well
than usual
Less Wle.ll
than usual
Less
than usual
Rather !DON!
than usual
Much ler.s" ,;
satisfied
well
/
Much le6"
well i;
le66=uS~/
135•. -fel t that you are playing a
wset'ul part 1n things?
-felt capable of Baking deei-
aione about thinga?
'; 1
37•
.. 38.
-felt you're just not able to
make a atart on anything?
-fel t yourself dreading' 'I ..
everything that you have to
do?
39. -felt constantly under
atrain?
4Q. -felt you couldn't over-
come your difficulties?
-been finding life a struggle
all the tillle?
~. -been able to enjoy your
normal day-to-day activities?
43
I •
I
.-been taking things hard?
!44. -been getting edgy and bad-
tempe~d?
,451 • -been getting scared or
panicky for no good reason?,
f
"46
I.:
! •
-been able to face up to
your proble-s?
-found everything get~ing on
top of you?
4a. -had the feeling that people
were looking at you?
I
ISo.
I,Sl •
-been feeling unhappy and
depressed?
~becn l08i~ confidence in
yourself?
-been thinking of yourself as
a.worthless peraon?i~
r
l~., -felt that life is entirely
hopeless?
-been feeling hopeful about
your own future?
--been feeling reasonably
happy, all things considered?
More 80
than usual
More 80
than usual
Not at all
Not at all
Not at all
Not at all
Not at all
More so
than usual
Not at
all
Not a~ all
Not at all
More so
than usual
Not at all
Not:at all
Not at all
Not at all
Not at all
Not at all
More so
than usual
More so
than usual
Same as
usual
Same as
usual
No more
than usual
No BOre
than usual
No more
than usual
No more
than usual
No InOre
than usual
Same as
usual
No IDOre
than usual
No more
than usual
No more
than usual
Same
as usual
No more
than usual
No more
than usual
No more
than usual
No more
than usual
No more
than usual
No,more
than usual
About same
as usual
About same
as usual
.Less useful Much less
than usual useful
Less so
than usual
Rather Dore
than usual
Rather 1ItOl'e
than usual
Rather more
than usual
Rather more
than usual
Rather BOre
than usual
Less so
than usual
Rather more
than usual
Rather more
than usual
Rather more
than usual
Less able
than usual
Rather more
than usual
Rather IDOre
than usual
Rather 1ItOl'e
than usual
Rather more
than usual
Rather more
than usual
.ather more
than usual
Less so
than usual
Less so
than usual
-.
Much less
capable
Much more
than usual
Much more
than usual
Much more
than usual
Much more
than usual
Much more
than usual
Much less
than usual
Much IIIOre
than usual
Much more
than usual
Much more
than usual
Much less
able
Much more
than usual
Much more
than usual
Much more
than usual
Much more
than usual
Much more
than usual
Much more
than usual
Much less
hopeful
Much. lees
than usual
55. -been feeling nervous and Not at all No IIIOre Ra ther BOre ~ch IIOre
strung-up all the t1ae? than usual than usual than usual
56. -felt that life isn't worth Not at all No IIOre Rather BOre Much IIOre
living? than usual than usual than usual
57. n"lought of the possibil1 ty Definitely I don't Has cf'Qssed Definitely
that you .ight aake a• .,. with not think so ay mind have
yourself?
SS. Found at t1aes you couldn't Not at all No IIIOre Rather more Muchmore
do anything because your than usual than usual than usual
nerves were to 0 bad :?
59. Found yourselr wishing you Not at all No IDOre Rather 1DOr;, ,Much more
were dead and away rrom it than usual than usual than usual
all?
60. Found that the idea of taking Derinitely I don't Has crossed Definitely
your own life kept coming Not think so .y lIIind has
into you Ilind?
•
APPENDIX 7
"TENSE - RELAXED' VISUAL ANALOGUE
APPENDIX 8
'TARGET - SYMPTOM" VISUAL ANALOGUE
At this I the first visit you mentioned that
•••••••••••••••••• particularly bothered you.
Could you show how much it bothered you over
the past week by marking clearly and at right
angles across the line below.
Not atall t------------------------------i E)(treme Iy bad,
could not be
worse.
APPENDIX 9
LETTER OF INVITATION
Dear
Benzodiazepines (Tranquillizers, Sleeping Tablets)
As you may be aware, t~ is growing concern over the longer term
use of certain medicines. The benzodiazepines have been in use now
for 25 years. It has become increasingly clear that whilst they were
a great advance on what was available before, they are not free from
problems. One such problem is that some patients find it difficult to
cope without them, but do not feel them to be very helpful either.
We are reviewing the use of these medicines, and would like you to
attend an appointment to discuss your treatment with benzodiazepines.
We are not suggesting that you stop your medication at present.
Your appointment is on •••••••••••••••••••••••••••• at •••••••••••••••
at : .
and will be with
It will take approximately 40 minutes.
Please let us know whether you will be able to keep this appointment
by phoning Mrs Swanson, at the University of Stirling (tel Stirling
73171, extension 2082) between 9.30 am and 12.30 pm any weekday.
If this time is not suitable for you, please phone the above number
to arrange an alternative appointment.
Thank you very much for your help.
Yours sincerely,
APPENDIX 10
BECK DEPRESSION INVENTORY
BECK INVENTORY
Name: . . . . . . . ... . . . . . . . Date: • . . . . . . . . .
On this questionnaire are groups of statements. Please read
each group of statements carefully, then pick out the one
statement in each group which best describes the way you have
been feeling during the past week, including to-day. Circle
the number beside the statement you picked. Please be sure
to read all the statements in each group before making your
choice.
1. 0
1
2
3
. 2. 0
1
2
3
3. 0
1
2
3
4. 0
1
2
3
5. 0
1
2
3
6. 0
1
2
3
7. 0
1
2
3
8. 0
1
2
3
9. 0
1
2
3
I do not feel sad
I feel sad
I am sad all the time and I can't snap out of it
I am so sad or unhappy that I can't stand it
I am not pa~ticularly discouraged about the future
I feel discouraged about the future
I feel I have nothing to look forward to
I feel that the future is hopeless and that things cannot improve
I do not feel like a failure
I feel I have failed more than· the average person
As I look back on my life, all I can see is a lot of failures
I feel I am a complete failure as a person
I get as much satisfaction out of things as I used to
I don't enjoy things the way I used to
I don't get real satisfaction out of anything anymore
I am dissatisfied or bored with everything
I don't feel particularly guilty
I feel guilty a good part of the time
I feel quite guilty most of the time
I feel guilty all of the time
I don't feel I am being punished
I feel I may be punished
I expect to be punished
I feel I am ,being punished
I don't feel disappointed in myself
I am disappointed in myself
I am disgusted with myself
I hate myself
I don't feel I am any worse than anybody else
I am critical of myself for my weakness or mistakes
I blame myself all the time for my faults
I blame ~se1f for everything bad that happens
I don't have any thoughts of killing myself
I have thoughts of killing myself, but I would not carry them out
I would like to kill myself
'I would kill myself if I had the chance
10. 0 I don't cry any more than usual
1 I cry more now than I used to
2 I cry all the time now
3. I used to be able to cry, but now I can't cry even though I want to
11. 0
1
2
3
12. 0
1
2
3
I am no more irritated now than. I ever was
I get annoyed or irritated more" easily than I used to
I feel irritated all the time now
I don't get irritated at all by the things that used to irritate me
I have not lost interest in other people
I am less interested in other people than I used to be
I have lost most of my interest in other people
I have lost all of my interest in other people
IP.T.O.
13
14. 0
1
2
15. 0
1
2
3
16 0
1
2
17. 0
1
2
3
18 0
1
2
3
19.
20. 0
1
21. 0
1·
2
3
o
1
2
3
I make decisions about as well as I ever could
I put off making decisions more than I used to
I have greater difficulty in making decisions than I used to
I can't make decisions at all anymore
3
I don't feel I look any worse than I used to
I am worried that I am looking old or unattractive
I feel that there are permanent changes in my appearance that
make me look unattractive
I believe that I look ugly.
I can work about as well as before
It takes an extra effort to get started at doing something
I have to push myself very hard to do anything
I can't do any work at all
3
I can sleep as well as usual
I don't sleep as well as I used to
I wake up 1-2 hours earlier than usual and find it hard to get
back to sleep
I wake up several hours earlier than I used to and cannot get
back to sleep
I don't get more tired than usual
I get tired more easily than I used to
I get tired from doing almost anything
I am too tired to do anything
My appetite is no worse than usual
My appetite is not as good as it used to be
My appetite is much worse now
I have no appetite at all anymore
o
1
2
3
I haven't lost much weight, if any, lately
I have lost more than 5 pounds
I have lost more than 10 pounds
I have lost more than 15 pounds
I am purposely trying to los e weight by· eating less. .... No ••••Yes
2
I am no more worried about my health than usual
I am worried ?bout physical problems such as aches and pains, or
upset stomach, or constipation
I am very worried about physical problems and it is hard to think
of much else
I am so worried about my physical problems, that I cannot think
about anything else
3
I have not noticed any recent change in my interest in sex
I am less interested in sex than I used to be
I am much less interested in sex now
I have lost interest in sex completely
APPENDIX 11
SOCIAL PROBLEMS QUESTIONNAIRE
SOCIAL QUESTIONNAIRE
Name ••••••••••••••••••••••
Please underline the most appropriate answer.
A. Housing (EVERYONE ANSWER)
1. Are your housing
conditions adequate
for you and your
family's needs?
2. How satisfied are
you with your present
accommodation ?
Adequate
Satisfied
Slightly
inadequate
Markedly
inadequate
Severely
inadequate
Slightly Markedly Severely
dissatisfied dissatisfied dissatisfied
B.Work (FOR ALL MEN AND WOMEN WORKING OUTSIDE THE HOME)
Tick box if not applicable
3. How satisfied are
you with your present
job ?
Satisfied
4. Do you have problems No problems
getting on with any of
the people at your
work ?
o
Slightly Markedly Severely
dissatisfied dissatisfied dissatisfied
Slight
problems
Marked
problems
Severe
problems
(FOR HOUSEWIVES WITH NO OUTSIDE WORK )
Tick box if not applicable o
5. How satisfied are
you with being a
housewife ?
·Satisfied Slightly Markedly Severely
dissatisfied dissatisfied dissatisfied
(FOR HOUSEWIVES WITH A FULL OR PART-TIME JOB OUTSIDE THE HOME)
Tick box if not applicable 0
6. How satisfied are
you with working and
running a home ?
Satisfied Slightly Markedly Severely
dissatisfied dissatisfied dissatisfied
(FOR THOSE WHO ARE NOT WORKING - RETIRED, UNEMPLOYED OR OFF ~)
Tick box if not applicable l__j
7. How satisfied are Satisfied
you with this situation?
C. Financial Circumstances
Slightly Markedly Severely
dissatisfied dissatisfied dissatisfied
(EVERYONE ANSWER)
8 • .Isthe money coming Adequate
in adequate for you
and your family's
needs ?
Slightly
inadequate
Severely
inadequate
Markedly
inadequate
Please turn over •••••
SOCIAL QUESTIONNAIRE (2)
9. Do you have any
difficulties in
meeting bills and
other financial
commitments?
No Slight Marked Severe
difficulties difficulties difficulties difficulties
10. How satisfied are Satisfied
you with your financial
position?
Slightly Markedly Severely
dissatisfied dissatisfied dissatisfied
D. Social Contacts (EVERYONE ANSWER)
11. How satisfied are
you with the amount
of time you are able
to go out ?
12. Do you have any
problems with your
neighbours ?
13. Do you have any
problems getting on
with any of your
friends ?
14. How satisfied are
you with the amount
of time you see your
friends ?
Satisfied
No problems
No problems
Satisfied
15. Do you have any No problems
problems getting on
with any close relative?
(include parents, in-
laws, or grown-up
children)
16. How satisfied are
you with the amount
of time you see your
relatives ?
Satisfied
Slightly Markedly Severely
dissatisfied dissatisfied dissatisfied
Slight
problems
Marked
problems
Severe
problems
Slight
problems
Severe
problems
Marked
problems
Slightly Markedly ·Severely
dissatisfied dissatisfied dissatisfied
Slight
problems
Marked
problems
Severe
problems
Slightly Markedly Severely
dissatisfied dissatisfied dissatisfied
E. Marriage and boyfriends I girlfriends .
17. What is your
marital status?
Single Married / Widowed
cohabiting
Separated Divorced
(FOR ALL THOSE WHO ARE MARRIED OR HAVE A STEADY RELATIONSHI~
Tick box if not applicable l__j
18. Do you have
difficulty confiding
in your pa~tner ?
No
difficulty
Slight
difficulty
Severe
difficulty
Marked
difficulty
Please turn over ..••••
SOCIAL QUESTIONNAIRE (3)
19. Are there any
sexual problems in
your relationship ?
20. Do you have any
other problems getting
on together ?
21. How satisfied in
general are you with
your relationship ?
No problems Slight Marked Severe
problems problems problems
No problems Slight Marked Severe
problems problems problems
Satisfied Slightly Markedly Severely
dissatisfied dissatisfied dissatisfied
22. Have you recently No
been so dissatisfied
that you have considered
separating from your
partner ?
Yes, planned
or recent
separation
Sometimes Often
,
(FOR ALL THOSE WHO ARE NOT MARRIED / DO NOT HAVE A STEADY RELATIONSHIP)
Tick box if not applicable 0
23. How satisfied are Satisfied
you with this situaticn ?
Slightly Markedly Severely
dissatisfied dissatisfieddissatisfied
F. Domestic Life (FOR THOSE WITH CHILDREN UNDER 18)
Tick box if not applicable
24. Do you have any
difficulties coping
with your children?
25. How satisfied do
you feel with your -,
relationship with the
children?
o
No Slight Marked Severe
difficulties difficulties difficultiesdifficulties
Satisfied Slightly Markedly Severely
dissatisfied dissatisfied dissatisfied
(FOR THOSE WITH CHILDREN OF SCHOOL AGE )
Tick box if not applicable o
26. Are there any No problems
problems involving your
children at school ?
Slight
problems
Severe
problems
Marked
problems
(FOR ALL THOSE WITH OTHER ADULTS LIVING WITH THEM - INCLUDING
RELATIVES BUT EXCLUDING SPOUSE )
27. Do you have any
problems about sharing
household tasks ?
oTick box if not applicable
No problems Slight
problems
Marked
problems
Severe
problems
Please turn over •••••••
SOCIAL QUESTIONNAIRE (4)
28. Do you have any
difficulties with the
other adults in your
household ?
29. How satisfied are
you with this
arrangement ?
No Slight Marked Severe
difficulties difficulties difficulties difficulties
Satisfied Slightly Markedly Severely
dissatisfied dissatisfied dissatisfied
G. Legal Matters (EVERYONE ANSWER)
30. Do you have any
legal problems
(custody, maintenance,
compensation etc. ) ?
No problems Slight
problems
Marked
problems
Severe
problems
H. For Those who are Living Alone
Tick box if not applicable D
31. Do you have any
difficulties living
and managing on your
own ?
No Slight Marked Severe
difficulties difficulties difficulties difficulties
32. How satisfied are Satisfied
you with living on your
own ?
Slightly Markedly Severely
dissatisfied dissatisfied dissatisfied
I. Other (EVERYONE ANSWER )
33. Do you have any
other social problems
or problems ?
If so please specify
No problems Slight
problems
Marked
problems
Severe
problems
· .
· .
· .
APPENDIX 12
BENZODIAZEPINE DEPENDENCY QUESTIONNAIRE
Name •••••••••••••••••••••••••
Benzodiazepine Study Patient Questionnaire
Please circle the most suitable reply to the following questions :-
1. How important is your medication in helping you cope?
Not
important
A little
important
Very
important
Vital /
essential
2. Does being on your medication concern you at all ?
Not concerned
at all
A little
concerned
Definitely
concerned
Very much
concerned/worried
3. How easy do you think it would be for you to stop your medication?
Very easy Fairly easy Fairly I
difficult
Very difficult
....
4. What do you think about your current medication dosage ?
Extremely high A little Just about
right
Extremely low
5. How willing would you be to stop your medication ?
Very
willing
Fairly
willing
Fairly
unwilling
Very
unwilling
6. How do you think you would feel if your medication was changed ?
Not concerned A little Definitely Very much
at all concerned concerned concerned/ worried
7. .How do you think you would feel if your medication was stopped ?
Not concerned A little Definitely Very much
at all concerned concerned concerned / worried
-fel t that you are playing a
uset'ul part 1n things?
-felt capable of Baking deci-
sions about things?
-felt you're JU8t not able to
make a start on anything?
-felt yourself dreading .~ ..
everything that you have to
do?
-felt constantly under
strain?
-felt you couldn't over-
come your difficulties?
-been finding life a struggle
all the tillle?
-been able to enjoy your
normal day-to-day activities?
-been taking things hard?
-been getting edgy and bad-
tempered?
-been getting scared or
panicky for no good reason?
-been able to face up to
your probletl8?
-found everything get~ing on
top of ,.ou?
-had the feeling that people
were looking at you?
-been feeling unhappy and
depressed?
~bean losi~ confidence in
Yourself?
-been thinking of yourself as
a.worthless peraon?
-felt that life is entirely
hopeless?
-been feeling hopeful about
Your own future?
--been feeling reasonably
happy, all things considered?
More so
than usual
More so
than usual
Not at all
Not at all
Not at all
Not at all
Not at all
More so
than usual
Not at
all
Not a~ all
Not at all
More so
than usual
Not at all
Not:at all
Not at all
Not at all
Not at all
Not at all
More so
than usual
More so
than usual
Same as
usual
Same as
usual
No IDOre
than usual
No ItOre
than usual
No IIIOre
than usual
No more
than usual
No JnOre
than usual
Same as
usual
No IDOre
than usual
No more
than usual
No more
.than usual
Same
as usual
No more
than usual
No more
than usual
No more
than usual
No more
than usual
No more
than usual
No·more
than usual
About same
as usual
About same
as usual
.Less useful Much less
than usual useful
Less Ba
than usual
Rather Dare
than usual
Rather IaOre
than usual
Rather more
than usual
Rather IIIOre
than usual
Rather ItOre
than usual
Less so
than usual
Rather more
than usual
Rather more
than usual
Rather more
than usual
Less able
than usual
Rather more
than usual
Rather IDOre
than usual
Rather IIIOre
than usual
Rather more
than usual
Rather more
than usual
.ather more
than usual
Less so
than usual
Less so
than usual
- .
Much less
capable
Much JDOre
than usual
Much IIIOre
than usual
Much lIlore
than usual
Much JDOre
than usual
Much 1II0re
than usual
Much less
than usual
Much IIIOre
than usual
Much eor-e
than usual
Much more
than usual
Much less
able
Much more
than usual
Much more
than usual
Much more
than usual
Much JDOre
than usual
Much more
than usual
Much more
than usual
Much less
hopeful
Much. Ieee
than usual
